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A Introduction 
 
1 Introduction to Skin and Hair 
 
1.1 The Skin 
The skin is one of the largest organs of a body and makes up for at least 6 percent of an 
individual’s total weight. It consists of two layers, which are called epidermis and dermis. 
The epidermis is the outermost layer of the skin and consists primarily of Merkel cells, 
keratinocytes, melanocytes, and Langerhans cells. Cells in the deepest layers are nourished 
by diffusion from blood capillaries beneath the epidermis since the epidermis itself doesn’t 
contain blood vessels. Beginning with the innermost layer the epidermis can be further 
divided into stratum basale, stratum spinosum, stratum granulosum, stratum lucidum (only 
in palms of hands and bottoms of feet), and stratum corneum (figure 1). 
At the stratum basale new cells are formed, which migrate up the strata changing shape 
and composition as they die due to the isolation from their blood source. The cytoplasm is 
released and replaced with keratin. When they reach the stratum corneum, which consists 
of about 15-350 layers of dead cells, they finally slough off (desquamation). This process 
takes place within about 27 days and is called keratinization (Matoltsy 1958, Flesch 1958, 
Achten 1956). 
 
Figure 1: Skin layers of human epidermis 
(From http://en.wikipedia.org/wiki/File:Skinlayers.png) 
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The dermis is structurally divided into the papillary region, which is adjacent to the 
epidermis and is composed of loose areolar connective tissue, strengthening the 
connection between the two layers of skin, and the reticular region, which is much thicker 
and is composed of irregular connective tissue (collagenous, elastic, and reticular fibers, 
ensuring strength, extensibility, and elasticity to the dermis), hair roots, sebaceous glands, 
sweat glands, receptors, and blood vessels (figure 2). 
 
Figure 2: The structure of human skin. (From MacNeil S. Progress and  
opportunities for tissue-engineered skin. Nature 2007; 445, 874-880) 
 
 
 
The skin is attached to the underlying bone and muscle, as well as supplied with blood 
vessels and nerves via the hypodermis. It consists of loose connective tissue and elastin. 
The most important functions of skin include flexible physical support and covering for 
underlying tissues, maintenance of a constant temperature through its extensive blood 
supply and sweat glands, removal of waste materials as salts and water via the skin’s 
sweat glands, photochemical production of vitamin D, sensing pressure, texture, 
temperature, and pain through the extensive network of sensory receptors, protection 
against the excesses of ultraviolet light through melanin pigments, prevention of 
desiccation of the inner organs as well as prevention of absorption of unwanted and 
potentially dangerous chemicals via the epidermis, and finally protection against the entry 
of  opportunistic pathogenic organisms (Proksch 2008, Madison 2003, Stücker 2002). 
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1.2 The Hair 
The hair follicle, as an appendage to the skin, is of great importance to many of the skins 
properties. Its main function is the protection against heat loss by trapping air adjacent to 
the skin, providing an invisible, insulating layer. Hair fibers help to protect the epidermis 
from minor abrasions and from ultraviolet light. Specialized hair such as eyebrows and 
eyelashes protect the eyes by channeling or sweeping away fluids, dust, and debris 
whereas nasal hair keeps air borne foreign particles from entering the lungs. Hair can also 
provide indications of sexual development through the onset of beard and pubic hair 
development and it may also play a role in attracting mates as an indicator of the general 
health and vitality of an individual based on color, distribution, and quality of the hair 
(Bubenik 2003, Sabah 1974,Robins 2002, Stenn 2001). 
An adult human being has about 5 million hair follicles spread across the body with about 1 
million on the head of which 100.000 cover the scalp. Only the palms of the hands and 
soles of the feet are skin regions devoid of hair follicles. The hair follicle can be recognized 
as a separate entity within the skin with formation and maintenance based on interaction 
between dermal and epidermal components. Keratin proteins are the primary components 
of hair fibers. 
The mature anagen hair follicle can be vertically divided into the upper follicle (infundibulum 
and isthmus), middle follicle (bulge), and lower follicle (suprabulbar and bulbar areas). Only 
the lower follicles regenerate with every new hair follicle cycle whereas the other 
compartments are permanent. 
The infundibulum describes the region between the epidermis and the opening of the 
sebaceous gland duct. Since its epithelium is continuous with the epidermis its cells can 
regenerate the epidermis and replenish it after wounding or injury. The inner cavity usually 
contains the hair shaft, keratin material, and natural oil produced by sebaceous glands 
(figure 3 D). 
The isthmus reaches from the opening of the sebaceous gland duct to the insertion of the 
arrector pili muscle. Across from the insertion site of the arrector pili muscle is located the 
bulge region. It is believed that hair follicle stem cells are located within this area. It is often 
difficult to identify in adult anagen hair follicles, but becomes prominent in the resting 
phase.  
Beneath the isthmus starts the suprabulbar area and stretches down to the bulb. This 
region consists of (outermost to innermost) the dermal sheath, outer root sheath, inner 
root sheath, and hair shaft, which give a description of the horizontal compartments of hair. 
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This is where the inner root sheath layers Henle’s layer, Huxley’s layer and the cuticle 
completely keratinize and become impossible to differentiate from one another. 
The dermal sheath envelops the epithelial components of the hair follicle and consists of 
the connective tissue sheath and the hyaline or vitreous membrane. This membrane is 
continuous with the interfollicular basement membrane and is most prominent around the 
outer root sheath at the bulb in anagen follicles. During catagen, it thickens in the lower 
portion of the follicle and then disintegrates. 
The outer root sheath is continuous with the epidermis and forms a non-keratinizing region 
at the periphery of the follicle (figure 3 A, B, C). It reaches down to the tip of the bulb, 
around which it consists of greatly flattened cells in two layers. It contains vacuoles, golgi 
complexes, smooth and rough endoplasmic reticulum, mitochondria and other cell 
organelles as well as lots of glycogen in the lower part of the follicle. Since glycogen is an 
energy source for protein synthesis during hair growth, the presence of glycogen in the 
outer root sheath suggests an energy-consuming activity in these cells. 
The inner root sheath stretches down from the isthmus to the base of the bulb. The lower 
part shows large eosinophilic cytoplasmic inclusions called trichohyaline granules. 
Trichohyaline as well as keratin fibers are produced in the cells of the inner root sheath. 
Three cell lineages can be distinguished within this sheath, depending on structure, 
patterns of keratinization, and incorporation of trichohyaline. Outermost is located the 
Henle’s layer (figure 3 A, B, C) that is only one cell layer thick. This layer is the first to 
develop trichohyaline granules and the first to cornify. It is followed by the Huxley’s layer 
(figure 3 A, B, C) which is two to four cell layers thick and cornifies above Henle’s layer at 
the region known as Adamson’s fringe. The innermost cuticle (figure 3 B) is again one cell 
layer thick and develops only a few trichohyaline granules. It keratinizes below the 
Adamson’s fringe. The cells overlap one another with their free edges oriented towards the 
deep portion of the follicle. They are in opposition to the cells of cuticle of the hair shaft that 
are oriented upwards, thereby anchoring the hair shaft in place. The fully cornified inner 
root sheath therefore anchors and directs the growth of the emerging hair shaft. The inner 
root sheath breaks down at the level of the sebaceous gland to leave only the hair cortex 
and surrounding cuticle to protrude above the epidermis. 
Above the scalp can be seen the hair shaft (figure 3 B), which reaches down to the bulb 
and consists mainly of dead cells. It is composed of the cuticle, the cortex, and the medulla 
(outermost to innermost). The cuticle consists of a single cell layer and lacks trichohyaline 
granules (in contrast to cells of the inner root sheath) as well as melanin (in contrast to 
cells destined to become the cortex). The main portion of the hair shaft is made up of the 
cortex which gives hair its elasticity and curl. It is packed with keratin strands, lying along 
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the length of the hair and also contains granules of melanin. The medulla is the central 
hollow core that can be seen in most of the terminal hairs. 
The lowest part of the hair follicle is the bulb (figure 3 A). It surrounds the dermal papilla 
and contains the matrix cells, which is a group of living, actively proliferating cells that 
differentiate and become keratinized to form the hair cortex and surrounding hair cuticle of 
the hair shaft at the center of which is situated the medulla (in terminal hairs). The rate of 
matrix cell proliferation is one of the highest in the body. As the cells grow and develop, they 
steadily push the previously formed ones upwards. When they reach the upper part of the 
bulb they begin to rearrange themselves into six cylindrical layers, one inside the other. The 
inner 3 cell layers turn out as the actual hair whereas the outer 3 cell layers become the 
inner root sheath. 
The dermal papilla (figure 3 A) is a pear shaped region of the hair follicle that directs and 
dictates the embryonic generation of hair follicles. It consists of fibroblasts, collagen 
bundles, stroma, nerve fibers, and a single capillary loop and is continuous with the dermal 
sheath. 
(Christiano 2010, Reynolds 1996, Jahoda 1994, Sperling 1991, Price 1985, Malkinson 
1978, Braun-Falco 1966). 
 
Figure 3: Follicular histomorphology: human skin. (From Stenn KS and Paus R. Controls of Hair Follicle 
Cycling. Am Physiol 2001; 81(1):449-494) 
 
The defined lineages are the outer root sheath 
(ORS), the companion layer (CL), the internal 
root sheath Henle's layer (He), internal root 
sheath Huxley's layer (Hu), the cuticle of the 
internal root sheath (Csth), the cuticle of the hair 
shaft (Csft), the cortex of the shaft (CTX), and 
the medulla of the shaft (Med). A: vertical 
section of proximal anagen follicle. B: vertical 
section of proximal anagen follicle. C: cross 
section of proximal anagen follicle. D: telogen 
shaft with anagen follicle below. Note the 
secondary hair germ epithelium at the base of 
the telogen follicle (arrow). CTS, connective 
tissue sheath; SG, sebaceous gland; Club, 
telogen shaft base; Anag, proximal anagen 
follicle; FP, follicular papilla; GE, germinative 
epithelium. 
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1.3 The Hair Growth Cycle 
Healthy hair growth in each hair follicle consists of three phases and occurs in a cycle 
(figure 4) (Van Scott 1968). Hair fiber is actively produced in the anagen phase. Hair follicle 
cells are dividing rapidly, adding to the hair shaft leading to a hair growth of about 1 cm 
every 28 days. It is genetically determined how long the hair follicle stays in the anagen 
phase. Scalp hair stays in this active phase of growth for two to six years. This is followed by 
the catagen phase which lasts for about two to three weeks while a club hair is formed (the 
outer root sheath shrinks and becomes attached to the hair shaft and cuts off the hair 
from its blood supply and from the cells that produce new hair fibers). This period signals 
the end of the active growth of a hair. The final telogen phase consists of a so-called resting 
state. About 10% to 15% of all hairs at any given time are in this phase. It lasts for about 3 
months for scalp hairs and much longer for eyebrows, eyelashes, arm or leg hairs. 
 
Figure 4 Hair Growth Cycle. (From Bergfeld WF & Mulinari-Brenner F.  
Shedding: a common cause of hair loss. Cleve Clin J Med 2001; 68(3):256-261) 
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2 Alopecia Areata 
 
2.1 History 
Two forms of alopecia characteristics were first described by Cornelius Celsus in 30 A.D 
(Robinson 1883). One form he described as a complete baldness occurring in people of all 
ages and the other form he called “ophiasis” due to a snake-like winding way the bald region 
spreads across the skin, which he suggested occurs only in children. In Sauvages 
publication “Nosologica Medica” in 176: (Lyons, France) the actual term “alopecia areata” 
was used for the first time. 
The cause of alopecia areata was considerably debated with the beginning of the 18::’s. 
One hypothesis suggested a parasitic infection (Gruby 1843, Radcliffe-Crocker 1903) 
because of the infection-like expansion of lesions and because of the apparent epidemics 
that were reported to occur in orphanages, schools, and other institutions where lots of 
people live together in close spaces (Bowen 1899, Colcott Fox 1913, Davis 1914). 
However, an infective organism could never be isolated from alopecia areata patients and 
transfers by inoculation have failed (Sabouraud 1896, Ormsby 1948, Ikeda 1967).  
Another hypothesis based on a nervous disorder (Von Barensrung 1858). This was 
supported by the frequency of observed emotional or physical stress and trauma in the 
onset stage of alopecia areata (Sequeira 1913, Kingsbury 1909). It was believed that 
emotional stress and physical damage adversely affect hair follicles via the nervous system. 
Joseph (1886) tried to proof this by cutting nerves in the necks of cats and thereby 
induced patchy hair loss but later it was suggested that the cats scratched themselves and 
therefore lost hair.  
The neuropathic hypothesis was put forward by Jacquet (1902). He suggested a nerve 
irritation that may occur through defective and diseased teeth as a source of initiation of 
alopecia areata. This was confirmed by Decelle (1909), although Bailly (1910) showed that 
dental disease occurred equally frequent in people without alopecia areata. Kinnear (1939) 
suggested eye strain as a cause of alopecia areata.  
A hormone dysfunction due to disorders of the endocrine gland was believed to be the 
cause with the start of the twentieth century (Sabouraud 1913) and another hypothesis 
developed at that time based on toxic agents (Adamson 1912) which was supported by the 
sudden remission and relapse of alopecia areata and its simultaneous action over the body. 
In addition, hair loss with the expression of exclamation point mark hairs – a diagnostic 
feature of alopecia areata (Roxburgh 1950) - could be induced by the injection of thallium 
acetate, which is a rat poison (Adamson 1912, Dixon 1927, Ormsby 1948). 
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Even though it was already shown in 1891 by Giovannini that alopecia areata affected hair 
follicles were invaded by inflammatory cells, the now widely believed hypothesis of an 
inflammatory autoimmune disease did not become popular until the 1950s. The first to 
discuss this view was Rothman, referring to a paper by Van Scott (1958). This hypothesis 
suggests that the patient’s immune system attacks tissue from its own organism and is 
supported by histological findings of “swarm of bees”-like perifollicular and intrafollicular 
inflammatory infiltrate around the hair follicle bulbs (see figure 5 as an example in rat skin). 
 
Figure 5: Histological ‘swarm of bees’ like perifollicular inflammatory infiltrate around the hair follicle 
bulbs (black arrows) in rat skin. A Horizontal cut B Vertical cut. 
  
 
However, attacks of the immune system usually result in the complete destruction of the 
targeted tissue. In the case of alopecia areata the hair follicles are just disrupted and 
prohibited from producing hair. Therefore it has been suggested that the immune system 
is directed not against the hair follicle tissue itself but against a controlling hair growth 
promoter mechanism (Price 1991). By immune cells and hair follicles produced cytokines 
are also discussed to adversely affect the hair follicle (Goldsmith 1991). Another theory is 
based on an existing antigen that is exposed just shortly at the initiation of alopecia areata 
that eventually leads to an imbalance in the immune system. 
 
Still, alopecia areata is nowadays defined as a non-scarring, inflammatory, hair loss disease 
that may affect men and women of all ages. Activating factors of the disease as well as the 
mechanisms of its development are still not fully understood. Though the disease is not life 
threatening, the psychological devastation of hair loss in an image orientated society is 
enormous. 
 
 
A B 
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2.2 The Hair Growth Cycle in Alopecia 
The hair growth cycle of alopecia areata patients lacks the catagen phase completely or 
enters it just shortly and rapidly proceeds to the telogen phase. Follicles that produce poor 
aberrant hair fibers due to the continued activity of the disease are described as being in a 
dystrophic anagen state (figure 5 B shows an example in rat skin). From some researchers 
it is believed that the hair follicles continue indefinitely to oscillate between rapid cycles of 
dystrophic anagen and telogen phases (Van Scott 1958, Messenger 1986). Others 
instead believe that many of the follicles are eventually arrested in telogen phase (Swanson 
1981), which is the most popular current hypothesis. This would mean the hair follicles 
would not express as many antigens and so antigenic stimulation of the immune cells would 
be reduced or removed. The immune cells would then disperse until the hair follicle 
reverted back to its active anagen state when the immune cells would return (McDonagh 
1994, Messenger 1986). By running through this repeated cycle of events, or by 
remaining in telogen, the hair follicle could avoid the worst of the tissue destruction. More 
than one of the above mentioned mechanisms may be involved. 
 
2.3 Clinical Features and Diagnosis 
Alopecia areata is usually seen with a single or several patches of hair loss about one to 
two centimeters in diameter on the scalp. Other parts of the body may be affected as well. 
The patches may expand in size, even leading to a complete loss of scalp hair (alopecia 
totalis) or a complete loss of all scalp and body hair (alopecia universalis). Usually, extensive 
hair loss develops gradually over time. But some individuals experience simultaneous hair 
loss all over the scalp and/or body leading to alopecia totalis or universalis in just a few 
weeks.  
 
Shed hair fibers can sometimes be used to diagnose alopecia areata. With scanning 
electron microscopy hair fibers are seen at the edge of an expanding bald patch as intact 
at the oldest part of the hair (furthest away from the scalp) whereas if you look at the 
newer part of the hair (close to the scalp) it can look aberrant. An increase of irregularity 
can be observed in the shape of the hair fiber. Deposits of unordered keratins are involved 
as well as constrictions. The cuticle might be missing and longitudinal cracks along the 
length of the hair might be observed. The constituent keratins are the same but seem to be 
abnormally assembled. This irregular construction of the hair leads to fracturing of the hair 
leaving back a stumpy, one to two millimeter long hair fiber also known as exclamation 
mark hair, often seen in expanding patches of alopecia areata. This abnormal hair 
formation may occur in other conditions as well and is therefore by itself not enough for a 
10 
 
save diagnosis of alopecia areata. Less severely damaged hairs may continue in anagen 
phase but produce dystrophic hairs as described earlier. Unpigmented or white hairs are 
less affected than pigmented hairs. In addition, some patients may experience sporadic or 
permanent changes in hair color during, or after, an episode of hair loss. There might also 
be times of spontaneous hair re-growth involved as well as aberrant nail formation (Muller 
1963, Baran 1984). Nail dystrophy varies from a diffuse, fine pitting to severe alteration in 
a few cases (Gollinck 1990). Brittle nails, longitudinal ridging, spotting of the lunulae (half-
moon resemblance at the base of the fingernail), onycholysis (loosening or separation of a 
fingernail or toenail from its nail bed), onychomadesis (complete shedding of a fingernail or 
toenail), and koilonychias (concavity of the outer surface of the nail) have been reported. 
These nail abnormalities can precede, follow or occur simultaneously with hair loss. 
There is no conclusive diagnostic test available so far leaving the dermatologist to deduce 
alopecia areata by an elimination process of other hair loss causes. Sometimes hair pull 
tests are conducted at the margins of the bald patches or small biopsies of the skin taken 
to check for focal inflammation of the hair follicles under a microscope. 
 
2.4 Pathology 
The pathogenesis of alopecia areata is still unknown, but evidence points to a substantial 
role of genetic factors, nonspecific immune- and organ-specific autoimmune reactions, as 
well as environmental triggers (Madani 2000, Norris 2004, McElwee 1999, Kalish 2003). 
The genetic component of the disease is supported by the accumulated occurrence in 
families (Duvic 2001). Between 10% and 42% of alopecia areata patients report a family 
history, with higher incidences in patients with an early onset of hair loss and in identical 
twins (Shellow 1992, Scerri 1992). Especially the HLA-region was found to be involved in 
several genetic studies (Pethukova 2010, Madani 2000, Colombe 1995, de Andrade 
1999), which supports the theory of loss of immune-privilege in hair follicles (Paus 1997, 
Paus 2003). Hair follicles usually do not express MHC class I and II molecules (Paus 1997, 
Christoph 2000, Westgate 1991, Paus 1994). There are only few Langerhans cells 
located around and within hair follicles, and they have functional impairment because they 
do not express MHC class II molecules, which normally play a role in antigen presentation. 
Furthermore, immunosuppressive cytokines are expressed prominently by the follicular 
epithelium (Teraki 1996). These cytokines are believed to maintain the immune privilege of 
the hair follicles and to induce peripheral tolerance (Gilhar 2007, Gilhar 2010). 
In the acute progressive state of alopecia areata granulomatous inflammation and 
lymphocytic infiltrates have been observed within the hair follicle and around late anagen 
hairs (Messenger 1986) (figure 6). The inflammatory cell infiltrate mostly consists of 
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activated T lymphocytes, with the presence of CD4, CD8, and Langerhans’ cells (Todes-
Taylor 1984, Perret 1984, Ranki 1984, Gollinck 1990). It can also be observed above the 
hair follicle bulb and may also invade follicular streamers. It is generally not observed in the 
bulge area and the region where the arrector pili muscle inserts into the hair follicle. Also 
the region where hair follicle stem cells are situated is usually not affected and might 
explain why follicles are not destroyed in alopecia areata. Via stem cell proliferation the 
damage to the hair follicles can be repaired if the stem cells are still intact. In long term 
chronic alopecia areata a slow decrease of inflammation activity and fewer lymphocytes, 
macrophages, and Langerhan’s cells can be observed, but is still more than is usual in 
healthy skin. 
 
Figure 6: Pathogenic model of alopecia areata. (From Gilhar A Collapse of Immune 
Privilege in Alopecia Areata: Coincidental or Substantial? J Invest Dermatol 2010; 130:2535-37) 
 
The normal hair follicle represents a site of immune privilege (IP). The guardians of IP include immune-
suppressive cytokines such as α-melanocyte stimulating hormone (α-MSH), transforming growth factor-β (TGF-
β), IK, indoleamine 2,3-dioxygenase (IDO), and IL-10. Patients with a specific genetic background are 
susceptible to developing alopecia areata (AA), most probably by downregulation of this immunosuppressive 
environment. It has been suggested that events such as stress, infection, or microtrauma might lead to 
downregulation of immunosuppressive cytokines. This downregulation enables the accumulation of natural 
killer (NK) cells around hair follicles. Furthermore, stress or other trauma may also alter the production of 
neuropeptides, including substance P (SP) and calcitonin gene–related peptide (CGRP). SP may upregulate 
the production of nerve growth factor, which in turn induces accumulation of mast cells around hair follicles. 
SP causes degranulation of mast cells, leading to a release of large amounts of TNF-α, which is known to 
inhibit hair growth. Furthermore, SP induces accumulation of CD8+ cells and induces these cells to produce 
large amounts of IFN-γ. IFN-γ, produced by the activated CD8+ cells and the NK cells, induces expression of 
major histocompatibility complex (MHC) class I molecules in the lower part of the follicular epithelium, 
resulting in presentation of follicular autoantigens to the CD8+ cells and loss of IP. IFN-γ also may induce MHC 
class II molecule expression by the follicular epithelium, leading to a second wave of CD4+ cells that may 
bolster CD8+ activity via released cytokines. Treg, regulatory T cell. 
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Some studies have also shown the presence of mast cells in addition to the lymphocytic 
infiltrate (Cetin 2009), whereas others have shown evidence of eosinophils in all stages of 
alopecia areata within the fibrous tracts and the peribulbar infiltrate (Müller 2011, Elston 
1997). At the apex of the dermal papilla pigment incontinence may be seen, and some of 
the pigment may be retained in follicular streamers (Lew 2009). 
Necrosis, apoptosis, and dark cell transformation have been reported as well as a 
circumscribed cystic change in the supra-bulbar region above the dermal papilla as 
patterns of hair follicle cellular degeneration in acute alopecia areata (Philpott 1996, 
Hoffmann 1999, Bodemer 2000). 
Most of the observed nail changes have been shown to be related to changes within the 
proximal matrix via light and electron microscopy. 
 
2.5 Treatment 
Even after many years of hair loss potentially everyone is capable of re-growing hair, due to 
the before mentioned fact that hair follicle stem cells are not affected. Since the underlying 
cause of the disease is still not known only symptoms can be treated but no cure is 
available. There is no strong evidence that the long term course of alopecia areata can be 
altered by drug induced remissions or therapies. Therefore treatment may promote hair 
re-growth but treatment has to be permanent to have a longtime hair growth promoting 
effect. 
The most popular drugs to treat patchy hair loss are corticosteroids as they are known to 
strongly inhibit the activation of T lymphocytes. Another treatment option is PUVA, a 
phototherapy that involves taking psoralen (P) two hours before exposure to long-wave 
ultraviolet light (UVA). 40 to 80 treatments may initiate hair re-growth, whereas a 
complete re-growth may take up to two years. Contact sensitizers like squaric acid 
dibutylester (SADBE) or diphenylcyclopropenone (DCP) might also be used as treatment in 
Europe or Canada, but are not FDA approved in the USA. Weekly treatments are 
necessary for complete hair re-growth and there might be side effects experienced like a 
mild eczematous reaction and enlargement of retroauricular lymph nodes. 
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3 Dundee Experimental Bald Rats (DEBR) 
 
3.1 History 
In the 1970s Druckrey crossed BD I rats with rats of the BD VIII strain and generated the 
BD IX strain by subsequently selecting brother-sister pairs for agouti coat color and dark, 
pigmented eyes (Druckrey 1971). Some of these rats were transferred around 1977 to 
the Medical Research Council Laboratory of Animal Health (LAH) center in Carshalton, 
Surry, England. There, a spontaneous mutation occurred leading to the alopecia areata 
phenotype. Because of exceptionally poor fecundity two BD IX rats were crossed with two 
wistar rats. The DEBR descendants of this cross were derived from full-sibling matings and 
were transferred in 1984 to the University of Dundee, Scotland (Michie 1991, Oliver 
1991). After that the strain moved to the University of Marburg in Germany and was 
supervised by Dr. Kevin J. McElwee (2004) before it was finally moved to the University of 
Cologne, CCG (dermatogenetics group), Germany in 2006. Since then the strain is 
supervised by Dr. Hans Christian Hennies. The original colonies have all passed away, so 
that the brown hooded substrain in Cologne is the only available colony in the world. 
 
3.2 Characterization 
There are no documentations about the current inbred generation of the DEBR colony. 
McElwee reported in 2003 an inbred generation of F38 in the ancestors of the current 
colony. Considering a further full sib pair mating of three times per year the inbred 
generation should be somewhere around F62 by the end of 2010. This high inbreeding 
status ensures a high homogeneity but fecundity in these animals is again very critical. The 
animals can only be successfully mated within the ages 3 to 5 months. The main problem 
seems to be the small size of and the low milk production in the mother animals so that the 
offspring animals soon start to dehydrate and are eventually killed and eaten by the mother 
animals. This problem could be partially solved by additional feeding of the mother animals 
and their offspring with a mix of curd cheese, smashed banana and honey. Since the animal 
husbandry capacity is not given for another crossing with Wistar or PVG rats, 318 DEBR 
embryos were cryoconserved at Harlan Laboratories Ltd, Füllinsdorf, Switzerland, to 
ensure the safety of the colony for future use. 
 
DEBR rats develop a full coat of hair within two weeks of birth. Starting with the age of 3 to 
4 months the rats start to lose their whiskers and beginning patchy hair loss can be 
observed on the head (figure 7 A) and on the tail, extending rapidly over the shoulders 
around the age of 5 to 6 months (figure 7 B). At the age of 6 to 8 months hair loss also 
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affects the flanks (figure 7 C) and extends within a few weeks over the whole body (figure 7 
D), including the throat and stomach. With the age of 1 year most animals are naked 
except for a few patches of hair left around the tailhead, at the feet and above the 
backbone in some animals. There are no non-affected animals in the colony and since 
2008 only one histologically affected animal (full pelage coat but infiltrate around anagen 
hair follicles) was observed. Females and males are affected alike, but hair loss starts in 
general in males about 1 to 2 months later as in females. In some females a change of 
brown coat color to grey could be observed after giving birth (figure 8). 
 
 
Figure 7: Progression of alopecia areata in DEBR rats. A) Beginning of hair loss behind ears, around eyes 
and nose as well as loss of whiskers. B) Hair loss patches get bigger and extend over the shoulders. C) 
Additional hair loss at the flanks. D) Severe hair loss on the whole body. 
 
Figure 8: Young female DEBR rat with a scant 
hair coat and a change in coat color. 
 
 
  
A B C D 
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B Objectives of this Doctoral Thesis 
 
As an animal model of Alopecia areata the rat strain Dundee Experimental Bald Rat (DEBR) 
was used. Prior to this study an intercross of DEBR with PVG rats gave an F2 population of 
320 female animals with which a whole genome scan for linkage with 176 microsatellite 
markers was performed at the CCG (dermatogenetics group), Cologne. This analysis 
resulted in one highly significant locus on chromosome 19 with a lod score of 20 amongst 
others with much lower lod scores.  
 
Based on these results the aim of this study will be to characterize the genetic basis of 
Alopecia areata in the rat model. This will be accomplished as follows: 
 
a) Saturation mapping will be performed with further microsatellite markers on 
chromosome 19 to identify a candidate region by haplotype analysis. 
 
b) Candidate genes will then be screened for mutations by sequencing and, if 
necessary, by next generation sequencing to identify the genetic basis of alopecia in 
the rodent model. 
 
c) In another approach a whole-transcript expression analysis will be performed with 
the Affymetrix Rat Gene 1.0ST Array and data will be processed with the softwares 
provided by Ingenuity Pathways Analysis to identify more candidate genes and 
possible pathways involved in the pathogenesis of alopecia areata (AA). 
 
d) Expression of candidate genes will then be validated and refined with quantitative 
real time PCR using the LC480 system and 
 
e) proteins of candidate genes will be immunohistologically stained in skin punch 
biopsies and, if necessary, in other organs to give further insights into the 
pathogenesis of AA in the rodent model. 
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In addition to the rodent model of AA human DNA from single patients and also from 
families with at least one AA affected person are available for this work. Prior to this study 
a whole genome scan for association and linkage with the Affymetrix Mapping 500K Array 
was performed at the CCG (dermatogenetics group) that resulted in one highly significant 
linked locus on chromosome 19.  
 
Based on these results the aim of this study will be to characterize the genetic basis of 
Alopecia areata in humans. This will be accomplished as follows: 
 
a) Fine mapping of the candidate region on chromosome 19 with SNPstream, 
Taqman, and Pyrosequencing analysis will be conducted and 
 
b) association as well as linkage analysis will be performed with the obtained data to 
define candidate genes which will then be screened for mutations with high 
resolution melting curve analysis combined with sequencing. 
 
c) In addition more samples will be collected for whole genome genotyping with 
Affymetrix Genome-Wide Human SNP Array 6.0. The data obtained with these 
samples together with the data that was obtained earlier will be analyzed again for 
association and linkage. 
 
d) Immunohistological stainings will also be done in human skin punch biopsies to 
validate the findings in the rodent model and to proof the importance of the DEB rat 
strain as an adequate model for the human disease.  
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C Materials and Methods 
 
1 Materials 
 
1.1 Rat Samples 
119 rats of the strain Dundee Experimental Bald Rat (DEBR) were used as well as 2 
Sprague Dawley (SD), 6 Wistar (Wi) and 3 PVG rats. The DEB rats were cared for under 
the supervision of Dr. Kevin McElwee, University of Marburg before they were brought to 
the CCG (dermatogenetics group), Cologne, in 2006. 
Of all animals skin and liver samples were collected. In addition to skin and liver, stomach, 
kidney, pancreas, small intestine, bladder, sexual organs, diaphragm, muscle, lung and 
heart were taken from all control rats and most of the DEBs.  
Samples for DNA and protein isolation were frozen immediately at -80°C, samples for RNA 
isolation were kept in RNA-Later overnight at 4°C and then stored for later use at -80°C, 
samples for fibroblast and keratinocyte isolation were stored in transportation medium and 
skin samples for histological analyzes were stored in 10% neutral buffered formaldehyde. 
 
In addition the DNA of 320 female F2 DEBs was analyzed for genetic variations. These 
animals were obtained prior to this work by cross-breeding DEBs with PVG/OlaHsd rats. 
129 F2 animals showed overt hair loss whereas 63 animals only showed a histological 
phenotype (full pelage coat but infiltrate around anagen hair follicles). 128 of the F2 
animals were not affected by alopecia areata. 
 
1.2 Human Samples 
Blood samples from alopecia areata patients and if possible from their family members 
were collected by Dr. med Hella Blech (CCG and private practice of dermatology, Rödental) 
under the supervision of Dr. Hans Christian Hennies, CCG (dermatogenetics group), 
Cologne. All participating persons gave their written consent to take part in this study and a 
standardized questionnaire that was developed by Dr. Rolf Hoffmann (Dermaticum, 
Practice for Dermatology, Freiburg) was filled out, giving background information about 
ancestry, further known diseases, and especially about the severity of hair loss in AA 
patients. In this study, the phenotype of AA patients is therefore categorized in five defined 
stages of severity by extent of hair loss and by localization of hair loss on the scalp and/or 
on other body parts, In total 1071 samples, including 199 parents with one affected child, 
80 affected sib-pair families and 110 single patients were analyzed. In addition to the blood 
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samples skin punch biopsies from one patient with alopecia areata and one patient with 
alopecia universalis were collected. 
 
352 control DNAs with european background provided by the University of Essen were 
used for SNPstream analysis and 2534 control DNAs from the biobank KORA, which is 
organized by the Helmholz Center in Munich, Germany, (project number: K26/11) and 
POPGEN, which is organized by the UKSH in Kiel, Germany, (project number: 
BSP+SPC/110217/83) were used for whole genome linkage and association analysis.  
 
1.3 Kits 
QIAamp DNA Blood Maxi Kit Qiagen GmbH 
Dneasy Blood & Tissue Kit Qiagen GmbH 
EXPRESS One-Step SYBR GreenER Universal Invitrogen GmbH 
KGM Gold Bullet Kit Lonza Sales AG 
LC480 HRM Master Roche Diagnostics GmbH 
RNase-FRee DNas Set (50) Qiagen GmbH 
Rneasy Midi Kit Qiagen GmbH 
Zonula Adherens Sampler Kit BD Transduction Laboratories 
 
1.4 Chemicals 
Aceton Carl Roth GmbH+Co.KG 
Albumin Sigma-Aldrich Chemie GmbH 
Alexa Fluor 488 Goat anti-mouse IgG Invitrogen GmbH 
Aseptisol Bode Chemie GmbH 
Baccilol VWR International GmbH 
Betaisodonna Mundipharma GmbH 
DAPI VWR International GmbH 
Dimethylsulfoxid (DMSO) Merck KGaA 
Dispase II Roche Diagnostics GmbH 
DMEM Invitrogen GmbH 
Dnase I (Rnase-free) Invitrogen GmbH 
Eosin G Carl Roth GmbH+Co.KG 
Essigsäure Merck KGaA 
Ethanol (unvergällt) Merck KGaA 
Ethanol (vergällt) Merck KGaA 
Ethylendiaminteraessigsäure (EDTA) Carl Roth GmbH+Co.KG 
Formalin Sigma-Aldrich Chemie GmbH 
Formamid Merck KGaA 
Fungizone Invitrogen GmbH 
Gentamicin (50mg/ml) Invitrogen GmbH 
Hämalaunlösung nach Mayer Carl Roth GmbH+Co.KG 
Isopropanol Carl Roth GmbH+Co.KG 
Methanol   Carl Roth GmbH+Co.KG 
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Methanol (ultareinst.)  Carl Roth GmbH+Co.KG 
Natriumchlorid Carl Roth GmbH+Co.KG 
PBS 1x Invitrogen GmbH 
Phenol Carl Roth GmbH+Co.KG 
Polyvinylalkohol-Einschlussmittel Sigma-Aldrich Chemie GmbH 
ProFreeze-CDM Lonza Sales AG 
Proteinase K Qiagen GmbH 
Qiazol Lysis Reagent Qiagen GmbH 
RNA Later Qiagen GmbH 
Rnase A Qiagen GmbH 
Roti-Histofix Carl Roth GmbH+Co.KG 
SDS Carl Roth GmbH+Co.KG 
Sodium Pyruvate MEM Invitrogen GmbH 
Trichlomethan/Chloroform Carl Roth GmbH+Co.KG 
Tris(hydroxymethyl-)aminomethan (TRIS) Carl Roth GmbH+Co.KG 
Triton X100 Carl Roth GmbH+Co.KG 
Trypsin, 0,05% mit 0,53 mM EDTA Invitrogen GmbH 
Tween20 Carl Roth GmbH+Co.KG 
Ultra Pure Distilled Water Invitrogen GmbH 
Water, distilled Invitrogen GmbH 
Xylol, Isomere Merck KGaA 
β-Mercapto-Ethanol Merck KGaA 
 
1.5 Machines and Robots 
2100 Bioanalyzer Agilent Technologies GmbH 
3730 DNA Analyzer Applied Biosystems GmbH 
7900HT Applied Biosystems GmbH 
AlphaImager Alpha Innotec GmbH 
Axiovert40CFL Zeiss 
B12 function line Thermo Fisher Scientific, Inc. 
BBD6220 Thermo Fisher Scientific, Inc. 
Biomek FXP Beckman Coulter GmbH 
Biotage PSQ HS96A Biotage GmbH 
Biowizard Xtra Golden Line Kojair Tech Oj 
BVC21NT vaccubrand GmbH + Co.KG 
Centrifuge 5810R Eppendorf AG 
CTR6500 Leica Microsystems GmbH 
DM6000B Leica Microsystems GmbH 
Galaxy MiniStar VWR International GmbH 
GeneAmp 9700 Applied Biosystems GmbH 
Genome Analyzer Iix Illumina, Inc. 
GenomeLab SNPstream Beckman Coulter GmbH 
Heraeus BIOFUGE fresco Thermo Fisher Scientific, Inc. 
HI 1210 Leica Microsystems GmbH 
Horizon 11-14 Life Technologies GmbH 
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Leica ASP200S Leica Microsystems GmbH 
Leica EG 1150H Leica Microsystems GmbH 
LEICA RM2255 Leica Microsystems GmbH 
LightCycler480 Roche Diagnostics GmbH 
Megafuge 1.0R Thermo Fisher Scientific, Inc. 
Microlab STAR Hamilton Messtechnik GmbH 
MiniSpin plus Eppendorf AG 
Mixer UZUSIO VTX-3000L LMS Consult GmbH + Co.KG 
MR3001K Heidolph Instruments GmbH + Co.KG 
Multifuge X1R Thermo Fisher Scientific, Inc. 
NanoDrop 8000 peqlab Biotechnologie GmbH 
NanoDrop ND-1000 peqlab Biotechnologie GmbH 
PSQ HS 96A Biotage GmbH 
Stuart SRT1 VWR International GmbH 
Stuart SRT9 VWR International GmbH 
TE124S Sartorius AG 
TE1502S Sartorius AG 
Tetrad2 Bio-Rad Laboratories, Inc.  
Thermomixer comfort Eppendorf AG 
TiMix Edmund Bühler GmbH 
TLP2824 Zebra Technologies Corporation 
VX-75 Systec 
Z2 Beckman Coulter GmbH 
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2 Methods on DNA-Level 
 
2.1 DNA-Isolation and Photometric Quantification 
 
a) DNA-Isolation from Rat Liver 
For the isolation of DNA from rat liver Qiagen DNeasy Blood & Tissue Kit was used. 
 
Qiagen DNeasy Blood & Tissue Kit Protocol: 
All centrifugation steps are carried out at room temperature in a microcentrifuge. 
Vortexing should be performed by pulse-vortexing for 5 – 10 seconds. Make sure that 
buffers ATL and AL didn’t form precipitates upon storage. If necessary, warm to 56°C until 
the precipitates have fully dissolved. Before using buffers AW1 and AW2 for the first time, 
ethanol (96-100%) has to be added as indicated on the bottle to obtain a working solution. 
Preheat a thermomixer to 56°C and equilibrate the sample to room temperature. 
 
 Cut up to 25 mg liver into small pieces, and place in 1.5 ml microcentrifuge tube. 
 Add 20 µl proteinase K, mix by vortexing, and incubate at 56°C in a thermomixer until 
completely lysed. 
 Add 4 µl RNase A (100mg/ml), mix by vortexing, and incubate for 2 min at room 
temperature. 
 Vortex for 15 seconds, add 200 µl buffer AL to the sample, and mix thoroughly by 
vortexing. Then add 200 µl ethanol (96-100%) and mix again thoroughly. 
 Pipet the mixture into a DNeasy Mini spin column in a 2 ml collection tube. Centrifuge at 
8.000 rpm for 1 min. Discard flow-through and collection tube. 
 Place the spin column in a new 2 ml collection tube, add 500 µl buffer AW1, and 
centrifuge for 1 min at 8.000 rpm. Discard flow-through and collection tube. 
 Place the spin column in a new 2 ml collection tube and add 500 µl buffer AW2. 
Centrifuge for 3 min at 14.000 rpm to dry the DNeasy membrane. Discard flow-through 
and collection tube. 
 Transfer the spin column to a new 1.5 ml or 2 ml microcentrifuge tube and add 200 µl 
buffer AE for elution. Incubate for 1 min at room temperature. Centrifuge for 1 min at 
8.000 rpm. Repeat this step for maximum DNA yield (ranges between 10 - 30 µg) or 
reload flow-through a second time for maximum DNA concentration. 
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b) DNA-Isolation from Human Blood 
For the isolation of DNA from human blood Qiagens QIAamp DNA Blood Maxi Kit and a 
manual method by Nukleon were used. 
 
QIAamp DNA Blood Maxi Kit Protocol: 
All centrifugation steps are carried out at room temperature in a microcentrifuge capable 
of running at 5.000 rpm equipped with a swing-out rotor and buckets accommodating 50 
ml centrifugation tubes. Make sure that buffer AL didn’t form precipitates upon storage. If 
necessary, warm to 56°C until the precipitates have fully dissolved. Protease stock solution 
is prepared by adding 5.5 ml distilled water into the vial of lyophilized Protease. Before 
using buffers AW1 and AW2 for the first time, ethanol (96-100%) has to be added as 
indicated on the bottle to obtain a working solution. Preheat a water bath to 70°C and 
equilibrate the samples to room temperature. 
 
 Pipet 500 µl protease into the bottom of a 50 ml centrifuge tube. 
 Add 10 ml blood and mix briefly. If sample volume is less than 5 ml, add the appropriate 
volume of PBS. 
 Add 12 ml buffer AL and mix thoroughly by inverting the tubes 15 times, followed by 
additional vigorous shaking for at least 1 min. Invert multiple tubes simultaneously by 
clamping them into a rack using another empty rack, grasping both racks, and inverting 
them together. 
 Incubate at 70°C for 10 min. 
 Add 10 ml of ethanol (96-100%) to the sample and mix again by vortexing. 
 Carefully transfer half of the solution onto the QIAamp Maxi column placed in a 50 ml 
centrifugation tube. Avoid spilling and do not moisten the rim of the column. Close the 
cap and centrifuge at 3.000 rpm for 3 min. 
 Remove the QIAamp Maxi column, discard the filtrate, and place the column back into 
the 50 ml centrifugation tube. Load the remainder of the solution onto the column, close 
the cap, and recentrifuge at 3.000 rpm for 3 min. 
 Remove the QIAamp Maxi column, discard the filtrate, and place the column back into 
the 50 ml centrifugation tube. 
 Carefully, without moistening the rim, add 5 ml buffer AW1 to the QIAamp Maxi column. 
Close the cap and centrifuge at 5.000 rpm for 1 min. 
 Carefully, without moistening the rim, add 5 ml of buffer AW2 to the QIAamp Maxi 
column. Close the cap and centrifuge at 5.000 rpm for 15 min. 
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 Discard the 50 ml centrifugation tube containing the filtrate, and place the QIAamp Maxi 
column in a clean 50 ml centrifugation tube. 
 Add 1 ml buffer AE, or distilled water, equilibrated to room temperature. Pipet directly 
onto the membrane of the QIAamp Maxi column and close the cap. Incubate at room 
temperature for 5 min and centrifuge at 5.000 rpm for 5 min. 
 For maximum concentration: Reload the 1 ml of eluate containing the DNA onto the 
membrane of the QIAamp Maxi column. Close the cap and incubate at room 
temperature for 5 min. Centrifuge at 5.000 rpm for 5 min. 
 For maximum yield: Pipet 1 ml of fresh buffer AE or distilled water, equilibrated to room 
temperature, onto the membrane of the QIAamp Maxi column. Incubate at room 
temperature for 5 min and centrifuge at 5.000 rpm for 5 min. 
 
Nukleon Protocol: 
All centrifugation steps are carried out at 4°C. Preheat a water bath to 37°C and a 
thermomixer to 65°C. Equilibrate the samples to room temperature and prepare following 
solutions: 
 
0,5 mol/L NaEDTA-Solution: 
Dilute 46,53 g Na-EDTA in 100 ml distilled water and equilibrate pH to 8 with NaOH. Add 
distilled water up to 250 ml. 
 
10 % SDS-Solution: 
Dilute 10 g SDS in 60 ml distilled water. Fill up to 100 ml with distilled water. Sterile filtrate 
the solution. 
 
Solution A: 
Dilute 1,2114 g Tris in 100 ml and equilibrate pH to 8 with HCl. Add 1,0165 g MgCl2, 
109,536 g Saccharose and 10 ml Triton X. Fill up to 1 Liter with distilled water and 
autoclave the solution. 
 
Solution B: 
Dilute 12.114 g Tris in 100 ml and equilibrate pH to 8 with HCl. Add 2,1915 g NaCl and 
30 ml NaEDTA-Solution. Fill up to 225 ml with distilled water and autoclave the solution. 
Then add 25 ml sterile filtered 10% SDS-Solution. 
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Solution C: 
Dilute 61,22 g Na-perchlorate in 60 ml distilled water. Fill up to 100 ml with distilled water. 
Autoclave the solution. 
 
 Pipet 500 µl Protease K (10 mg/ml) into the bottom of a 50 ml centrifuge tube. 
 Add blood sample and mix briefly. 
 Add 4x the volume of Solution A to each sample and mix gently by inverting the tubes 
several times. Centrifuge at 2.500 rpm for 5 min. 
 Discard flow-through and dry cell pellet by placing the tube bottom-up on a paper towel. 
 Add 2 ml Solution B and vortex to dissolve pellet. Transfer solution to a 15 ml tube. 
 Add 15 µl RNase A (50 µg/ml) and incubate at 37°C for 30 min. 
 Add 500 µl Solution C and invert 15 times. 
 Add 2 ml chloroform, invert 15 times, and centrifuge at 2.500 rpm for 5 min. 
 Take off supernatant into a new 15 ml tube and repeat chloroform step if the solution is 
not clear yet. If the solution is clear then add same volume ice cold isopropanol and 
invert 15 times. 
 Pick milky DNA-thread with a glass rod and put in an eppendorf tube filled with 1 ml 70% 
ethanol. Centrifuge at 13.000 rpm for 15 min. Take off Ethanol and leave pellet to dry. 
 Add 270 µl distilled water and dissolve pellet in a thermomixer at 65°C for 1 hour. 
 Add 30 µl 10x TE-buffer and leave in a thermomixer at 65°C for another 30 min. 
 
c) Quality Control of isolated DNA 
To check the concentration and quality of the isolated DNA the absorbance at 280 nm, 
260 nm and 230 nm was measured for all samples with NanoDrop2000/8000 (Thermo 
Scientific). The purity of DNA is determined by the ratio of A260/A280 and should be 
between 1.8 – 2.0. If the ratio value is off there is probably a contamination with proteins, 
phenol or other substances that absorb strongly at or near 260nm. A secondary measure 
of nucleic acid purity is given by the ratio of A260/A230 and should be between 2.0 – 2.2. 
If the ratio value is off there is probably a contamination with other substances absorbing 
230 nm as for example EDTA, carbohydrates or phenol. 
The length of the isolated DNA can be checked by running a 1% agarose gel. After the 
electrophoresis is done there should be seen a strong, single band. If there is a smear the 
DNA is degraded. 
If a very accurate measurement of yield, purity and length was needed the samples were 
measured by Bioanalyzer (Agilent Technologies), a microfluidics-based platform. 
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2.2 PCR and Gelelectrophoresis 
PCR allows for duplication of specific DNA fragments per cycle. This means that from a 
single DNA fragment arises 235 = 34 billion molecules after 35 cycles.  
 
Standard PCR protocol: 
12.48 µl water  
1.50 µl PCR - buffer (10x) 
0.3 µl  forward primer (10 µM) 
0.3 µl  reverse primer(10 µM) 
0.3 µl  dNTPs 
0.12 µl Taq (5 U/µl) 
10 ng  DNA, dry 
 
PCR - Settings: 
95°C for 1 minute 
35 x 95°C for 30 seconds, 60°C (primer dependent) for 45 seconds, 72°C for 30 seconds 
72°C for 5 minutes 
Hold 4°C 
 
Polarized macromolecules like DNA can be separated in a gel matrix depending on their 
charge, size, and tertiary structure by an electrical field in gel electrophoresis. The gel 
matrix works like a sieve where small, highly charged molecules are exposed to a smaller 
resistance and therefore travel a larger distance in the same time than larger, less 
charged molecules. Ethidium bromide is added to the gel which intercalates in the DNA and 
makes it visible in UV light. For sizing the samples a kb-ladder is included in one slot of the 
gel matrix.  
 
2% agarose gel protocol: 
1.6 g agarose 
80 ml 1x TBE-buffer 
5 µl ethidium bromide 
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2.3 Sequencing 
Sequencing is a method to identify the nucleotide succession in a DNA molecule. 
 
a) Sanger Sequencing 
After amplification of a primer specific DNA fragment using PCR and Exo/SAP treatment 
the product is used for the sequencing reaction. Another amplification step is started, but 
this time only one primer and not only dNTPs are used but also differently fluorescence 
labeled ddNTPs. These lead to a chain determination since they don’t have a 3’-hydroxy 
group and inhibit therefore the elongation of the DNA. This leads to amplified DNA 
fragments with different sizes that can be separated by capillary electrophoresis and 
detected after excitation by a laser. Sequences were viewed with the program SeqMan 
which is part of the DNASTAR software package. 
 
Exo/SAP protocol: 
8 µl  PCR product 
1.625 µl water 
0.3 µl  SAP 
0.075 µl Exo I (20 U/µl) 
 
Exo/SAP - settings: 
37 for 25 minutes 
72°C for 15 minutes 
 
Sequencing protocol: 
5.25 µl water 
2 µl  Exo/SAP product 
2 µl  sequencing buffer 
0.5 µl  ABI Big Dye version 1.1 
0.25 µl forward or reverse primer (10 µM) 
 
Sequencing settings: 
31 x 96°C for 10 seconds, 55°C for 55 seconds, 60°C for 4 minutes 
Hold 4°C 
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b) Next Generation Sequencing (NGS) using Illumina Genome Analyzer IIx 
Via a Covaris sonicator 3 µg of genomic DNA was reduced into 50 to 400 base pair 
fragments. DNA fragments were then subjected to end-repair, phosphorylation and 3`-
adenylation. Illumina paired-end adaptors were ligated to the ends. For downstream 
enrichment templates were size selected by purification on a 2% TAE-agarose gel and 
excision of fragments 250 +/- 25 base pairs in length. Fifteen rounds of PCR followed to 
amplify the purified DNA templates. The DNA library fragment lengths were validated on an 
Agilent Technologies 2100 Bioanalyzer using the Agilent DNA 1000 chip kit. Instead of 
making thousands of PCRs DNA enrichment can be done using an array based technology. 
In this case 385,000 unique, overlapping, 60 to 90 nucleotides long probes were designed 
across the target region of chr19:32.897.608..37.770.047 (RGSC v3.4; rn4). For the 
enrichment step at least 21 µg of DNA per sample have to be provided at a minimum 
concentration of 200 ng/µl in TE buffer or nuclease-free water. DNA quality must be 
proven as non-degraded, showing a single, high molecular band (>12kb) on an agarose gel 
with OD260/280 values at or above 1,8 and OD260/230 values at or above 1,5. The 
amplified fragments are then hybridized to a Roche NimbleGen Sequence Capture 385K 
microarray for about 72 hours at 42°C with a Roche NimbleGen Hybridization System 4. 
Afterwards the array is washed and DNA fragments can be eluted. A PCR-based 
amplification of the DNA fragments follows. Successful enrichment (at least 10 µg of 
enriched DNA) is verified by quantitative real-time PCR. The DNA library was then 
sequenced on a PE flow cell and a 2x50 bp run was conducted using Illumina Genome 
Analyzer IIx according to the manufacturers’ recommendations. The sequencing workflow 
includes template hybridization, isothermal amplification, linearization, blocking, sequencing 
primer hybridization, and sequencing-by-synthesis of Read 1. After completion of the first 
read, the newly sequenced strands are stripped off and the complementary strands are 
bridge amplified to form clusters. The original templates are then cleaved and removed 
before the reverse strands undergo sequencing-by-synthesis. 
DNA library preparation and data processing and analysis were done by the NGS team of 
the CCG, Cologne. The design of and hybridization to a customized NimbleGen rat genomic 
385K array was done by ATLAS Biolabs GmbH, Berlin. Samples were DNA from a PVG, 
Wistar, BD IX, affected DEB, histologically affected, and unaffected DEB rat. 
 
c) Pyrosequencing 
As a template for pyrosequencing single stranded DNA is used and sequenced by 
synthesizing the complementary strand base by base. In iterative steps dXTPs are added to 
the reaction. When the complementary nucleotide is incorporated onto the template by the 
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polymerase pyrophosphate (PPi) is released. This is quantitatively converted to ATP by 
sulfurylase in the presence of adenosine 5’ phosphosulfate and fuels the luciferase-
mediated conversion of luciferin to oxyluciferin. This reaction generates visible light in 
amounts that are proportional to the amount of ATP and is detected by a camera. 
Unincorporated nucleotides and ATP are degraded by apyrase, and the reaction starts 
again with another nucleotide. 
 
Pyrosequencing PCR settings: 
95°C for 5 minutes 
45 x 95°C for 15 seconds, 62°C for 30 seconds, 72°C for 15 seconds 
72°C for 5 minutes 
Hold 4°C 
 
Pyrosequencing PCR Protocol: 
8.66 µl water 
1.5 µl  PCR - buffer II (10x) 
0.24 µl dNTPs  
0.24 µl biotinylated forward primer (10 µM) 
0.24 µl reverse Primer (10 µM) 
0.12 µl Taq (5 U/µl) 
4 µl  DNA 
 
After PCR amplification the product is mixed with 70 µl 3% cepharose solution and left to 
incubate for five minutes on a shaker. Turn on the vacuum pump of the PyroMark Vacuum 
Prep Workstation and wash the adapter in water before aspirating the PCR product. Then 
place the adaptor for several seconds in 70% ethanol and then in 1 M sodium hydroxide to 
separate DNA strands. Neutralize several seconds in 1x washing buffer and turn off the 
pump. Shake off ssDNA in a new plate containing a solution of 11.64 µl AB-buffer with 0.36 
µl sequencing primer in each well. Incubate for 2 minutes at 85°C and leave to cool to room 
temperature before placing the plate in the Biotage PSQ HS96A Pyrosequencer. 
 
2.4 Microsatellite Analysis 
Microsatellites are short tandem repeats, mostly located in non-coding DNA regions. A 
single repeat unit’s length is usually restricted between 2 to 7 bases whereas the number 
of repeat units can be highly variable and can therefore be used as markers to establish 
29 
 
linkage groups in crosses and to map genetically identified mutations to chromosomal 
positions. 
 
Microsatellite PCR Protocol: 
8,32 µl water  
1 µl  PCR - buffer (10x) 
0.2 µl  fluorescence labeled forward primer (10 µM) 
0.2 µl  reverse primer (10 µM) 
0.2 µl  dNTPs 
0.08 µl Taq (5 U/µl) 
6 ng  DNA, dry 
 
Microsatellite PCR settings: 
94°C for 3 minutes 
3 x 94°C for 30 seconds, 61°C for 45 seconds, 72°C for 1 minute 
3 x 94°C for 30 seconds, 59°C for 45 seconds, 72°C for 1 minute 
3 x 94°C for 30 seconds, 57°C for 45 seconds, 72°C for 1 minute 
3 x 94°C for 30 seconds, 55°C for 45 seconds, 72°C for 1 minute 
72°C for 10 minutes 
Hold 4°C 
 
Mix 6.3 µl formamide with 0.7 µl Rox500 standard per sample and add 3µl diluted PCR 
product. The dilution factor has to be optimized and is usually between 1:50 and 1:200. 
The fragments can then be resolved by capillary electrophoresis. The number of repeat 
units can be determined using for example GeneMapper software. 
 
2.5 High Resolution Melting (HRM) Curve Analysis 
High resolution melting curve analysis was performed using Roche’s High Resolution 
Melting Master (see table 1 for protocol) and Light Cycler 480 system.  
 
  Table 1: 10-µl reaction with 20 ng dry DNA 
x mM MgCl2 1,0 1,5 2,0 2,5 3,0 3,5 
Mastermix 2x 5,0 5,0 5,0 5,0 5,0 5,0 
Primer F 0,2 0,2 0,2 0,2 0,2 0,2 
Primer R 0,2 0,2 0,2 0,2 0,2 0,2 
MgCl2 0,4 0,6 0,8 1,0 1,2 1,4 
ddH2O 4,2 4,0 3,8 3,6 3,4 3,2 
Target in ng, dry 20,0 20,0 20,0 20,0 20,0 20,0 
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This method is used for detection of sequence variants among several samples. In a first 
step primer specific DNA fragments are amplified in a PCR reaction. After each cycle a 
single measure of fluorescence activity is made so that the formation of amplicon during 
PCR can be monitored real time. The amplification step is followed by high resolution 
melting. The samples are heated from 60 to 95°C and fluorescence is measured 
continuously (table 2).  
 
The fluorescence dye used in this kit is ResoLight, which is a fluorescence dye that 
intercalates in double stranded DNA and is more sensitive than SYBR Green. It is excited by 
light with a wavelength between 450 and 500 nm. The emission maximum is at 503 nm.  
 
Table 2: PCR Parameters for HRM 
Setup 
Detection Format SYBR Green I 
Programs 
Program Name Cycles Analysis Mode 
Preincubation 1 None 
Amplification 45 Quantification 
High Resolution Melting 1 Melting Curves 
Cooling 1 None 
Temperature Targets 
Target (°C) Acquisition Mode 
Hold  
(mm:ss) 
Ramp Rate  
(°C/s) 
Acquisitions 
(per °C) 
Preincubation 
95 None 10:00 4.4 - 
Amplification 
95 None 00:10 4.4 - 
primer dependent None 00:10 2.2 - 
72 Single 00:20 4.4 - 
High Resolution Melting 
95 None 01:00 4.4 - 
40 None 01:00 2.2 - 
60 None 00:01 1 - 
95 Continuous - - 25 
Cooling 
40 None 00:10 4.4 - 
 
For best results the amplified DNA-fragments should not be longer than 500 base pairs 
because the sensitivity of variant detection will decrease. In addition, for each primer the 
conditions of PCR have to be optimized by adjusting the MgCl2 concentration, the annealing 
temperature, and the number of cycles. 
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Melting curve analysis verifies the specifity of the amplification reaction by showing a single 
melting peak at the same temperature for all samples (figure 9). Depending on the melting 
curve shapes (figures 10 and 12) gene scanning software can then distinguish between up 
to 6 different genotypes (see figures 11 and 13).  
 
Figure 9: Melting curve analysis for fragment ZNF568_e7.9. 
First negative derivative of the sample fluorescence versus temperature showing one melting peak for all 
samples. This indicates a pure, homogenous  amplification of a single PCR product. 
 
 
Figure 10: Normalized and temperature shifted melting curve data for fragment ZNF568_e7.9. 
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Figure 11: Normalized and temperature shifted difference plot for fragment ZNF568_e7.9. 
Samples are divided in 3 genotypes. 
 
 
Figure 12: Normalized and temperature shifted melting curve data for fragment ZNF568_e7.2. 
 
 
Figure 13: Normalized and temperature shifted difference plot for fragment ZNF568_e7.2. 
All samples have the same genotype. 
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2.6 Taqman 
SNP genotyping with Taqman assays works with two MGB (minor groove binding) probes 
which are labeled with either VIC or 6FAM fluorescent dye at the 5’ end. This allows 
genotyping of the two possible variant alleles at the SNP site in a DNA target sequence. 
Probes anneal to the complementary template during PCR and are cleaved by the 
polymerase in the amplification step. This separates the nonfluorescent quencher at the 3’ 
end of the probe from the reporter dyes, so that the fluorescence of the probe dyes is no 
longer suppressed and can be detected.  
 
3 µl reaction with 10 ng DNA protocol: 
1,5 µl  2x PCR-Mastermix 
0,075 µl 40x Taqman Genotyping Assay 
1,425 µl ddH2O 
10 ng  dry DNA 
 
PCR parameters: 
95°C for 10 minutes 
40 x 92°C for 15 seconds and 60°C for 1 minute 
Hold 4°C 
 
2.7 SNPstream 
SNP genotyping with SNPstream allows for detecting 48 SNPs in 384 samples in each 
run. In a first step primers are designed with the online software of Beckman&Coulter 
(www.autoprimer.com) and pooled as needed. PCR amplification follows. Then the products 
are purified with SBE Clean-Up, split on two plates, mixed with tagged sequencing primers, 
and TAMRA- or BODIPY- fluorescein labeled nucleotide terminator extension mixes. The 
products can then be spatially resolved by hybridization to the complementary 
oligonucleotide tag on a SNPware Tag Array. Assay results are finally read by direct two – 
color fluorescence on SNPstream Array Imager. 
 
Primerpool preparation for 96 PCR-Primers: 
Primer stocks are concentrated at 250 µM.  
A 1:100 dilution is needed to get a 2,5 µM concentration. 
Pipet 10 µl of each Primer in a tube and add 40 µl ddH2O to reach a final volume of 1000 µl.  
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SNPware Primer Panel 1 (S-TCAG) preparation: 
Primer stocks are concentrated at 250 µM. 
A 1:50 dilution is needed to get a 5 µM concentration. 
Pipet 10 µl of all S-TCAG Primers in a tube and add ddH2O to reach a final volume of 500 µl. 
 
SNPware Primer Panel 2 (S-CGAT) preparation: 
Primer stocks are concentrated at 250 µM. 
A 1:50 dilution is needed to get a 5 µM concentration. 
Pipet 10 µl of all S-CGAT Primers in a tube and add ddH2O to reach a final volume of 500 µl. 
 
5 µl 48plex reaction with 8 ng DNA protocol: 
0,1 µl TaqGold 
0,045 µl dNTPs (2,5 mM each) 
1 µl MgCl2 (25 mM) 
0,1 µl Primerpool (2,5 µM each) 
0,5 µl 10x PCR-Buffer II 
3,255 µl ddH2O 
8 ng dry DNA 
 
PCR parameters: 
94°C for 1 minute 
40 x 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute 
Hold 4°C 
 
SBE Clean-Up protocol for a 384 well plate: 
50 µl SBE Clean-Up Reagent 
1.200 µl SBE Clean-Up Diluent 
Mix thoroughly and add 3 µl to each well onto the 5 µl of PCR product. 
Seal PCR plates and spin briefly. 
 
SBE Clean-Up parameters: 
37°C for 30 minutes 
96°C for 10 minutes 
Hold 4°C 
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After SBE Clean-Up transfer 4 µl of each well to a new 384 well plate. One of the plates will 
then be used for the S-TCAG primer extension reaction, whereas the other plate will be 
used for the S-CGAT primer extension reaction. 
 
3,5 µl S-TCAG primer extension reaction protocol for a 384 well plate: 
2.116 µl ddH2O 
2.658 µl Extension Mix Diluent 
63 µl TC Extension Mix 
63 µl AG Extension Mix 
21 µl SNPware Primer Panel 1 
15 µl DNA Polymerase 
Add 3,5 µl to each well onto one of the SBE Clean-Up plates. 
3,5 µl S-CGAT primer extension reaction protocol for a 384 well plate: 
2.116 µl ddH2O 
2.658 µl Extension Mix Diluent 
63 µl CG Extension Mix 
63 µl AT Extension Mix 
21 µl SNPware Primer Panel 1 
15 µl DNA Polymerase 
Add 3,5 µl to each well onto the second SBE Clean-Up plate. 
 
Universal SBE program: 
96°C for 3 minutes 
60x 94°C for 20 seconds and 40°C for 11 seconds 
Hold 4°C 
 
Preparation of SNPware plates: 
30 ml Wash Buffer I 
570 ml ddH2O 
 
Wash SNPware plate 3 times with 1:20 SNPware Wash Buffer I. 
Place SNPware plate face down on a soft tissue in a centrifuge and spin for 2 minutes at 
1.500 rpm to dry the plate. 
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Preparation of Hybridization Solution: 
825 ml 2x Hybridization Solution 
14,172 ml Hybridization Additive 
 
Add 7 µl Hybridization Solution into each well of one of the primer extension reaction plates. 
Mix by pipetting up and down and transfer everything onto the second primer extension 
reaction plate, so that everything is pooled again. Transfer then 16 µl from each well to a 
prewashed SNPware plate. Tap gently at the plate to ensure equal dispersion. 
 
Hybridization protocol: 
Incubate the SNPware plate for 2 hours at 42°C with humidity close to 100%. 
 
After hybridization dilute SNPware Wash Buffer II 1:64 and wash the SNPware plate 3 
times. Place SNPware plate face down on a soft tissue in a centrifuge and spin for 2 
minutes at 1.500 rpm to dry the plate. Load the SNPware plate into the SNPstream 
Imager to capture the plate image and analyze the data. 
 
2.8 Affymetrix Genome-Wide Human SNP Array 6.0 and GeneChip Human Mapping 
500K Array 
SNP arrays are a microarray based technology with which a high number of genome wide 
SNPs can be genotyped for each sample in a short period of time. In this study genotyping 
was conducted with the Affymetrix Genome-Wide Human SNP Array 6.0 (906,600 SNPs 
and 946,000 copy number variation probes) and with Affymetrix GeneChip Human 
Mapping 500K Array (500,000 SNPs). DNA from human blood samples was processed 
and hybridized according to the manufacturer’s instructions by the Affymetrix platform 
Team of the CCG, Berlin. Data was then processed and analyzed by Dr. Franz Rüschendorf, 
Max Delbrück Center for Molecular Medicin, Berlin. 
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3 Methods on RNA Level 
 
3.1 RNA-Isolation and Quality Control 
 
a) RNA-Isolation from Rat and Human Tissues 
 Cut up to 100 mg of tissue into little pieces with a scalpel and put fragments in a tube 
containing 1 ml of Trizol. 
 Homogenize sample and incubate for 5 minutes on ice. 
 Centrifuge at maximum speed for 5 minutes at 4°C to pellet debris. 
 Transfer supernatant to a new tube, add 0.2 ml chloroform/ml trizol and vortex for 15 
seconds. 
 Incubate for up to 5 minutes to allow phase separation. 
 Centrifuge at maximum speed for 30 minutes at 4°C 
 Transfer entire upper, aqueous layer to a new tube, add same volume of 100% ethanol 
and vortex. 
 Centrifuge at maximum speed for 10 minutes at 4°C 
 Take off supernatant and wash pellet with 80% ethanol. 
 Centrifuge at maximum speed for 10 minutes at 4°C 
 Take off supernatant, dry pellet and resuspend in 100 µl RNase free water. 
 
b) RNA-Isolation from Rat Fibroblasts 
For the isolation of RNA from rat fibroblasts Qiagen’s RNeasy Midi Kit was used. 
 
RNeasy Midi Kit Protocol: 
Do not use more than 3-4 x 107 cells per RNeasy midi column to avoid overloading and 
clogging the column. Add 10 µl beta-mercaptoethanol per 1 ml buffer RLT needed and add 
100% of ethanol as indicated on the bottle before using buffer RPE for the first time. All 
steps, including centrifugation, are performed at room temperature. 
 Resuspend the cell pellet in 4 ml RLT buffer and homogenize cells using a conventional 
rotor-stator homogenizer for at least 45 seconds at maximum speed until the sample is 
uniformly homogeneous. 
 Add 1 volume of 70% ethanol to the lysate, and mix thoroughly by shaking vigorously. 
 Apply the sample, including any precipitate that may have formed, to an RNeasy midi 
column placed in a15 ml centrifuge tube. Centrifuge at 3.000 – 5.000 g for 5 minutes. 
Discard the flow-through. 
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 Add 2 ml buffer RW1 to the column and centrifuge at 3.000 – 5.000 g for 5 minutes. 
Discard the flow-through. 
 Add 20 µl DNase I stock solution to 140 µl buffer RDD. Mix by gently flicking the tube, 
and centrifuge briefly to collect residual liquid from the sides of the tube. 
 Pipet the DNase I incubation mix directly onto the RNeasy silica-gel membrane, and 
place on the benchtop for 15 minutes at room temperature. 
 Pipet 2 ml buffer RW1 into the column, and place on the benchtop for 5 minutes. 
Centrifuge at 3.000 – 5.000 g for 5 minutes. Discard the flow-through. 
 Add 2.5 ml buffer RPE to the column and centrifuge at 3.000 – 5.000 g for 2 minutes. 
Discard flow-through. 
 Add another 2.5 ml buffer RPE to the column and centrifuge at 3.000 – 5.000 g for 5 
minutes. Remove the RNeasy column from the centrifuge tube carefully so the column 
does not contact the flow-through as this will result in carryover of ethanol. 
 Transfer the column to a new 15 ml collection tube. Pipet 150 µl RNase-free water 
directly onto the RNeasy silica-gel membrane. Let it stand for 1 minute, and then 
centrifuge for 3 minutes at 3.000 – 5.000 g. 
 Repeat the elution step as described with a second volume of RNase-free water. 
 
c) Quality Control of isolated RNA 
To check the concentration and quality of the isolated RNA the absorbance at 280 nm, 
260 nm and 230 nm was measured for all samples with NanoDrop2000/8000 (Thermo 
Scientific). The purity of RNA is determined by the ratio of A260/A280 and should be 
between 1.9 – 2.1. If the ratio value is off there is probably a contamination with proteins, 
phenol or other substances that absorb strongly at or near 260nm. A secondary measure 
of nucleic acid purity is given by the ratio of A260/A230 and should be above 1.8. If the 
ratio value is off there is probably a contamination with other substances absorbing 230 
nm as for example EDTA, carbohydrates or phenol. 
If a very accurate measurement of yield and purity was needed the samples were 
measured with the Bioanalyzer (Agilent Technologies), a microfluidics-based platform. 
 
3.2 Quantitative Real Time PCR (qRT - PCR) 
qRT-PCR was performed using Invitrogen’s EXPRESS One-Step SYBR GreenER Kit and 
Roche’s Light Cycler 48: system. 
In a first step the RNA has to be transcribed to cDNA followed by primer specific 
amplification and a melting curve analysis (table 3). The melting curve is used to check that 
all samples have amplified the exact same fragment, so there is no variation that would 
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influence expression value calculations. For relative quantification samples as well as 
controls have to be analyzed for the candidate gene and for a housekeeping gene. After 
amplification the software will calculate expression levels by comparing the samples to the 
controls and normalizing the values with the comparison of the housekeeping gene 
samples to the housekeeping gene controls (formula 1). 
 
Table 3: PCR Parameters for qRT-PCR 
Setup 
Detection Format SYBR Green I 
Programs 
Program Name Cycles Analysis Mode 
cDNA Synthesis 1 None 
Pre Incubation 1 None 
Amplification 45 Quantification 
Melting Curve 1 Melting Curves 
Cooling 1 None 
Temperature Targets 
Target (°C) Acquisition Mode 
Hold 
(mm:ss) 
Ramp Rate 
(°C/s) 
Acquisitions 
(per °C) 
cDNA synthesis 
55 None 05:00 4.4 - 
Preincubation 
95 None 02:00 4.4 - 
Amplification 
95 None 00:10 4.4 - 
primer dependent None 00:30 2.2 - 
72 Single 00:06 4.4 - 
Melting Curve 
95 None 00:05 4.4 - 
60 None 01:00 2.2 - 
97 Continuous - 0.11 5 
Cooling 
40 None 00:10 1.5 - 
 
 
 
Formula 1: Normalization of expression values 
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20-µl reaction with 10 ng RNA protocol: 
10 µl EXPRESS SYBR GreenER qPCR SuperMix Universal 
0.4 µl 10 µM Primer F (200 nM final) 
0.4 µl 10 µM Primer R (200 nM final) 
0.5 µl EXPRESS SuperScript Mix for One-Step SYBR GreenER 
3.7 µl RNase free water 
5 µl Template RNA (2 ng/µl) 
 
3.3 Whole-Transcript Expression Analysis using Affymetrix Rat Gene 1.0 ST Array 
The Affymetrix Rat Gene 1.0 ST Array is a single-labeled high-density oligonucleotide 
expression array offering whole-transcript coverage with the representation of 27,342 
well-characterized genes by approximately 26 probes spread across the full length of the 
gene. RNA from 6 DEB and Wistar rat skins and 3 DEB and Wistar heart samples were 
processed and hybridized according to the manufacturer’s instructions by the Affymetrix 
platform team of the CCG, Berlin. Data was then processed and analyzed by Dr. Peter 
Frommolt, CCG, Cologne. 
 
3.4 Ingenuity Pathways Analysis 
With Ingenuity Pathways Analysis software expression data from the Affymetrix Rat Gene 
1.0 ST Array was further analyzed. The whole set of expression data as well as the 
expression data of chromosome 19 genes within the candidate region 
19:32.986.041..36.535.127 only were downloaded and checked for promising protein 
networks, pathways and genes. The software integrates data from a variety of 
experimental platforms and allows an easy search of scientific literature. Dynamic pathway 
models can be built and complex experimental data can be quickly analyzed to give key 
insights into relationships, mechanisms, functions, and pathways of relevance. 
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4 Methods on Protein Level 
 
4.1 Histology  
 
a) Fixation, Paraffin Embedding and Sectioning 
Skin samples were punched with a 6 mm punch biopsy and heart was horizontally sliced in 
the middle. The punches and slices were then put in a cell safe capsule. Each cell safe 
capsule was placed in a processing cassette and fixation was performed with the tissue 
processor LEICA ASP200S with a protocol shown in table 4. 
 
Table 4: Fixation protocol 
Step Time Reagent Step Time Reagent 
1 2 hours Formalin 7 1 hour 100% Ethanol 
2 1,5 hours Formalin 8 1,5 hours Xylol 
3 1,5 hours 70% Ethanol 9 1,5 hours Xylol 
4 1,5 hours 80% Ethanol 10 1,5 hours Histowax (62°C) 
5 1 hour 100% Ethanol 11 1,5 hours Histowax (62°C) 
6 1 hour 100% Ethanol 12 1,5 hours Histowax (62°C) 
 
After fixation samples were kept in the paraffin station LEICA EG1150H preheated to 65°C 
until further processing. Skin samples were then halved with a scalpel and put in a stainless 
steel base mold with the cutting edge on the downside. Heart samples were also put in 
steel base molds. The processing cassette was put on top and the mold filled with 65°C 
warm paraffin. The molds were left to cool on a cold plate until the paraffin block could be 
easily retrieved.  
5 µm thin sections were cut with the fully automated rotary microtome LEICA RM2255 and 
put in a water bath with 37°C from where the sections could be easily transferred to 
coated slides. The slides were left to dry on a heating plate with 37°C for one hour and then 
transferred to an incubator with 37°C overnight. 
 
b) Haematoxylin - Eosin (HE) Staining 
Haematoxylin is extracted from the bark of the logwood tree and stains cell nuclei blue. As 
a counterstain Eosin is used, which is a fluorescent red dye staining cytoplasm, collagen, 
muscle fibers and blood cells. 
Place slides in a slide holder and deparaffinize sections in a glass chamber filled with xylol 
for 15-20 minutes. Wipe off excess xylol on a paper towel and rehydrate sections two 
times in 100% ethanol, two times in 80% ethanol, two times in 30% ethanol, and two 
times in deionized water for three minutes each. Then place slides in a glass chamber filled 
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with haematoxlin solution for three to five minutes, rinse with deionized water and develop 
stain under tap water for 10-15 minutes. Rinse again with deionized water, then incubate 
slides in eosin G-solution (add 1 drop of acidic acid per 100 ml eosin G-solution) for three 
minutes and rinse before dehydrating samples by placing the slides in water, two times in 
30% ethanol, two times in 80% ethanol, 100% ethanol, and finally in xylol for three minutes 
each. Mount slides and view under a microscope. 
 
c) Immunohistochemical Staining 
Before the actual staining an antigene retrieval step has to be performed due to the 
formation of methylene bridges during fixation, which cross-link proteins and mask 
antigenic sites. Therefore Tris-EDTA buffer is brought to the boil in a microwave, Take out of 
the microwave and incubate deparaffinized and rehydrated sections for one hour. Wash 
two times in TBST buffer and incubate in blocking solution for two hours. Wipe around the 
sections with soft tissue paper and apply primary antibody diluted as shown in table 5 in 
antibody dilution solution. Incubate overnight at 4°C. Wash sections two times in TBST 
buffer, apply secondary antibody Alexa Fluor Goat anti_mouse 488 (yellow fluorescence, 
dilution factor 1:400), and incubate for one hour at room temperature. Wash three times 
in TBST buffer and continue with DAPI staining. 
 
Tris-EDTA buffer (10mM Tris Base, 1mM EDTA Solution, 0,05% Tween 20, pH 9.0): 
1.21 g  Tris 
0.37 g  EDTA 
1000 ml distilled water 
0.5 ml  Tween 20 
 
TBST buffer (20mM Tris.HCl, pH 7.4, 150 mM NaCl, 0.04% Tween 20): 
100 ml Tris.HCl 
40 g  NaCl 
4900 ml distilled water 
0.9 ml  Tween 20 
 
Blocking solution (10% FCS, 1% BSA): 
50 ml  FCS 
5 g  BSA 
450 ml PBS 
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Antibody dilution solution (1% BSA, 0.025% Triton X-100): 
5 g  BSA 
500 ml PBS 
125 µl  Triton X-100 
 
Table 5: Dilution factors for primary antibodies 
Primary Antibody Isotype Dilution Factor 
VE-Cadherin/Cadherin 5 IgG1 1:500 
E-Cadherin/Cadherin 1 IgG2a 1:5000 
M-Cadherin/Cadherin 15 IgG2a 1:250 
N-Cadherin/Cadherin 2 IgG1 1:2500 
P-Cadherin/Cadherin 3 IgG1 1:250 
R-Cadherin/Cadherin 4 IgG1 1:500 
Alpha-Catenin IgG1 1:250 
Beta-Catenin IgG1 1:500 
Gamma-Catenin/Plakoglobin/Jup IgG2a 1:2000 
Desmoglein IgG1 1:1000 
P120 Catenin IgG1 1:1000 
 
 
d) DAPI Staining 
DAPI ―4’,6-diamidino-2-phenylindole) is used for nuclear and chromosome counterstaining. 
It is excited at 345 nm and emits blue fluorescence at 458 nm upon binding to AT regions 
of DNA. 
Incubate slides for 3 minutes in DAPI solution (10 µg/ml). Wash thoroughly five times in 
TBST, mount coverslips and leave overnight at 4-8°C to dry before viewing. 
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5 Methods for Cell Culture 
 
5.1 Cell Culture Media 
All Media must be prepared under a cell culture hood in a sterile environment. 
 
Transportation medium for tissue samples: 
10 ml  FCS 
2 ml  Fungizone (250 µg/ml) 
1 ml  Penicillin/Streptomycin (10.000 IU/ml) 
200 µl  Gentamycin (50 mg/ml) 
Add. 100 ml  DMEM (without L-Glutamine/Sodium Pyruvate) 
 
Washing solution: 
500 ml PBS 
30 ml  Fungizone (250 µg/ml) 
20 ml  Penicillin/Streptomycin (10.000 IU/ml) 
4 ml  Gentamycin (50 mg/ml) 
 
HEK-Medium for rat fibroblasts: 
430 ml MEM with NEAA (without L-Glutamine/Sodium Pyruvate) 
50 ml  FCS 
10 ml  Sodium Pyruvate (100 mM) 
5 ml  Glutamine (200 mM) 
5 ml  Penicillin/Streptomycin (10.000 IU/ml) 
 
KGM-Gold Keratinocyte Growth Medium BulletKit (Lonza): 
500 ml KGM-Gold Basal Medium 
+  Bovine Pitutary Extract 
+  hEGF 
+  Insulin 
+  Hydrocortisone 
+  GA-1000 (Gentamicin, Amphotericin-B) 
+  Epinephrine 
+  Transferrin 
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5.2 Isolation and Culture of Rat Fibroblasts 
For all steps sterile working under a cell culture hood is necessary. Use only sterile 
instruments and consumables.  
Take out skin samples of the transportation medium with forceps, place in 50 ml tube filled 
with 30 ml washing solution, and shake vigorously. Repeat this step two times with fresh 
washing solution. Then put the skin sample in Betaisodona for 30 seconds and shake 
vigorously. Wash again three to five times with washing solution until all Betaisodona is 
washed off. Cut off as much dermis as possible with scissors and place pieces on a culture 
dish. The rest of the skin will be used for isolation of keratinocytes. Leave dermis pieces to 
dry for several minutes, so that the samples stick to the dish when medium is added. 
Carefully add HEK-Medium until the sample pieces are completely covered. Place in an 
incubator with 37°C, 95% air humidity and 5% CO2. Medium has to be changed every three 
to four days.  
After several days the fibroblasts will start to grow out of the tissue pieces. As soon as the 
cells are confluent they can be harvested by taking off all medium and putting on 5 ml 
Trypsin-EDTA per dish for three minutes. Prod gently, add 5 ml HEK-Medium to stop the 
trypsinization reaction followed by a centrifugation step with 1.200 rpm for five minutes. 
Take off all medium and resuspend in 9 ml fresh HEK-Medium. Plate cells in three T225 
cell culture bottles and add 50 ml HEK-Medium. Keep the cells in an incubator with 37°C, 
95% air humidity and 5% CO2. Medium has to be changed every three to four days.  
When the cells are confluent again take off medium, trypsinize with 10 ml Trypsin-EDTA for 
5 minutes, stop reaction with 10 ml HEK-Medium and centrifuge with 1.200 rpm for five 
minutes. Take off all medium and resuspend two pellets in 3.6 ml FCS with 10% DMSO 
each. Take six cryoconservation tubes, put 1.2 ml of resuspended cells in each and freeze 
in a nitrogen tank for later cell culture. The third pellet was stored for RNA-isolation at -
20°C.  
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5.3 Isolation and Culture of Rat Keratinocytes 
Place skin with the epidermis on the downside in a new cell culture dish and add 20 ml 
dispase II (1.5 U/ml). Keep overnight at 4-8°C. The next day the epidermis can be 
separated from the dermis using forceps. The dermis can be cut in smaller pieces and 
used for isolation of fibroblasts as described in chapter 5.1. Put the epidermis in 10 ml 
Trypsin-EDTA and heat for 30 minutes at 37°C in a water bath shaking vigorously with a 
magnetic stir bar. Stop trypsinization reaction by adding 10 ml Trypsin-Inhibitor (0.5 
mg/ml) and filter through a 70 µm cell filter to get rid of debris and undigested particles. 
Centrifuge cell suspension at 1.400 rpm for 10 minutes. Take off supernatant and 
resuspend pellet in 9 ml KGM-Gold medium. Put 3 ml of resuspended cells in each T225 
cell bottle, add 50 ml KGM-Gold Medium and keep in an incubator with 37°C, 95% air 
humidity and 5% CO2. The next day the medium has to be changed. Afterwards medium has 
to be changed every second day. 
Once the cells are confluent up to 60% they need to be trypsinized using 10 ml Trypsin-
EDTA for 8 to 10 minutes. Stop reaction with same amount of trypsin inhibitor and 
centrifuge at 1.400 rpm for 10 minutes. Take off supernatant and resuspend two of the 
three pellets in 3.6 ml Keratinocyte Freezing Medium each. Store in nitrogen tank for later 
cell culture. The third pellet was stored at -20°C for RNA isolation. 
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D Results – Rat Samples 
 
1. Short Summary of the study design and the obtained results 
For reasons of clarity and better interpretation of the results a short summary of the study 
design and the obtained results will be given at this point. Results are demonstrated in 
detail within the next chapters and partially in the Appendix. 
 
Former results of a whole genome scan linkage analysis in 320 F2 females with 176 
microsatellite markers pointed to a highly significant locus on chromosome 19 with a non 
parametric lod score of 20. This analysis was conducted by the dermatogenetic group at 
the CCG, Cologne. In a first step, saturation mapping was performed in this study with 13 
more microsatellite markers. Haplotype analysis of the affected and non-affected F2 
animals led to a candidate region of about 3.5 Mb. Most genes within that region were 
exon-sequenced but no mutation as a potential cause for the disease could be identified. In 
a next step the whole candidate region was therefore sequenced again by next generation 
sequencing but as before, no immediate mutation could be detected as a potential cause 
for the disease.  
 
In another approach to find candidate genes expression analysis was performed using the 
Affymetrix Rat Gene 1.0ST Array. Highest fold changes were obtained for keratin genes 
and other genes involved in skin, hair, and nail structure as well as several immunologically 
relevant genes. Functional analysis and Network Explorer analysis as tools of the Ingenuity 
Pathway Analysis revealed an indication for the importance of cadherins for the expression 
data obtained from genes within the candidate region. Therefore expression levels of some 
candidate genes, including keratins, cadherins, desmogleins, and catenins were validated 
and refined by quantitative real time PCR. In addition immunohistological stainings were 
made for proteins involved in adherens junctions and desmosomes showing abnormalities 
for the catenin plakoglobin. 
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2 Saturation mapping of Chromosome 19 with Microsatellites 
Former results of a whole genome scan linkage analysis in 320 F2 females with 176 
microsatellite markers pointed to a highly significant locus on chromosome 19 with a non 
parametric lod score of 20. This analysis was conducted by the dermatogenetic group at 
the CCG, Cologne. In a first step, saturation mapping was performed in this study with 13 
more microsatellite markers followed by haplotype analysis on 129 affected and 128 
unaffected F2 females. The criteria for selection of the candidate region flanking markers 
were arbitrarily set assuming that markers in the candidate interval have the highest 
frequency of DEBR alleles in affected animals as compared to unaffecteds.  
 
In affected animals flanking markers were therefore set where at least two animals are 
heterozygous for the DEBR and the PVG allele framing a region of homozygous DEBR 
alleles. The results of the 6 most informative haplotypes are given in table 6 for the 
affected F2 animals showing animal 127 homozygous with the DEBR allele beginning with 
marker D19Rat33. Since no other of the affected F2 animals showed homozygosity with 
the DEBR allele at this marker and also not for the next two markers, these were not 
accepted as flanking markers for the candidate region. Marker D19Rat46 is the first 
upstream marker that is homozygous for the DEBR allele in more than one affected F2 
animal and therefore marker D19Rat118 is accepted as the upstream flanking marker of 
the candidate region. The same method resulted in the downstream flanking marker 
RM24C19N53 framing a 3,5 Mb large region (19:32986041..36535127) where all but 
one of the 129 affected F2 animals are homozygous for the DEBR allele. 
 
In unaffected animals flanking markers were set where at least two animals are 
homozygous for the DEBR allele framing a region of heterozygosity. Therefore marker 
D19Rat91 was accepted as the upstream and RM22C19N47 as the downstream 
flanking marker. The results of the 6 most informative haplotypes are given in table 7 for 
the unaffected F2 animals. These results support the underlying hypothesis of higher DEBR 
allele frequency within the candidate region in affected animals since there are no 
unaffected animals found homozygous for the DEBR allele within the candidate region. 
 
In the next step exons of candidate genes from this defined region were sequenced to look 
for possible mutations that might cause alopecia areata. 
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Table 6: Positions of microsatellite markers and their allele sizes for the 6 most informative 
haplotypes of affected F2 animals. Blue = DEBR allele, green = PVG allele, x = missing data. 
Position Marker affected F2 animals 
5 
 
49 
 
127 
 
100 
 
124 
 
57 
55447056 D19Rat60 7 7 
 
6 7 
 
6 7 
 
6 6 
 
6 6 
 
6 6 
47444682 D19Rat7 149 149 
 
137 149 
 
137 149 
 
137 137 
 
137 137 
 
137 137 
46282836 D19Rat70 169 169 
 
163 169 
 
163 169 
 
x x 
 
x x 
 
163 163 
45668882 D19Rat88 221 221 
 
205 221 
 
205 221 
 
205 205 
 
205 205 
 
205 205 
45090802 D19Mit7 107 107 
 
99 107 
 
99 107 
 
99 99 
 
99 99 
 
99 99 
45001545 D19Rat66 14 14 
 
8 14 
 
8 14 
 
8 8 
 
8 8 
 
8 8 
44186608 D19Rat90 227 227 
 
196 227 
 
196 227 
 
196 196 
 
196 196 
 
196 196 
42862032 D19Rat9 9 9 
 
7 9 
 
7 9 
 
7 7 
 
7 7 
 
7 7 
40725526 D19Rat117 201 201 
 
197 201 
 
197 201 
 
197 197 
 
197 197 
 
197 197 
40062222 D19Rat35 8 8 
 
17 8 
 
17 8 
 
17 17 
 
17 17 
 
17 17 
39448152 D19Arb2 349 349 
 
357 349 
 
357 349 
 
357 357 
 
357 357 
 
357 357 
38910730 D19Rat72 151 143 
 
x x 
 
151 143 
 
151 151 
 
x x 
 
x x 
38295381 D19Rat24 165 172 
 
165 172 
 
165 172 
 
165 165 
 
165 165 
 
x x 
37769951 D19Rat91 80 89 
 
80 89 
 
80 89 
 
80 80 
 
80 80 
 
x x 
37324190 D19Rat33 204 224 
 
204 224 
 
204 204 
 
204 204 
 
204 204 
 
x x 
36614365 D19Rat22 128 132 
 
128 132 
 
128 128 
 
128 128 
 
x x 
 
128 128 
36535127 D19Rat118 242 238 
 
242 238 
 
x x 
 
242 242 
 
242 242 
 
242 242 
36472017 D19Rat46 7 18 
 
7 7 
 
7 7 
 
7 7 
 
7 7 
 
7 7 
36405081 D19Rat23 173 170 
 
173 173 
 
173 173 
 
173 173 
 
173 173 
 
173 173 
34910174 D19Rat53 x x 
 
116 116 
 
116 116 
 
116 124 
 
116 116 
 
116 116 
34781500 RM20C19N6 x x 
 
227 227 
 
227 227 
 
227 229 
 
227 227 
 
227 227 
32986041 RM24C19N53 261 261 
 
261 261 
 
261 261 
 
261 257 
 
261 257 
 
261 257 
32795927 RM22C19N47 309 309 
 
309 309 
 
309 309 
 
309 311 
 
309 311 
 
309 311 
32388800 RM22C19N8 207 207 
 
207 207 
 
207 207 
 
207 203 
 
207 203 
 
207 203 
31926069 RM25C19N3 236 236 
 
236 236 
 
236 236 
 
236 222 
 
236 222 
 
236 222 
29575651 D19Rat30 16 16 
 
16 16 
 
16 16 
 
16 7 
 
16 7 
 
16 7 
29207613 D19Rat110 8 8 
 
8 8 
 
8 8 
 
8 11 
 
11 11 
 
8 11 
27497109 D19Rat12a 7 7 
 
7 7 
 
7 7 
 
7 8 
 
8 8 
 
7 8 
2265038 D19Rat34 6 6 
 
6 6 
 
6 6 
 
x x 
 
7 7 
 
7 7 
15426254 D19Rat15 6 6 
 
6 6 
 
6 6 
 
6 12 
 
12 12 
 
12 12 
11311216 D19Rat81 8 8 
 
8 8 
 
8 8 
 
8 11 
 
11 11 
 
11 11 
7316493 D19Rat98 109 109   109 109   109 109   x x   111 111   111 111 
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Table 7: Positions of microsatellite markers and their allele sizes for the 6 most informative 
haplotypes of not affected F2 animals. Blue = DEBR allele, green = PVG allele, x = missing data. 
Position Marker not affected F2 animals 
248 
 
619 
 
256 
 
580 
 
574 
 
601 
55447056 D19Rat60 6 6 
 
6 6 
 
6 6 
 
6 7 
 
6 7 
 
6 7 
47444682 D19Rat7 137 137 
 
137 137 
 
137 137 
 
137 149 
 
137 149 
 
x x 
46282836 D19Rat70 163 163 
 
163 163 
 
163 163 
 
163 169 
 
163 169 
 
x x 
45668882 D19Rat88 205 205 
 
205 205 
 
205 205 
 
205 221 
 
205 221 
 
205 221 
45090802 D19Mit7 99 99 
 
99 99 
 
99 99 
 
99 107 
 
99 107 
 
99 107 
45001545 D19Rat66 8 8 
 
8 8 
 
8 8 
 
8 14 
 
8 14 
 
8 14 
44186608 D19Rat90 196 196 
 
196 196 
 
196 196 
 
x x 
 
x x 
 
x x 
42862032 D19Rat9 7 7 
 
7 7 
 
7 7 
 
7 9 
 
7 9 
 
7 9 
40725526 D19Rat117 197 197 
 
197 197 
 
197 197 
 
197 201 
 
197 201 
 
197 201 
40062222 D19Rat35 17 17 
 
17 17 
 
17 17 
 
17 8 
 
17 8 
 
17 8 
39448152 D19Arb2 357 357 
 
357 357 
 
357 357 
 
357 349 
 
357 349 
 
357 349 
38910730 D19Rat72 151 151 
 
151 151 
 
151 151 
 
x x 
 
x x 
 
x x 
38295381 D19Rat24 165 165 
 
165 165 
 
165 172 
 
165 172 
 
165 172 
 
165 172 
37769951 D19Rat91 80 80 
 
80 80 
 
80 89 
 
80 89 
 
80 89 
 
80 89 
37324190 D19Rat33 204 224 
 
204 224 
 
204 224 
 
x x 
 
x x 
 
x x 
36614365 D19Rat22 128 132 
 
128 132 
 
128 132 
 
x x 
 
x x 
 
128 132 
36535127 D19Rat118 242 238 
 
242 238 
 
242 238 
 
242 238 
 
242 238 
 
242 238 
36472017 D19Rat46 7 18 
 
x x 
 
7 18 
 
7 18 
 
7 18 
 
7 18 
36405081 D19Rat23 173 170 
 
173 170 
 
173 170 
 
173 170 
 
x x 
 
173 170 
34910174 D19Rat53 116 124 
 
116 124 
 
116 124 
 
116 124 
 
116 124 
 
116 124 
34781500 RM20C19N6 x x 
 
227 229 
 
227 229 
 
227 229 
 
227 229 
 
227 229 
32986041 RM24C19N53 261 257 
 
261 257 
 
261 257 
 
261 257 
 
261 257 
 
261 261 
32795927 RM22C19N47 x x 
 
309 311 
 
x x 
 
309 311 
 
309 309 
 
309 309 
32388800 RM22C19N8 207 203 
 
207 203 
 
207 203 
 
207 207 
 
207 207 
 
207 207 
31926069 RM25C19N3 236 222 
 
236 222 
 
236 222 
 
236 236 
 
236 236 
 
236 236 
29575651 D19Rat30 16 7 
 
16 7 
 
16 7 
 
16 16 
 
16 16 
 
16 16 
29207613 D19Rat110 8 11 
 
8 11 
 
8 11 
 
8 8 
 
8 8 
 
8 8 
27497109 D19Rat12a 7 8 
 
7 8 
 
7 8 
 
7 7 
 
16 16 
 
7 7 
2265038 D19Rat34 6 7 
 
6 7 
 
6 7 
 
6 6 
 
16 16 
 
6 6 
15426254 D19Rat15 6 12 
 
6 12 
 
6 12 
 
6 6 
 
6 6 
 
6 6 
11311216 D19Rat81 8 11 
 
8 11 
 
8 11 
 
8 8 
 
8 8 
 
8 8 
7316493 D19Rat98 111 111 
 
109 111 
 
109 111 
 
109 109 
 
109 109 
 
109 109 
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3 Exon Sequencing of Candidate Genes 
After saturation mapping of chromosome 19 a candidate region of 3.5 Mb in size was 
detected between markers D19Rat118 and RM24C19N53. In the next step exons of 
candidate genes within this region were sequenced and screened for mutations. 
 
Following genes have been exon sequenced (in alphabetical order): Acd, Agrp, Atp6v0d1, 
Cdh1, Cdh3, Cenpt, Ctcf, Ctrl, Ddx28, Dpep2, Dpep3, Dus2l, Edc4, Fam65a, Gfod2, 
Hsd11b2, Kctd19, Lcat, Lin10, Lypla3, Nfatc3, Nol3, Ntf2, Pard6a, Prmt7, Pskh1, 
Psmb10, Ranbp10, Rbm35b, RGD1307357, RGD1561415, Slc7a6, Slc7a6os, Slc9a5, 
Slc12a4, Smpd3, Thap11, Tradd, Tsnaxip1 and Zfp90. All variations found are given in 
table 8. A mutation as a potential cause for hair loss in alopecia areata could not be 
identified since all found amino acid changes can also be detected in other species without 
an association to hair loss and intronic variations could not be ascribed to known splice 
sites. 
 
Therefore the region was sequenced in toto by genomic sequencing in the next step. 
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Table 8: Variations found by sanger sequencing 
Gene Variation f Position  Gene Variation Position 
Acd g.2503A>C Intron  Kctd19 g.10G>A Gly4Ser 
Agp g.258delG Intron  Kctd19 g.15587G>A Exon 3 
Agp g.252T>G Intron  Kctd19 g.1721T>C Intron 
Agp g.251_252insT Intron  Kctd19 g.18853C>G Ser282Cys 
Agp g.859_860insG 3'UTR  Kctd19 g.20330A>G Met402Val 
Atp6v0d1 g.37476T>C Intron  Kctd19 25797A>G Intron 
Atp6v0d1 g.43805T>C 3'UTR  Lcat g.851_852insCG Intron 
RGD1307357 g.1621C>G Ala125Gly  Lcat g.1351delT Intron 
RGD1307357 
g.1782_1786del 
CGTGT 
Intron 
 
Lin10 g.15172G>A Intron 
RGD1307357 g.4037T>C Intron  Lypla3 g.4627T>A Intron 
RGD1307357 g.4159T>C Tyr317His  Nol3 g.902C>A 3'UTR 
RGD1307357 g.4280T>C 3'UTR  Nol3 g.782_811del Glu193_Pro202del 
Cdh3 g.20354G>T Intron  Ntf2 g.16841T>C Intron 
Cdh3 g.23205G>A 3'UTR  Pard6a g.837T>C Intron 
Cenpt g.4285G>A Val290Met  Pard6a g.1560T>A Leu311His 
Cenpt g.4343A>G Intron  Pard6a g.1840T>C 3'UTR 
Cenpt g.4409G>C Intron  Pskh1 g.12459T>C Exon 2 
Cenpt g.6153C>T Intron  Pskh1 g.31521A>G Exon 3 
Ctcf g.718T>A Exon 1  Psmb10 g.85C>T 5'UTR 
Ctcf g.19452A>G 3'UTR  Psmb10 g.1145T>C Intron 
Ddx28 g.442A>G Ile148Val  Psmb10 g.2283C>T Intron 
Dpep2 g.9T>C 5'UTR  Ranbp10 g.48822A>G Intron 
Dpep2 g.97G>T Intron 
 
Ranbp10 
g.57607_57608insTC
CTTCCT 
3'UTR 
Dpep2 g.99_102delTGGG Intron  Slc9a5 g.78878A>G Intron 
Dpep2 g.2902G>A Exon 7  Slc9a5 g.15760T>C Exon 16 
Dpep2 g.6176T>C Exon 11  Slc9a5 g.18439C>G Exon 17 
Dpep3 g.1986C>A Intron  Slc12a4 g.18675G>A Exon 18 
Dpep3 g.5659G>A Intron  Slc12a4 g.21384A>G 3'UTR 
Edc4 g.3616T>C Exon 2  Slc12a4 g.21745G>A 3'UTR 
Edc4 g.7244T>C Exon 13 
 
Thap11 g.559_560insACAACA 
Gln114_Gln115insGl
nGln 
Edc4 g.9947T>C Exon 23  Thap11 g.82778G>A 3'UTR 
Edc4 g.10289A>G Exon 24  Tsnaxip1 g.13269C>T Intron 
Fam65a g.4496A>G Intron  Tsnaxip1 g.13792A>C Intron 
Fam65a g.4554C>T Intron  Tsnaxip1 g.14640T>C Intron 
Fam65a g.5213C>G Intron  Tsnaxip1 g.15332C>T Intron 
Fam65a g.5362T>C Cys906Arg  Tsnaxip1 g.15881G>C Intron 
Hsd11b2 g.4668A>T Thr388Ser  Tsnaxip1 g.16912G>C Val536Ile 
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4 Next Generation Sequencing of the Candidate Region 
Exon sequencing of most of the genes within the defined candidate region did not lead to 
any mutations that might cause alopecia. Therefore the whole candidate region was 
sequenced again by next generation sequencing (NGS). 
 
The candidate region (19:32986041..36535127) was sequenced by NGS in one BDIX, 
one PVG, and one Wistar rat as control sequences as well as in one unaffected DEB rat 
(DEB722), one histologically affected DEB rat (DEB807), and one severely affected DEB rat 
(DEB806). Target enrichment was accomplished in combination with Roche NimblGen 
hybridization System 4 which resulted in 70.1% sequence capture of the target region. In 
total, 117 variations with a coverage of at least 30 were found that were specific for the 
affected DEB806 rat and not found in any of the other samples and not in the official 
reference sequence rn4. No non-synonymous coding variation specific for DEB806 only 
could be detected. 337 variations with a coverage of at least 30 are specific for the 
histologically affected DEB807 and 91 variations with a coverage of at least 30, including 
one non-synonymous variation in the pseudogene RGD1562390 (Pro764Thr), are specific 
for DEB806 and DEB807 together. Detailed results are given in table 9. 
 
 Table 9: Variations found by NGS analysis specific for affected DEB806 only,  
 histologically affected DEB807 only, and DEB806 in common with DEB807 only. 
  First number states all variations found, second number states all variations found  
  with a coverage of at least 30. 
Variation Type Specific for DEB 806 Specific for DEB 807 
Specific for  
DEB806 and DEB807 
Intergenic 230/87 534/304 75/73 
Intronic 47/29 57/32 20/16 
Non-synonymous coding 0/0 0/0 1/1 
Synonymous coding 1/1 0/0 0/0 
UTR 2/0 1/1 1/1 
Total 280/117 592/337 97/91 
 
 
In addition, NGS data was compared to the findings of the Sanger sequencing data. Some 
variations found by Sanger sequencing could not be verified in the NGS analysis (marked 
with an x in table 10). All other detected variations could also be found in other samples 
than the affected DEB806 (table 10). A mutation as a potential cause for hair loss in 
alopecia areata could still not be identified. 
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Table 10: Comparison of variations found by sanger sequencing with NGS data 
Gene Ensembl ID Variation Position NGS-Data: variation found in 
Acd ENSRNOG00000038973 g.2503A>C Intron BDIX, DEB722, DEB806, DEB807 
Agrp ENSRNOG00000039001 g.258delG Intron x 
Agrp ENSRNOG00000039001 g.252T>G Intron DEB807 
Agrp ENSRNOG00000039001 g.251_252insT Intron DEB807 
Agrp ENSRNOG00000039001 g.859_860insG 3'UTR x 
Atp6v0d1 ENSRNOG00000017235 g.37476T>C Intron BDIX, DEB722, DEB806, DEB807 
Atp6v0d1 ENSRNOG00000017235 g.43805T>C 3'UTR BDIX, DEB806, DEB807 
RGD1307357 ENSRNOG00000024364 g.1621C>G Ala125Gly x 
RGD1307357 ENSRNOG00000024364 
g.1782_1786delCG
TGT 
Intron x 
RGD1307357 ENSRNOG00000024364 g.4037T>C Intron x 
RGD1307357 ENSRNOG00000024364 g.4159T>C Tyr317His x 
RGD1307357 ENSRNOG00000024364 g.4280T>C 3'UTR x 
Cdh3 ENSRNOG00000020129 g.20354G>T Intron DEB722, PVG 
Cdh3 ENSRNOG00000020129 g.23205G>A 3'UTR x 
Cenpt ENSRNOG00000024178 g.4285G>A Val290Met BDIX, DEB722, DEB806, DEB807 
Cenpt ENSRNOG00000024178 g.4343A>G Intron BDIX, DEB722, DEB806, DEB807 
Cenpt ENSRNOG00000024178 g.4409G>C Intron BDIX, DEB722, DEB806, DEB807 
Cenpt ENSRNOG00000024178 g.6153C>T Intron BDIX, DEB722, DEB806, DEB807 
Ctcf ENSRNOG00000017674 g.718T>A Exon 1 BDIX, DEB722, DEB806, DEB807 
Ctcf ENSRNOG00000017674 g.19452A>G 3'UTR BDIX, DEB722, DEB806, DEB807 
Ddx28 ENSRNOG00000019817 g.442A>G Ile148Val BDIX, DEB722, DEB806, DEB807 
Dpep2 ENSRNOG00000023303 g.9T>C 5'UTR x 
Dpep2 ENSRNOG00000023303 g.97G>T Intron DEB806, DEB807 
Dpep2 ENSRNOG00000023303 g.99_102delTGGG Intron x 
Dpep2 ENSRNOG00000023303 g.2902G>A Exon 7 BDIX, DEB722, DEB806, DEB807 
Dpep2 ENSRNOG00000023303 g.6176T>C Exon 11 BDIX, DEB722, DEB806, DEB807 
Dpep3 ENSRNOG00000019757 g.1986C>A Intron BDIX, DEB722, DEB806, DEB807 
Dpep3 ENSRNOG00000019757 g.5659G>A Intron x 
Edc4 ENSRNOG00000024025 g.3616T>C Exon 2 x 
Edc4 ENSRNOG00000024025 g.7244T>C Exon 13 x 
Edc4 ENSRNOG00000024025 g.9947T>C Exon 23 x 
Edc4 ENSRNOG00000024025 g.10289A>G Exon 24 x 
Fam65a ENSRNOG00000017604 g.4496A>G Intron x 
Fam65a ENSRNOG00000017604 g.4554C>T Intron x 
Fam65a ENSRNOG00000017604 g.5213C>G Intron x 
Fam65a ENSRNOG00000017604 g.5362T>C Cys906Arg x 
Hsd11b2 ENSRNOG00000017084 g.4668A>T Thr388Ser BDIX, DEB722, DEB806, DEB807 
Kctd19 ENSRNOG00000016760 g.10G>A Gly4Ser BDIX, DEB722, DEB806, DEB807 
Kctd19 ENSRNOG00000016760 g.15587G>A Exon 3 BDIX, DEB722, DEB806, DEB807 
Kctd19 ENSRNOG00000016760 g.1721T>C Intron BDIX, DEB722, DEB806, DEB807 
Kctd19 ENSRNOG00000016760 g.18853C>G Ser282Cys BDIX, DEB722, DEB806, DEB807 
Kctd19 ENSRNOG00000016760 g.20330A>G Met402Val BDIX, DEB722, DEB806, DEB807 
Kctd19 ENSRNOG00000016760 25797A>G Intron BDIX, DEB722, DEB806, DEB807 
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Gene Ensembl ID Variation Position NGS-Data: variation found in 
Lcat ENSRNOG00000019573 g.851_852insCG Intron x 
Lcat ENSRNOG00000019573 g.1351delT Intron x 
Lin10 ENSrNOG00000014668 g.15172G>A Intron x 
Lypla3 ENSRNOG00000019859 g.4627T>A Intron x 
Nol3 ENSRNOG00000015588 g.902C>A 3'UTR BDIX, DEB722, DEB806, DEB807 
Nol3 ENSRNOG00000015588 g.782_811del 
Glu193_Pro202d
el 
x 
Ntf2 ENSRNOG00000018945 g.16841T>C Intron x 
Pard6a ENSRNOG00000017746 g.837T>C Intron x 
Pard6a ENSRNOG00000017746 g.1560T>A Leu311His x 
Pard6a ENSRNOG00000017746 g.1840T>C 3'UTR x 
Pskh1 ENSRNOG00000019290 g.12459T>C Exon 2 BDIX, DEB722, DEB806, DEB807 
Pskh1 ENSRNOG00000019290 g.31521A>G Exon 3 BDIX, DEB722, DEB806, DEB807 
Psmb10 ENSRNOG00000019494 g.85C>T 5'UTR BDIX, DEB722, DEB806, DEB807 
Psmb10 ENSRNOG00000019494 g.1145T>C Intron BDIX, DEB722, DEB806, DEB807 
Psmb10 ENSRNOG00000019494 g.2283C>T Intron BDIX, DEB722, DEB806, DEB807 
Ranbp10 ENSRNOG00000018000 g.48822A>G Intron BDIX, DEB722, DEB806, DEB807 
Ranbp10 ENSRNOG00000018000 
g.57607_57608ins
TCCTTCCT 
3'UTR x 
Slc9a5 ENSRNOG00000028844 g.78878A>G Intron BDIX, DEB722. DEB806, DEB807 
Slc9a5 ENSRNOG00000028844 g.15760T>C Exon 16 BDIX, DEB722. DEB806, DEB807 
Slc9a5 ENSRNOG00000028844 g.18439C>G Exon 17 BDIX, DEB722. DEB806, DEB807 
Slc12a4 ENSRNOG00000019657 g.18675G>A Exon 18 x 
Slc12a4 ENSRNOG00000019657 g.21384A>G 3'UTR x 
Slc12a4 ENSRNOG00000019657 g.21745G>A 3'UTR x 
Thap11 ENSRNOG00000000257 
g.559_560insACAA
CA 
Gln114_Gln115in
sGlnGln 
x 
Thap11 ENSRNOG00000000257 g.82778G>A 3'UTR x 
Tsnaxip1 ENSRNOG00000018954 g.13269C>T Intron x 
Tsnaxip1 ENSRNOG00000018954 g.13792A>C Intron x 
Tsnaxip1 ENSRNOG00000018954 g.14640T>C Intron x 
Tsnaxip1 ENSRNOG00000018954 g.15332C>T Intron x 
Tsnaxip1 ENSRNOG00000018954 g.15881G>C Intron x 
Tsnaxip1 ENSRNOG00000018954 g.16912G>C Val536Ile x 
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5 Expression Analyzes 
 
5.1 Affymetrix Rat Gene 1.0 ST Array 
In addition to the direct search of candidate genes by genetic analyzes another approach 
was directed through the analysis of expression data. Therefore expression analysis was 
performed using the Affymetrix Rat Gene 1.0ST Arrays for 6 skin and 3 heart samples 
from affected DEBR rats as well as from Wistar rats as controls.  
 
The 50 most upregulated genes in skin expression have fold changes ranging between 
1,3055 and 1,6866 (see table 11 in the appendix). 10 of the 50 genes are key 
components in skin, hair, and nail structure including 3 keratin genes under the top 4 
upregulated genes. 21 of the 50 genes are involved in immunological pathways. 
 
The 50 most downregulated genes in skin expression have fold changes ranging between 
0,5822 and 0,7606, including 6 genes (5 casein genes and Lalba) involved in milk 
production (see table 12 in the appendix). 
 
Skin expression data of the candidate region Chr19:32.986.041..36.535.127, which 
includes 72 genes, resulted in fold changes ranging between 0.9274 at the lowest and 
1.1515 at the highest (see table 13 in the Appendix). 
 
The 50 most up- and downregulated genes in heart expression have fold changes ranging 
between 1.2244 and 1.4408 for the upregulated genes and between 0.6622 and 0.8528 
for the downregulated genes respectively. 13 of the 50 most upregulated genes are 
involved in immunological pathways (see table 14 in the Appendix). 
 
Heart expression data of the candidate region resulted in fold changes ranging between 
0.9160 at the lowest and 1.1527 at the highest (see table 15 in the Appendix). 
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5.2 Ingenuity Pathways Analysis (IPA) 
Functional analysis of the whole expression data set with IPA revealed significant 
associations to biological functions like cellular development (p-value 1,90E-19 - 2,21E-04, 
including 1071 genes), hematological system development and function (p-value 4,19E-19 - 
2,39E-04, including 1032 genes), and hematopoiesis (p-value 4,19E-19 - 1,31E-04, 
including 553 genes) amongst others (figure 14). The p-values are calculated using the 
right-tailed Fisher Exact Test, considering for a given function the number of functional 
analysis molecules that participate in that function and the total number of molecules that 
are known to be associated with that function in the Ingenuity Knowledge Database.  
 
Figure 14: IPA functional analysis of the whole data set. 
 
 
Functional analysis of the expression data set from the candidate region on chromosome 
19 with IPA revealed significant associations to biological functions like cell-to-cell signaling 
and interaction (p-value 3,78E-06 - 3,71E-02, 5 genes), hair and skin development and 
function (p-value 3,78E-06 - 3,14E-02, 3 genes), and tissue development (p-value 3,78E-06 
- 4,10E-02, 4 genes) amongst others (figure 15). 
 
In addition to the functional analysis of the expression data set from the candidate region 
the IPA tool Network Explorer was used to visualize molecular relationships (figure 16). 
Molecules colored in red indicate an upregulation of expression values, grey colored 
molecules did not show any significant up- or downregulation, and white colored molecules 
were not included in the uploaded data set but were added from the Ingenuity Knowledge 
Base to specifically connect two or more smaller networks by merging them into a larger 
one. 
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Figure 15: IPA bio functions for candidate region data set. 
 
Figure 16 shows a significant network including 35 genes with the associated functions of 
cell-to-cell signaling and interaction (p-value 6,57E-09 – 6,98E-03, 15 genes), connective 
tissue development and function (p-value 6,57E-09 – 2,25E-02, 11 genes), and tissue 
development (p-value 6,57E-09 – 6,98E-03, 15 genes). In this network, especially cadherin 
genes seem to be of importance. 
 
Figure 16: IPA network explorer showing molecular relationships of candidate genes. 
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5.3 Quantitative Real Time – PCR (qRT-PCR) 
The expression of the 4 keratin genes Krt25, 26, 27, and 73 found most upregulated in 
the chip based expression analysis as well as selective cadherins, catenins and 
desmogleins were validated and refined by qRT-PCR using the LightCycler 480 System 
(Roche). For each analysis RNA from 6 affected DEBs as well as 6 Wistar or 6 BD IX rats 
respectively as controls were used. Expressions were normalized with 6 housekeeping 
genes (Actin beta, Tbp, Ywhaz, Rps18, Mrp2, and Prdx2). 
 
The left hand side of figure 17 shows the mean skin expression value for keratin 27 in each 
sample. There are big differences in the expression levels of keratin 27 between the 6 
samples with the lowest fold change of about 185 in sample DEB800 and the highest fold 
change of about 660 in sample DEB811. The average keratin 27 expression in the 6 
samples is shown on the right hand side in figure 17 with a fold change of approximately 
411. Therefore keratin 27 is significantly upregulated in the DEB sample set. 
 
Figure 17: Keratin 27 expression in 6 DEBR skins in comparison to 6 Wistar skins 
 
Figure 18 shows skin expression values for keratins 25, 26, and 73. Fold changes for 
keratin 25 vary between 47 in DEB810 and 204 in DEB811. Fold changes of keratin 26 
vary between 9 in DEB810 and 80 in DEB804. Fold changes of keratin 73 vary between 
25 in DEB810 and 114 in DEB811. The average fold change in keratin 25 is 118, in 
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keratin 26 it is 31, and in keratin 73 it is 68. All three keratins are therefore upregulated in 
the DEB sample set. 
 
Figure 18: Keratin expressions in 6 DEBR skins in comparison to 6 Wistar skins 
 
Figure 19 shows skin expression values for the genes catenin alpha 1 (Ctnna1), catenin 
beta 1 (Ctnnb1), catenin delta 1 (Ctnnd1), catenin gamma (Jup), desmoglein 1 beta 
(Dsg1b), desmoglein 2 (Dsg2), desmoglein 3 (Dsg3), cadherin 1 (Cdh1), cadherin 2 (Cdh2), 
cadherin 3 (Cdh3), cadherin 4 (Cdh4), and cadherin 15 (Cdh15). Expression in all catenins, 
Dsg3, and all cadherins except Cdh15 is not significantly altered. Dsg1b shows a slight 
decrease of expression in 4 of the samples with fold changes ranging between 0,54 in 
DEB8:6 and :,77 in DEB8:9. DEB835 doesn’t show any altered expression in 
comparison to the control samples whereas DEB807 shows an overexpression in Dsg1b 
with a fold change of 7.34. All samples, except for DEB807, show an underexpression in 
Dsg2 with fold changes ranging between 0.16 in DEB810 and 0.50 in DEB809. Sample 
DEB807 is normally expressed with a fold change of 1.14. All samples, except for DEB810, 
show an underexpression in Cdh15 with fold changes ranging between 0.21 in DEB809 
and 0.64 in DEB807. Sample DEB810 is slightly overexpressed with a fold change of 2.69. 
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Figure 19: Candidate gene expressions in 6 DEBR skins in comparison to 6 BDIX skins 
 
Figure 20 shows the expression values for Desmoglein 4 (Dsg4) in skin samples. Individual 
expression is very different between the samples with fold changes ranging between 0.75 
in DEB810 and 33 in DEB809. Therefore the average fold change of Dsg4 in the skin 
samples is 13.05, pointing to a general overexpression. 
 
Figure 20: Dsg4 expression in 6 DEBR skins in comparison to 6 BDIX skins 
Ctnna1 Ctnnb1 Ctnnd1 Jup Dsg1b Dsg2 Dsg3 Cdh1 Cdh2 Cdh3 Cdh4 Cdh15
804 Skin 1,3620 1,0410 1,8261 0,4796 0,7050 0,4206 0,8117 1,2623 1,7073 0,2173 0,8571 0,4202
806 Skin 1,7642 1,1568 1,9393 1,5224 0,5351 0,3866 1,1543 1,8515 1,4158 1,1905 0,6478 0,3699
807 Skin 2,5812 1,7930 3,5512 1,1654 7,3427 1,1374 1,7483 1,8578 1,2622 1,1788 1,4529 0,6367
809 Skin 1,8238 1,5357 2,4355 1,6893 0,7707 0,4980 1,8908 1,6613 0,4064 1,2520 0,9352 0,2088
810 Skin 0,6856 1,7849 0,6893 0,5777 0,7322 0,1642 0,7731 0,7886 2,4558 0,4709 0,3933 2,6864
835 Skin 2,3653 1,2243 1,4967 1,3143 1,0649 0,3656 1,5690 1,5395 2,0398 0,7919 2,4732 0,4895
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Figure 21 shows heart expression values for the same genes as in figure 19 plus 
Desmoglein 4 (Dsg4). The expression value variation between individuals in heart samples 
is a lot lower than in skin samples. Expression in all catenins, Dsg3, and all cadherins except  
 
Figure 21: Candidate gene expressions in 6 DEBR hearts in comparison to 6 BDIX hearts 
 
Cdh1 is not altered. Downregulation can be seen in Dsg1b with the fold changes ranging 
between 0.50 in DEB806 and 0.71 in DEB807, in Dsg2 with the fold changes ranging 
between 0.13 in DEB835 and 0.16 in DEB810, and in Cdh1 with fold changes ranging 
between 0.32 in DEB806 and 0.69 in DEB804. Dsg 4 is downregulated in sample 
DEB809 with a fold change of 0.25. In all other samples it is slightly downregulated with 
fold changes ranging between 0.57 in DEB807 and 0.81 in DEB835. 
 
Figure 22 shows a comparison of the average gene expression values in the skin and heart 
samples for all analyzed genes. In all catenin genes expression is a little higher in skin 
samples compared to heart samples. The average Dsg1b skin expression is higher than in 
the heart samples because of the very high overexpression in sample DEB807 (see figure 
19). Without this sample the average fold change would be about 0.7 and therefore be 
very close to that in heart with an average fold change of 0.63 pointing to a slight 
downregulation of the gene in both tissues. Dsg 2 is significantly downregulated in both 
tissues with an average fold change of 0.14 in heart and 0.5 in skin samples. Dsg3 is 
normally expressed in both tissues whereas Dsg4 is upregulated in skin samples but 
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slightly downregulated in heart samples. Cadherin 1 expression is downregulated in heart 
samples, but not in skin samples. There are no expression changes in cadherin 2 and 
cadherin 4 compared to the control samples. Cadherins 3 and 15 are slightly 
downregulated in both skin and heart samples. 
 
Figure 22: Average candidate gene expressions in 6 DEBR skins and hearts in comparison to BDIX 
  
Ctnna1 Ctnnb1 Ctnnd1 Jup Dsg1b Dsg2 Dsg3 Dsg4 Cdh1 Cdh2 Cdh3 Cdh4 Cdh15
Skin 1,76 1,42 1,99 1,12 1,86 0,50 1,32 13,05 1,49 1,55 0,85 1,13 0,80
Heart 1,05 0,96 0,98 1,05 0,63 0,14 0,96 0,61 0,48 1,09 0,87 1,13 0,91
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5.4 Comparison of qRT-PCR data with Affymetrix RatGeneChip data 
In qRT-PCR analysis Wistar and BDIX samples respectively were used as controls whereas 
in the chip based analysis Wistar RNA was used as controls. 
 
Figure 23 shows the average fold change values for keratin genes 25, 26, 73, and 27 
generated by qRT-PCR using the LightCycler480 (LC480) system from Roche and the 
RatGeneChip microarray (GeneChip) from Affymetrix in the skin samples. The expression 
values generated with qRT-PCR show a strong overexpression of all genes. In comparison 
the expression values of the GeneChip show just a slight overexpression for all genes. 
 
Figure 23: Comparison of expression values generated by qRT-PCR and by RatGeneChip microarray 
 
Figure 24 and 25 show the average fold change values for desmoglein genes 1b, 2, 3, and 
4 as well as cadherin genes 1, 2, 3, and 15 generated by qRT-PCR using the 
LightCycler480 (LC480) system from Roche and the RatGeneChip microarray (GeneChip) 
from Affymetrix in the skin samples. The expression values generated with the 
RatGeneChip don’t show any expression changes except for a slight upregulation in Dsg4 
with a fold change of 1.32. In comparison the expression values generated by qRT-PCR 
show a significant upregulation in Dsg4, a slight upregulation in Dsg1b, a slight 
downregulation in cadherins 3 and 15, and a stronger downregulation in Dsg2. All other 
genes are commonly expressed. 
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Figure 24: Comparison of expression values generated by qRT-PCR and expression chips 
 
 
Figure 25: Comparison of expression values generated by qRT-PCR and expression chips 
 
Figure 26 shows the average fold change values for catenin genes a1, b1, d1, and Jup 
generated by qRT-PCR using the LightCycler480 (LC480) system from Roche and the 
RatGeneChip microarray (GeneChip) from Affymetrix in the skin samples. The expression 
values generated with qRT-PCR show a slight overexpression in Ctnna1 and Ctnnd1,. All 
other genes show normal expression. In comparison the expression values of the GeneChip 
show normal fold changes in all genes. 
 
Figure 27 shows the average fold change values for catenin genes a1, b1, d1, and Jup, as 
well as for desmogleins 1b, 2, 3, and 4, and cadherins 1, 2, 3, and 15 generated by qRT-
PCR using the LightCycler480 (LC480) system from Roche and the RatGeneChip 
microarray (GeneChip) from Affymetrix in the heart samples. The expression values 
generated with the GeneChip show normal fold changes in all genes. In qRT-PCR analysis 
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the expression of Dsg2 and Cdh1 is downregulated. Genes Dsg1b and Dsg 4 are slightly 
downregulated. All other genes show normal expression. 
 
Figure 26: Comparison of expression values generated by qRT-PCR and expression chips 
 
 
Figure 27: Comparison of expression values generated by qRT-PCR and expression chips 
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6 Histology 
 
6.1 HE – Staining 
From all rats skin sections were made and HE-stained to check for signs of inflammation 
and the structure and ratio of anagen, catagen, and telogen hairs to confirm the diagnosis 
of alopecia areata. 
 
In addition to skin heart sections were HE-stained for some rats. Figure 28 shows in the 
top row (figure 28 A-C) HE-stained heart sections showing the papillary muscle of BDIX rats 
which are used as controls. The bottom row (figure 28 D-F) shows the same magnifications 
in heart sections from DEB rats with severe hair loss. Large gaps can be seen between the 
cells in the DEBR heart that are not present in the BDIX heart. 
 
Figure 28 HE staining of the papillary muscle in rat heart sections. 
A-C) wildtype heart sections from a BDIX rat D-F) heart sections from a DEB rat with severe hair loss 
A+D) 10x magnification B+E) 20x magnification C+D) 40x magnification. 
 
 
 
  
BDIX rat 10x BDIX rat 20x
DEB rat 10x DEB rat 20x DEB rat 40x
A B C
D E F
BDIX rat 40x
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6.2 Immunohistochemical Staining 
Since the Network Explorer analysis with the Ingenuity Pathways Analysis software pointed 
to an important role of cadherins in the data set the Zonula Adherens Sampler Kit was 
bought allowing immunohistochemical (IHC) stainings of cadherins 1, 2, 3, 4, 5, 15, 
catenins alpha, beta, gamma (also known as plakoglobin), p120, and desmoglein 1. No 
differences could be observed in the DEB rat skins and hearts in comparison to the PVG 
rat control skins and hearts in all IHC stainings but catenin gamma. As is shown in figure 
29 the hair follicles as well as the epidermis show a strong staining of catenin gamma 
(figure 29 A+D) in PVG wildtype skins. The fluorescence intensity decreases slightly with the 
onset of AA in DEB rat skin (figure 29 B+E) and is no longer detectable at all in skin 
sections from DEB rats with developed AA.  
 
Figure 29: IHC staining of catenin gamma (yellow) and DAPI (blue) in rat skin.  
10x magnification A-C) vertical sections D-F) horizontal sections A+D) wildtype skin sections from a PVG rat 
B+E) skin sections of a DEB rat with beginning hair loss C+D) skin sections of a DEB rat with severe hair loss 
 
 
The same phenomenon can be seen in heart sections (figure 30). In addition, strong 
catenin gamma staining in heart sections of BDIX rats with 40x magnification show that 
catenin gamma is concentrated in a dense line between two adjoining cells. This is also 
observed in DEB rats with an onset of AA but additionally some cells show diffuse 
localization of catenin gamma within the cell. These cells then do not show a defined line of 
catenin gamma between two adjoining cells (figure 30 A, B). In case of developed AA 
catenin gamma can no longer be detected (figure 30 C). 
 
PVG   control rats DEB  rats – onset of AA DEB  rats – developed AA 
A B C 
D E F 
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Figure 30: IHC staining of catenin gamma (yellow) and DAPI (blue) in rat heart. 40x magnification 
White arrows in B show diffuse localization of catenin gamma within cells that have lost the focused 
localization between two adjoining cells. 
 
.  
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E Results – Human Samples 
 
1. Short Summary of the study design and the obtained results 
For reasons of clarity and better interpretation of the results a short summary of the study 
design and the obtained results will be given at this point. Results are demonstrated in 
detail within the next chapters and partially in the Appendix. 
 
Former results of a whole genome scan linkage analysis with 253.487 SNP markers of the 
Affymetrix GeneChip Human Mapping 500K Array in 112 families, including 411 
individuals, pointed to a significant locus on chromosome 19 with a non parametric lod 
score of 5 for a peak at 42.4 Mb (Build 36.3) and 4 for a second peak at 40.7 Mb (Build 
36.3). This analysis was conducted by the dermatogenetic group at the CCG, Cologne. In a 
first step, fine mapping with SNP markers was performed in this study using SNPstream, 
Taqman, and Pyrosequencing. Association analysis of the data did not lead to significant 
results. Linkage Analysis, however, resulted in significant non parametric lod scores of 4.7 
for a peak at 42.1 Mb (Build 36.3) and 3.7 for a second peak at 41.9 Mb (Build 36.3). 
Nearest genes to the SNPs with the highest lod scores were the zinc finger genes 567 as 
well as 568. These genes were therefore screened for mutations using high resolution 
melting curve analysis together with sequencing but all variations found are known as 
SNPs. 
 
In addition, more samples were collected and genotyped using the Affymetrix Genome-Wide 
Human SNP Array 6.0. This allowed for case control (CaCo) analysis with 357 cases, 
transmission disequilibrium test (TDT) with 259 families and family based linkage (FAM) 
analysis with 259 families, including 855 individuals. Associations could be detected for two 
regions each on chromosome 5 and 6 (including the HLA region) as well as a region on 
chromosome 16 in a dominant model of CaCo. P-values obtained in the TDT analysis did 
not exceed the significance threshold. FAM analysis revealed significant regions on 
chromosomes 10 and 19 with non parametric lod scores as high as 4 and 6 respectively. 
 
Finally, immunohistological stainings were made for proteins involved in adherens junctions 
and desmosomes showing abnormalities for the catenin plakoglobin, cadherin 3 and 15. 
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2 Fine mapping of the Candidate Region on Chromosome 19 
 
A former linkage analysis with 112 families, including 411 individuals, that was performed 
at the CCG (dermatogenetics group) pointed to a significant region on chromosome 19. 
This region, which includes 60 genes and is about 10.6 Mb in size, was therefore fine 
mapped in this study using SNPstream analysis. Some SNPs that failed were genotyped 
again with either Taqman analysis or Pyrosequencing. Table 16 shows the analyzed SNPs 
and their genomic location (GRCH37) on chromosome 19.  
 
Table 16: Genotyped SNPs and their genomic positions on chromosome 19. 
SNP Position (GRCH37) SNP Position (GRCH37) SNP Position (GRCH37) 
rs11672876 30.231.605 rs2301617 36.041.707 rs472226 37.458.213 
rs583121 34.718.558 rs17776451 36.043.949 rs475026 37.458.517 
rs2290652 35.174.708 rs2733743 36.050.469 rs17639910 37.466.629 
rs12110 35.660.008 rs2285421 36.168.414 rs1667354 37.481.651 
rs541169 35.718.520 rs231233 36.270.639 rs7246473 37.533.839 
rs12975589 35.839.230 rs437168 36.333.919 rs8102196 37.581.704 
rs8107905 35.921.197 rs2285424 36.498.673 rs1533736 37.654.476 
rs409093 35.940.748 rs1008328 36.594.936 rs11084878 37.667.969 
rs926026 35.966.924 rs3108186 37.184.470 rs12459637 37.689.498 
rs11880530 35.968.644 rs1830031 37.202.749 rs320890 37.703.600 
rs8102875 35.969.289 rs826986 37.237.210 rs172786 37.712.484 
rs8113518 35.976.659 rs1673082 37.240.641 rs2460950 37.752.739 
rs6510490 35.976.809 rs1227820 37.257.017 rs1530500 37.823.311 
rs7976 35.977.799 rs2245366 37.263.834 rs3745765 37.853.735 
rs17638216 35.977.958 rs8107274 37.284.893 rs10422527 37.893.968 
rs2293690 35.978.077 rs11670106 37.296.831 rs12461941 37.984.150 
rs10407971 35.978.964 rs1148399 37.328.805 rs8109103 37.993.611 
rs11880364 35.988.294 rs1144540 37.330.113 rs12977460 38.023.771 
rs2293693 35.989.472 rs1035441 37.353.291 rs1038084 38.030.182 
rs4254439 35.997.862 rs10403306 37.374.779 rs10500277 38.056.902 
rs7245699 35.998.991 rs543518 37.385.711 rs4803277 38.072.427 
rs7254211 36.003.221 rs7250197 37.388.970 rs17245425 38.074.094 
rs4806163 36.003.606 rs16971772 37.394.406 rs2927743 38.131.834 
rs1108552 36.011.495 rs547483 37.440.865 rs35153242 38.151.242 
rs2106446 36.011.584 rs496730 37.450.939 rs2909109 38.168.855 
rs17705633 36.015.152 rs569371 37.453.497 rs17246792 38.183.762 
rs12151182 36.023.232 rs474017 37.453.619 rs241941 38.307.516 
rs17705657 36.024.242 rs565721 37.455.331 rs1469698 38.993.056 
rs11882238 36.030.898 rs7251087 37.455.403 rs8103362 39.759.691 
rs2239945 36.032.960 rs519551 37.455.448 rs759120 40.357.183 
rs7599 36.037.890 rs7254717 37.456.902 rs744389 40.904.102 
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2.1 Association Analyzes (CaCo; TDT) 
Case control (CaCo) genetic association analysis was conducted with the software PLINK. 
760 individuals were included with 407 cases and 353 controls. 131 individuals were 
male and 629 individuals were female. The data set was checked for mendelian errors and 
unlikely genotypes prior to case control analysis. Therefore a total of 51 genotypes were 
deleted. Table 17 (see Appendix) shows the calculated p – values for each SNP in a 
dominant and a recessive model of the case control study. The significance threshold is not 
reached by any SNP in either model. Figures 31 and 32 show the results as a scatter plot. 
 
Figure 31: Scatter plot for case control analysis with a recessive model using PLINK. 
Positions in Build36.3 
 
 
Figure 32: Scatter plot for case control analysis with a dominant model using PLINK. 
Positions in Build36.3 
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Transmission Disequilibrium Test (TDT) analysis was performed with the software PLINK. 
199 families were included. The data set was checked for mendelian errors and unlikely 
genotypes prior to TDT analysis. Therefore a total of 89 genotypes were deleted. Table 18 
(see Appendix) shows the calculated p – values for each SNP of which neither one reached 
significance. 
 
 
2.2 Linkage Analyzes (ASP; FAM) 
An Affected Sib Pair (ASP) linkage analysis was performed with the software MERLIN for 
77 families including 320 individuals. The data set was checked for mendelian errors and 
unlikely genotypes prior to linkage analysis. Therefore a total of 130 genotypes were 
deleted. Table 19 (see Appendix) shows the calculated npLOD and HLOD values for each 
SNP. 
 
Figures 33 and 34 show the results graphically in a plot. There are two separate regions 
with SNPs that exceed the significance threshold of 2.6. The first region is defined by SNPs 
rs3108186 and rs1830031 with the highest HLOD score for SNP rs1830031 of 2.886 
and the highest npLOD score of 3.240. This first region includes the gene ZNF567 only. 
The second region is defined by SNPs rs10403306 and rs2460950 with the highest 
HLOD score for SNP rs496730 of 2.971 and the highest npLOD score of 3.510. This 
second region includes 9 genes. 6 of them are zinc finger proteins with ZNF568 lying 
closest to the SNP with the highest LOD scores. 
 
Figure 33: Plot of –log(p-value) in a parametric ASP linkage analysis using MERLIN. 
Positions in Build36.3. Disease allele with frequency of 0.01. Penetrances are 0.00, 0.8, 0.8 for wildtype 
homozygotes, heterozygote carriers and risk allele homozygotes, respectively 
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Figure 34: Plot of –log(p-value) in a non-parametric ASP linkage analysis using MERLIN. 
Positions in Build36.3 
 
 
A family based linkage analysis (FAM) was performed with the software MERLIN for 301 
families including 1131 individuals. The data set was checked for mendelian errors and 
unlikely genotypes prior to linkage analysis. Therefore a total of 144 genotypes were 
deleted. Table 20 (see Appendix) shows the calculated npLOD and HLOD values for each 
SNP. 
 
Figures 35 and 36 show the results graphically in a plot. There are two separate regions 
with SNPs that exceed the significance threshold of 3.6. The first region is defined by SNPs 
rs3108186 and rs1830031 with the highest HLOD score of 3.739 and the highest  
 
Figure 35: Plot of –log(p-value) in a family based parametric linkage analysis using MERLIN. 
Positions in Build36.3. Disease allele with frequency of 0.01. Penetrances are 0.00, 0.8, 0.8 for wildtype 
homozygotes, heterozygote carries and risk allele homozygotes, respectively 
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npLOD score of 3.730 for SNP rs1830031. This first region includes the gene ZNF567 
only. The second region is defined by SNPs rs1144540 and rs10422527 with the highest 
HLOD score of 4.374 and the highest npLOD score of 4.740 for SNP rs496730. This 
second region includes 14 genes. 8 of them are zinc finger proteins with ZNF568 lying 
closest to the SNP with the highest LOD scores. 
 
Figure 36: Plot of –log(p-value) in a family based non-parametric linkage analysis using MERLIN. 
Positions in Build36.3  
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3 Mutation Screening in Candidate Genes ZNF567 and ZNF568 
Fine mapping of chromosome 19 with SNP markers resulted in two closely neighboring 
regions with significant lod scores. The SNP markers with the highest lod score in these 
regions are either in or next to the genes ZNF567 and ZNF568 respectively. Therefore 
these genes were scanned for mutations with high resolution melting curve analysis using 
the LightCycler480 system from Roche. 46 samples from the most affected family 
members of affected sib pair families were used as well as CEPH control DNA and one 
negative control. Table 21 shows the number of genotypes found for each amplicon. Two 
samples of each genotype group were then sequenced to check for variations. If there 
were more than 6 genotype groups all samples were sequenced. No mutations were found 
since all differing genotype groups were due to known SNP variants. In future experiments 
this region will be sequenced again by NGS. 
 
Table 21: Number of genotypes found by HRM curve analysis in genes ZNF567 and ZNF568 
PCR amplicon 
Number of 
detected 
genotypes 
PCR amplicon 
Number of 
detected 
genotypes 
PCR amplicon 
Number of 
detected 
genotypes 
ZNF567_e1F 2 ZNF568_e6F 5 ZNF568_e8.1F >6 
ZNF567_e2-3F 5 ZNF568_e7.1F 2 ZNF568_e8.2F 6 
ZNF567_e4F 1 ZNF568_e7.2F 1 ZNF568_e8.2_2F >6 
ZNF567_e5.1F 4 ZNF568_e7.3F 4 ZNF568_e9F 2 
ZNF567_e5.2F 5 ZNF568_e7.4F 3 ZNF568_e10F >6 
ZNF567_e5.3R 2 ZNF568_e7.5F 4 ZNF568_e11F 5 
ZNF567_e5.4F 2 ZNF568_e7.6F 6 ZNF568_e12_2F 1 
ZNF567_e5.5F 1 ZNF568_e7.7F 1 ZNF568_e13_2F 4 
ZNF567_e5.6F 1 ZNF568_e7.8R 2 ZNF568_e14F 4 
ZFN568_e1F 2 ZNF568_e7.9F 3 ZNF568_e15.1F 1 
ZNF568_e2F 1 ZNF568_e7.10F 6 ZFN568_e15.2F >6 
ZNF568_e3R 1 ZNF568_e7.11_2F >6 ZNF568_e15.3F 5 
ZFN568_e4F 1 ZNF568_e7.12_2F 2 ZNF568_e15.4F 5 
ZNF568_e5F 1 ZNF568_e7.13F 3 
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4 Whole Genome Association and Linkage Data Analyzes with a Larger 
Sample Set 
 
4.1 Association Analyzes (CaCo; TDT) 
Case control (CaCo) genetic association analysis including 258.673 SNPs was conducted 
with the software PLINK. 2891 individuals were included with 357 cases and 2534 
controls. The data set was checked for mendelian errors and unlikely genotypes prior to 
case control analysis. Therefore a total of 88069 genotypes were deleted. There were no 
significant results using a recessive model. Figure 37 shows the results of a dominant 
model in a manhattan plot, pointing to significant regions on chromosomes 5, 6, and 16. 
 
Figure 37: Manhattan plot for case control analysis with a dominant model using PLINK. 
Positions in Build36.3 
 
 
Figure 38 shows a scatter plot for the case control analysis using a dominant model on 
chromosome 5 pointing to 2 significant clusters exceeding the significance threshold of 1e-
06. The first region is defined by SNPs rs10512779 and rs4473739 with the lowest p-
value of 5.55e-6 for SNP rs7720820. This first region includes the gene ADAMTS16 only. 
The second region is defined by SNPs rs6596007 and rs12653237 with the lowest p-
value of 8.76e-7 for SNP rs27421. This second region includes 7 genes (CDC42SE2, 
LOC100505941, RAPGEF6, FNIP1, ACTBP4, LOC100505572, LOC728637). Tables 22 
and 23 (see Appendix) show the significant cluster regions in detail with the according 
SNPs and their p-values. 
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Figure 38: Scatter plot for case control analysis with a dominant model using PLINK for chr 5 only. 
Positions in Build36.3 
 
 
Figure 39 shows a scatter plot for the case control analysis on chromosome 6 pointing to 
3 significant SNP clusters exceeding the significance threshold of 1e-06. The first region is 
defined by SNPs rs123367 and rs2523405 with the lowest p-value of 4.87e-06 for SNP 
rs29228. This first region includes 5 genes (HLA-F, ZFP57, MOG, and 2 pseudogenes).  
 
Figure 39: Scatter plot for case control analysis with a dominant model using PLINK for chr 6 only. 
Positions in Build36.3 
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The second region is defined by SNPs rs3135363 and rs3892710 with the lowest p-value 
of 4.34e-09 for SNP rs9268856. This second region includes 7 genes. All of these genes 
are part of the HLA complex. The third region is defined by SNPs rs6557200 and 
rs2181923 with the lowest p-value of 3.14e-07 for SNP rs5017316. This region includes 
5 genes (ULBP1, LOC646024, RAET1L, LOC100131886, and 1 pseudogene). Tables 24, 
25 and 26 (see Appendix) show the significant cluster regions in detail with the according 
SNPs and their p-values. 
 
Figure 40 shows a scatter plot for the case control analysis on chromosome 16 pointing 
to one significant SNP clusters exceeding the significance threshold of 1e-06. This region is 
defined by SNPs rs6498146 and rs9746695 with the lowest p-value of 7.40e-07 for SNP 
rs3893660. This first region includes 1 pseudo gene and CLEC16A. Table 27 (see 
Appendix) shows the significant cluster regions in detail with the according SNPs and their 
p-values. 
 
Figure 40: Scatter plot for case control analysis with a dominant model using PLINK for chr 16 only. 
Positions in Build36.3 
 
 
Figure 41 shows the results of a trend model in a manhattan plot, pointing to significant 
clusters on chromosomes 5 and 6 reaching p-values lower than 1e-06.  
 
Figure 42 shows a scatter plot for the case control analysis on chromosome 5 pointing to 
2 significant clusters exceeding the significance threshold of 1e-06. The first region is  
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Figure 41: Manhattan plot for case control analysis with a trend model using PLINK. 
Positions in Build36.3 
 
 
Figure 42: Scatter plot for case control analysis with a trend model using PLINK for chr 5 only.  
Positions in Build36.3 
 
defined by SNPs rs2913657 and rs4473739 with the lowest p-value of 1.81e-7 for SNP 
rs7720820. This first region includes the gene ADAMTS16 only. The second region is 
defined by SNPs rs17165964 and rs253943 with the lowest p-value of 6.59e-6 for SNP 
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rs11242095. This second region includes 9 genes. Tables 28 and 29 (see Appendix) 
show the significant cluster regions in detail with the according SNPs and their p-values. 
 
Figure 43 shows a scatter plot for the case control analysis on chromosome 6 pointing to 
3 significant SNP clusters exceeding the significance threshold of 1e-06. The first region is 
defined by SNPs rs1611699 and rs2517595 with the lowest p-value of 7.69e-06 for SNP 
rs1264702. This first region includes 35 genes of which most belong to the HLA complex. 
The second region is defined by SNPs rs9268429 and rs9296044 with the lowest p-value 
of 5.35e-12 for SNP rs9469220. This second region includes 10 genes. All of these genes 
are part of the HLA complex. The third region is defined by SNPs rs4870174 and 
rs11155699 with the lowest p-value of 3.31e-8 for SNP rs5017316. This third region 
includes 5 genes of which 3 are pseudogenes. Tables 30, 31 and 32 (see Appendix) show 
the significant cluster regions in detail with the according SNPs and their p-values. 
 
Figure 43: Scatter plot for case control analysis with a trend model using PLINK for chr 6 only.  
Positions in Build36.3 
 
 
A Transmission Disequilibrium Test (TDT) was performed for 259 families with the 
software PLINK. The data set was checked for mendelian errors and unlikely genotypes 
prior to TDT analysis. Therefore a total of 88069 genotypes were deleted. Figure 44 shows 
the results in a manhattan plot. No SNP clusters reached the significance threshold. 
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Figure 44: Manhattan plot for a transmission disequilibrium test using PLINK. 
Positions in Build36.3 
 
4.2 Linkage Analyzes (FAM) 
A family based linkage analysis (FAM) with a set of 271.150 SNPs was performed with the 
software MERLIN for 259 families including 855 individuals. The data set was checked for 
mendelian errors and unlikely genotypes prior to linkage analysis. Therefore a total of 
88.069 genotypes were deleted. Figure 45 shows the results in a plot, pointing to 
significant clusters on chromosomes 10 and 19 reaching npLOD scores of 3.6 or higher. 
 
Figure 45: Plot of npLOD scores in a family based non parametric linkage analysis with 271.150 SNPs 
using MERLIN. Positions in Build36.3 
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Figure 46 shows a plot of Chr10 for the family based linkage analysis with 271.150 SNPs 
pointing to 3 significant SNP clusters exceeding the significance threshold of 3.6. The first 
region is defined by SNPs rs12246970 and rs17136375 with the highest npLOD score 
of 3.99 for SNPs rs1539231, rs11252693, and rs2096134. This first region includes 3 
genes (DIP2C, LOC642278, C10orf108). The second region is defined by SNPs 
rs17294166 and rs11250965 with the highest npLOD score of 3.77 for SNPs rs7082514, 
rs11250838, rs4077784, rs9919410, rs10794793, and rs10794794. There are no genes 
located within this region. The third region is defined by SNPs rs10751884 and rs1909690 with 
the highest npLOD score of 3.88 for SNPs rs2065683, rs2184413, rs2065685, and 
rs11251502. There are no genes within this region. Tables 33, 34, and 35 (see Appendix) 
show the calculated npLOD values for each SNP in the 3 clustered regions. 
 
Figure 46: Plot of npLOD scores in a family based non parametric linkage analysis for chromosome 10 
only using MERLIN. Positions in Build36.3 
 
 
Figure 47 shows a plot of chromosome 19 for the family based linkage analysis with 
271.150 SNPs pointing to 1 significant SNP cluster exceeding the significance threshold of 
3.6. The region is defined by SNPs rs2432055 and rs41465446 with the highest npLOD 
score of 6.13 for SNPs rs713256 and rs256733. This region contains 48 genes, 
including 27 zinc finger genes. The highest npLOD score is found within gene ZNF527. 
Table 36 (see Appendix) shows the calculated npLOD values for each SNP in the clustered 
region. 
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Figure 47: Plot of npLOD scores in a family based non parametric linkage analysis for chromosome 19 
only using MERLIN. Positions in Build36.3 
 
A family based linkage analysis (FAM) with a set of 62.990 SNPs was performed with the 
software MERLIN for 259 families including 855 individuals. The data set was checked for 
mendelian errors and unlikely genotypes prior to linkage analysis. Therefore a total of 
88.069 genotypes were deleted. Figure 48 shows the results in a plot, pointing to a 
significant cluster on chromosomes 19 reaching an npLOD score of 4.15. 
 
Figure 48: Plot of npLOD scores in a family based non parametric linkage analysis with 62.990 SNPs 
using MERLIN. Positions in Build36.3 
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Figure 49 shows a plot of Chr19 for the family based linkage analysis with 62.990 SNPs 
pointing to 1 significant SNP cluster exceeding the significance threshold of 3.6. The region 
is defined by SNPs rs16970276 and rs2278431 with the highest npLOD score of 4.15 
for SNP rs256733. This region contains 93 genes, including KRTDAP, DMKN, and SBSN 
and 30 zinc finger genes. The highest npLOD score is found within gene ZNF527. Table 37 
(see Appendix) shows the calculated npLOD values for each SNP in the clustered region. 
 
Figure 49: Plot of npLOD scores in a family based non parametric linkage analysis for chromosome 19 
only using MERLIN. Positions in Build36.3 
 
 
A family based linkage analysis (FAM) with a set of 83.371 SNPs was performed with the 
software MERLIN for 259 families including 855 individuals. The data set was checked for 
mendelian errors and unlikely genotypes prior to linkage analysis. Therefore a total of 
35.601 genotypes were deleted. Figure 50 shows the results in a plot, pointing to a 
significant cluster on chromosomes 19 reaching an npLOD score of 3.87. 
 
Figure 51 shows a plot of Chr19 for the family based linkage analysis with 83.371 SNPs 
pointing to 1 significant SNP cluster exceeding the significance threshold of 3.6. The region 
is defined by SNPs rs16970293 and rs12462868 with the highest npLOD score of 3.87 
for SNP rs2239945. This region contains 31 genes, including KRTDAP, DMKN, and SBSN. 
The highest npLOD score is found within gene GAPDHS. Table 38 (see Appendix) shows the 
calculated npLOD values for each SNP in the clustered region. 
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Figure 50: Plot of npLOD scores in a family based non parametric linkage analysis with 83.371 SNPs 
using MERLIN. Positions in Build36.3 
 
 
Figure 51: Plot of npLOD scores in a family based non parametric linkage analysis for chromosome 19 
only using MERLIN. Positions in Build36.3 
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3 Histology 
 
3.1 HE – Staining 
Perifollicular inflammatory infiltrate was evident in all 3 HE – stained samples (figure 52). 
 
Figure 52: HE staining in human skin sections. 
A-C)10x magnification D-F) 20x magnification A+D) skin from an alopecia areata patient, taken from a spot on 
the head where hair was still growing B+E) skin from the same alopecia areata patient but taken from the 
center of a hairless patch C+F) skin from an alopecia univeralis patient. 
 
 
3.2 Immunohistochemical Staining 
Immunohistochemical (IHC) stainings of cadherins 1, 2, 3, 15, catenins alpha, beta, 
gamma, p120, and desmoglein 1 were done in human skin samples. Differences between 
the samples could be observed in the catenin gamma, cadherin 15, and cadherin 3 
stainings only.  
As is shown in figure 53 the hair follicles show a strong staining of catenin gamma in an 
alopecia areata skin sample where hair is still growing (figure 53 A+D). The fluorescence 
intensity decreases slightly in the alopecia areata skin sample from a central area of hair 
loss (figure 53 B+E) and is no longer detectable in skin sections from an alopecia 
universalis sample (figure 53 C+F). 
 
Figure 54 shows the IHC staining of cadherin 15 in human skin. There is a strong staining 
of the epidermis in the alopecia areata skin sample (figure 54 A, B, D, E) whereas there is 
Alopecia areata_wHair_10x Alopecia areata_w/oHair_10x
Alopecia areata_wHair_20x Alopecia areata_w/oHair_20x Alopecia universalis_20x
A B C
D E F
Alopecia universalis_10x
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only a slight staining of the stratum granulosum evident in the alopecia universalis skin 
sample (figure 54 C+F). 
 
Figure 53: IHC staining of catenin gamma (yellow) and DAPI (blue) in human skin. 
A-C)10x magnification D-F) 20x magnification A+D) skin from an alopecia areata patient, taken from a spot on 
the head where hair was still growing B+E) skin from the same alopecia areata patient but taken from the 
center of a hairless patch C+F) skin from an alopecia univeralis patient. 
 
 
Figure 54: IHC staining of cadherin 15 (yellow) and DAPI (blue) in human skin. 
20x magnification A-C) cadherin 15 staining D-F) merged picture with bright light, cadherin 15 and DAPI 
staining A+D) skin from an alopecia areata patient, taken from a spot on the head where hair was still 
growing B+E) skin from the same alopecia areata patient but taken from the center of a hairless patch 
C+F) skin from an alopecia univeralis patient. 
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Figure 55 shows the IHC staining of cadherin 3 in human skin. There is a strong staining of 
the epidermis in the alopecia areata skin sample (figure 55 A, B, D, E) whereas there is only 
a slight staining of the stratum granulosum evident in the alopecia universalis skin sample 
(figure 55 C+F). 
 
Figure 55: IHC staining of cadherin 3 (yellow) and DAPI (blue) in human skin. 
20x magnification A-B) cadherin 3 and DAPI staining C) cadherin 3 staining D-F) merged picture with bright 
light, cadherin 3 and DAPI staining A+D) skin from an alopecia areata patient, taken from a spot on the head 
where hair was still growing B+E) skin from the same alopecia areata patient but taken from the center of a 
hairless patch C+F) skin from an alopecia univeralis patient. 
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F Discussion 
 
1. Expression Analyzes 
In this study only < 2 fold changes could be detected with the microarray analysis for DEB 
rat skin and heart samples compared to Wistar rats. The highest obtained fold change in 
skin was 1.6866 and in heart it was 1.4408. Expression of genes within the candidate 
region of chromosome 19 only reached fold changes between 0.92 and 1.15 in skin and 
heart samples. As will be discussed below, differential expression detection and sensitivity 
is significantly reduced in this expression range. Still, an overall tendency of upregulation in 
genes affecting the immune system in skin and heart samples could be detected. In 
addition several genes affecting the skin, hair and nail structure could be found among the 
top 50 upregulated genes in skin samples, including several keratin genes such as Krt25 
(fold change 1.6866), Krt27 (fold change 1.6133), Krt 73 (fold change 1.5567), and 
Krt26 (fold change 1.4687).  
 
Keratins are the typical intermediate filament proteins of epithelia. They form heterodimers 
with one type I ―“acidic”‖ and one type II ―“basic to neutral”‖ keratin protein in a α-helical 
coiled-coil confirmation. These dimers assemble to tetramers, then to octamers and form 
eventually intermediate filaments (IF). Single keratins deviating from equimolar type I/type II 
amounts are rapidly degraded (Lu and Lane 1990). It has been shown that bundled IFs 
braid the nucleus inside the cell, span through the cytoplasm and are attached to the 
cytoplasmic plaques of desmosomes which are the typical epithelial cell-cell adherens 
junctions (Waschke 2008). Therefore keratins are crucial for the mechanical stability and 
integrity of epithelial cells and tissues. In addition to this mechanical function of keratins, 
several regulatory functions have been discovered. Among them are the protection of the 
placental and trophoblast barrier function (Jaquemar 2003; Hesse 2000), the protection 
from apoptosis (Caulin 2000, Tong 2006), the protection of the liver against stress and 
from injury (Zatloukal 2000, Ku 2003), and the regulation of protein synthesis and cell size 
during wound healing involving intracellular signaling pathways (Kim 2006). In addition, they 
may also play a role in epithelial polarity and membrane traffic (Oriolo 2007). 
Some epithelial keratins are specifically expressed in and closely restricted to the 
compartments of the hair follicle inner root sheath. These include type I keratins K25-K28 
and type II keratins K71-74 (Langbein 2004, 2006). Compared to the masses of hair and 
epidermal keratins these hair follicle keratins are quantitatively under-representated in the 
tissue. Human hair disorders related to these keratins have not yet been discovered (Moll 
2008). Figure 56 gives an overview of the expression sites of all hair and hair follicle 
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specific keratins in the human hair follicle. Interestingly, all keratins found with a tendency to 
overexpression via microarray in this study belong to the inner root sheath specific 
keratins. As has been stated in the introduction to hair, the cornified inner root sheath 
anchors and directs the growth of the emerging hair shaft. These findings lead to the 
assumption of a structural defect as a secondary effect to the basic cause of alopecia. 
 
Figure 56: Summary schemes of the expression of all hair and hair follicle-specific keratins in the human 
hair follicle. (From Moll R. The human keratins: biology and pathology. Histochem Cell boil 2008; 129:705-
733) 
 
 
 
 
 
Human keratins are clustered at two chromosomal regions. All type I keratins (except 
KRT18) are found at chromosome site 17q21.2 whereas all type II keratins and KRT18 
are found at chromosome site 12q13.13. It has been demonstrated in knock-out 
experiments and in genetic diseases that mutations in keratin genes often cause more 
severe defects than the complete loss of a keratin gene whose failure might be 
compensated by other keratins (Moll 2008). Regulation of keratin gene expression in the 
skin is mostly found at the transcriptional level (Stellmach 1991). It has been shown, that 
certain sequences in the 5’ upstream region of the genes are involved in regulation 
processes, as for example AP2-binding sites (Fuchs 1995). 
 
Among the potentially downregulated genes in rat skin several caseins stand out. Caseins 
are major components of milk. Therefore a downregulation in these proteins might explain 
why the mother rats do not produce enough milk for their offspring so that they finally 
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dehydrate and die or get eaten by the mother animal. This problem was overcome by 
feeding the newborns with curd cheese mixed with mashed bananas as early as possible 
giving proof that the initial problem of dehydration was due to the lack of milk production in 
the mother animal and not due to physiological problems in the offspring. There is no 
reason to believe that this phenomenon is related to AA, though, and is probably an artifact 
resulting from the extreme homogeneity of the strain after about 63 generations of 
inbreeding.  
 
For better interpretation of the data it was loaded into the IPA program and functional 
analysis was performed. This resulted in an obvious association to biological functions like 
cellular development, hematological system development and function as well as 
hematopoiesis with p-values as low as 4.19E-19. These findings further emphasize the 
immunological component in AA pathology. Functional analysis with expression data from 
the candidate region on chromosome 19 only revealed associations to biological functions 
as cell-to-cell signaling and interaction, hair and skin development and function, and tissue 
development with p-values as low as 3,78E-06 indicating an underlying structural defect. 
One might speculate upon these findings if there is first a structural defect, for example in 
hair formation, and thereafter the immune system is activated or if the primary cause is an 
immunological defect attacking hair structures and with that inducing an upregulation in 
hair and skin structure gene expression. Exploring molecular relationships for genes within 
the candidate region with the Network Explorer function of IPA produced a network of 35 
genes in total pointing again to biological functions like cell-to-cell signaling and interaction, 
connective tissue development and function as well as tissue development in general with 
p-values as low as 6,57E-09. Especially cadherin genes stood out as important genes within 
the network. 
 
Cadherins are a superfamily of about 80 members of single-pass transmembrane proteins 
involved in Ca2+-dependent homotypic cell adhesion and are characterized by an 
extracellular, a transmembrane, and an intracellular domain (Tepass 2000). Depending on 
their domain composition, genomic organization, and structure cadherin molecules are 
divided into six subgroups. These are type I (classical), type II, desmosomal, proto-, Flamingo, 
and FAT-like cadherins (Gooding 2004). In this context especially type I and desmosomal 
cadherins are of importance and shall be therefore further described.  
With their extracellular domain classical cadherins mediate homotypic as well as hetero-
typic cell-cell or cell-matrix interactions which are often sufficient to provide Ca2+-dependent 
adhesion. In addition interactions of the cadherin cytoplasmic tail with the cytoskeleton 
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significantly increase the strength of cadherin-mediated adhesion (Yap 1997). This is for 
example accomplished by building a protein complex of Cadherin 1 (also known as E-
cadherin; one of the best characterized cadherins) with catenin beta or catenin gamma 
and catenin alpha, which in turn links the complex either directly to the actin cytoskeleton 
or indirectly through alpha-actinin, vinculin, ZO-1, or spectrin (Yamada & Geiger 1997). 
Cadherin 1 mediates not only the assembly of adherens junctions, but also affects the 
formation of desmosomes and tight junctions (Gumbiner 1988, Wheelock & Jensen 
1992). The cytoplasmic domain of cadherin becomes unstructured when unbound to 
catenin beta (Huber 2001), which is in addition to its function in cadherin-based adhesion 
an important mediator in the Wnt-signaling pathway (Miller 1999, Peifer 2000) that 
controls several events in development like differentiation, proliferation, and morphogenesis 
(Wodarz & Nusse 1998). The function of cadherins is therefore not limited to linking cells 
together and forming protein complexes inside the cells, but they also interact in signaling 
pathways of differentiation, proliferation, and migration (Knudsen 1998). They do that 
either by organizing signaling components or by the formation of close cell-cell contact, 
which affects the signaling mechanisms indirectly (Fagotto & Gumbiner 1996). 
Besides desmoplakin, plakoglobin, and plakophilin the desmosomal cadherins desmoglein 
and desmocollin are major components of desmosomes (Huen 2002). Desmosomes 
ensure very strong cell-cell contacts and are crucial to all tissues under constant 
mechanical stress, such as the skin, myocardium, bladder, and gastrointestinal mucosa 
(Getsios 2004, Holthofer 2007). With electron microscopy three distinct areas can be 
identified which is the extracellular core region (desmoglea), the outer dense plaque (ODP), 
and the inner dense plaque (IDP) (Kowalczyk 1994, Garrod & Chidgey 2008). The 
extracellular domains of the desmogleins and desmocollins mediate cell-cell adhesion, 
whereas the cytoplasmic tails bind linker proteins, such as plakoglobin and plakophilin, in 
the ODP region. Desmoplakin associates with both linker proteins and finally attaches to 
intermediate filaments within the IDP region, tethering the cytoskeletal network to the 
adhesion complex (Figure 57) (Delva 2009). Seven desmosomal cadherins (desmoglein 1-
4 and desmocollin 1-3) are known at present which are differentially expressed as 
keratinocytes undergo terminal differentiation (Kottke 2006, Holthofer 2007). 
Desmogleins 1 and 4, as well as desmocollin 1 are mainly expressed in the upper layers of 
the epidermis, whereas desmogleins 2 and 3, as well as desmocollins 2 and 3 are mainly 
expressed in the lower layers (Figure 58). Genetic mouse models as well as a number of 
inherited and acquired human diseases (as for example arrhythmogenic right ventricular 
cardiomyopathy and pemphigus) implicate that a tight regulation of desmosomal cadherin 
expression pattern is crucial for correct tissue homeostasis and have therefore important  
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Figure 57: A structure model of desmosomes. (From Delva E, Tucker DK, Kowalczyk AP. The desmosome. 
Cold Spring Harb Perspect Biol 2009; 1:a002543) 
 
(A) Electron micrograph of 
a desmosome.  
(B) Schematic of desmoso-
mal proteins and relative 
distance from the plasma 
membrane (PM). The des-
mosomal cadherins, the 
desmogleins and desmo-
collins, extend into extra-
cellular core and outer 
dense plaque (ODP) to 
establish contact and 
adhere to neighboring 
cells in a Ca2+-dependent 
manner. The cadherin 
cytoplasmic tails associate 
linker proteins, plakoglobin 
(PG), the plakophilins 
(PKP), and desmoplakin 
(DP). DP binds to keratin 
intermediate filaments 
(KIF) within the inner 
dense plaque (IDP), 
serving to tether the 
intermediate filaments to 
the plasma membrane. 
 
 
 
Figure 58: Expression patterns of the desmosomal cadherins in the epidermis. (From Delva E, Tucker DK, 
Kowalczyk AP. The desmosome. Cold Spring Harb Perspect Biol 2009; 1:a002543) 
 
Expression patterns of the desmosomal cadherins in the epidermis. The epidermis is a stratified epithelium 
comprised of four distinct layers—the basal layer, spinous layer, granular layer, and the stratum corneum. 
Keratin filaments are shown connecting to desmosomes at sites of cell–cell contact and to 
hemidesmosomes at the basement membrane. The relative expression profiles of the various desmosomal 
cadherins and plaque proteins in the epidermal layers are depicted on the right. 
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functions in epithelial proliferation and differentiation, as well as the strong cell-cell adhesion 
that is required for tissue integrity (Delva 2009). 
 
DNA microarrays, such as Affymetrix GeneChips, are a powerful and cost-effective tool to 
analyze expression from thousands of genes simultaneously. But when analyzing and 
interpreting the data one has to keep in mind, that there are no standard methods 
available for that, yet, and that therefore fold-changes can vary greatly depending on the 
algorithms used. More than 50 methodological proposals for processing Affymetrix 
GeneChip data have been published (Noriega 2009). In addition, a certain level of fold 
change compression (often two- to tenfold compared to qRT-PCR) has to be expected for 
microarrays (Conway and Schoolnick 2003). This phenomenon might be due to various 
technical limitations like limited dynamic range, signal saturations, and cross-hybridizations 
as well as by certain data-processing/normalization algorithms that aim to reduce 
variances (Wang 2006). To reduce cross-hybridization effects Affymetrix GeneChips probe 
pairs consist of a perfect match (PM) sequence and a mismatch (MM), which have one 
mismatched base pair located at the center of the sequence (Noriega 2009). However, it 
is also debated on which method is best to integrate PM and MM hybridization signal 
intensities into an assembled signal for each gene (Irizarry 2006). Further factors causing 
variation in data analysis are differences in RNA quality or quantity, the microarray 
manufacturing process, hybridization conditions, and scanning efficiency (Noriega 2009). 
Wang et al (2006) have shown that microarrays have acceptable sensitivity and accuracy 
in detecting differential expression, especially for genes with high and medium expression 
levels and for detecting > 2-fold changes. Therefore microarray performance can be 
accepted as a reliable exploratory tool for genome-wide gene expression analysis. At low 
expression levels, however, the overall accuracy of differential expression detection 
decreases significantly and the detection of small fold changes < 2-fold is relatively poor in 
sensitivity (Wang 2006). 
 
Because of the limitations of microarrays it is strongly recommended to verify data of the 
most suggestive genes with qRT-PCR (Ehrenreich 2006). This method does not require 
post-amplification manipulation, produces quantitative data with an accurate dynamic 
range of 7 to 8 log of magnitude, and is characterized by single-copy sensitivity (Morrison 
1998, Palmer 2003). It has lower coefficients of variation (SYBR Green at 14.2%) than 
end point assays such as probe hybridization (45.1%) (Schmittgen 2000), it can 
discriminate between messenger RNAs with almost identical sequences (Wong 2005), 
and results can be obtained rapidly (Derveaux 2009). Therefore qRT-PCR is referred to as 
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the “gold standard” for gene expression measurements ―Wang 2::6, Mackay 2::2‖. On 
the contrary the limitations of qRT-PCR are not to be underestimated. Due to its very high 
sensitivity accuracy of the results and reliability of conclusions extremely depend on critical 
quality issues. First of all RNA purity and integrity have to be assured as well as absence of 
contaminating DNA. The last issue might be limited by proper DNase treatment after 
sample extraction and using intron spanning primers in the qRT-PCR reaction (Derveaux 
2009). In addition, minor variations in reaction components (Bustin 2002), thermal cycling 
conditions, enzyme efficiencies, and mispriming events during the early stages of the 
reaction can lead to differing amounts of amplified products (Wong 2005). PCR inhibitors 
like transcriptase enzyme carried over from cDNA synthesis or inhibitors originating from 
the samples and carried over during RNA preparation may affect reaction kinetics (Liss 
2002, Lekanne Deprez 2002, Tichopad 2004). Secondary structure of RNA and protein 
complexes bound to the RNA template may also interfere with cDNA synthesis by causing 
enzyme pausing, dissociation, or skipping over looped regions (Liss 2002). Furthermore 
one has to keep in mind that complex in vivo tissues, such as skin biopsies, contain several 
different cell types and composition can vary greatly from sample to sample. This inevitably 
results in the averaging of the expression of different cell types and the expression profile of 
a specific cell type may be masked, lost or ascribed to and dismissed as illegitimate 
transcription because of the bulk of the surrounding cells (Bustin 2002). Finally it has also 
been reported that significant variations are due to the person performing the experiment 
(Bustin 2002) and that precision pipeting and pipet calibration are essential for preventing 
cumulative error (Wong 2005). Even the most careful pipeting technique may have a 1% 
relative error which will result with a 10-fold dilution in a 1% error in amplification efficiency 
(Peirson 2003). Another very much discussed aspect of qRT-PCR concerns normalization 
to internal reference genes (Bustin 2002, Hruz 2011). Reference genes are expected to 
be stable in their expression and therefore correlate strongly with the total amounts of 
mRNA present in each sample. It has been repeatedly shown, though, that expression 
stability is very much tissue dependent and some may also be affected by experimental 
conditions (Hong Cai 2007). To reduce this effect, it is recommended to use several 
reference genes for normalization if many target genes are assayed (Vandesompele 
2002). The numbers of reference genes used are a trade-off between practical 
considerations and assay validity within an experimental design (Hong Cai 2007).  
 
To verify the expression data obtained by microarray for the most suggestive keratin, 
cadherin, catenin and desmoglein genes qRT-PCR analysis was conducted. As expected, 
due to fold change compression, fold change levels obtained from gene expression analysis 
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using qRT-PCR were generally higher. This is especially true for the analyzed keratin genes 
in skin samples, which reached expression levels of approximately 20 to 250fold and 
desmoglein 4 expression in skin samples with a tenfold higher expression level compared 
to the array data. In contrast to the array data the qRT-PCR data showed a decrease of 
desmoglein 2 expression in DEBR skin (fold change 0.5) and heart samples (fold change 
0.14), as well as decreased expression levels of cadherin 1 (fold change 0.48) , desmoglein 
1 (fold change 0.63) and 4 (fold change 0.61) in DEBR heart samples. In addition greater 
variances in expression levels were detected between samples (especially in skin) leading to 
higher standard deviations as in the data obtained by microarray analysis. These findings 
might be ascribed to the higher sensitivity of the qRT-PCR method and to the fact that skin 
is a complex tissue with varying cell type composition in different samples. 
 
Both, microarrays and qRT-PCR, measure the steady state mRNA levels only. When 
interpreting the data one has to keep in mind, that these methods give no information 
about transcription levels, mRNA stability, post-transcriptional regulation, or post-
translational modifications. In addition the data obtained is totally uninformative about 
protein activity and possible mutations that the target gene might harbor. Therefore in 
some cases it might be necessary to obtain additional insight through immunohisto-
chemical stainings or biochemical assays. (Bustin 2002) 
 
To further clarify the findings from these expression analyzes immunohistological stainings 
of adherens junction and desmosomal proteins were made to check for protein levels and 
protein localizations within the cells. 
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2. Histological Analyzes 
Standard HE-stainings were made for the diagnosis of alopecia areata in all rat skin 
samples. In addition immunohistological stainings were made for cadherins 1 – 5 and 15, 
desmoglein 1, and catenins alpha, beta, gamma, and p120 in skin samples from DEB and 
PVG rats. No differences in protein level or localization could be detected between the 
different rat strains except for catenin gamma which is also known as plakoglobin or 
junctional plakoglobin (Jup). Protein levels of plakoglobin decreased with continuing hair loss 
in DEB rat skin cumulating in a complete loss of plakoglobin in severely affected animals. 
 
As mentioned above, plakoglobin is an important linker protein in desmosomes as well as 
adherens junctions and interacts with several other proteins like desmogleins 1 and 2, 
desmocollin 1, desmoplakin, cadherin 1, 2, and 3, catenin alpha and beta (Troyanovsky 
1994, Hazan 1998, Sacco 1995, Klingelhöfer 2000, Ozawa 1995, Kowalczyk 1997). It is 
mainly expressed in the skin and the heart with mutations in its gene giving rise to a broad 
spectrum of phenotypes affecting these two organs (Pigors 2011). It shares high 
sequence identity (>80%) with catenin beta which can substitute for plakoglobin at many 
cellular junctions as has been shown in plakoglobin null-mutant mice (Bierkamp 1999). But 
the affinity of catenin beta to desmogleins is a lot lower suggesting why rather plakoglobin 
than catenin gamma locates to desmosomes (Choi 2009). Plakoglobin therefore plays a 
crucial role in normal desmosome plaque assembly. Deletions or loss-of-function give rise 
to diminished plaques with loss of desmoplakin and intermediate filaments attachment 
(Acehan 2008). Plakoglobin null-mutant mice usually die between E10.5 and birth, due to 
fragility of the myocardium (desmosomes are absent, but extended adherens junctions 
contain desmosomal components) and acantholysis (Bierkamp 1996, Ruiz 1996, Acehan 
2008). The few mutant mice offspring that are born show serious epidermal fragility, 
severe cardiac defects, and early postnatal lethality (Bierkamp 1996). Furthermore 
evidence has been found that plakoglobin translocation initiates nuclear signaling in 
epidermis and in myocardium that alter the Wnt/catenin beta signaling pathway (Hu 
2003, Garcia-Gras 2006) and it has been shown that plakoglobin overexpression in mouse 
epidermis decreases keratinocyte proliferation and shortens the anagen phase of the hair 
cycle (Charpentier 2000). 
In humans plakoglobin gene mutations are known to be associated for example with Naxos 
disease (first described by Protonotarios 1986) which is an autosomal recessive disorder 
characterized by arrhythmogenic right ventricular cardiomyopathy (ARVC), woolly hair, and 
palmoplantar keratoderma. The rest function of a truncated form of plakoglobin prevents 
embryological death, skin fragility and limiting palmoplantar keratoderma to non-
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epidermolytic and might be the explanation for the milder phenotype in humans versus 
mice (Bolling 2009). Another plakoglobin mutation associated with the disease ARVD12 
has been described by Asimaki et al. in 2007 with an autosomal dominant mode of 
inheritance in a family with non-syndromic ARVC. The patients also showed normal hair and 
skin growth. Just recently a new plakoglobin homozygous nonsense mutation has been 
found by Pigors et al. (2011) in a patient with a very severe phenotype. This mutation leads 
to a complete loss of plakoglobin in the patient’s skin. The expression and distribution of 
desmosomal components is severely affected, only very few abnormal desmosomes are 
formed and no adhesion structures between keratinocytes are recognizable. This leads to 
extreme congenital skin fragility with generalized epidermolysis and massive 
transcutaneous fluid loss causing perinatal death. Cardiac dysfunctions were not observed 
but might have developed later in life, similar to patients with Naxos disease and ARVD12. 
In addition qRT-PCR analysis showed reduced expression of direct binding partners of 
plakoglobin at the transcriptional level in the patient, suggesting regulatory functions of 
plakoglobin for gene expression of desmosomal cadherins and desmoplakin (Lewis 1997). 
Interestingly, the parents of the child were first cousins and one of the other 3 children was 
affected by alopecia totalis. Further examination of the patient also revealed complete 
absence of the scalp hair and onycholysis. 
 
Due to the fact, that plakoglobin is not only an important protein in normal skin structure 
but also in heart tissue immunohistological as well as standard HE-stainings were repeated 
in DEB rat and BDIX rat heart sections. As observed in skin, no changes in protein level or 
localization were found between the different rat strains except for plakoglobin. These 
findings suggest that the mRNA downregulation of cadherin 1, desmoglein 1 and 4 
observed with qRT-PCR analysis in DEBR heart samples are either an artifact (for 
explanations see discussion above) or the generated mRNA is still enough to produce the 
amount of protein needed in the cells. One has to keep in mind though, that protein 
quantification is not precise with immunohistochemical staining and small variations in 
protein levels might not be discerned. Plakoglobin instead, showed normal expression levels 
of mRNA in both microarray and qRT-PCR analysis. The immunohistochemical stainings, 
however, showed a prominent decrease in protein level with continuing hair loss in DEB rat 
skin and heart samples cumulating in a complete loss of plakoglobin in severely affected 
animals. In addition, DEBR heart sections enlarged with 40x magnification showed some 
cells with a lost concentrated localization of plakoglobin at cell-cell contact sites. It is found 
diffusely within the cell instead. Taking into account the expression analysis data one might 
speculate that plakoglobin is expressed in normal levels and is incorporated in cell-cell 
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adhesion complexes in a regular manner. With ongoing hair loss plakoglobin seems to lose 
its binding capacity to the cell-cell adhesion complex and is therefore found diffusely within 
the cytoplasm of the cell, where it is degraded over time. One of the binding partners of 
plakoglobin is desmoglein 2 in desmosomes found in heart cells (Bannon 2001, Wahl 
2000, Ozawa 1995). As mentioned above, decreased desmoglein 2 mRNA levels in DEBR 
skin and especially prominent in heart were detected with qRT-PCR. Another binding 
partner of plakoglobin is the desmosomal cadherin 1 (Knudsen 1992) which also showed 
downregulated mRNA levels in DEBR heart tissue but was not peculiar in immune-
histochemical stainings compared to the control skins. As mentioned before, though, one 
has to keep in mind that protein quantification is not precise with immunohistochemical 
staining and small variations in protein levels might not be discerned. However, these 
findings again support the assumption of a structural defect as a secondary effect to the 
basic cause of alopecia. 
 
In addition to skin, some heart samples were also HE-stained. These showed no 
abnormalities in DEB rats with an early onset of hair loss. In DEB rats with a severe 
phenotype, however, a loss of cell-cell adhesion could be observed in anterior and posterior 
papillary muscle. It is not clear if this observation is due to the advanced age of the severely 
affected DEB rats or if this observation is linked with the progressive state of alopecia 
areata in the rats. Studies of age-related variations in the papillary muscle of rats have 
been reported previously showing that the density of myocytes, connective-tissue, 
capillaries, cross-sectional area of myocytes, as well as physical and biochemical 
characteristics of the papillary muscle are dependent upon age (Maifrino 2009). On the 
contrary, qRT-PCR analysis showed a decrease in desmoglein 2 at the transcriptional level 
which functions as a protein besides desmocollin 2 as the extracellular linkers in 
desmosomes of the myocardium but not in skin where desmogleins 1, 3, 4, desmocollins 1 
and 3 as well as corneodesmosin form the extracellular linkage (Maifrino 2009). This 
might explain why only the heart tissue is affected whereas there is no tissue rupture 
observed in the skin. In humans, cumulating heart anomalies have not been reported in 
alopecia patients. 
 
Luckily, it was possible to obtain scalp biopsies from a patient with alopecia areata (one 
biopsy from an area on the scalp where the hair is still growing normally and one biopsy 
from the center of a hair loss patch) and a patient with alopecia universalis. These samples 
were also used for standard HE and immunohistological stainings. HE staining supported 
the diagnosis of alopecia. The immunohistological staining of plakoglobin showed the same 
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phenomena in humans as found in the DEBR skin. Plakoglobin is strongly expressed and 
localized in a dense line at cell-cell adhesion sites in the skin that was obtained from a hairy 
patch of the scalp in the alopecia areata patient. The fluorescence decreases considerably 
in the hairless patch of the alopecia areata patient and is finally completely absent in the 
skin of the alopecia universalis patient. Due to these findings and the functions and 
importance of plakoglobin in cell-cell adhesion, it would be very interesting to obtain heart 
biopsies from alopecia patients for immunohistological stainings and expression analysis, 
even though heart diseases are not common among affecteds. Still, there might be an 
underlying asymptomatic defect. In addition to plakoglobin, cadherin 3 and 15 also showed 
abnormalities. Both proteins show an intense staining at the cell-cell adhesion sites in the 
epidermis and only little staining can be detected within the cytoplasm in the skin biopsy of 
the alopecia areata patient from a patch where hair is still growing. In the hairless patch of 
skin the fluorescence intensity decreases at the cell-cell adhesion sites and in addition 
increases within the cytoplasm of the cells. In the alopecia universalis patient no staining is 
possible in all but the granular layer of the epidermis. 
 
Cadherin 3, also known as P-cadherin, is one of the major classical cadherins expressed in 
human epidermis and is localized only at the cell membrane of basal cells in normal 
epidermis (Hakuno 2001). Hakuno et al. (2001) demonstrated P-cadherin staining in the 
basal as well as the suprabasal layers similar to the findings in this study in acantholytic 
lesion of pemphigus vulgaris and pemphigus foliaceus. The upregulation of P-cadherin might 
be due to altered signaling pathways involved in proliferation and differentiation like the 
Wnt/catenin beta signaling pathway. Furthermore, P-cadherin is involved in hair follicle 
morphogenesis (Jamora 2003). Mutations in the gene encoding P-cadherin have been 
found to cause hypotrichosis with juvenile macular dystrophy (HJMD) as well as ectodermal 
dysplasia, ectrodactyly and macular dystrophy (EEM) which both are characterized by 
abnormal hair conditions (Shimomura 2008). 
 
Cadherin 15, also known as M-cadherin, is another member of the classical cadherins and 
has been described as an important mediator of cell adhesion and complex formation with 
catenins in myogenic mouse cells (Kuch 1997), especially during skeletal muscle cell 
differentiation (Donalies 1991). It is also expressed in the brain and cerebellum and 
mutations in M-cadherin have been shown to cause decreased cell adhesions that might be 
responsible for causing autosomal dominant mental retardation-3 (MRD3) (Bhalla 2008). 
However, Hollnagel et al. (2002) hypothesized that M-cadherin is not necessarily required 
for muscle and cerebellar development since experiments with M-cadherin null-mutant 
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mice showed an almost complete compensation by N-cadherin. Up to date, M-cadherin has 
not been described in combination with skin defects. 
 
In conclusion, the findings from the expression analysis in combination with the histological 
findings point to an important role of desmosomes and adherens junctions in the 
pathogenesis of alopecia areata. An underlying involvement of signaling pathways, such as 
the Wnt/catenin beta signaling pathway is probable and should be further analyzed. In 
addition, electron microscopic analyzes are planned to have a closer look at the structure 
of desmosomes and adherens junctions in the skin of DEB rats in different phenotype 
stages. This, in combination with refined expression analysis, should result in a better 
understanding of the point of time in which plakoglobin loses its binding capacity to the 
adhesion complex and gives deeper insights into the structural consequences before and 
after losing the most important linker protein in the desmosomal protein complex.  
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3. Genetic Analyzes 
Prior to this study DEB rats were intercrossed with PVG rats that gave an F2 population 
with 320 females. A whole genome scan for linkage was performed by the dermatogenetic 
group of the CCG using 176 microsatellite markers which gave significant results for a 
locus on chromosome 19 with a highly significant lod score of 20. Therefore this region 
was mapped with 13 more microsatellite markers and haplotype analysis resulted in a 
candidate region between 33 and 36.5Mb (rn4). All exons of the most suggestive genes 
were then sequenced but no mutations could be found that would give clues to the causes 
of alopecia. Consequently, the candidate region was then sequenced again in toto by Next 
Generation Sequencing (NGS). 6 DNA samples in total were used for that from 3 control 
rat strains (Wistar, PVG, and BDIX), 1 unaffected DEB rat, 1 histologically affected DEB rat, 
and one affected DEB rat. A target sequence capture of 70.2% was reached. To genetically 
characterize the affected DEB rats the variations specific for the affected DEB rat were 
identified by deleting all variations found in common with any of the variations found in the 
other samples. This resulted in 117 specific variations with a base coverage of at least 30 
for the affected DEB rat, including 87 intergenic, 29 intronic, and 1 synonymous coding 
variation. The same procedure resulted in 337 specific variations with a base coverage of 
at least 30 characterizing the histologically affected DEB rat, including 304 intergenic, 32 
intronic, and 1 UTR variation. The affected and the histologically affected DEB rat have 91 
variations with a base coverage of at least 30 in common, including one non-synonymous 
amino acid change (Pro764Thr) in the pseudogene RGD1562390 besides 73 intergenic, 
16 intronic, and 1 UTR variation. Additionally, NGS data was compared to the results 
obtained by Sanger sequencing. Some of the variations found by Sanger sequencing could 
not be reproduced in the NGS data. Other variations found were also detected in the 
control rat strains. In conclusion, a mutation as a potential cause for hair loss in alopecia 
areata could again not be identified. Due to the very high lod score of 20 obtained in linkage 
analysis and the high number of intergenic variations found in the DEB rats the data should 
be analyzed again with the aid of bioinformatic software to check for unknown genes in the 
candidate region and for sequences of regulatory elements such as promoters or 
enhancers. 
 
Also prior to this study, a genome wide association study (GWAS) has been conducted by 
the dermatogenetic group of the CCG with human samples pointing to a significant region 
on chromosome 19. This region was then fine mapped in 1420 samples, including 353 
unrelated controls, using SNPstream analysis, pyrosequencing and Taqman analysis in this 
study. The obtained data was cleaned of mendelian errors and unlikely phenotypes and then 
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further processed with the softwares PLINK and Merlin. Testing for association with PLINK 
in a dominant and a recessive model in 407 cases and 353 unrelated controls gave no 
significant results since all calculated p-values were considerably higher than 0.05. In 
addition a transmission disequilibrium test (TDT) was performed with the PLINK software 
using data from 199 trio families which also did not give significant results. With the 
software package MERLIN an affected sib pair (ASP) linkage analysis was performed for 77 
families including 320 individuals resulting in 2 significant loci with lod scores above 2.6. 
The first region was defined at chr19:41876810..41895089 (Build36.3) with the highest 
HLOD score for SNP rs1830031 of 2.886 and the highest npLOD score of 3.240. This 
first region includes the gene ZNF567 only. The second region was defined at 
chr19:42067119..42445079 (Build36.3) with the highest HLOD score for SNP 
rs496730 of 2.971 and the highest npLOD score of 3.510. This second region includes 9 
genes of which 6 are zinc finger proteins with ZNF568 lying closest to the SNP with the 
highest lod score. Another analysis performed with MERLIN was a family based linkage 
analysis showing two significant loci with lod scores above 3.6. The first region was defined 
at chr19:41876810..41895089 (Build36.3) with the highest HLOD score of 3.739 and 
the highest npLOD score of 3.730 for SNP rs1830031. This region is therefore identical 
to the first region found with ASP analysis but with higher lod scores. The second region 
was defined at chr19:42022453..42586308 (Build36.3) with the highest HLOD score of 
4.374 and the highest npLOD score of 4.740 for SNP rs496730. This second region 
overlaps with the second region found with ASP analysis and gives the highest lod score 
with the same SNP. This region includes 14 genes of which 8 are zinc finger proteins with 
ZNF568 lying closest to the SNP with the highest lod score. The zinc finger genes ZNF567 
and ZNF568 were then screened for mutations with a combination of high resolution 
melting curve analysis and sequencing but no mutations could be found. All variations could 
be accounted for as known SNPs. 
 
Zinc finger proteins are relatively small molecules folding around one or more zinc ions. 
Depending on their function and the arrangement of their zinc-binding residues more than 
20 classes of zinc finger proteins have been identified (Krishna 2003). About 2% of the 
proteins encoded by the human genome contain zinc finger domains (Matthews 2002). 
The common feature of all zinc finger domains in protein complexes is to mediate 
interactions with DNA, RNA, other proteins, or lipids (Wolfe 2000, Brown 2005, Mackay 
1998, Matthews 2002). The majority of zinc finger proteins are classified as classical or 
C2H2 zinc fingers, which ligate zinc with pairs of cysteine and histidine residues and are 
known for their involvement in transcriptional regulation (Matthews 2002). ZNF567 and 
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ZNF568 are examples of classical zinc fingers since both of them are characterized by 15 
C2H2-type zinc fingers. Nothing has been reported up to date about their specific function 
but data from the Human Protein Atlas Project show the absence of ZNF567 expression in 
skin via immunohistological stainings and a low RNA abundance of ZNF568 in skin but no 
evidence at protein level in the cell line A-431 derived from skin (www.proteinatlas.org). 
 
Additionally, more blood samples of alopecia patients and if possible from their family 
members were collected and genotyped with the Affymetrix Genome-Wide Human SNP 
Array 6.0. Together with the aforementioned samples that have already been genotyped 
with the Affymetrix Human Mapping 500K Array a case control genetic association 
analysis could be conducted with the software package PLINK including 258.673 SNPs 
after checking for mendelian errors and unlikely genotypes. Data of 2.891 individuals was 
used in this analysis including 357 cases and 2534 unrelated controls from the biobank 
KORA and POPGEN. Under the assumption of a recessive mode of inheritance no 
significant p-values were reached. The assumption of a dominant mode of inheritance, 
instead, showed loci on chromosomes 5, 6, and 16 exceeding the significance threshold of 
1e-06. Two significant loci were found on chromosome 5. The first region was defined at 
Chr5:5334408..5361229 (Build36.3) with the lowest p-value of 5.55e-6 for SNP 
rs7720820 including the gene ADAMTS16 only.  
ADAMTS16 is one of 19 members in the disintegrin and metalloproteinase with 
thrombospondin motifs protein family. Molecules in this family are characterized by several 
distinct protein modules, including a signal peptide, a propeptide region, a metallo-
proteinase domain, a disintegrin-like domain, as well as a thrombospondin type 1 motif and 
a cysteine rich domain (Porter 2005). Functions of these proteins include the degradation 
of aggrecan (a large aggregating proteoglycan which is a major structural component of 
cartilage) at specific loci with ADAMTS5 as the major aggrecanase in cartilage destruction 
in mice (Glasson 2005), degradation of cartilage oligometric matrix protein (Dickinson 
2003), and collagen biosynthesis (Colige 2002). ADAMTS16 is highly expressed in fetal 
lung and kidney as well as adult brain and ovary (Cal 2002) but has not been found 
expressed in skin. The function of the protein is still unknown but a weak aggrecanase 
activity has been shown recently in a recombinant truncated form of ADAMTS16 (Zeng 
2006) and a full length recombinant ADAMTS16 is capable of cleaving the proteinase 
inhibitor alpha2-macroglobulin (Gao 2007). 
 
The second region exceeding the significance threshold of 1e-06 found on chromosome 5 
was defined at Chr5:130616449..131269677 (Build36.3) with the lowest p-value of 
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8.76e-7 for SNP rs27421 including 7 genes (CDC42SE2, LOC100505941, RAPGEF6, 
FNIP1, ACTBP4, LOC100505572, LOC728637).  
As an immunologically relevant gene it has been suggested that CDC42SE2 might induce 
actin filament assembly in the cytoskeleton by acting downstream of CDC42 and that it 
may play a role in CDC42-mediated F-actin accumulation at the immunological synapse in 
activated T-cells (Pirone 2000, Ching 2005). It is widely expressed but at higher levels in T 
lymphocytes (Ching 2005). 
 
Three significant loci were found on chromosome 6. The first region was defined at 
Chr6:29730199..29803284 (Build36.3) with the lowest p-value of 4.87e-06 for SNP 
rs29228 including 5 genes (HLA-F, ZFP57, MOG, and 2 pseudogenes). The second region 
was defined at Chr6:32497626..32790840 (Build36.3) with the lowest p-value of 4.34e-
09 for SNP rs9268856 including 7 HLA genes. HLA stands for human leukocyte antigen 
system and is part of the human major histocompatibility complex (MHC). HLA genes play 
an important role in the immune system and autoimmunity by presenting antigens to killer 
T-cells or T-lymphocytes. The third region was defined at Chr6:150314225..150403682 
(Build36.3) with the lowest p-value of 3.14e-07 for SNP rs5017316 including 5 genes 
(ULBP1, LOC646024, RAET1L, LOC100131886, and 1 pseudogene). ULBPs are ligands 
for the NKG2D receptor and belong to the MHC class I family. They are stress induced 
molecules that activate multiple signaling pathways in primary natural killer cells, resulting 
in the production of cytokines and chemokines (Eagle 2007, Sutherland 2002). Petukhova 
et al. (2010) suggested that ULBP3 is capable of inducing autoimmune destruction in the 
dermal sheath of the hair follicle in alopecia areata. 
 
The one significant loci on chromosome 16 was found at Chr16:11014208..11115395 
(Build36.3) with the lowest p-value of 7.40e-07 for SNP rs3893660 including one 
pseudogene and CLEC16A. CLEC16A (C-type lectin domain family 15) belongs to the 
CLEC16A/gop-1 family and is almost exclusively expressed in immune cells, including 
dendritic cells, B lymphocytes, and natural killer cells (Hakonarson 2007). Polymorphisms 
in CLEC16A have been associated with an increased risk of multiple sclerosis (Nischwitz 
2011) and type 1 diabetes (Zoledziewska 2009) but the function of the protein is basically 
still unclear. 
 
Calculation under the assumption of a trend model (using the Armitage Trend Test) led to 
the same significant loci on chromosomes 5 and 6 whereas the locus on chromosome 16 
was not found significant. The second region found significant on chromosome 6 including 
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the HLA cluster reached p-values as low as 5.35e-12. In addition to case control analysis a 
TDT was performed using PLINK software but no SNP clusters could be detected that 
reached the significance threshold. A family based linkage analysis with 259 families 
including 855 individuals and 271.150 SNPS using the MERLIN software, however, 
resulted in significant SNP clusters on chromosomes 10 and 19 reaching npLOD scores of 
at least 3.6. Three significant SNP clusters were detected for chromosome 10 but only the 
first one at chr10:414200..698293 (Build36.3) with the highest npLOD score of 3.99 
includes 3 genes (DIP2C, LOC642278, C10orf108). There are no known genes within the 
other SNP cluster regions. DIP2 genes encode members of the disco-interacting protein 
homolog 2 family which share high similarity with a Drosophila protein that interacts with 
the transcription factor disco and are expressed in the nervous system (Tanaka 2010, 
Mukhopadhyay 2002). DIP2B has been reported to be associated with at least one human 
neurocognitive disorder (Winnepenninckx 2007). There is no gene information available for 
the hypothetical gene LOC642278 and C10orf108. 
 
One significant SNP cluster could be detected for chromosome 19 at Chr19:41413208.. 
43454980 (Build 36.3) with the highest npLOD score of 6.13 for SNPs rs713256 and 
rs256733 within gene ZNF527. This region contains 48 genes, including 27 zinc finger 
genes. ZNF527 is another example of a classical zinc finger characterized by 12 C2H2-
type zinc fingers. It is weakly expressed in epidermal skin cells (www.proteinatlas.org). Its 
protein function is also unknown but due to its classification an involvement in 
transcriptional regulation is probable. 
 
Using a defined smaller set of markers (62.990 SNPs) looses the significant locus on 
chromosome 10 but the npLOD score still reaches 4.15 within the defined region at 
Chr19:40562188..43398829 (Build36.3) which contains 93 genes, including KRTDAP, 
DMKN, SBSN, and 30 zinc finger genes. Lowest npLOD scores were obtained for 
chromosome 19 using a family based linkage analysis with 83.371 SNPs resulting in the 
highest npLOD score of 3.87 for SNP rs2239945. The SNP cluster reaching npLOD 
scores above 3.6 is defined at Chr19:40590481..41163676 (Build36.3). This region 
contains 31 genes, including KRTDAP, DMKN, and SBSN. Again, chromosome 10 did not 
show significant loci with this analysis.  
 
KRTDAP may act as a soluble regulator of keratinocyte differentiation and is probably 
important in embryonic skin morphogenesis. In human skin it is exclusively expressed in 
lamellar granules of granular keratinocytes and in the intracellular space of the stratum 
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corneum. It has been found upregulated and expressed more widely throughout suprabasal 
keratinocytes in situ in psoriatic skin (Tsuchida 2004). DMKN (dermokine) is another 
protein that may act as a soluble regulator of keratinocyte differentiation that is expressed 
in the epidermis (Naso 2007). This gene has been found upregulated in inflammatory 
diseases and differentially uses promoters and terminators to generate isoforms with 
specific cellular distributions and domain components (Naso 2007, Toulza 2006). SBSN 
(suprabasin) has been found upregulated in differentiating keratinocytes and therefore may 
play a role in epidermal differentiation (Park 2002). 
 
The findings of the human GWAS in this study for the HLA and ULBP region on 
chromosome 6 is in accordance with the results of the GWAS analysis conducted by 
Pethukova et al. (2010) with 1.054 cases and 3.278 controls, which further reinforces the 
common concept of an autoimmune mechanism as the basis for alopecia. The second 
region found significant for chromosome 5 containing the gene CDC42SE2 in this study 
has also been found in the analysis of Pethukova et al. (2010) with the lowest p-value within 
that region of 7.13e-06 for rs1295686. Since they set the significance threshold to 1e-07 
this region was only declared near significant in their analysis. Since both analyzes resulted 
in a tight SNP cluster in this region it can be suggested that an association with alopecia is 
probable and further emphasizes the immunological character of the disease due to the 
suggested function of CDC42SE2. The same applies for a region on chromosome 16 which 
has been found in association with alopecia in our study including the gene CLEC16A which 
is exclusively expressed in immune cells, but reached only near significance in the analysis 
by Pethukova et al. with a p-value of 2.75e-5 for SNP rs12934193.  
 
The family based linkage analyses in this study gives further insight into the multifactorial 
character of this complex disease. The genes KRTDAP, DMKN, and SBSN found within a 
significant region on chromosome 19 have been implicated to mediate keratinocyte 
differentiation. Keratins, as described earlier, are not only the major component of skin and 
hair fibers, but are also important signal molecules in different pathways. Since keratin 
expression is regulated on transcription level it is also intriguing that transcription factor 
genes like zinc fingers and DIP2C were found within significant regions on chromosome 19 
and 10 in this study. To further elucidate these new findings a NGS analysis spanning the 
region of chromosome 19 with the genes KRTDAP, DMKN, SBSN, and the zinc finger 
cluster will be conducted shortly.  
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G Abstract 
 
Alopecia areata (AA) (MIM 104000) is a chronic inflammatory, multifactorial disorder of 
the hair follicles with a strong genetic basis. It is characterized by circular regions of hair 
loss on the head or also on other parts of the body. The pathogenesis of the AA is still 
unknown but a tissue-specific autoimmune mechanism has been suggested. 
 
As an animal model of AA the Dundee Experimental Bald Rat (DEBR) was used. An 
intercross of DEB with PVG rats gave rise to 320 female F2 rats with which a whole 
genome scan for linkage with microsatellite markers was performed prior to this study that 
resulted in one highly significant locus on chromosome 19 with a lod score of 20. In this 
study saturation mapping of this chromosome with more microsatellite markers was 
conducted which identified a candidate region at 33 to 36.5 Mb (rn4). Exons from most 
genes within this region were sequenced but mutations could not be detected. The 
following sequencing of the candidate region in toto by Next Generation Sequencing (NGS) 
did also not lead to causative mutations but the high number of intergenic variations 
suggest the existence of unknown genes within that region or there might be a mutation in 
a regulatory element of a gene as for example in the promoter or enhancer region. This will 
have to be checked by further bioinformatic analyzes. 
In another approach expression analysis was conducted using the Affymetrix GeneChip® 
Rat Gene 1.0 ST Arrays. This revealed expression differences for various (hair) keratin 
genes and genes of other structural components, immunoregulatory genes such as 
chemokines, and H2 genes, the HLA orthologs. Further analysis of the expression data 
from genes of the candidate region on chromosome 19 with the network explorer tool 
from Ingenuity Pathways Analysis pointed to an important role of cadherins. Therefore a 
set of cadherins, catenins, and desmogleins were immunohistochemically stained in skin 
samples. This experiment showed a decrease in catenin gamma concentration 
corresponding to the phenotype. In samples of rats with a severe hair loss catenin gamma 
was no longer detectable at all. These histological findings could also be seen in rat heart 
samples and in human skin. In addition to catenin gamma, M- and P-cadherin also showed 
abnormal protein localizations in the epidermis of human skin. The expression results of 
suggestive genes were then validated and refined in rat skin and partially also in heart 
samples with qRT-PCR using the LightCycler 480 System. The expression and staining 
results point to an involvement of the Wnt/catenin beta signaling pathway and a defect in 
the cell-cell adherent structures in the pathology of alopecia. In the next step 
immunohistological stainings will be repeated in rat skin of different stages of hair loss and 
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looked at with electron microscopy, focusing on desmosomes in hair follicles and the 
epidermis to obtain further insight into the defective structure of cell-cell-adhesion 
complexes and the point of time of destruction. 
 
A whole-genome scan for linkage with SNP markers was performed with human samples 
prior to this study showing one significant locus on chromosome 19. Further fine mapping 
of the locus on chromosome 19 in 301 families (1131 individuals) was performed in this 
study with SNPstream, Taqman, and Pyrosequencing. Linkage analysis identified a 
candidate interval in the region between 37 Mb to 38 Mb (GRCH37) including several zinc 
finger genes. Highest non parametric lod scores were obtained for SNPs in or near the 
genes ZNF567 and ZNF568. Therefore these genes were screened for mutations with 
high resolution melting curve analysis and sequencing. No mutations could be found since 
all detected variations were due to known SNP markers. 
In addition more samples were collected and genotyped with Affymetrix Genome-Wide 
Human SNP Array 6.0 for a SNP based genome-wide association study (GWAS) including 
357 cases and 2534 controls. Significantly associated loci were found on chromosomes 5, 
6 (including the HLA region), and 16 (CLEC16A). Linkage analysis with 259 families (855 
individuals) furthermore resulted in significant regions on chromosomes 10 and 19 (zinc 
finger region). With a defined set of SNP markers a candidate region at 35,9 Mb to 36,5 
Mb (GRCH37) on chromosome 19 could be identified. In the next step the combined region 
of 35,9 Mb to 38 Mb (GRCH37) will be sequenced in toto by NGS and screened for 
mutations. 
 
In conclusion, this study shows a strong association of cellular defects in the skin with the 
disease which will be further addressed in future experiments with the rat model DEBR in 
the dermatogenetics group at the CCG. In addition to the already known immunoregulatory 
genes associated with AA, this study also revealed significant linkage results for loci on 
chromosome 10 and even more so for chromosome 19, including a zinc finger cluster. 
These results point out anew that several complex mechanisms contribute to the disease 
susceptibility. 
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H Zusammenfassung 
 
Alopecia areata (AA) (MIM 104000) ist eine chronisch entzündliche Erkrankung der Haar-
follikel mit einer starken genetischen Komponente. Sie ist durch einen kreisrunden 
Haarverlust am Kopf oder aber auch an anderen Körperstellen charakterisiert. Die 
Krankheitsentstehung ist nach wie vor unklar, wobei ein gewebespezifischer Autoimmun-
mechanismus vermutet wird. Als Tiermodell für AA wurde der Rattenstamm Dundee 
Experimental Bald Rat (DEBR) verwendet.  
Aus einer dieser Studie vorangegangenen Kreuzung aus DEB und PVG Ratten gingen 320 
weibliche F2-Tiere hervor, die genomweit mit Mikrosatelliten auf Kopplung analysiert 
wurden, was zu einem hoch signifikanten Lokus auf Chromosom 19 mit einem LOD-Score 
von 20 führte. In dieser Arbeit wurde daher eine Sättigungskartierung für dieses Chromo-
som mit weiteren Mikrosatellitenmarkern durchgeführt, die eine Kandidatenregion bei 33 
bis 36.5 Mb (rn4) identifizierte. Exone der meisten Gene innerhalb dieser Region wurden 
sequenziert wobei keine Mutationen als potentielle Ursache für Haarausfall identifiziert 
werden konnten. Die anschließende komplette Sequenzierung der Kandidatenregion mittels 
Next Generation Sequencing (NGS) offenbarte ebenfalls keine kausativen Mutationen wobei 
die hohe Anzahl an intergenetischen Varianten das Vorkommen von bisher unbekannten 
Genen innerhalb der Kandidatenregion suggerieren oder es könnte sich bei diesen um 
Mutationen in regulatorischen Elementen wie beispielsweise in Promotor- oder Enhancer- 
Regionen handeln. Dies muss in weiteren bioinformatischen Analysen geklärt werden.  
Ein weiterer Ansatz wurde mit der Expressionsanalyse mittels Affymetrix GeneChip Rat 
Gene 1.0 ST Arrays verfolgt. Diese ließ Abweichungen in der Expression von verschiedenen 
(Haar-) Keratingenen, Genen von weiteren strukturellen Komponenten sowie immun-
regulatorischen Genen wie Chemokine und H2 Gene (Orthologe zu HLA) erkennen. Weiter-
gehende Auswertungen der Expressionsdaten von Genen der Kandidatenregion auf 
Chromosom 19 mit dem Programm „Network Explorer“ von Ingenuity Pathways Analysis 
verwiesen auf eine wichtige Rolle von Cadherinen. Daher wurden einige Cadherine, 
Catenine und Desmogleine immunohistochemisch in Hautproben angefärbt. Dieses 
Experiment zeigte eine Reduzierung in der Konzentration von Catenin gamma in Überein-
stimmung mit dem Phänotyp. In Proben von Ratten mit einem ausgeprägten Haarverlust 
war Catenin gamma nicht mehr nachweisbar. Zusätzlich zu Catenin gamma zeigte M- und 
P- Cadherin ebenfalls eine anormale Proteinlokalisierung in der humanen Epidermis der 
Haut. Die Resultate der Expressionsanalyse von Kandidatengenen wurden schließlich in 
Rattenhaut und teilweise auch in Herzproben mittels qRT-PCR (Light Cycler 480 System 
von Roche) validiert und vertieft. Die Ergebnisse der Expressionsanalyse und der Färbungen 
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weisen auf eine Beteiligung des Wnt/Catenin beta Signalweges und einem Defekt in den 
Zell-Zell-Verbindungsstrukturen in der Krankheitsentwicklung von Alopezie hin. Im nächsten 
Schritt werden immunohistochemische Färbungen in Rattenhaut in verschiedenen Stadien 
von Haarverlust wiederholt und elektronenmikroskopisch untersucht, wobei der Fokus auf 
Desmosomen der Haarfollikel und der Epidermis liegt, um ein tiefergehendes Verständnis 
in die strukturellen Defekte der Zell-Zell-Verbindungskomplexe und dem Zeitpunkt der 
Zerstörung zu bekommen. 
 
Eine genomweite Kopplungsanalyse mit SNP Marker wurde im Vorfeld zu dieser Studie mit 
humanen Proben durchgeführt, welche auf einen signifikanten Lokus auf Chromosom 19 
verwies. Im Rahmen dieser Studie wurde eine Feinkartierung dieses Lokus auf Chromosom 
19 in 301 Familien (1131 Individuen) mittels SNPstream, Taqman und Pyrosequencing 
durchgeführt. Eine Kopplungsanalyse identifizierte eine Kandidatenregion bei 37 bis 38 Mb 
(GRCH37), welche mehrere Zinkfingergene beinhaltet. Die höchsten nichtparametrischen 
LOD-Scores wurden für SNPs in oder nahe der Gene ZNF567 und ZNF568 erzielt. Daher 
wurden diese Gene auf Mutationen mittels Schmelzkurvenanalyse und Sequenzierung 
untersucht. Es konnten keine Mutationen gefunden werden, da alle aufgetretenen 
Varianten auf bekannte SNPs zurückzuführen sind. Zusätzlich wurden für eine SNP 
basierte genomweite Assoziationsstudie (GWAS) mit 357 Fällen und 2534 Kontrollen 
weitere Proben gesammelt und mit Affymetrix Genome-Wide Human SNP Array 6.0 
genotypisiert. Signifikante assoziierte Loci wurden für die Chromosomen 5, 6 (welches die 
HLA Region beinhaltet) und 16 (CLEC16A) ausfindig gemacht. Außerdem resultierte eine 
Kopplungsanalyse mit 259 Familien mit 855 Individuen in signifikanten Regionen auf 
Chromosom 10 und 19 (Zinkfingerregion). Mit einer definierten Auswahl an SNP Marker 
wurde eine Kandidatenregion bei 35.9 Mb bis 36.5 Mb (GRCH37) auf Chromosom 19 
identifiziert. In einem nächsten Schritt soll die kombinierte Region von 35.9 Mb bis 38 Mb 
in Gänze mit NGS sequenziert und nach Mutationen untersucht werden. 
 
Abschließend weist die vorliegende Studie auf eine starke Assoziation von zellulären 
Defekten in der Haut mit AA hin, was in weiterführenden Experimenten mit dem Ratten-
modell DEBR in der Dermatogenetikgruppe des CCG weitergehend untersucht werden soll. 
Zusätzlich zu den bereits bekannten immunoregulatorischen Genen, die mit AA assoziiert 
sind, konnte diese Studie signifikante Kopplungsbefunde für Loci auf Chromosom 10 und 
besonders Chromosom 19, welcher ein Zinkfingercluster beinhaltet, ausfindig machen. 
Diese Resultate machen erneut deutlich, dass komplexe Mechanismen zu der 
Suszeptibilität der Krankheit beitragen.  
113 
 
I Danksagung 
 
An erster Stelle möchte ich aus tiefstem Herzen meinen Eltern danken. Ihr seid einfach 
spitze und absolut unersetzlich! Vielen Dank für eure Unterstützung und euren Zuspruch. 
Mein besonderer Dank gilt ebenso Dr. Mohammad Reza Toliat, der mir während der 
letzten Jahre ein hervorragender Lehrer und Mentor gewesen ist. Meine Kolleginnen 
Kerstin Becker, Janine Kurtenbach und Kerstin Wodecki sind Freundinnen geworden und 
ich werde euch und unser regelmäßiges, gemeinsames Brainstorming genauso wie unsere 
regelmäßigen CCG Girl’s Day Veranstaltungen sehr vermissen. Wir waren sowohl beruflich 
als auch privat ein tolles Team und unser gemeinsamer Abenteuerurlaub in New York City 
wird für uns alle ganz bestimmt unvergessen bleiben. Vielen Dank für eure Unterstützung 
Mädels! Ihr seid eine Bereicherung für mein Leben. 
Außerdem möchte ich unbedingt dem ganzen Team vom Barista in der Kyffhäuserstraße in 
Köln danken. Bei euch haben wir gelacht und geweint, Pläne geschmiedet und die Seele 
baumeln lassen und haben nebenbei immer den stadtbesten Kaffee und die 
verführerischste Tiramisu bekommen. Macht weiter so! 
Ganz besonders bedanken möchte ich mich auch bei den beiden Alopeziepatienten 
Andreas K. und Sandra S. Ohne ihre Kopfhautspenden wären viele Einsichten in das 
Krankheitsbild nicht möglich gewesen und ich hoffe, dass die Ergebnisse meiner Arbeit 
vielen weiteren Wissenschaftlern Anregungen geben werden weiter zu forschen und 
letztlich des Rätsels Lösung zu finden. 
 
  
114 
 
J List of Literature 
D. Acehan, C. Petzold, I. Gumper, D. D. Sabatini, E. J. Muller, P. Cowin, and D. L. Stokes. Plakoglobin is required for effective 
intermediate filament anchorage to desmosomes. J.Invest Dermatol. 128 (11):2665-2675, 2008. 
G. Achten. [Keratinization of the skin in humans]. Arch.Belg.Dermatol.Syphiligr. 12 (2):104-106, 1956. 
H.G. Adamson. Coulstonian lectures on modern views upon the significance of skin. London, John Bale, Sons and 
Danielsson Ltd 1912 
A. Asimaki, P. Syrris, T. Wichter, P. Matthias, J. E. Saffitz, and W. J. McKenna. A novel dominant mutation in plakoglobin 
causes arrhythmogenic right ventricular cardiomyopathy. Am.J.Hum.Genet. 81 (5):964-973, 2007. 
Bailly. L’origine gingivodentaire de la pelade. Lyons, France. 191: 
L. J. Bannon, B. L. Cabrera, M. S. Stack, and K. J. Green. Isoform-specific differences in the size of desmosomal 
cadherin/catenin complexes. J.Invest Dermatol. 117 (5):1302-1306, 2001. 
R. Baran, R.P.R. Dawber. Diseases of the nails and their management. Oxford, Blackwell Scientific Publications 1984. 
K. Bhalla, Y. Luo, T. Buchan, M. A. Beachem, G. F. Guzauskas, S. Ladd, S. J. Bratcher, R. J. Schroer, J. Balsamo, B. R. 
DuPont, J. Lilien, and A. K. Srivastava. Alterations in CDH15 and KIRREL3 in patients with mild to severe intellectual 
disability. Am.J.Hum.Genet. 83 (6):703-713, 2008. 
C. Bierkamp, H. Schwarz, O. Huber, and R. Kemler. Desmosomal localization of beta-catenin in the skin of plakoglobin null-
mutant mice.  Development 126 (2):371-381, 1999. 
C. Bodemer, M. Peuchmaur, S. Fraitaig, L. Chatenoud, N. Brousse, and Prost Y. De. Role of cytotoxic T cells in chronic 
alopecia areata. J.Invest Dermatol. 114 (1):112-116, 2000. 
M. C. Bolling and M. F. Jonkman. Skin and heart: une liaison dangereuse. Exp.Dermatol. 18 (8):658-668, 2009. 
J.T. Bowen. Two epidemics of alopecia areata in an asylum for girls. J of Cutaneous and Genito-Urinary Disease 17:399-
404, 1899. 
O. Braun-Falco. [Dynamics of normal and pathological hair growth]. Arch.Klin.Exp.Dermatol. 227 (1):419-452, 1966. 
R. S. Brown. Zinc finger proteins: getting a grip on RNA. Curr.Opin.Struct.Biol. 15 (1):94-98, 2005. 
G.A. Bubenik. Why do humans get “goosebumps” when they are cold, or under other circumstances? Scientific American 
2003 
S. A. Bustin. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. 
J.Mol.Endocrinol. 29 (1):23-39, 2002. 
J. H. Cai, S. Deng, S. W. Kumpf, P. A. Lee, P. Zagouras, A. Ryan, and D. S. Gallagher. Validation of rat reference genes for 
improved quantitative gene expression analysis using low density arrays. Biotechniques 42 (4):503-512, 2007. 
S. Cal, A. J. Obaya, M. Llamazares, C. Garabaya, V. Quesada, and C. Lopez-Otin. Cloning, expression analysis, and structural 
characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 
domains. Gene 283 (1-2):49-62, 2002. 
C. Caulin, C. F. Ware, T. M. Magin, and R. G. Oshima. Keratin-dependent, epithelial resistance to tumor necrosis factor-
induced apoptosis. J.Cell Biol. 149 (1):17-22, 2000. 
E. D. Cetin, E. Savk, M. Uslu, M. Eskin, and A. Karul. Investigation of the inflammatory mechanisms in alopecia areata. 
Am.J.Dermatopathol. 31 (1):53-60, 2009. 
E. Charpentier, R. M. Lavker, E. Acquista, and P. Cowin. Plakoglobin suppresses epithelial proliferation and hair growth in 
vivo. J.Cell Biol. 149 (2):503-520, 2000. 
K. H. Ching, A. E. Kisailus, and P. D. Burbelo. The role of SPECs, small Cdc42-binding proteins, in F-actin accumulation at 
the immunological synapse. J.Biol.Chem. 280 (25):23660-23667, 2005. 
H. J. Choi, J. C. Gross, S. Pokutta, and W. I. Weis. Interactions of plakoglobin and beta-catenin with desmosomal cadherins: 
basis of selective exclusion of alpha- and beta-catenin from desmosomes. J.Biol.Chem. 284 (46):31776-31788, 2009. 
T. Christoph, S. Muller-Rover, H. Audring, D. J. Tobin, B. Hermes, G. Cotsarelis, R. Ruckert, and R. Paus. The human hair 
follicle immune system: cellular composition and immune privilege. Br.J.Dermatol. 142 (5):862-873, 2000. 
F.T. Colcott. On a small epidemic of alopecia areata. Br.J.Dermatol. 25:51-56 1913. 
115 
 
A. Colige, I. Vandenberghe, M. Thiry, C. A. Lambert, Beeumen J. Van, S. W. Li, D. J. Prockop, C. M. Lapiere, and B. V. 
Nusgens. Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and 
ADAMTS-3. J.Biol.Chem. 277 (8):5756-5766, 2002. 
B. W. Colombe, V. H. Price, E. L. Khoury, M. R. Garovoy, and C. D. Lou. HLA class II antigen associations help to define two 
types of alopecia areata. J.Am.Acad.Dermatol. 33 (5 Pt 1):757-764, 1995. 
T. Conway and G. K. Schoolnik. Microarray expression profiling: capturing a genome-wide portrait of the transcriptome. 
Mol.Microbiol. 47 (4):879-889, 2003. 
H. Davis. Epidemic alopecia areata. Br.J.Dermatol. 26:207-210 1914. 
Andrade M. de, C. M. Jackow, N. Dahm, M. Hordinsky, J. D. Reveille, and M. Duvic. Alopecia areata in families: association 
with the HLA locus. J.Investig.Dermatol.Symp.Proc. 4 (3):220-223, 1999. 
Decelle. Bull.et.Mem.Soc.Med.de.Hop.de.Paris 21:72 1909 
E. Delva, D. K. Tucker, and A. P. Kowalczyk. The desmosome. Cold Spring Harb.Perspect.Biol. 1 (2):a002543, 2009. 
S. Derveaux, J. Vandesompele, and J. Hellemans. How to do successful gene expression analysis using real-time PCR. 
Methods 50 (4):227-230, 2010. 
S. C. Dickinson, M. N. Vankemmelbeke, D. J. Buttle, K. Rosenberg, D. Heinegard, and A. P. Hollander. Cleavage of cartilage 
oligomeric matrix protein (thrombospondin-5) by matrix metalloproteinases and a disintegrin and metalloproteinase with 
thrombospondin motifs. Matrix Biol. 22 (3):267-278, 2003. 
W. E. Dixon. Thallium. Proc.R.Soc.Med. 20 (8):1197-1200, 1927. 
M. Donalies, M. Cramer, M. Ringwald, and A. Starzinski-Powitz. Expression of M-cadherin, a member of the cadherin 
multigene family, correlates with differentiation of skeletal muscle cells. Proc.Natl.Acad.Sci.U.S.A 88 (18):8024-8028, 
1991. 
H. Druckrey. Genotypes and phenotypes of ten inbred strains of BD-rats. Arzneimittelforschung. 21 (8):1274-1278, 
1971. 
M. Duvic, A. Nelson, and Andrade M. de. The genetics of alopecia areata. Clin.Dermatol. 19 (2):135-139, 2001. 
R. A. Eagle and J. Trowsdale. Promiscuity and the single receptor: NKG2D. Nat.Rev.Immunol. 7 (9):737-744, 2007. 
A. Ehrenreich. DNA microarray technology for the microbiologist: an overview. Appl.Microbiol.Biotechnol. 73 (2):255-273, 
2006. 
D. M. Elston, M. L. McCollough, W. F. Bergfeld, M. O. Liranzo, and M. Heibel. Eosinophils in fibrous tracts and near hair 
bulbs: a helpful diagnostic feature of alopecia areata. J.Am.Acad.Dermatol. 37 (1):101-106, 1997. 
F. Fagotto and B. M. Gumbiner. Cell contact-dependent signaling. Dev.Biol. 180 (2):445-454, 1996. 
P. FLESCH. Chemical data on human epidermal keratinization and differentiation. J.Invest Dermatol. 31 (1):63-73, 1958. 
E. Fuchs. Keratins and the skin. Annu.Rev.Cell Dev.Biol. 11:123-153, 1995. 
S. Gao, Geyter C. De, K. Kossowska, and H. Zhang. FSH stimulates the expression of the ADAMTS-16 protease in mature 
human ovarian follicles. Mol.Hum.Reprod. 13 (7):465-471, 2007. 
E. Garcia-Gras, R. Lombardi, M. J. Giocondo, J. T. Willerson, M. D. Schneider, D. S. Khoury, and A. J. Marian. Suppression 
of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right 
ventricular cardiomyopathy. J.Clin.Invest 116 (7):2012-2021, 2006. 
D. Garrod and M. Chidgey. Desmosome structure, composition and function. Biochim.Biophys.Acta 1778 (3):572-587, 
2008. 
S. Getsios, A. C. Huen, and K. J. Green. Working out the strength and flexibility of desmosomes. Nat.Rev.Mol.Cell Biol. 5 
(4):271-281, 2004. 
A. Gilhar, R. Paus, and R. S. Kalish. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J.Clin.Invest 117 
(8):2019-2027, 2007. 
A. Gilhar. Collapse of immune privilege in alopecia areata: coincidental or substantial? J.Invest Dermatol. 130 (11):2535-
2537, 2010. 
S. Giovannini. Recherches sur l’histologie pathologique de la pelade. Annales de Dermatologie et de Syphiligraphie. 3:923-
957 1891 
116 
 
S. S. Glasson, R. Askew, B. Sheppard, B. Carito, T. Blanchet, H. L. Ma, C. R. Flannery, D. Peluso, K. Kanki, Z. Yang, M. K. 
Majumdar, and E. A. Morris. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of 
osteoarthritis. Nature 434 (7033):644-648, 2005. 
L. A. Goldsmith. Summary of alopecia areata research workshop and future research directions. J.Invest Dermatol. 96 
(5):98S-100S, 1991. 
H. Gollinck, C.E. Orfanos. Nature et traitment de la pelade – la pelade d’origine dentaire. Ann.Dermatol.et.de.Syph. 3:18:-
190 1902. 
J. M. Gooding, K. L. Yap, and M. Ikura. The cadherin-catenin complex as a focal point of cell adhesion and signalling: new 
insights from three-dimensional structures. Bioessays 26 (5):497-511, 2004. 
B. Gumbiner. Cadherins: a family of Ca2+-dependent adhesion molecules. Trends Biochem.Sci. 13 (3):75-76, 1988. 
H. Hakonarson, S. F. Grant, J. P. Bradfield, L. Marchand, C. E. Kim, J. T. Glessner, R. Grabs, T. Casalunovo, S. P. Taback, E. 
C. Frackelton, M. L. Lawson, L. J. Robinson, R. Skraban, Y. Lu, R. M. Chiavacci, C. A. Stanley, S. E. Kirsch, E. F. Rappaport, J. 
S. Orange, D. S. Monos, M. Devoto, H. Q. Qu, and C. Polychronakos. A genome-wide association study identifies KIAA0350 
as a type 1 diabetes gene. Nature 448 (7153):591-594, 2007. 
M. Hakuno, M. Akiyama, H. Shimizu, M. J. Wheelock, and T. Nishikawa. Upregulation of P-cadherin expression in the 
lesional skin of pemphigus, Hailey-Hailey disease and Darier's disease. J.Cutan.Pathol.  28 (6):277-281, 2001. 
R. B. Hazan and L. Norton. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin 
cytoskeleton. J.Biol.Chem. 273 (15):9078-9084, 1998. 
M. Hesse, T. Franz, Y. Tamai, M. M. Taketo, and T. M. Magin. Targeted deletion of keratins 18 and 19 leads to trophoblast 
fragility and early embryonic lethality. EMBO J. 19 (19):5060-5070, 2000. 
R. Hoffmann. The potential role of cytokines and T cells in alopecia areata. J.Investig.Dermatol.Symp.Proc. 4 (3):235-238, 
1999. 
A. Hollnagel, C. Grund, W. W. Franke, and H. H. Arnold. The cell adhesion molecule M-cadherin is not essential for muscle 
development and regeneration. Mol.Cell Biol. 22 (13):4760-4770, 2002. 
B. Holthofer, R. Windoffer, S. Troyanovsky, and R. E. Leube. Structure and function of desmosomes. Int.Rev.Cytol. 264:65-
163, 2007. 
T. Hruz, M. Wyss, M. Docquier, M. W. Pfaffl, S. Masanetz, L. Borghi, P. Verbrugghe, L. Kalaydjieva, S. Bleuler, O. Laule, P. 
Descombes, W. Gruissem, and P. Zimmermann. RefGenes: identification of reliable and condition specific reference genes 
for RT-qPCR data normalization. BMC.Genomics 12:156, 2011. 
P. Hu, P. Berkowitz, E. J. O'Keefe, and D. S. Rubenstein. Keratinocyte adherens junctions initiate nuclear signaling by 
translocation of plakoglobin from the membrane to the nucleus. J.Invest Dermatol.  121 (2):242-251, 2003. 
A. H. Huber and W. I. Weis. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse 
ligand recognition by beta-catenin. Cell 105 (3):391-402, 2001. 
A. C. Huen, J. K. Park, L. M. Godsel, X. Chen, L. J. Bannon, E. V. Amargo, T. Y. Hudson, A. K. Mongiu, I. M. Leigh, D. P. Kelsell, 
B. M. Gumbiner, and K. J. Green. Intermediate filament-membrane attachments function synergistically with actin-
dependent contacts to regulate intercellular adhesive strength. J.Cell Biol. 159 (6):1005-1017, 2002. 
T. Ikeda. Produced alopecia areata based on the focal infection theory and mental motive theory. Dermatologica 134 
(1):1-11, 1967. 
R. A. Irizarry, Z. Wu, and H. A. Jaffee. Comparison of Affymetrix GeneChip expression measures. Bioinformatics. 22 
(7):789-794, 2006. 
C. A. Jahoda and A. J. Reynolds. Dermal-epidermal interactions. Adult follicle-derived cell populations and hair growth. 
Dermatol.Clin. 14 (4):573-583, 1996. 
C. Jamora, R. DasGupta, P. Kocieniewski, and E. Fuchs. Links between signal transduction, transcription and adhesion in 
epithelial bud development. Nature 422 (6929):317-322, 2003. 
D. Jaquemar, S. Kupriyanov, M. Wankell, J. Avis, K. Benirschke, H. Baribault, and R. G. Oshima. Keratin 8 protection of 
placental barrier function. J.Cell Biol. 161 (4):749-756, 2003. 
I Joseph. Linde 1886-1951. Conn.State Med.J. 15 (10):924, 1951. 
R. S. Kalish and A. Gilhar. Alopecia areata: autoimmunity--the evidence is compelling. J.Investig.Dermatol.Symp.Proc. 8 
(2):164-167, 2003. 
117 
 
S. Kim, P. Wong, and P. A. Coulombe. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. 
Nature 441 (7091):362-365, 2006. 
J.T. Kinnear. Gardiner’s handbook of skin diseases. 4th edition. Edinburgh, E&SLivingstone. 224-228 1939. 
J. Klingelhofer, R. B. Troyanovsky, O. Y. Laur, and S. Troyanovsky. Amino-terminal domain of classic cadherins determines 
the specificity of the adhesive interactions. J.Cell Sci. 113 ( Pt 16):2829-2836, 2000. 
K. A. Knudsen and M. J. Wheelock. Plakoglobin, or an 83-kD homologue distinct from beta-catenin, interacts with E-
cadherin and N-cadherin. J.Cell Biol. 118 (3):671-679, 1992. 
K. A. Knudsen, C. Frankowski, K. R. Johnson, and M. J. Wheelock. A role for cadherins in cellular signaling and 
differentiation. J.Cell Biochem.Suppl 30-31:168-176, 1998. 
M. D. Kottke, E. Delva, and A. P. Kowalczyk. The desmosome: cell science lessons from human diseases. J.Cell Sci. 119 (Pt 
5):797-806, 2006. 
A. P. Kowalczyk, T. S. Stappenbeck, D. A. Parry, H. L. Palka, M. L. Virata, E. A. Bornslaeger, L. A. Nilles, and K. J. Green. 
Structure and function of desmosomal transmembrane core and plaque molecules. Biophys.Chem. 50 (1-2):97-112, 
1994. 
A. P. Kowalczyk, E. A. Bornslaeger, J. E. Borgwardt, H. L. Palka, A. S. Dhaliwal, C. M. Corcoran, M. F. Denning, and K. J. 
Green. The amino-terminal domain of desmoplakin binds to plakoglobin and clusters desmosomal cadherin-plakoglobin 
complexes. J.Cell Biol. 139 (3):773-784, 1997. 
S. S. Krishna, I. Majumdar, and N. V. Grishin. Structural classification of zinc fingers: survey and summary. Nucleic Acids 
Res. 31 (2):532-550, 2003. 
N. O. Ku, R. M. Soetikno, and M. B. Omary. Keratin mutation in transgenic mice predisposes to Fas but not TNF-induced 
apoptosis and massive liver injury. Hepatology 37 (5):1006-1014, 2003. 
C. Kuch, D. Winnekendonk, S. Butz, U. Unvericht, R. Kemler, and A. Starzinski-Powitz. M-cadherin-mediated cell adhesion 
and complex formation with the catenins in myogenic mouse cells. Exp.Cell Res. 232 (2):331-338, 1997. 
L. Langbein, H. Spring, M. A. Rogers, S. Praetzel, and J. Schweizer. Hair keratins and hair follicle-specific epithelial keratins. 
Methods Cell Biol. 78:413-451, 2004. 
L. Langbein, M. A. Rogers, S. Praetzel-Wunder, B. Helmke, P. Schirmacher, and J. Schweizer. K25 (K25irs1), K26 
(K25irs2), K27 (K25irs3), and K28 (K25irs4) represent the type I inner root sheath keratins of the human hair follicle. 
J.Invest Dermatol. 126 (11):2377-2386, 2006. 
R. H. Lekanne Deprez, A. C. Fijnvandraat, J. M. Ruijter, and A. F. Moorman. Sensitivity and accuracy of quantitative real-
time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions. Anal.Biochem. 307 (1):63-69, 
2002. 
B. L. Lew, M. K. Shin, and W. Y. Sim. Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable 
prognosis. J.Am.Acad.Dermatol. 60 (1):85-93, 2009. 
J. E. Lewis, J. K. Wahl, III, K. M. Sass, P. J. Jensen, K. R. Johnson, and M. J. Wheelock. Cross-talk between adherens 
junctions and desmosomes depends on plakoglobin. J.Cell Biol. 136 (4):919-934, 1997. 
B. Liss. Improved quantitative real-time RT-PCR for expression profiling of individual cells. Nucleic Acids Res. 30 (17):e89, 
2002. 
X. Lu and E. B. Lane. Retrovirus-mediated transgenic keratin expression in cultured fibroblasts: specific domain functions 
in keratin stabilization and filament formation. Cell 62 (4):681-696, 1990. 
I. M. Mackay, K. E. Arden, and A. Nitsche. Real-time PCR in virology. Nucleic Acids Res. 30 (6):1292-1305, 2002. 
J. P. Mackay and M. Crossley. Zinc fingers are sticking together. Trends Biochem.Sci. 23 (1):1-4, 1998. 
S. Madani and J. Shapiro. Alopecia areata update. J.Am.Acad.Dermatol. 42 (4):549-566, 2000. 
K. C. Madison. Barrier function of the skin: "la raison d'etre" of the epidermis. J.Invest Dermatol. 121 (2):231-241, 2003. 
L. B. Maifrino, R. C. Araujo, C. C. Faccini, E. A. Liberti, E. F. Gama, A. A. Ribeiro, and R. R. Souza. Effect of exercise training 
on aging-induced changes in rat papillary muscle. Arq Bras.Cardiol. 92 (5):356-7, 387, 2009. 
F. D. Malkinson and J. T. Keane. Hair matrix cell kinetics: a selective review. Int.J.Dermatol. 17 (7):536-551, 1978. 
A. G. MATOLTSY. Keratinization of embryonic skin. J.Invest Dermatol. 31 (6):343-346, 1958. 
118 
 
J. M. Matthews and M. Sunde. Zinc fingers--folds for many occasions. IUBMB.Life 54 (6):351-355, 2002. 
A. J. McDonagh and A. G. Messenger. Alopecia areata. Clin.Dermatol. 19 (2):141-147, 2001. 
K.. J. McElwee. Spontaneous Rat Model of Alopecia Areata in Dundee Experimental Bald Rat (DEBR). In: Animal Models of 
Human Inflammatory Skin Diseases by L. S. Chan. Boca Raton, Fla, CRC Press, 2004. 
K. J. McElwee, D. J. Tobin, J. C. Bystryn, L. E. King, Jr., and J. P. Sundberg. Alopecia areata: an autoimmune disease? 
Exp.Dermatol. 8 (5):371-379, 1999. 
K. J. McElwee, P. Freyschmidt-Paul, J. P. Sundberg, and R. Hoffmann. The pathogenesis of alopecia areata in rodent 
models. J.Investig.Dermatol.Symp.Proc. 8 (1):6-11, 2003. 
A. G. Messenger, D. N. Slater, and S. S. Bleehen. Alopecia areata: alterations in the hair growth cycle and correlation with 
the follicular pathology. Br.J.Dermatol. 114 (3):337-347, 1986. 
H. J. Michie, C. A. Jahoda, R. F. Oliver, and B. E. Johnson. The DEBR rat: an animal model of human alopecia areata. 
Br.J.Dermatol. 125 (2):94-100, 1991. 
J. R. Miller, A. M. Hocking, J. D. Brown, and R. T. Moon. Mechanism and function of signal transduction by the Wnt/beta-
catenin and Wnt/Ca2+ pathways. Oncogene 18 (55):7860-7872, 1999. 
R. Moll, M. Divo, and L. Langbein. The human keratins: biology and pathology. Histochem.Cell Biol. 129 (6):705-733, 2008. 
T. B. Morrison, J. J. Weis, and C. T. Wittwer. Quantification of low-copy transcripts by continuous SYBR Green I monitoring 
during amplification. Biotechniques 24 (6):954-8, 960, 962, 1998. 
M. Mukhopadhyay, P. Pelka, D. DeSousa, B. Kablar, A. Schindler, M. A. Rudnicki, and A. R. Campos. Cloning, genomic 
organization and expression pattern of a novel Drosophila gene, the disco-interacting protein 2 (dip2), and its murine 
homolog. Gene 293 (1-2):59-65, 2002. 
C. S. Muller and L. El Shabrawi-Caelen. 'Follicular Swiss cheese' pattern--another histopathologic clue to alopecia areata. 
J.Cutan.Pathol. 38 (2):185-189, 2011. 
E. Muller, R. Caldelari, Bruin A. De, D. Baumann, C. Bierkamp, V. Balmer, V, and M. M. Suter. Pathogenesis in pemphigus 
vulgaris: A central role for the armadillo protein plakoglobin. J.Invest Dermatol. 115 (2):332, 2000. 
S. A. MULLER and R. K. WINKELMANN. ALOPECIA AREATA. AN EVALUATION OF 736 PATIENTS. Arch.Dermatol. 88:290-
297, 1963. 
M. F. Naso, B. Liang, C. C. Huang, X. Y. Song, L. Shahied-Arruda, S. M. Belkowski, M. R. D'Andrea, D. A. Polkovitch, D. R. 
Lawrence, D. E. Griswold, R. W. Sweet, and B. Y. Amegadzie. Dermokine: an extensively differentially spliced gene 
expressed in epithelial cells. J.Invest Dermatol. 127 (7):1622-1631, 2007. 
S. Nischwitz, S. Cepok, A. Kroner, C. Wolf, M. Knop, F. Muller-Sarnowski, H. Pfister, P. Rieckmann, B. Hemmer, M. Ising, M. 
Uhr, T. Bettecken, F. Holsboer, B. Muller-Myhsok, and F. Weber. More CLEC16A gene variants associated with multiple 
sclerosis. Acta Neurol.Scand. 123 (6):400-406, 2011. 
N. C. Noriega, S. G. Kohama, and H. F. Urbanski. Gene expression profiling in the rhesus macaque: methodology, 
annotation and data interpretation. Methods 49 (1):42-49, 2009. 
D. Norris. Alopecia areata: current state of knowledge. J.Am.Acad.Dermatol. 51 (1 Suppl):S16-S17, 2004. 
R. F. Oliver, C. A. Jahoda, K. A. Horne, H. J. Michie, T. Poulton, and B. E. Johnson. The DEBR rat model for alopecia areata. 
J.Invest Dermatol. 96 (5):97S, 1991. 
A. S. Oriolo, F. A. Wald, V. P. Ramsauer, and P. J. Salas. Intermediate filaments: a role in epithelial polarity. Exp.Cell Res. 
313 (10):2255-2264, 2007. 
O.S. Ormsby, H. Montgomery. Diseases of the skin. 7th edition. London. Henry Kimpton. 1365-1375 1948. 
M. Ozawa, H. Terada, and C. Pedraza. The fourth armadillo repeat of plakoglobin (gamma-catenin) is required for its high 
affinity binding to the cytoplasmic domains of E-cadherin and desmosomal cadherin Dsg2, and the tumor suppressor APC 
protein. J.Biochem. 118 (5):1077-1082, 1995. 
S. Palmer, A. P. Wiegand, F. Maldarelli, H. Bazmi, J. M. Mican, M. Polis, R. L. Dewar, A. Planta, S. Liu, J. A. Metcalf, J. W. 
Mellors, and J. M. Coffin. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human 
immunodeficiency virus type 1 RNA in plasma. J.Clin.Microbiol. 41 (10):4531-4536, 2003. 
G. T. Park, S. E. Lim, S. I. Jang, and M. I. Morasso. Suprabasin, a novel epidermal differentiation marker and potential 
cornified envelope precursor. J.Biol.Chem. 277 (47):45195-45202, 2002. 
119 
 
R. Paus, S. Eichmuller, U. Hofmann, B. M. Czarnetzki, and P. Robinson. Expression of classical and non-classical MHC class 
I antigens in murine hair follicles. Br.J.Dermatol. 131 (2):177-183, 1994. 
R. Paus. Immunology of the hair follicle in: Bos JD, ed. The skin immune system. Boca Raton, FL: CRC Press. 377 1997. 
R. Paus, N. Ito, M. Takigawa, and T. Ito. The hair follicle and immune privilege. J.Investig.Dermatol.Symp.Proc. 8 (2):188-
194, 2003. 
M. Peifer and P. Polakis. Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science 287 
(5458):1606-1609, 2000. 
S. N. Peirson, J. N. Butler, and R. G. Foster. Experimental validation of novel and conventional approaches to quantitative 
real-time PCR data analysis. Nucleic Acids Res. 31 (14):e73, 2003. 
C. Perret, L. Wiesner-Menzel, and R. Happle. Immunohistochemical analysis of T-cell subsets in the peribulbar and 
intrabulbar infiltrates of alopecia areata. Acta Derm.Venereol. 64 (1):26-30, 1984. 
L. Petukhova, M. Duvic, M. Hordinsky, D. Norris, V. Price, Y. Shimomura, H. Kim, P. Singh, A. Lee, W. V. Chen, K. C. Meyer, 
R. Paus, C. A. Jahoda, C. I. Amos, P. K. Gregersen, and A. M. Christiano. Genome-wide association study in alopecia areata 
implicates both innate and adaptive immunity. Nature 466 (7302):113-117, 2010. 
M. P. Philpott, D. A. Sanders, J. Bowen, and T. Kealey. Effects of interleukins, colony-stimulating factor and tumour necrosis 
factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia 
areata. Br.J.Dermatol. 135 (6):942-948, 1996. 
M. Pigors, D. Kiritsi, S. Krumpelmann, N. Wagner, Y. He, M. Podda, J. Kohlhase, I. Hausser, L. Bruckner-Tuderman, and C. 
Has. Lack of plakoglobin leads to lethal congenital epidermolysis bullosa: a novel clinico-genetic entity. Hum.Mol.Genet. 20 
(9):1811-1819, 2011. 
D. M. Pirone, S. Fukuhara, J. S. Gutkind, and P. D. Burbelo. SPECs, small binding proteins for Cdc42. J.Biol.Chem. 275 
(30):22650-22656, 2000. 
S. Porter, P. N. Span, F. C. Sweep, V. C. Tjan-Heijnen, C. J. Pennington, T. X. Pedersen, M. Johnsen, L. R. Lund, J. Romer, 
and D. R. Edwards. ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. Int.J.Cancer 118 
(5):1241-1247, 2006. 
M. L. Price and W. A. Griffiths. Normal body hair--a review. Clin.Exp.Dermatol. 10 (2):87-97, 1985. 
V. H. Price. Alopecia areata: clinical aspects. J.Invest Dermatol. 96 (5):68S, 1991. 
E. Proksch, J. M. Brandner, and J. M. Jensen. The skin: an indispensable barrier. Exp.Dermatol. 17 (12):1063-1072, 
2008. 
N. Protonotarios, A. Tsatsopoulou, P. Patsourakos, D. Alexopoulos, P. Gezerlis, S. Simitsis, and G. Scampardonis. Cardiac 
abnormalities in familial palmoplantar keratosis. Br.Heart J. 56 (4):321-326, 1986. 
A. Ranki, U. Kianto, L. Kanerva, E. Tolvanen, and E. Johansson. Immunohistochemical and electron microscopic 
characterization of the cellular infiltrate in alopecia (areata, totalis, and universalis). J.Invest Dermatol. 83 (1):7-11, 1984. 
A. J. Reynolds and C. A. Jahoda. Hair follicle stem cells: characteristics and possible significance. Skin Pharmacol. 7 (1-
2):16-19, 1994. 
C.R. Robins. Chemical and Physical Behavior of Human Hair. New York. Springer Verlag. 2002. 
T. Robinson. Baldness and Greyness, Their Etiology, Pathology and Treatment. 2nd edition. London. Kimpton. 1883. 
P. Ruiz, V. Brinkmann, B. Ledermann, M. Behrend, C. Grund, C. Thalhammer, F. Vogel, C. Birchmeier, U. Gunthert, W. W. 
Franke, and W. Birchmeier. Targeted mutation of plakoglobin in mice reveals essential functions of desmosomes in the 
embryonic heart. J.Cell Biol. 135 (1):215-225, 1996. 
A.C. Roxburgh. Common skin diseases. 9th edition. London. HK Lewis & Co. LTD. 406-412, 1950. 
N. H. Sabah. Controlled stimulation of hair follicle receptors. J.Appl.Physiol 36 (2):256-257, 1974. 
R. Sabouraud. Sur les origins de la pelade. Annales de Dermatologie et Syphiligraphie. 3:253-277, 1896. 
R. Sabouraud. Nouvelles recherché sur l’etiologie de la pelade ―pelade et menopause‖. Annales de Dermatologie et 
Syphiligraphie. 5:88-97, 1913. 
P. A. Sacco, T. M. McGranahan, M. J. Wheelock, and K. R. Johnson. Identification of plakoglobin domains required for 
association with N-cadherin and alpha-catenin. J.Biol.Chem. 270 (34):20201-20206, 1995. 
120 
 
Sauvages. Nosologica Medica. Lyons. 1760 
L. Scerri and J. L. Pace. Identical twins with identical alopecia areata. J.Am.Acad.Dermatol. 27 (5 Pt 1):766-767, 1992. 
R. J. Schaffer, E. N. Friel, E. J. Souleyre, K. Bolitho, K. Thodey, S. Ledger, J. H. Bowen, J. H. Ma, B. Nain, D. Cohen, A. P. 
Gleave, R. N. Crowhurst, B. J. Janssen, J. L. Yao, and R. D. Newcomb. A genomics approach reveals that aroma 
production in apple is controlled by ethylene predominantly at the final step in each biosynthetic pathway. Plant Physiol 
144 (4):1899-1912, 2007. 
T. D. Schmittgen, B. A. Zakrajsek, A. G. Mills, V. Gorn, M. J. Singer, and M. W. Reed. Quantitative reverse transcription-
polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods.  Anal.Biochem. 285 
(2):194-204, 2000. 
Sequeira. Trans XVII Int Cong Med. London. 13:142, 1913. 
W. V. Shellow, J. E. Edwards, and J. Y. Koo. Profile of alopecia areata: a questionnaire analysis of patient and family. 
Int.J.Dermatol. 31 (3):186-189, 1992. 
Y. Shimomura, M. Wajid, L. Shapiro, and A. M. Christiano. P-cadherin is a p63 target gene with a crucial role in the 
developing human limb bud and hair follicle. Development 135 (4):743-753, 2008. 
Y. Shimomura and A. M. Christiano. Biology and genetics of hair. Annu.Rev.Genomics Hum.Genet. 11:109-132, 2010. 
L. C. Sperling. Hair anatomy for the clinician. J.Am.Acad.Dermatol. 25 (1 Pt 1):1-17, 1991. 
V. Stellmach, A. Leask, and E. Fuchs. Retinoid-mediated transcriptional regulation of keratin genes in human epidermal and 
squamous cell carcinoma cells. Proc.Natl.Acad.Sci.U.S.A 88 (11):4582-4586, 1991. 
K. S. Stenn and R. Paus. Controls of hair follicle cycling. Physiol Rev. 81 (1):449-494, 2001. 
M. Stucker, A. Struk, P. Altmeyer, M. Herde, H. Baumgartl, and D. W. Lubbers. The cutaneous uptake of atmospheric 
oxygen contributes significantly to the oxygen supply of human dermis and epidermis. J.Physiol 538 (Pt 3):985-994, 
2002. 
C. L. Sutherland, N. J. Chalupny, K. Schooley, T. VandenBos, M. Kubin, and D. Cosman. UL16-binding proteins, novel MHC 
class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J.Immunol. 168 
(2):671-679, 2002. 
N. A. Swanson, A. J. Mitchell, M. S. Leahy, J. T. Headington, and L. A. Diaz. Topical treatment of alopecia areata. 
Arch.Dermatol. 117 (7):384-387, 1981. 
M. Tanaka, K. Murakami, S. Ozaki, Y. Imura, X. P. Tong, T. Watanabe, T. Sawaki, T. Kawanami, D. Kawabata, T. Fujii, T. Usui, 
Y. Masaki, T. Fukushima, Z. X. Jin, H. Umehara, and T. Mimori. DIP2 disco-interacting protein 2 homolog A (Drosophila) is a 
candidate receptor for follistatin-related protein/follistatin-like 1--analysis of their binding with TGF-beta superfamily 
proteins. FEBS J. 277 (20):4278-4289, 2010. 
U. Tepass, K. Truong, D. Godt, M. Ikura, and M. Peifer. Cadherins in embryonic and neural morphogenesis. 
Nat.Rev.Mol.Cell Biol. 1 (2):91-100, 2000. 
Y. Teraki, K. Imanishi, and T. Shiohara. Cytokines in alopecia areata: contrasting cytokine profiles in localized form and 
extensive form (alopecia universalis). Acta Derm.Venereol. 76 (6):421-423, 1996. 
A. Tichopad, A. Didier, and M. W. Pfaffl. Inhibition of real-time RT-PCR quantification due to tissue-specific contaminants. 
Mol.Cell Probes 18 (1):45-50, 2004. 
N. Todes-Taylor, R. Turner, G. S. Wood, P. T. Stratte, and V. B. Morhenn. T cell subpopulations in alopecia areata. 
J.Am.Acad.Dermatol. 11 (2 Pt 1):216-223, 1984. 
X. Tong and P. A. Coulombe. Keratin 17 modulates hair follicle cycling in a TNFalpha-dependent fashion. Genes Dev. 20 
(10):1353-1364, 2006. 
E. Toulza, M. F. Galliano, N. Jonca, H. Gallinaro, M. C. Mechin, A. Ishida-Yamamoto, G. Serre, and M. Guerrin. The human 
dermokine gene: description of novel isoforms with different tissue-specific expression and subcellular location. J.Invest 
Dermatol. 126 (2):503-506, 2006. 
S. M. Troyanovsky, R. B. Troyanovsky, L. G. Eshkind, R. E. Leube, and W. W. Franke. Identification of amino acid sequence 
motifs in desmocollin, a desmosomal glycoprotein, that are required for plakoglobin binding and plaque formation. 
Proc.Natl.Acad.Sci.U.S.A 91 (23):10790-10794, 1994. 
S. Tsuchida, M. Bonkobara, J. R. McMillan, M. Akiyama, T. Yudate, Y. Aragane, T. Tezuka, H. Shimizu, P. D. Cruz, Jr., and K. 
Ariizumi. Characterization of Kdap, a protein secreted by keratinocytes. J.Invest Dermatol. 122 (5):1225-1234, 2004. 
121 
 
E. J. VAN SCOTT. Morphologic changes in pilosebaceous units and anagen hairs in alopecia areata. J.Invest Dermatol. 31 
(1):35-43, 1958. 
E. J. VAN SCOTT. Keratinization and hair growth. Annu.Rev.Med. 19:337-350, 1968. 
J. Vandesompele, Preter K. De, F. Pattyn, B. Poppe, Roy N. Van, Paepe A. De, and F. Speleman. Accurate normalization of 
real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3 
(7):RESEARCH0034, 2002. 
J. K. Wahl, J. E. Nieset, P. A. Sacco-Bubulya, T. M. Sadler, K. R. Johnson, and M. J. Wheelock. The amino- and carboxyl-
terminal tails of (beta)-catenin reduce its affinity for desmoglein 2. J.Cell Sci. 113 ( Pt 10):1737-1745, 2000. 
Y. Wang, C. Barbacioru, F. Hyland, W. Xiao, K. L. Hunkapiller, J. Blake, F. Chan, C. Gonzalez, L. Zhang, and R. R. Samaha. 
Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide 
microarrays. BMC.Genomics 7:59, 2006. 
J. Waschke. The desmosome and pemphigus. Histochem.Cell Biol. 130 (1):21-54, 2008. 
G. E. Westgate, R. I. Craggs, and W. T. Gibson. Immune privilege in hair growth. J.Invest Dermatol. 97 (3):417-420, 1991. 
M. J. Wheelock and P. J. Jensen. Regulation of keratinocyte intercellular junction organization and epidermal 
morphogenesis by E-cadherin. J.Cell Biol. 117 (2):415-425, 1992. 
B. Winnepenninckx, K. Debacker, J. Ramsay, D. Smeets, A. Smits, D. R. FitzPatrick, and R. F. Kooy. CGG-repeat expansion 
in the DIP2B gene is associated with the fragile site FRA12A on chromosome 12q13.1. Am.J.Hum.Genet. 80 (2):221-
231, 2007. 
A. Wodarz and R. Nusse. Mechanisms of Wnt signaling in development. Annu.Rev.Cell Dev.Biol. 14:59-88, 1998. 
S. A. Wolfe, L. Nekludova, and C. O. Pabo. DNA recognition by Cys2His2 zinc finger proteins. 
Annu.Rev.Biophys.Biomol.Struct. 29:183-212, 2000. 
M. L. Wong and J. F. Medrano. Real-time PCR for mRNA quantitation. Biotechniques 39 (1):75-85, 2005. 
K. M. Yamada and B. Geiger. Molecular interactions in cell adhesion complexes. Curr.Opin.Cell Biol. 9 (1):76-85, 1997. 
A. S. Yap, W. M. Brieher, M. Pruschy, and B. M. Gumbiner. Lateral clustering of the adhesive ectodomain: a fundamental 
determinant of cadherin function. Curr.Biol. 7 (5):308-315, 1997. 
K. Zatloukal, C. Stumptner, M. Lehner, H. Denk, H. Baribault, L. G. Eshkind, and W. W. Franke. Cytokeratin 8 protects from 
hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies. Am.J.Pathol. 
156 (4):1263-1274, 2000. 
W. Zeng, C. Corcoran, L. A. Collins-Racie, E. R. Lavallie, E. A. Morris, and C. R. Flannery. Glycosaminoglycan-binding 
properties and aggrecanase activities of truncated ADAMTSs: comparative analyses with ADAMTS-5, -9, -16 and -18. 
Biochim.Biophys.Acta 1760 (3):517-524, 2006. 
M. Zoledziewska, G. Costa, M. Pitzalis, E. Cocco, C. Melis, L. Moi, P. Zavattari, R. Murru, R. Lampis, L. Morelli, F. Poddie, P. 
Frongia, P. Pusceddu, M. Bajorek, A. Marras, A. M. Satta, A. Chessa, M. Pugliatti, S. Sotgiu, M. B. Whalen, G. Rosati, F. 
Cucca, and M. G. Marrosu. Variation within the CLEC16A gene shows consistent disease association with both multiple 
sclerosis and type 1 diabetes in Sardinia. Genes Immun. 10 (1):15-17, 2009. 
 
  
122 
 
J Appendix 
 
1. Primer Sequences 
For Sanger-Sequencing of rat samples: 
Acd_e1F         AGTGGGCATAGGTCTTTAGGTG       
Acd_e1R         GGTGGTCCCTAGAGAAACAGTG       
Acd_e2F         GAAAAAGCTCAATAAATGCCTTG      
Acd_e2R         TTACAGCGACTTACTGAAGAACG      
Acd_e3F         GCGCTTTTCTTAGGAGGTGTC        
Acd_e3R         CTGGAGTTCTGGAGAGAATCATC      
Acd_e4.1F       GGGTGGCTAATGGACTGTTTAG       
Acd_e4.1R       TAGTCTCACCCAGACAGAGTGG       
Acd_e4.2F       ACATGCCCCTACTTCATACCAG       
Acd_e4.2R       TGTCATACAAGCCTACCCTTCC       
Acd_e5F         GAGAGGGAAGGGTAGGCTTG         
Acd_e5R         AGGAGAGAGCCTGGAAAGAAAC       
Acd_e6F         ATAAATATGGGACACCCTCTGC       
Acd_e6R         AACCAAGCCTCTTCCTCCATAC       
Agrp_e1F        GGATCAACAAGCAAAGGTAAGC       
Agrp_e1R        GGACTAGGGAAGGAGGGTTTAG       
Agrp_e2F        CTTCCCTAGTCCCAAGCTTAAC       
Agrp_e2R        ATAGGATGGCAGTGGAGTGTG        
Agrp_e3F        AACTGCAGACCATCCCTGAC         
Agrp_e3R        ATGACAAAGATGATGCGGTAGC       
Arhgap10_e10F   CTGTAATCCTTCCTGCAGTC         
Arhgap10_e10R   CAACTACACAGTGACCAACG         
Arhgap10_e11F   CTGGAGGCAAATCATGAGG          
Arhgap10_e11R   GAATACCAGCTCCAGCAAG          
Arhgap10_e12F   GTAAAGCAGGGACGAAGAC          
Arhgap10_e12R   CTAGGGGACAAACAATGAGG         
Arhgap10_e13F   GCATCACGAAGCCTCTTCT          
Arhgap10_e13R   GCGTGCTGCGTATAAAGTTC         
Arhgap10_e14F   TAGTGGAGATCTTGGAGTGC         
Arhgap10_e14R   GGACACAACCAACCCAAGTA         
Arhgap10_e15F   GAAACTGTCGTTTGGCCACT         
Arhgap10_e15R   AGACTTCTCGGGCCAGTAA          
Arhgap10_e16F   GTTAGCCTCAGAGTGCACAAG        
Arhgap10_e16R   TGGGCTCAGGTCAATACTAC         
Arhgap10_e17F   AAGGTGGAGGGACAGTTTAG         
Arhgap10_e17R   GTCTAATACGCAGCCTGGTC         
Arhgap10_e18F   CTGCTGTTTGGTTCAGACAC         
Arhgap10_e18R   GGAATAAGTCCACAGCAAGC         
Arhgap10_e19F   TGTATCCTGGCTACCTTCC          
Arhgap10_e19R   GTCACCCTCCCTGTTAATC          
Arhgap10_e1F    GATCAGCAGACATCAGCAC          
Arhgap10_e1R    GGGTGCAGTAAAACCTGAC          
Arhgap10_e20F   CAGAAGTATCTGCGTGCTC          
Arhgap10_e20R   ACCTGAACTCTGGAAGTCAC         
Arhgap10_e21F   CTGTCCCAGTGGTTTGAAG          
Arhgap10_e21R   ACAATACCCAGGAGTGACTG         
Arhgap10_e22F   GGAAACCCACCACTTACTTG         
Arhgap10_e22R   CATCTCTACAAGCCGGTGT          
Arhgap10_e23F   AATCCCTCGGCATGGTAAG          
Arhgap10_e2-3F  GCTCTTCTACCCCTCCTAAC         
Arhgap10_e23R   AAGTTCCATCCCCTCCCTA          
Arhgap10_e2-3R  TCAGGCTTGGCTAAACAG           
Arhgap10_e4F    GTGCAGCCTTTTAGTACGTC         
Arhgap10_e4R    CAGAGGTAAGCCACGTGTA          
Arhgap10_e5F    GCATTGCCTCAGAAGCTC           
Arhgap10_e5R    CCCCAATCCACTGAAGAA           
Arhgap10_e6F    GACCTCTGGTTTGATGGTC          
Arhgap10_e6R    CCTCCCAACAGTTTGATG           
Arhgap10_e7F    TTGCTTGCTTCCATGCAC           
Arhgap10_e7R    GCTACAGTGCAGCTTGTTAC         
Arhgap10_e8F    CGTCGTCTCATCCTCTCTAT         
Arhgap10_e8R    CAGAGCACTTTCCACTCTTG         
Arhgap10_e9F    CGAACTCCTAGAGATAGTCCTG       
Arhgap10_e9R    ACAGCGACAAGTTCTACTCC         
Atp6v0d1_e1F    GTTGTTGGGCTCACCAAAGT         
Atp6v0d1_e1R    AGGGTTTTGGAGCCAAATGT         
Atp6v0d1_e2.1F  GCCTAACCCGGGAAAACTAA         
Atp6v0d1_e2.1R  ATAAAGCTCCGGGAAGAACG         
Atp6v0d1_e2.2F  GTCACCTGACGCACTTGACA         
Atp6v0d1_e2.2R  TTTCTGACATGCCCACGAT          
Atp6v0d1_e3F    CATGGGAGGAGGTGGTCTTAG        
Atp6v0d1_e3R    AGAGCTGCCATCTGATCACC         
Atp6v0d1_e4F    GACAGTCCCTCTGGAGCCTA         
Atp6v0d1_e4R    GCCGCCTACAATCCATAAAA         
Atp6v0d1_e5F    TCAGGGATCTCCAGTACTTAGCTT     
Atp6v0d1_e5R    CCATAGACCCACCCACTGAC         
Atp6v0d1_e6F    TGAAGAGGGGAGATCAAACTGAC      
Atp6v0d1_e6R    TAGCCAGTCAGTTGGCAGAG         
Atp6v0d1_e7F    CTGCCAACTGACTGGCTATG         
Atp6v0d1_e7R    CTCCAGGGTCTTGTCTCCAG         
Atp6v0d1_e8F    TGAGTGCCCTAGCTGACAAG         
Atp6v0d1_e8R    CAGAATCAGGCCCAAGTCAC         
Atp6v0d1_e9.1F  GTTGTGACTTGGGCCTGATT         
Atp6v0d1_e9.1R  GGGGATCTTGGTCCATTCTT         
Atp6v0d1_e9.2F  ATTGCCCTGGGATTGGTT           
Atp6v0d1_e9.2R  GTAGAAACTGCCACCCTCCA         
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C16orf48_e1F    GTCATTTGACCCCTGACCTC         
C16orf48_e1R    AGCTCTGTAGCCCCGTGGT          
C16orf48_e2F    GGTACCACGGGGCTACAGAG         
C16orf48_e2R    CTTGGGCTGAAGAGCAAGAC         
C16orf48_e3F    CCTACTCTCTGCCCGGACTA         
C16orf48_e3R    TCAAGGCGGTTAAGAAGCAC         
C16orf48_e4F    GGGTAGGGTGTGAATCTGTATG       
C16orf48_e4R    TCTTTGTGAACACACCACACAC       
C16orf48_e5F    AAGGGGAATGGTCTTGTGGT         
C16orf48_e5R    GCAGAGACATGGCAAGCAT          
C16orf48_e6F    GAGGATTTAAAGGCCATCTTCC       
C16orf48_e6R    CTTTCGAGCTTCAGCTTCCTT        
C16orf48_e7F    AGTGCAGTGAGGGAATCCTG         
C16orf48_e7R    CATGGGAAGTGTGAGTGTTGG        
C16orf48_e8.1F  TCAGAGTGAGTACATGGGCAAG       
C16orf48_e8.1R  CTACGAAGTGCTTTCGATTCTG       
C16orf86_e1F    AACAGGATCCTTACCTCTCAACC      
C16orf86_e1R    ACTTGGCCTGGCAGTTAGAAG        
C16orf86_e2F    TTCCTATTCTGTGGCCAATATG       
C16orf86_e2R    TTCTAGAGAAACAGGAGCTGGAG      
C16orf86_e3F    AAGCCCTAGGTTCAAGACACAG       
C16orf86_e3R    TTCCTGCAAGAACCCAAGG          
C16orf86_e4.1F  GCATCTGCACCCACAGAGAC         
C16orf86_e4.1R  CTTGGGTTGTCTTATCCACCTC       
C16orf86_e4.2F  CTGCCCTAATCCATTACACCAC       
C16orf86_e4.2R  AAAGACTAAATCCCTTCTTCCATC     
Cdh1_e10F       TGACATCACTCATCCCACCTAC       
Cdh1_e10R       GTTGATCCACTCATGGGAAGAC       
Cdh1_e11F       TATTTGTTCTGTGGGAGTGGTG       
Cdh1_e11R       AGGACGACCTAGTGAGAACCTG       
Cdh1_e12F       CTGTAACAAGTGAAGAGGACCTG      
Cdh1_e12R       AAGGAATGAAATCCCACCCTAC       
Cdh1_e13F       ACCTGCTGAGGGATCACAGATA       
Cdh1_e13R       TGTAAGGAACTAGGGCCGAATA       
Cdh1_e14F       GCACTTTGGTTCCCTAAACATT       
Cdh1_e14R       TGTACTCCAACTACCAGCTCCTC      
Cdh1_e15F       GATGGCTGCTTCCTCTGC           
Cdh1_e15R       TACAGCAGGGTGAATGAAGTAG       
Cdh1_e16F       ACAGTCTGTGATGCCATGAAGC       
Cdh1_e16R       AAGGCAACATTCCTCACTGG         
Cdh1_e17.1F     GATTTGTGCTAGGGTGTGTCTG       
Cdh1_e17.1R     CTGGTAGGTAGAGTGGGACCAG       
Cdh1_e17.2F     ATGATGTCAGTGGTCTTTCAGC       
Cdh1_e17.2R     ACACTATCCAGCTCAGTTGCAC       
Cdh1_e17.3F     CACTAAGTTCCTGAATTCTGTTGC     
Cdh1_e17.3R     ACTCATGACAGTGGTCAGGTTC       
Cdh1_e17.4F     TTTCTTGCGTTTCTTTCAAACC       
Cdh1_e17.4R     ATACCAGGCTGACCTTGAACTC       
Cdh1_e17.5F     AACTGAGACTATGCTGGGTGTG       
Cdh1_e17.5R     AGAGAACAGTTCCGATTGCTTG       
Cdh1_e17.6F     GATAGCGTGCCCTTTGTATGTAG      
Cdh1_e17.6R     GAGGCTTCCAACTCCATAACC        
Cdh1_e1F        ATTTACAGACGGGTGGAGGAAG       
Cdh1_e1R        AGGGAAGTGGAACCACAGAAG        
Cdh1_e2F        GGGAAGGGTTACTCTTGGTTTC       
Cdh1_e2R        TCCATCCTACCGACAAAGTAGC       
Cdh1_e3F        GGGTCTGGAAATGAACAGTTAGTC     
Cdh1_e3R        AAGAGGACCCAACATTGTAAGC       
Cdh1_e4F        TGCATCTTGTATGATGAACGTG       
Cdh1_e4R        ACAGGTATTTGTTCTGGGCATC       
Cdh1_e5F        GACGTCCATGGGATAGATGAAC       
Cdh1_e5R        TGGAAAGGCAAGATCTCCAC         
Cdh1_e6F        GAAGGCACTCCTGAGAGAAGAG       
Cdh1_e6R        GTCCAGGACATCCAAACTGG         
Cdh1_e7f        TTCATTAAGTAGCAACACACAGC      
Cdh1_e7R        GTGGCTTTCAAAGAGCGTGTC        
Cdh1_e8F        GTGACAAAGTGTGCTTGTCTCC       
Cdh1_e8R        AAAGCTGGGCCACTTACACTAC       
Cdh1_e9F        GCCCAGCTTTACGTCTAATTCC       
Cdh1_e9R        GGGAAGAGGTTCTAAAGGGTTC       
Cdh3_e10F       GCCTTGTTTCTTTACTGTGAGC       
Cdh3_e10R       AACAAACTTTATGGAGAAGAGCAAG    
Cdh3_e11F       ACTTGATCTGAGGAGGCTCTG        
Cdh3_e11R       CCACCATTCCCTGCTAAGG          
Cdh3_e12F       GAAGCTGATCGAGTAGTCTTAGGG     
Cdh3_e12R       GGGAGGTGTGTGAGTCCTATTG       
Cdh3_e13F       GTGCTGAGGCTGTTCTCAAAC        
Cdh3_e13R       AACGGATGAACAATATGGATGC       
Cdh3_e14F       ATCAATCATCAATGCTCTGTGC       
Cdh3_e14R       ATGAAGACTGATGGGCTTGC         
Cdh3_e15F       CAGAGGAGTAAGATGTGACTGGTG     
Cdh3_e15R       AGAAAGCCAGTGTTTGTTCTCC       
Cdh3_e16.1F     GATGGGTATAGAGGCTCAGCAG       
Cdh3_e16.1R     GTCACATCCTCCCATTTGAAAG       
Cdh3_e16.2F     CTCCTGAGGACTCTGAAGCTC        
Cdh3_e16.2R     CCTGGAGATCAGAGAAATGTACC      
Cdh3_e16.3F     GGGCAGGGTGCAGACATC           
Cdh3_e16.3R     CAGAGTCTAAAGCCCACCAAAC       
Cdh3_e1F        GTTTGACCAATCAGCAGCTACC       
Cdh3_e1R        AAGGAGCACAGCCCTAAGATTC       
Cdh3_e2F        CAAGGATGGGTGTACAGAACC        
Cdh3_e2R        CCAGCTCTGGTCTAGACAACTC       
Cdh3_e3F        AGTAAGCCAAGGCCCTGAGTG        
Cdh3_e3R        AGACTCTGGCCAGCAGAAATC        
Cdh3_e4F        TCTCCTGAGAGCTGGGAGTATG       
Cdh3_e4R        GATACCCAGCAGCAAGAAGC         
Cdh3_e5F        AAAGGCCTAAGAACAAGGCTTC       
Cdh3_e5R        CGCACCATTCTCAGATACAGC        
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Cdh3_e6F        TTCAGCACCCAACGTAGATATG       
Cdh3_e6R        GTTTCAAATGTGAATGCCAGAG       
Cdh3_e7F        ACTTCACAGGGTTCCAAGGTAG       
Cdh3_e7R        CTCTAGCCCAAAGAAGTTGTGG       
Cdh3_e8F        GCAGTTTCTCATTACCCAGGTG       
Cdh3_e8R        GTGGGTTGGTTTGAGAGAAGC        
Cdh3_e9F        CAGCTGCTGGAGAGTGGTG          
Cdh3_e9R        AGTACCTGGAGCCACTGTCTTG       
Cenpt_e1.1F     ATGGCCTACATTTGCAACG          
Cenpt_e1.1R     GAAAAGCATGGAGCCAGTTC         
Cenpt_e1.2F     AAATCAATTTATGATCATGTCAGACC   
Cenpt_e1.2R     CTAGGAAAGTGCTCTACCACTGAG     
Cenpt_e10F      AGGCCCTTAGCAATTAGGAGAG       
Cenpt_e10R      CTGTGCTTGGCAGTCATCTG         
Cenpt_e11F      GGCTTGAAGGTGTTGTACCC         
Cenpt_e11R      CTGCCAAGAAGGTTGCAATAG        
Cenpt_e12F      CTAGCATGTGAGTGGGTACAGG       
Cenpt_e12R      GGAAAAGAGGATCAAACAGAATTAAC  
Cenpt_e13F      AGACTGTGAAGCCAAAGGACTTAGAG  
Cenpt_e13R      ATACTCCAATGTTGCTAACCTTCTTC   
Cenpt_e2F       ACTCTTAAACCACAACCCCTTG       
Cenpt_e2R       CCCTCAAGTTAGGCTTCAAAAC       
Cenpt_e3F       CCGTGACTGACTTGTTAGAACC       
Cenpt_e3R       GGGCTGACAAAGAAAGGAATC        
Cenpt_e4F       GGGTATCAGCCTGCAGTTAAAG       
Cenpt_e4R       GACATATCAGAAAGCCCAATTTTAG    
Cenpt_e5F       AAGCCAGCACAAGTACCAGAAG       
Cenpt_e5R       TTACTCAAGCCCAAGAAAGCTC       
Cenpt_e6F       TCCTCTTGGGAGTAGAAAAGACC      
Cenpt_e6R       TGTTAGGACGGAAGCAGATACC       
Cenpt_e7F       TCCTGGGGTTTATACAATCTGG       
Cenpt_e7R       AGCAGCCCTGAGTTAGTAGAGC       
Cenpt_e8F       TTTCGCTGCCTCTACCTTTTAG       
Cenpt_e8R       CAGAAAAGGAGGGAGTCCTGAG       
Cenpt_e9F       AGGACTCCCTCCTTTTCTGAAG       
Cenpt_e9R       CAGTGGTAGAGCGCTTGCTTAG       
Ctcf_e1.1F      CACCTGCCACCCAAAAGT           
Ctcf_e1.1R      TGCAGGGTTATGATTTGGGTA        
Ctcf_e1.2F      AGGTGGTCCAGGATGTCAAC         
Ctcf_e1.2R      CCCCTGCTCTAGTGTCTCCA         
Ctcf_e1.3F      TTGCAGAAAGTGAACCGATG         
Ctcf_e1.3R      CCCCAAATGGGTTTACGAGT         
Ctcf_e10.1F     CATCTGAAGCCGTGCCTATC         
Ctcf_e10.1R     AGCACTTCACAGTAAACCCTCA       
Ctcf_e10.2F     CGAAAACTTCAAGGATGATGTTAG     
Ctcf_e10.2R     TGCTGGGTTTTCTTACACTGC        
Ctcf_e10.3F     GGTCAAGCCTGTAAATAACCTTTT     
Ctcf_e10.3R     ACAATTCATGTGCAAGAATCAC       
Ctcf_e10.4F     CTGGGCCAAAACATTTCACT         
Ctcf_e10.4R     ATCACCTGCCAGGATCATCT         
Ctcf_e2F        TCCTCAAGAGAAGTAAAACTGTGAA    
Ctcf_e2R        TCAACTTCCTATTGAAGTAATCTTGG   
Ctcf_e3F        TCCAGGGCTCCCTGTAACTA         
Ctcf_e3R        TGGAATAGGTGTCCCCCTAAA        
Ctcf_e4F        ACCCCCATCTCCTTAGACTG         
Ctcf_e4R        GTAAGCCCTGGGTGCACAT          
Ctcf_e5F        ATGTCTGCCACTCCGCTATT         
Ctcf_e5R        GAGAGGGGGAGCTAAGCAAT         
Ctcf_e6F        ACTCAGGCTCTCACATTGCTT        
Ctcf_e6R        CACACAGAAACCGTATCTCAATTT     
Ctcf_e7F        GAAAGTCATAGGGTGTGTGTGC       
Ctcf_e7R        GTGGCAAAAACTGCATTCTG         
Ctcf_e8F        CCCCACTCTCTCACACACCT         
Ctcf_e8R        TGCTAACTTCTGGGGGTCAT         
Ctcf_e9F        GCCCAGGACTTTTCTTAGGG         
Ctcf_e9R        TGAGCATCTGTGCTGAGACC         
Ctrl_e1F        TCTCAGGCCCAAGACTTCTG         
Ctrl_e1R        AACCAGGCTGGCCTCTTATC         
Ctrl_e2-3F      GCACCTTGAGGAAGACATTAGG       
Ctrl_e2-3R      AGGGGAAGTGGGAAGAGATG         
Ctrl_e4F        CCAATCCATCTCTTCCCACT         
Ctrl_e4R        AATTCCCATGTCCAAAGCAG         
Ctrl_e5F        TCTGCTTTGGACATGGGAAT         
Ctrl_e5R        CTGGTGTCACGTTGCCTGT          
Ctrl_e6F        TGGTGTGGGTAAGGACTTGG         
Ctrl_e6R        GGAAGCAAAGGGGAAAAGTC         
Ctrl_e7F        CTGTCCCGTGGTACACTTCC         
Ctrl_e7R        CCAATAGAACCCCCAAGAGC         
Ddx28_e1.1F     TCTTAAGGATCCTCCCTCCTTC       
Ddx28_e1.1R     GCTCTATGGAAAAATGGTCCTG       
Ddx28_e1.2F     GGTGCTAGTGCAACCTGGTC         
Ddx28_e1.2R     ATTCTCGGGAAGGTACCAGAAC       
Ddx28_e1.3F     ATCTACTGCCCCTATTTCAACG       
Ddx28_e1.3R     GTTTAGGCCTTCTGGAAATGTG       
Ddx28_e1.4F     AGATGAAAGCTTCGTGGAACTG       
Ddx28_e1.4R     AGTATGTTTTGGGAGCCCTTCT       
Ddx28_e1.5F     CTGTCCTGGTATTCTGCAACAG       
Ddx28_e1.5R     CCTGGAAGGCTTCTCCTTCTAC       
Ddx28_e1.6F     CGGGGACTGTTACCAGTTTTG        
Ddx28_e1.6R     TGACCCAATGTCATCAAAAGAC       
Dpep2_e10F      TGGCTCACAACCATCTATCTGT       
Dpep2_e10R      CAGTGGTCAGCAGCTCTCTCT        
Dpep2_e11F      TAAGGGCCTGACAGGTACTCAC       
Dpep2_e11R      AATGCCTAGTTCCACAAACCAC       
Dpep2_e1F       GGCCTACAAGGACAGGAACTAA       
Dpep2_e1R       GGAGAGATGGACGGAAATGAAT       
Dpep2_e2F       TGAATCGATGACCTCAAACATC       
Dpep2_e2R       ATTAGTCCAGCAGGCTCAGAAC       
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Dpep2_e3F       CGAGTACTGGGATCACAAGCAG       
Dpep2_e3R       GTCATTTCAGGAGCACCAATTT       
Dpep2_e4F       CCACAAGTCTGTCCGTTGTAAA       
Dpep2_e4R       TCAGAGCTGTAGGCATAGGTCA       
Dpep2_e5F       CCTATTCAGGGTATTGGGGAAT       
Dpep2_e5R       AGTCTCAAATTCGAGGGCAAAT       
Dpep2_e6F       TGAATTAGCTCTATGGGATTGC       
Dpep2_e6R       AGTTTAGGAGAAGGGTGTCAGG       
Dpep2_e7F       TGAGGGATACTTCACACAAACG       
Dpep2_e7R       TTAGAGGCCATGGTTTATGGTT       
Dpep2_e8F       GCTTTCTCACAGGGGTTATAGG       
Dpep2_e8R       CAGAAAGCCTAGGAGGAATTTG       
Dpep2_e9F       ACTGTGAACAAAGGAGGAGTGG       
Dpep2_e9R       AGAGAGGTTGAATGGGCAAAG        
Dpep3_e1.1F     CAGTGGCGCCCTCTAGCG           
Dpep3_e1.1R     TTGTGTCATTAGGAATGCCTGGAG     
Dpep3_e1.2F     GTAACCTGCAACCAGACTACTCC      
Dpep3_e1.2R     GTGTATAGTGGTGGTGGTGGTG       
Dpep3_e10F      CAGGTTTGTTAAGCTACAATCAGA     
Dpep3_e10R      TGTTCTATGCGCTCTGTGAGTT       
Dpep3_e2F       GTACCTCCCCTCCCTTTGAC         
Dpep3_e2R       TGCATGCTCTAAATGCCTAGTT       
Dpep3_e3F       CTGTGGGCGCTAAGGAAG           
Dpep3_e3R       GACCTAGAAAGGTTGGCAGGAG       
Dpep3_e4F       GAGTTGGAGCTTGTGACCTCAG       
Dpep3_e4R       CAAAAGGGTCGCTTTAACTTCA       
Dpep3_e5F       GATGTAGGATGGAAAAACAGAGC      
Dpep3_e5R       AAGAGTGTGTCAGGGAGCAAAG       
Dpep3_e6F       CTAGCATGTCCCCTCTCCTCTA       
Dpep3_e6R       TCTCGATCCAAGGTTGAGAGTT       
Dpep3_e7F       CCCAAGAGAAAAGGTTCTTTCA       
Dpep3_e7R       GACATCTTCTGTCCTGGAGACC       
Dpep3_e8F       AGCTGCCACAGCCAGGAG           
Dpep3_e8R       GGCTGGAAGACCAGAACTTGTA       
Dpep3_e9F       CAGCAGGTTCTAGACCAGGATT       
Dpep3_e9R       GACCTCTGCCAGTTAACACTCC       
Dus2l_e10F      GCTTGAGGTTCAGTAGGAAGGA       
Dus2l_e10R      GCCATCCCAGTTTTCTATGCTA       
Dus2l_e11F      CTCCGTCACCACTTAGAGTCCT       
Dus2l_e11R      TTAGGGAGTAGAGGCAGGAGAA       
Dus2l_e12F      CTCTAAGAGGCCCGTTCCTT         
Dus2l_e12R      CATACACATCTCTGGTCCCTCA       
Dus2l_e13F      CCAGCTCCGAAAAAAAGAACC        
Dus2l_e13R      GCTTGACAATATTCATATAAAACAGC   
Dus2l_e14F      GTGGCTGATTGGTGGTTCTT         
Dus2l_e14R      GCTGCGAGTGTACTACAGAGAGG      
Dus2l_e15F      GGTGGGAGTGGGAGAAGTC          
Dus2l_e15R      CACAACACACCCAAGTCTTGTAG      
Dus2l_e16.1F    GTATTTGTAGGCTCAGGGCTTC       
Dus2l_e16.1R    CATTTCTTGGCACTTGTTTCAG       
Dus2l_e1F       CCGGCTAAAGCCATATTTCTC        
Dus2l_e1R       ACTCCTTCTTCCACCGAGTACC       
Dus2l_e2F       CTTATGCAGCAAGCCCTTTTC        
Dus2l_e2R       AAACACTGCCATACCCAAAGAT       
Dus2l_e3F       AAGCCATGAGTCGTTGTCAGTA       
Dus2l_e3R       CAACAAGAAAGGACCCTGGAG        
Dus2l_e4F       TAGAATCCACCCTTTTCCCTCT       
Dus2l_e4R       ATACAGCATAGCACAGGCATTC       
Dus2l_e5F       ACCAAACAAACAAGCAAAACCT       
Dus2l_e5R       AGCCTCCAGATACCACAGAGAA       
Dus2l_e6F       CAGGAGCTCAGAATCCTTTACC       
Dus2l_e6R       TCTTTCTAGCCCAGCAAATGTT       
Dus2l_e7F       AGGGACTTAGCTACCTTGTTGC       
Dus2l_e7R       GGCCCCAAATAGAGAATCTAGG       
Dus2l_e8F       CATGGGCCTTGTAGATGTGTTA       
Dus2l_e8R       TTCTGACTCCTAAACCTGCTCA       
Dus2l_e9F       GAGCTGAGCAGGTTTAGGAGTC       
Dus2l_e9R       AGCTGTTTGTCACGTAGGGTCT       
Edc4_e10F       GTGGTGGTACATTGGAAAGAGC       
Edc4_e10R       CATGGGAACTCTCTGAAAGGAC       
Edc4_e11-12F    GAGGAGGAGAGTGACAGTCTGG       
Edc4_e11-12R    GTCGAGACTCTCCAAATGCTG        
Edc4_e13F       ACACTGCTCATGAGGACTTCAG      
Edc4_e13R       ATGCAGAGATCTGGGAAGAGC        
Edc4_e14F       ATGCTTTCATGACACCTACCG        
Edc4_e14R       TTATAGTCAGGCTGCCATCTAGC      
Edc4_e15F       GCTCTCTAACAGCTGTGTCTGC       
Edc4_e15R       TTTCCATTGCCCCTCTACCAC         
Edc4_e16.1F     TTCTGTTAGATGATGTCTAACCACTAC 
Edc4_e16.1R     GTGCTGTAGGCCAGACTTGAC        
Edc4_e16.2-17F  TGCCTCAGCACTACACCTACTG       
Edc4_e16.2-17R  GAAGGCTGAGTGTCTGCTCAC        
Edc4_e18-19F    GTGAGCACAATCTTGTTCCTTG       
Edc4_e18-19R    GCCAGAAGCACTGACACTTAC       
Edc4_e1F        TGTAGTGCTCTGTCGTCTCCTG       
Edc4_e1R        TCCTGAATCTGGCTAAAGGAAC       
Edc4_e20F       AAGGGAGCACCTTTCTACCC         
Edc4_e20R       AGTCGCCGTTCTGTGGTA           
Edc4_e21F       ATGAGCAAGAGCGTATCCTTG        
Edc4_e21R       GGAGACAC CTAGGAGAGACAGG      
Edc4_e22F       CTATCCCAGGCTTTGTCTTCAG       
Edc4_e22R       GGCAATGGCATCTGTTAAGTTC       
Edc4_e23F       GCTACTCAAGTCCAAGGTGATG      
Edc4_e23R       CAGCTGCTGCAAATCTAAAGG       
Edc4_e24F       CTCAGGAATGTGAGTGTTGTCC       
Edc4_e24R       GCTAAGATTGATTCCTGCAAGC       
Edc4_e25F       GCCACTGTGTCTAGCAGTGTTC       
Edc4_e25R       AAAGTATCAACGAGCCTGATGG    
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Edc4_e26F       GAATCCAACTTTGGTCTTCTGG 
Edc4_e26R       GGGAGCAGGTAAGAGTGAGTTG 
Edc4_e27F       CCAGTTCCCATATGAGGCTTAG 
Edc4_e27R       TCACAAGGCCGTGTAACATTAG 
Edc4_e28F       CTGATCCACACAACTCACTTG 
Edc4_e28R       AGGACCCAAGAAGGCACAATAC    
Edc4_e29F       TTTCTTGCTCCTCTGCCTATTC  
Edc4_e29R       TAGAGCCCTCAAAGCTGATCTC   
Edc4_e2F        CTGGACATAACAAATGCTCCTG  
Edc4_e2R        GATCATCCAGAAGAGAGGAAGC    
Edc4_e30F       GGGCAGTATCAGGTAAACAAGG  
Edc4_e30R       CAAAGATTTGGACTGGGAAGAG    
Edc4_e31F       ACCCAATCTGTGCTTACCATTC  
Edc4_e31R       ATATTCTGCAGAGCTCACATGG  
Edc4_e3F        ATTAACCTCATTTGCCAGAAGG   
Edc4_e3R        AAAGTGGTTCCCATAGGAATTG  
Edc4_e4F        ATGTCAGTGGGTGTTAGGTTTG  
Edc4_e4R        GGGACAAACCTCTACTGTACGC  
Edc4_e5F        CTGAGGGAGCTGGTCAGG       
Edc4_e5R        AAGGCTACATAGGTAGATGATGATG  
Edc4_e6F        CAGTATCCATTCCCAGGCAAG    
Edc4_e6R        ATATCCAAGTCCCACACCTCAG       
Edc4_e7F        ATGAAGACCGGGTGAGAGG      
Edc4_e7R        GAGCCAGGTTGTCTTCAACATC  
Edc4_e8F        GTTGGTTGGCCCTGTTCACTAC  
Edc4_e8R        GACACCTGCAGGCAGACAG     
Edc4_e9F        GCAAACCATTCGGTAAACTAGAG  
Edc4_e9R        AGGCTGTAAGGGCTGTGACTAC    
Ednra_e1F       GGGTTGGGAGATTTCTTG           
Ednra_e1R       CTCTTAAACCGTCTGAGCTG         
Ednra_e2F       CTGGTCACAAGTTCACACTG         
Ednra_e2R       AGGAGGCTAGTTGTGTCTCA         
Ednra_e3F       GGAAGGCATTTTCCAGTC           
Ednra_e3R       AGTCAGCACAGTAGCCTTGT         
Ednra_e4F       CAGGTCTTCACTGCTGACA          
Ednra_e4R       GCATTGTTGGATGGTACG           
Ednra_e5F       GGTTAATGGCTCCTCCAT           
Ednra_e5R       CTCAGGAAGGAAGTGACAAG         
Ednra_e6F       TCCCTGCAGTGCTTCTTA           
Ednra_e6R       GTGCCTGATCAAAGCAGTAG         
Ednra_e7F       GGCATCTCTCACTGGATG           
Ednra_e7R       GGACAGTACTCAGGAAAGACC        
FAM65A_e10F     GCGATCAATATGAGGTATGAGG       
FAM65A_e10R     TGGGAGAATGACACAAGGAATC       
FAM65A_e11F     CTCAAGTAACCTGCATGTCCTC       
FAM65A_e11R     TGACTGTAGAAGCAGCTGAAGG       
FAM65A_e12F     GTTGTGGCTGTGGATATCAATG       
FAM65A_e12R     TCCCATTCTCTAACTCCTCCTG       
FAM65A_e13.1F   AGTCCACCAGATACACCCTCAC       
FAM65A_e13.1R  TCTGGATATACAAGTGGGCTAGG      
FAM65A_e13.2F   GGACTCTCAGCCACATCAGTG        
FAM65A_e13.2R  GAGTTGGGCTTGTGGTAGTCTG       
FAM65A_e13.3F   GCCTAACTTCCACCACTGTAGG       
FAM65A_e13.3R  TAGGGAGTAGAGGTTGGGTGAC       
FAM65A_e13.4F   CAGACCACTACAAGTCCCATTTC      
FAM65A_e13.4R  CCTCCTTACCATGAGCAGACTC       
FAM65A_e13.5F   GGACAGAAGGCTCGAAGAGG         
FAM65A_e13.5R  TAAGGAGAATCAGGGCTACTGC       
FAM65A_e14F     GGAGAGTCTGCTCATGGTAAGG       
FAM65A_e14R     ACAAGCCCATCCTCATGTATTC       
FAM65A_e15F     TGTTACTCATTGCTGGTTACCG       
FAM65A_e15R     GAGGTTTAGAAGGTTGGATTGG       
FAM65A_e16F     GCATGCTGGGATCTGTACTCC        
FAM65A_e16R     TGAGTCCCTCTGTACACTGGTC       
FAM65A_e17F     ACATCTGCCCAGGAAGGTAAAG       
FAM65A_e17R     TTTCTTCAGTGCTCGATTTGTC       
FAM65A_e18F     ACTGACAAATCGAGCACTGAAG       
FAM65A_e18R     GGTGCTTTGTTCTCATCATCTC       
FAM65A_e19F     ATTCTGGTCTCATGGGTGGTC        
FAM65A_e19R     ATCCTCATCCTCAAGCTGGTC        
FAM65A_e1F      GTTATACGAGCCAAACCTGCAC       
FAM65A_e1R      GTTCCAGTCTTGGCAGTCTCAG       
FAM65A_e20F     CGGGAAAGGGTGAGTTTG           
FAM65A_e20R     ATTGAGGCATTGAGACAGGTTC       
FAM65A_e21F     GGGCTGTATCAAGGTGATTCC        
FAM65A_e21R     CTTCCCTTCCCTGGCATTAC         
FAM65A_e22.1F   ATTTGGGATCTTGGCTATTGG        
FAM65A_e22.1R  AAACCAAGGGATGTGGTGAG         
FAM65A_e2F      ATGAGGCTGAGACTGCCAAG         
FAM65A_e2R      CTGAAGAAGAAAGCGCCTTTAG       
FAM65A_e3F      TACGCGACAAGGGTATTAATGG       
FAM65A_e3R      AGTCAACTTATCCAGCCTCTCG       
FAM65A_e4F      CCCAAGATTCCACATAGGTTTC       
FAM65A_e4R      GGATAGAAACACCTACTAGCTCACC    
FAM65A_e5-6F    GGAAGAGGACTGTCAAAGAAGG       
FAM65A_e5-6R    CTCACCACTGAGAACCACAGAG       
FAM65A_e7F      GAGATCATGGAGAAGAGGGAAG       
FAM65A_e7R      AGAAGACACATGCTCTGGGAAG       
FAM65A_e8-9F    TGTGACAGAGCCACAAGGTG         
FAM65A_e8-9R    ATTCGGCCTCGTAACTTCCAG        
Gfod2_e1F       ATGCGCAGCTCTCTATCCTG         
Gfod2_e1R       GTATACTCGCTTCCAACCTCAG       
Gfod2_e2F       TCCAAATTGCCTTAGAATCTCG       
Gfod2_e2F       TCCAAATTGCCTTAGAATCTCG       
Gfod2_e2R       CTAGGAGAGGGCAGTGAGCTG        
Gfod2_e2R       CTAGGAGAGGGCAGTGAGCTG        
Gfod2_e3.1F     TTCTAGGACAGCCAAAGCTACC       
Gfod2_e3.1R     ATTCTGCCTCACAAAGGTCTTG       
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Gfod2_e3.2F     CTATGGCTGGATTTGTGATGAG       
Gfod2_e3.2R     GCAAGGCCTGAACCATATAGAC       
Gfod2_e3.3F     GGAGGAGCTGCTAGTGAGAGAC       
Gfod2_e3.3R     ACCTTCAGTTGGCTCCTAACC        
Hsd11b2_2_e1.1R  GGCACAGCCAGTCGAGAG          
Hsd11b2_2_e1.2F   CAGCAAAGAAAGCGAGTATCC       
Hsd11b2_e2F     CAGGTGCCTAGATTCCACCT         
Hsd11b2_e2R     CCTGACAGCAAACATGTAATCC       
Hsd11b2_e3F     GGCTGGAGAGTGTGAAGGAG         
Hsd11b2_e3R     GATAGAATGGGGACGCTCAG         
Hsd11b2_e4F     CAAGGGGACGTATTGTGACC         
Hsd11b2_e4R     AGCCAAAGGCCACTCATCTA         
Hsd11b2_e5.1F   GAGCATGTAGTGTGGCTTGG         
Hsd11b2_e5.1R   CTCAGTGCTCGGGGTAGAAG         
Hsd11b2_e5.2F   GGGGCTCATGTATTTCATCC         
Hsd11b2_e5.2R   GGTCGTGCCTGGTAGGGTAT         
Hsd11b2_e5.3F   GGAGGTGGAATTTGCTAGTGA        
Hsd11b2_e5.3R   CCCAGGATCTCCCAAGAAGT         
Kctd19_2_e18F   CTGATAAGGGAACCACCTCATA       
Kctd19_2_e18R   TTATCATTGGCTGGGGATGT         
Kctd19_e10F     TGTAAACATTACCCACCAAAGC       
Kctd19_e10R     ATGTGACAAGTCCCAAAGATGC       
Kctd19_e11F     ATAAAAATCTCCAGCCCTGCTC       
Kctd19_e11R     TACAACCAAGGGTTCTCTTTGC       
Kctd19_e12F     GTTATTGCTCGAGGCAGCTT         
Kctd19_e12R     TGGCAGATGAAAACATCTGTAAG      
Kctd19_e13F     GCCTGACCAATTAATGGATGG        
Kctd19_e13R     CCCTTGAACCCTGTGGTG           
Kctd19_e14.1F   GGCTGTCTTAAAGCCTAGCTGA       
Kctd19_e14.1R   TCCCACTCCCTTACCAAAGATA       
Kctd19_e14.2F   CCAAGAAGAAGTGCACCACTATAA     
Kctd19_e14.2R   CCCCTGCTCTGTCACTAACTCT       
Kctd19_e15F     CCAAAAAGTGGGAGGATGTACT       
Kctd19_e15R     TAGGGCAGGGAGAAGTGTAGAG       
Kctd19_e16F     CTCTACACTTCTCCCTGCCCTA       
Kctd19_e16R     CTTATCCCTGCCTTTTCAGCTA       
Kctd19_e17F     TGAAAAGGCAGGGATAAGAGTGC      
Kctd19_e17R     CTGGCCTGGCCCAACAGTA          
Kctd19_e1F      TGTGATTTCCCTAGGATGTTGT       
Kctd19_e1R      CCTCAGAACCCAACATAGAAAA       
Kctd19_e2F      CCTTGCCATTTTGTATTTTGTG       
Kctd19_e2R      AGCTCAGATGAGGCTAACGTCT       
Kctd19_e3F      AGAAACTGATGCCTAGGTGGTC       
Kctd19_e3R      GTAACCAACAAATGGACCTTGC       
Kctd19_e4-5F    GATGAAGAATCTGCCAGGACAT       
Kctd19_e4-5R    AGAGGACATGCAGGGTTTTAAG       
Kctd19_e6F      AACAAACATCTCCCCCTTACAG       
Kctd19_e6R      AGACAGCATATGCCTAGGAAGC       
Kctd19_e7F      CACATAAGTCCTAAGCGGGGTA       
Kctd19_e7R      TTTAGCTCATGGGAGAGGCTTA       
Kctd19_e8-9F    TTATTCTGGTGCCACATTTGAT       
Kctd19_e8-9R    TCCTTCCCTCCCTAGTCTACAA       
Lcat_e1F        AAGACGGAACTGAACCCAAGT        
Lcat_e1R        TATCTGCTGCTGTCTGGCTTAG       
Lcat_e2F        AGAACCTGGAAGGTGTACGAGA       
Lcat_e2R        GTAGACAACCCTGGGGACAGT        
Lcat_e3F        GTATGTCCCATGTGGTCTACCC       
Lcat_e3R        GTAGCCTGTGGGGAGAAAAA         
Lcat_e4F        GGGCTCTTTTTGGCCTTC           
Lcat_e4R        ATGGGTCGATAGGTCAGGGTAG       
Lcat_e5F        CCGTAAGTGTTTGCAGGTGAT        
Lcat_e5R        GACAGCTAGCTCTGTGATCTGC       
Lcat_e6.1F      CTTGGAATAAAGGTCAGGATGG       
Lcat_e6.1R      CTACGTGTGGCTACAGTGTCGT       
Lcat_e6.2F      GCGCCTGGTGTAGAAGTATATTG      
Lcat_e6.2R      AGAGACCTTACCAGAGCCCATT       
Lin10_2_e16.2F  AGCTGCCCTAAGGACTTCAC         
Lin10_2_e16.2R  CCACAGCCAGCTCATCAAG          
Lin10_2_e5F     GCAATCCCAATGCCTAAGAG         
Lin10_2_e5R     CCAAGGACCTGAGATGAGGAG        
Lin10_2_e6F     TCTCAGGTCCTTGGATAGGTG        
Lin10_2_e6R     TCTACCCATTCTCTCTCTTGACC      
Lin10_e10F      GCTTACACAATTAAGGCACACG       
Lin10_e10R      CTCCCAGAAGGTCACACAGG         
Lin10_e11F      TCTGATCGAAGACTCCAAGTAGG      
Lin10_e11R      CACTCAAAGCACTGGGTTCA         
Lin10_e12F      GCAGGTACGTAAGGCTCTGG         
Lin10_e12R      CCGGCTCAAGAACTACACTCT        
Lin10_e13F      CCACATTTTTCGAACCAACC         
Lin10_e13R      GTCCTAGACATGCCCACCTG         
Lin10_e14F      AGTACCAGGTGGGCATGTCT         
Lin10_e14R      GGATCCCTAGCCCAGAAACT         
Lin10_e15F      GTAACCCGCATCCCAAAAG          
Lin10_e15R      TGTTAACCCACAATTCCTTAATCA     
Lin10_e16.1F    CACGCCATGTGTGTACCTTC         
Lin10_e16.1R    AGCCTTCCAAACCCAAAGTC         
Lin10_e16.3F    GAAGACGGGGCTCTTTCTCT         
Lin10_e16.3R    GAGGCAAACAAGATGGAGACA        
Lin10_e1F       CCGCCTCTGTGATTTAGCTC         
Lin10_e1R       GAGGGTAGGAAAAGGCGAAG         
Lin10_e2F       AGGCTTCAGGGAACAATGCT         
Lin10_e2R       ACACAGCAACTCCTCCCAAC         
Lin10_e3F       CTGTGTGTTGCAGCCTTGTT         
Lin10_e3R       AACAGCACATTAGTCAGCTCCA       
Lin10_e4F       CCCAGCCTTGAACTCTTGAT         
Lin10_e4R       TGAAGGCAGTAGATAAAGCTGGT      
Lin10_e7F       ACCGTGAGTGCCAGGGAATA         
Lin10_e7R       CAGAAGGAACAAGGCATGG          
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Lin10_e8F       GCCTCCAGGATACCAAGTGA         
Lin10_e8R       AACACGCCTACAAACCAGGA         
Lin10_e9F       GCTAGCTTTTCAGAACCTCTGG       
Lin10_e9R       GAACAGACTCTCTGTGGAAACCT      
Lypla3_e1F      CGTTCGTAGCGGAGAGTTACA        
Lypla3_e1R      TTTAGAGGGTGCCAGACCAC         
Lypla3_e2F      TCCTGGCATTGTGGGATT           
Lypla3_e2R      AAGAAGATGAACAGCAAGAAGAAA     
Lypla3_e3F      CCTTTAGACCTCAGACCAAACC       
Lypla3_e3R      ACACCACACCCACAGAGACAAT       
Lypla3_e4F      CCACTTCAGGGAGACAGATG         
Lypla3_e4R      TCAGAGAGAGCCCAAGGAC          
Lypla3_e5F      TCTTGGCAGAGGTAGAGACTAAG      
Lypla3_e5R      CAGGGAGGAGTTATGAAGGATG       
Lypla3_e6.1F    TCCACATACAGAAAGACGGAAA       
Lypla3_e6.1R    GGTCACGATCAGGAAAGTTCTC       
Lypla3_e6.2F    GTACCGCCTGGTGTAGAGCTG        
Lypla3_e6.2R    AGACTTAGGACCTTGGATGACG       
Lypla3_e6.3F    CTTGGCTTATCTGAAACGTGTG       
Lypla3_e6.3R    TGTGGAACCTTCTATGACAGGA       
Lypla3_e6.4F    GCCATGCAATCCTCTTATCTTC       
Lypla3_e6.4R    TCAGTACTGGAACCTGCATCAC       
Lypla3_e6.5F    ACCTCTCATTTAGTGGCATCCT       
Lypla3_e6.5R    TCCCTGCTGTCACAGAGACTAT       
Lypla3_e6.6F    GGGAAACAGTCCAGAGATTTGA       
Lypla3_e6.6R    AAGTTCAGGCAGAGGGATAATG       
Nfatc3_e10F     AAAACAGTACTGGGCAGTGGAT       
Nfatc3_e10R     TCCTTTGTAGCACATGCAAATC       
Nfatc3_e11.1F   AAGAGAGGAAAAGAAACCCTCA       
Nfatc3_e11.1R   AGCTCATTTCCCACAGCTTAAA       
Nfatc3_e1F      CTTTCTAGTCGGAACGGAACAC       
Nfatc3_e1R      GCCTCCTCCTCAAATTAAATCA       
Nfatc3_e2.1F    GCATTTTGGTGTCCAGATTTTT       
Nfatc3_e2.1R    GCCTTTCCAAATATTCCCTTTC       
Nfatc3_e2.2F    GTGGTCCTAAACCCTTTGAATG       
Nfatc3_e2.2R    CTGGATCTAGGAGAGTGGCAAG       
Nfatc3_e2.3F    CTCACCTCTGACTTCTCCAGGT       
Nfatc3_e2.3R    CCCTTGATCATCTGAACAGACC       
Nfatc3_e2.4F    CCGTTTCCATTTCAGTACTGTGT      
Nfatc3_e2.4R    GGAGAGGGGAGAGAGAAAAGAA       
Nfatc3_e3F      ACATTGAACCTGGCAAAGAGAT       
Nfatc3_e3R      CCAAGAAAATACAGCCACATCA       
Nfatc3_e4.2F    TGGGTTACTTCTACTGTCTGTTTTG    
Nfatc3_e4.2R    TCATTTACAAAGGTTTTAAGTTACCTG  
Nfatc3_e5F      CTGGGATTATAGGTGTGCATGA       
Nfatc3_e5R      CCAGCAACTCACACTCAATAGC       
Nfatc3_e6F      TCCCAGTGTTTATTTTATAGTTTGG    
Nfatc3_e6R      TTTTCAATAAAACCCAGTGCTT       
Nfatc3_e7F      CTCCCTGCCAGTAATTTGTGAT       
Nfatc3_e7R      CTCTTAACCACTGAGCCATTTC       
Nfatc3_e8F      TCATGAATTGCTTTGAATTTGA       
Nfatc3_e8R      CAACAAAAATAGTATGTTGGCATT     
Nfatc3_e9.1F    TGAGTTCATCCCCATTGTGTTA       
Nfatc3_e9.1R    AGGCAGGATTCATAGGAAGACA       
Nfatc3_e9.2F    CTGGCAAAGAACAGCACATAAT       
Nfatc3_e9.2R    TAGGCTGTAAATGGGAAGAAGG       
Nfatc3_e9.3F    CCCACCTCATCTGCAGTCAA         
Nfatc3_e9.3R    ACCAGGTGGAAACGATGCT          
Nfatc3_e9.4F    CATTCTGGACAGCACTCAACTC       
Nfatc3_e9.4R    CAAGGCCAGCTTAACTCAAAAT       
Nol3_e1.1F      TTCTGTGCCCCTGGTCTC           
Nol3_e1.1R      GCACAGCGCAGTAGTTCCT          
Nol3_e1.2F      CCTGAGTATGAAGCCTTGGATG       
Nol3_e1.2R      CTCTCCCTTACCCTTTGCTTC        
Nol3_e2.1F      GGGAGAGCAGAGAATGTAGAGG       
Nol3_e2.1R      TCTTGGAAGTCAGGCTCTGC         
Nol3_e2.2F      AAGAAATGGAACCAGAACCAGA       
Nol3_e2.2R      AGTGGGATTCAGACCATTCTTG       
Nol3_e2.3F      CAATGCAGCAAGACTCCATTTA       
Nol3_e2.3R      AGGCCAGACAATTAAAGAGCAG       
Nol3_e2.4F      GTCCATCCACACACAGAGAGAA       
Nol3_e2.4R      ATTCAGGCCAGAAGTACAGACC       
Nr2c3_e1.1F     AATGGTCACAGGTCCTCCAC         
Nr2c3_e1.2F     CCGGCAAATCTCAACAACTC         
Nr2c3_e1.3F     AGCAAGCACTCATGTTCAGG         
Nr2c3_e1F       GCAGCTCCATAGATGCAA           
Nr2c3_e1F       GCAGCTCCATAGATGCAA           
Nr2c3_e1F2      CCTTGCATTCAGCAAGACAA         
Nr2c3_e1F3      TCATTCATGCCTGACTCTGC         
Nr2c3_e1F4      GCAGCATGAAATCTCCAATC         
Nr2c3_e1F5      CACGACGTTCCTTTCCCTAA         
Nr2c3_e1F6      GAATCTTAGGACCACCTGTGC        
Nr2c3_e1F7      CAATATCTTTATCACGGTCACCT      
Nr2c3_e1R       ATGACTTTTGCGGGTCAG           
Nr2c3_e1R       ATGACTTTTGCGGGTCAG           
Nr2c3_e1R1      GTTCCTTGGATTCCAGCTCA         
Nr2c3_e1R2      AGCGGGCTGCTAACAGAAG          
Nr2c3_e1R3      GCAGAGGGACGTTATTTGGA         
Nr2c3_e1R4      ATGTACTGGACAATGTTGAGC        
Nr2c3_e1R5      CCCATCATCTGGTTCTTGCT         
Nr2c3_e1R6      ACAGGTCACCGTGTGGTTTC         
Nr2c3_e2F       GCCAAGACTGTCGAAGAT           
Nr2c3_e2R       GAACTGGAGCAAGAGACAAC         
Nr2c3_e3F       CCTGTTTGCCTCTACTGTGT         
Nr2C3_e3R       GGAGTTTTGTCCCTGGTTAG         
Nr2c3_e4F       GTACTCCTTTTGGCACAGAG         
Nr2c3_e4R       AGTCTTCCGTACTTGAGCAG         
Nr2c3_e5F       CGTAGGTGTCTGTGGAATTG         
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Nr2c3_e5R       GGGCTCGTTTCAGTAGACTC         
Nr2c3_e6F       GCCCTGACTTAGCATCTCTA         
Nr2c3_e6R       GGGTAAGCGTAGGCAGTAA          
NTF2_e1F        CGTTCTAGCCAAGTTCACTAACG      
NTF2_e1R        AGGGCCTCGAAGCAGAAG           
NTF2_e2F        TGAGGAGGCTAGGAAAAGACAG       
NTF2_e2R        AAAGAAAGCCCAAACTTCCTATC      
NTF2_e3F        CTCCCTAAGCAAGATCCTTTTG       
NTF2_e3R        GGCTCTGCAAGAGGAAGAATAG       
NTF2_e4F        TAAGTAAAGGCCAGACATGAGG       
NTF2_e4R        TGACTGTTCCCACAATAAGCAG       
NTF2_e5.1F      GTACCTGATCCCAAAGTTGTAATACC   
NTF2_e5.1R      GCTGGTACAACACAAACTTTTCCTGT   
Pard6a_2_e3.1F  CCAGGGCTCTCAGACTTTACAT       
Pard6a_2_e3.1R  GGAGCCACACGAACACTCAT         
Pard6a_3.2bF    AACCTCATTGTCACTGTCAAGC       
Pard6a_e1aF     TCTCTGTAGTGTTTAGCCTTTGGA     
Pard6a_e1aR     TACGTCATTACGCTATGGTTCG       
Pard6a_e1bF     ATTTCGGTTCTGTGTGAGACCT       
Pard6a_e1bR     CTCTTCACCTCGACGATGCTAT       
Pard6a_e1F      TAGACTCCGCGTTTCTTGGT         
Pard6a_e1R      GAAGTGGAGGATGGAGGACA         
Pard6a_e2F      CCTCACCTGACAGCCTCAGT         
Pard6a_e2R      GTCTGAGAGCCCTGGGTATG         
Pard6a_e3.2aF   CGTGGACCTACTACCTGAGACC       
Pard6a_e3.2aR   TACAGAAGAAGGCCCTGTCAGA       
Pard6a_e3.2R    CAAGGAGGGCAGAGAGCTG          
Pard6a_e3.2R    CAAGGAGGGCAGAGAGCTG          
Pard6a_e3.3F    GCCACCCTCCCTGTTCTAAT         
Pard6a_e3.3R    AGGAAGGTCTCTCCCATGCT         
Prmt7_e10F      AGCCACATGAAGACAAACACC        
Prmt7_e10R      TATCTGCTTTGGCACAGTATCC       
Prmt7_e11F      GTCCCAGGAAGGGAGTAAGG         
Prmt7_e11R      CTCCTGGTTGTGATGCTTCTG        
Prmt7_e12F      AGCCAGGCCTCAAGCATAC          
Prmt7_e12R      GACATCACAGCATTTAGCCAAG       
Prmt7_e13F      TGAATGAATGAATGAACGAACG       
Prmt7_e13R      CTGTTTCCTCTGCACACAAGAG       
Prmt7_e14F      TACCTTTACCTCCCAAGCACTG       
Prmt7_e14R      GGCAGTCTTTCCAAGTATCCTG       
Prmt7_e15F      TGACAATATGTTGCTCCATGTG       
Prmt7_e15R      TTGACCCAGGAGTTAAGAGTCC       
Prmt7_e16F      GATGGGACTGGTTGAGGTTTC        
Prmt7_e16R      AGGGCATTCACAGCACAAG          
Prmt7_e17.1F    CCTGTTCAGGGCAGATAGCTC        
Prmt7_e17.1R    CATTCTCAGGATCACAAACTGTTC     
Prmt7_e1F       CCCAGAACTGAGATTGAAGGTC       
Prmt7_e1R       GCAGGAACCACTCACTATCCTC       
Prmt7_e2F       AGCATTTATAGGTGGGAACTCG       
Prmt7_e2R       GAAAGGTGGCTTCTCTGAACTG       
Prmt7_e3F       GGTTCCTGTCTTAAACTGTGCTG      
Prmt7_e3R       GGAACCCTGTCTGACTCATCTC       
Prmt7_e4F       GACCTGAGATGGGTATTATCTTGC     
Prmt7_e4R       GACTGACTGCTGTGACACTCG        
Prmt7_e5F       GAGTTAACGGGTTCTGAGCTG        
Prmt7_e5R       CGGGAGTATGGAGATTCTGAAG       
Prmt7_e6F       TGACAGGAAGGCCTTAGAGTTAC      
Prmt7_e6R       AAGTTTCCACAGAAACCTGTCC       
Prmt7_e7F       AGCTGAGTCCTTTCCACATCAG       
Prmt7_e7R       TCTTCTTTGCCTTTGACTGAATC      
Prmt7_e8F       TCTCTTTGCATCTGATTGTTGG       
Prmt7_e8R       CTTGGCTACAAGCACCTTTACC       
Prmt7_e9F       GGATTTGAACTCAGGACCTCTG       
Prmt7_e9R       CTAGCATCTGCTCCAGAGGAAG       
Pskh1_e1F       AAGCTCCGCCTCTCTTCCTC         
Pskh1_e1R       GGGCCGAAGGCTCAGAGTC          
Pskh1_e2.1F     AGGAAAAGGGAAGACGACTTTT       
Pskh1_e2.1R     GTCAAATTTGGCCCTGTACTTT       
Pskh1_e2.2F     CCCTGGTGCTCCCACTACT          
Pskh1_e2.2R     AGTGAAAGAACCCTTGGCAATA       
Pskh1_e2.3F     TTTGAGACACAGGAACGGGTAT       
Pskh1_e2.3R     GGTGCCACTGAGCAGGAT           
Pskh1_e2.4F     AGTACATTGCTCCTGAGGTTCT       
Pskh1_e2.4R     CCTTCTGACCAGGAGCTTCA         
Pskh1_e3.1F     CTAATTCTGTGGTGGTCTGTGGC      
Pskh1_e3.1R     GCTGTTGATAGCGCAGGTTAAG       
Pskh1_e3.2F     AGAGCACCAAATCTTCCCAGT        
Pskh1_e3.2R     GACTCAGTCCTGCACCTTTTTC       
Psmb10_2_e1F    ACCTGGGACTAGAAGCAAAGG        
Psmb10_2_e1R    CCTCTACTTGGTCACCCAACAT       
Psmb10_2_e7F    GAATGGAGGGAAGAGAAAGGAT       
Psmb10_2_e7R    GACCGACCGACAGACAGC           
Psmb10_2-3F     TAGAGGCTTAACCCAGGAGATG       
Psmb10_2-3R     ACTGGCCCGGTAGATACTGAC        
Psmb10_e4F      ACATAAGTTGCACTGTCGCTCAC      
Psmb10_e4R      GGTCTCACCTCCTGTCATCCC        
Psmb10_e5F      GGACTCAGACCAAAAAGCAATA       
Psmb10_e5R      GCTGCAGCTGCTGAGGTATAA        
Psmb10_e6F      AAATGAATCTTGCTCCTGCAAC       
Psmb10_e6R      CTTTACCCCTACAAGCCTTCCT       
Psmb10_e7F      AGCAACTTGTCTAGGCTTCGAG       
Psmb10_e7R      CTTTTAGATCGCAGCCTGTTCT       
Psmb10_e8F      GTGTGTGTCTGCTGTCTGTCG        
Psmb10_e8R      CCAGGAACTGAGAATGAAGTCC       
Ranbp10_e1.1F   GCTACAGAACTGAGGCAGGAG        
Ranbp10_e1.1R   GTTCCTGCTCTCCAGGTGAC         
Ranbp10_e1.2F   CAATAGCAGCTCCCTCCAAG         
Ranbp10_e1.2R   ACCCCTCTACTCCGGATGAT         
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Ranbp10_e10F    CTAGATTGGGTGGAAGGGAAAG       
Ranbp10_e10R    ACAACAGAGGGGAAGGTAAAGG       
Ranbp10_e11F    AGGACCCATTATGGTCTCTCAG       
Ranbp10_e11R    AGAGGAAGTGGGCATTAGGACT       
Ranbp10_e12F    GGTAGACTTAGGCTTCCCCACT       
Ranbp10_e12R    TGCAGACACGACTAGAGTCCAT       
Ranbp10_e13F    GTGCTGTGTTCTGTCCTCCTCT       
Ranbp10_e13R    ATGAGTCCTAAAAGCCCAGGAG       
Ranbp10_e14.1F  TGGCTAGGACACTCAAACATTG       
Ranbp10_e14.1R  AACCAGCCAATACTGAGTCACA       
Ranbp10_e2F     GGAGGGTTTGAAGTTATCATGG       
Ranbp10_e2R     TCATCCGTTAATACTAGCTCTGGA     
Ranbp10_e3F     GAGTCTCATCATGGCCTCTTCAGAT    
Ranbp10_e3R     ACCCTCCCAAGTCTCTGAGCTG       
Ranbp10_e4F     TCCTGAGTGCTGGCTAAGGT         
Ranbp10_e4R     GTGCAGAGGCTCCATGATTC         
Ranbp10_e5F     AAGGCCCAGGCCTAAAACTA         
Ranbp10_e5R     ACACCCTGCACTTGGAGGTA         
Ranbp10_e6F     GCAGAGCCATGGAAGTGAAGAG       
Ranbp10_e6R     AGCATGCCCACCACTACAACTG       
Ranbp10_e7F     ATATGTGTAGTCTGTCCCCTCCAG     
Ranbp10_e7R     CTCCAGGATGGTGTGGATAAGGT      
Ranbp10_e8F     GTCTGGTCCCTGCCTTCAGT         
Ranbp10_e8R     AAGGGAGCAGAGCATTGGT          
Ranbp10_e9F     GTCCTCAGCTTGTACCCAGAGC       
Ranbp10_e9R     TTCTAAGCCCACCAGGAAAGGTATG    
Rbm35b_e10F     ATATTCCATTCCCCACACTGTC       
Rbm35b_e10R     ACAGGTTTATCACGCTAATTGGAG     
Rbm35b_e11F     CCCCAATATGCTGCTTCTTC         
Rbm35b_e11R     GCACCTTGTAAGCAGTTTGTCA       
Rbm35b_e12F     GGCATCTACATGGTAGGAAAGG       
Rbm35b_e12R     GTCCGTAGTTACCCTGGTTAGG       
Rbm35b_e13F     GTGGGAACCAAGCTGTTCTAAG       
Rbm35b_e13R     GGCCAGAAATGAGTCAGGATCT       
Rbm35b_e14F     GTACAGGAGAGGATGGTCTTGG       
Rbm35b_e14R     CCACTCTTTAGGGGCTTGTAAC       
Rbm35b_e15F     TCAGTGTCTTTCAAGCCTACCA       
Rbm35b_e15R     AGAAGCCACTGGGTTGAGAGTA       
Rbm35b_e1F      CAAGCTCGTCTGTCTGCTGTC        
Rbm35b_e1R      ACCTAAAAGCACCAGGGGTAAT       
Rbm35b_e2F      ACAGGTAGGTTGGAAAGAGGTG       
Rbm35b_e2R      CCCTCCCACAAGGGGGTA           
Rbm35b_e3F      CTGAGTCCCTCCCTCCTCCTAC       
Rbm35b_e3R      GAGTGGGGATGAACAGGTAACTA      
Rbm35b_e4F      CCAAGGCCCCTGTTGTAAA          
Rbm35b_e4R      CATCGTGCACATGCTTGG           
Rbm35b_e5F      AGGATTCTGCGGGTGTTTAG         
Rbm35b_e5R      GCAAGAGGACTCTGAGGAAGTC       
Rbm35b_e6-7F    ATCCCCTCACCTGTCCTATTTT       
Rbm35b_e6-7R    CTGTGGAGCCAGTGTTGTTAGT       
Rbm35b_e8-9F    GATTCTTCAAAGGGCTCAACAT       
Rbm35b_e8-9R    AGGAATCCCTTGCTGGTTTAAT       
RGD_e10F        CCTTAGTCTGTCTCCTGAGC         
RGD_e10R        CTGACACGTTCCTTTACTCC         
RGD_e11F        GAAAGCAGTGTCAGAAGGAG         
RGD_e11R        CCTCAGAGGAAATGATAGCC         
RGD_e12.1F      TCCAAGTACAAGCAGGAGAG         
RGD_e12F        ACGGGCTATCATTTCCCTC          
RGD_e12R        CACGAGGTGACCCTTTTT           
RGD_e1F         AACCTAGTGCTCCCAGAAC          
RGD_e1R         GAGCCCAGTATGGAATGAC          
RGD_e2F         AGTTCCACTTGCTGGAGTC          
RGD_e2R         GACATAAGCCCACGAGTTC          
RGD_e3F         TTTGCAGAGGAGGTAGAGAG         
RGD_e3R         ATGACTGGCAATGAGGTG           
RGD_e4F         TAGCCATCTTGCTAGTCCTC         
RGD_e4R         GTGGACTGTTAGCACCTTTG         
RGD_e5F         TCTTCTCGCAGCTTTGAC           
RGD_e5R         CTTACCGCTACAGGCAAC           
RGD_e6F         ACTGCTAGGCTCCCATTT           
RGD_e6R         TGGCTCTGATCCTGGAAT           
RGD_e7F         GCGCTTAACCACTAACCA           
RGD_e7R         AGGAATAGCCAGGCAGTAGT         
RGD_e8F         CTGTGGTGTGGCATTGAG           
RGD_e8R         TGTGGGTATCAAGTGTCCTC         
RGD_e9.1F       AATCCAGGGGATCAGTATC          
RGD_e9.2F       GGAGAAAGACCAGCACTGTA         
RGD_e9F         CCGCCAGTGTACTCTTGAT          
RGD_e9R         CCACAGTCTAACCTGGGAAC         
Slc12a4_2_e1F   CTCTCGCCACCTCCTCAAC          
Slc12a4_2_e1R   AAGTGGAGTCCCGCATGG           
Slc12a4_2_e2F   GGGTTGGCTTTCTGGATTG          
Slc12a4_2_e2R   CTGGATGGCTGCAAAGAGG          
Slc12a4_2_e3F   AAGCAAGAACAGGGATCAGG         
Slc12a4_e10F    TAAGATCTCCATGCCCACAC         
Slc12a4_e10R    CCAGCACCCTAGTGGTCTTC         
Slc12a4_e11F    CATGCAAACCTGGAGACCTTAAC      
Slc12a4_e11R    GGCTAGAGTGAGGGCAAAAAAAG      
Slc12a4_e12F    TTTTTCCTGACCCCTGACAC         
Slc12a4_e12R    AACCTCACCGCATCTGAATC         
Slc12a4_e13F    GTGACTTGTGGCTGCAAATG         
Slc12a4_e13R    GAGGAGCTGGGGTACTCAGG         
Slc12a4_e14F    AGGAGTGGGTTCCTGGAGTT         
Slc12a4_e14R    TCCCCCTGTGGTAACCTGTA         
Slc12a4_e15F    CAGCTTCTGACTTGGGACCT         
Slc12a4_e15R    CCACTGCCAACCTAACCAAT         
Slc12a4_e16F    GAGAGAGGGAGGGAGGGAAGGAGTC   
Slc12a4_e16R    CTATGATCTCCTGGGGGACACTAC     
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Slc12a4_e17F    TTGGGAAAAGGCCAGACC           
Slc12a4_e17R    CCCTTATATGCCTGTTGCAC         
Slc12a4_e18F    TCCAAGGTCTCCCTGTGAAC         
Slc12a4_e18R    CCTGTGACCCTCTGGTCTCT         
Slc12a4_e19F    GTTAAAGTGAGGTGGCAGAGACCAG    
Slc12a4_e19R    TGCCCAGCCAGCTGGAGCACCTTA     
Slc12a4_e20F    GGTGTGATGAACCAGTCACG         
Slc12a4_e20R    GGTGATGAGTACTGGGATGC         
Slc12a4_e21F    GGTGGTAGAGATGGTGAGCTG        
Slc12a4_e21R    TTTACCAAACCCGAACCAAG         
Slc12a4_e22F    GACAGGCAGGATAGCCATGT         
Slc12a4_e22R    CTGGCCCATCTACACAGCAT         
Slc12a4_e23F    GTAGATGGGCCAGGGACAG          
Slc12a4_e23R    CACAGGGCCAAGACAACTTT         
Slc12a4_e24.1F  CCCTCTCCTTGAGTGGAAAG         
Slc12a4_e24.1R  CACCAGTCATCTCGAGTCAGG        
Slc12a4_e24.2F  CCTTGCAATGGGAATGGAT          
Slc12a4_e24.2R  TGGGTTCAGTTCCGTCTTTC         
Slc12a4_e3R     TGTTCAACACCACAAAGGAAA        
Slc12a4_e4-5F   GACTAGGGCCTCCTTCCTGT         
Slc12a4_e4-5R   TGCCTGAGGAGGAAAGACAA         
Slc12a4_e6F     TGTGGAGGTTTGCTACAAGAGA       
Slc12a4_e6R     TGCTGGCTAGGCATGATAGA         
Slc12a4_e7F     CCAAAATGACAGGTTTCACTCC       
Slc12a4_e7R     CCCAAGCAATCTGAGGGATA         
Slc12a4_e8F     GATGCTCCGTATCCCTCAGA         
Slc12a4_e8R     GCTCTGTGCTCTGCTTTCCT         
Slc12a4_e9F     CTTCCCTGGGGACATCAGT          
Slc12a4_e9R     TGCCTCCAAAAACAGACAAG         
Slc7a6_e1.1F    TCCTGCTGTGTTGTATGTGTTG       
Slc7a6_e1.1R    CCCTGACTTGGTGATAGTGGTC       
Slc7a6_e1.2F    ACTGCTTCCTATGGGTTGTCAC       
Slc7a6_e1.2R    ACGTCTCACATCTTCCTTCCTC       
Slc7a6_e2F      TGCTGTTTACCTGTTCCAGTTC       
Slc7a6_e2R      AAATGTGCTGAGAGATGAAGC        
Slc7a6_e3F      GGGAGGTTCTGGTTATTGTTCC       
Slc7a6_e3R      CCTCCTAACTGGAGAAGGGAAG       
Slc7a6_e4F      AGAGGAGCCTGTCTCAAAGACC       
Slc7a6_e4R      AAACGCCTACCGTCTACCCTAC       
Slc7a6_e5F      GGGATGGGTCTAGGTAGGGTAG       
Slc7a6_e5R      AATGCCATTGTTAAGAGGATGC       
Slc7a6_e6F      AGCGTGAGTAATGGGCTAGG         
Slc7a6_e6R      ACTACGCTTCAACAAACCTTGG       
Slc7a6_e7F      TTTCAGCTCTGACAGACCACTG       
Slc7a6_e7R      CTGCTAGTGTGCATGAGTTGTG       
Slc7a6_e8F      AGTCCTCTGGAAGAGCCATCTC       
Slc7a6_e8R      GCCATAAGGAAGGTGGAAGAG        
Slc7a6_e9.1F    GTGTGCCTATGGGACAGGTG         
Slc7a6_e9.2R    GCTCCTTTAATTCAGACGGTTTAG     
Slc7a6os_e1F    CTGTGGGAAGCACTCCACTC         
Slc7a6os_e1R    CTGCTGGATTGGCTCCTC           
Slc7a6os_e2F    GTGCGATCTCAGGTATGAGAAG       
Slc7a6os_e2R    AGGTAGAATGAGGTCAACCTTTAG     
Slc7a6os_e3F    CTAGCCAGGGCTACATAGAATG       
Slc7a6os_e3R    TTATGCCCTTCTCCTCTTAGACC      
Slc7a6os_e4F    GGGTCTGGGCCCTAAATTAC         
Slc7a6os_e4R    AAGAACAGCCAGTGCTCTTAGC       
Slc7a6os_e5.1F  AAGAACTGACTCCTGGAGGTTG       
Slc7a6os_e5.1R  CATGCTTGGCTTCACTTATCAC       
Slc9a5_2_e6F    ACCCCCACTGGCTGTTTAC          
Slc9a5_2_e6R    TTGGACTGAGGGATGGGTAG         
Slc9a5_e1.1F    AGGGGATCCCAACTGCTAGA         
Slc9a5_e1.1R    CACACACTCACCGATTTTGG         
Slc9a5_e1.2F    CCGTTAGGTGAGCCTCCAG          
Slc9a5_e1.2R    ACAATGCAAGACGCAGGACT         
Slc9a5_e10F     TGGCTGAGACTCATACCAAGAA       
Slc9a5_e10R     AGCCCCTCGCTAACAAGTCT         
Slc9a5_e11F     GGCTCTGGCTCAAAACAAAG         
Slc9a5_e11R     GAGGCAGGGATATGTGTGCT         
Slc9a5_e12F     GGAAGGATCCACCAACACC          
Slc9a5_e12R     ACGCCTGTTGAGTCCATGAT         
Slc9a5_e13F     GAGGAACATGTTGGGGTTGT         
Slc9a5_e13R     AACCCCTGACGGTGACTAAA         
Slc9a5_e14F     GAGTGGTGGACCCTTGTGAT         
Slc9a5_e14R     GAGGAGAGGAACCCAGCTCT         
Slc9a5_e15F     AGAGAGCTGGGTTCCTCTCC         
Slc9a5_e15R     AACATGCAGCTCACAAGGAA         
Slc9a5_e16F     TGGTATCAAGAAGCAGCCACT        
Slc9a5_e16R     ACTGGCCTCCTAAGGCAGA          
Slc9a5_e17.1F   CTTGGTGCATTTGAGGATTC         
Slc9a5_e17.1R   GGGGGAAAGCAAAGCTAGAG         
Slc9a5_e17.2aF  CTGGAACCAGAGCATCTCATC        
Slc9a5_e17.2aR  CCAGGAAACCCTTCTGACC          
Slc9a5_e17.2F   GTTCCTCAACATGGGCAGAG         
Slc9a5_e17.2R   AAAGCAAGATGTGGGGACAC         
Slc9a5_e17.3F   AGGATCAGTGCACAGGCAAT         
Slc9a5_e17.3R   CCTGGGTTTAAGGTACAAAGCA       
Slc9a5_e17.4F   CCCAGAGTCACTGCACCATT         
Slc9a5_e17.4R   CCATTTGTGGATTCCCAGTT         
Slc9a5_e17.5F   TTCCAGTATTGTCCCACTAGCA       
Slc9a5_e17.5R   CCCTGGAGCTTGAATTCCTA         
Slc9a5_e17.6F   GCTTCCACATGTAGCACCAC         
Slc9a5_e17.6R   AGACCACAATGGCCTTGAAC         
Slc9a5_e2.1F    TATTACAGGTCAGGCTGTGG         
Slc9a5_e2.1R    CGGCATGAAATAGCCAGAGT         
Slc9a5_e2.2F    GTGGCCAAGAAGGCTGAGTA         
Slc9a5_e2.2R    AGATGCCCGGAGTTAGGG           
Slc9a5_e3F      GGAAGTGTTGTCAGAGGCAGA        
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Slc9a5_e3R      TCTAAGCCTGGTCAGATAGCC        
Slc9a5_e4F      TGGGGAGGAAATAGGATCTG         
Slc9a5_e4R      GGTCGCAACAATCCAGAAAA         
Slc9a5_e5F      GGTGGGTGCCCTTCTCTATT         
Slc9a5_e5R      TTTAAGACCTTGCATTTGGCTA       
Slc9a5_e7F      GCCAGACCTTAGCCCAGATA         
Slc9a5_e7R      CCTCAACCCATCACACTCAA         
Slc9a5_e8-9F    GTGATGGGTTGAGGCAAAAC         
Slc9a5_e8-9R    TTCTCAGAAGGGTGGCATATC        
Smpd3_e1F       GCGTCTCCATTGGCTAGG           
Smpd3_e1R       AGGACACGTCCCATCAACTC         
Smpd3_e2.1F     CCAAACACTCCGTGTGAAAC         
Smpd3_e2.1R     TGAAGAGTACGGTGCAGAACAG       
Smpd3_e2.2F     CCCTCATCTTCCCATGTTACTG       
Smpd3_e2.2R     CACTGATGGAGGTGTTGGTG         
Smpd3_e2.3F     CAAAGAGATTGGGCAGAGAATC       
Smpd3_e2.3R     TGCCACCACTGTCTTGTCC          
Smpd3_e2.4F     AGATGCCCAACCACAATCAG         
Smpd3_e2.4R     ACGCCTACCTTGAGAAACAGAG       
Smpd3_e3F       TAGCCAGAGTCTAGCCAGGAG        
Smpd3_e3R       GACAGAGACCAGACTGTGAAGC       
Smpd3_e4F       GGTTCAATACCTGGGACCTG         
Smpd3_e4R       CTGTGACCATGCCTGGAG           
Smpd3_e5-6F     AACTGACAGGAACCAGCTGATAG      
Smpd3_e5-6R     CAGGGTTCCACTCCTTGTTAAG       
Smpd3_e7F       TCTGGTCTCCTCCCTCTTACTG       
Smpd3_e7R       GGGTTGTACAGAGGATTTCAGG       
Smpd3_e8.1F     CCAGAACTTCCCTTCACAGAAC       
Smpd3_e8.1R     TACGAACCCTTGGGTTACAAAC       
Smpd3_e8.2F     CATCTCTGCGGACAGAGGAC         
Smpd3_e8.2R     AAATGTAATCGCCCTTGAATG        
Smpd3_e8.3F     AAACAATCAGAACCAGCCAAAG       
Smpd3_e8.3R     CAGGCAAGTGTTCCTGAGC          
Smpd3_e8.4F     CGACAGGTTTGTAGCTTCTTCC       
Smpd3_e8.4R     CCTCAAATCAGTAGCTCAGCAG       
Smpd3_e8.5F     CTGCTAGAAGCCCACTGCTC         
Smpd3_e8.5R     TCCTAGCTCTGGACACTCAAAC       
Smpd3_e8.6F     CTTCAGAGTATGGCAGCTTGG        
Smpd3_e8.6R     GGCTTCAGAACCTGACTGTGTAG      
Smpd3_e8.7F     ATCCTTCTCTCCTTCCCAACTC       
Smpd3_e8.7R     AAAGATGAACTGAATGGTCTTTCC     
Smpd3_e8.8F     CAGGGACCACTTGAATCCTAAC       
Smpd3_e8.8R     AAATAAGTACAGACAAGATGCCAGTC  
Thap11_e1.1F    GGCGTAGTCCTCCTTTCCAG         
Thap11_e1.1R    GAAGTGAACGCTGCAGAGAC         
Thap11_e1.2F    CTTCTACACGTTTCCCAAGGAC       
Thap11_e1.2R    ACATCATCTCCCGAGGAAGTAG       
Thap11_e1.3F    GCCGTGCTTCTTACTCTTCAG        
Thap11_e1.3R    TTTCATCTTCACTTCCATCAGG       
Thap11_e1.4F    CGACCACTCATACTCTTTGTCG       
Thap11_e1.4R    AGTTCAACATCTGCCTGAGGAT       
Tmem34_e10F     GGAGGGGAAGCTACTTTTAG         
Tmem34_e10R     AGACCCTTGAGTTTGAGGTC         
Tmem34_e1F      CCGTAGCTGACCAATCAT           
Tmem34_e1R      GTTTTGCAGACCTCAAGC           
Tmem34_e2 3F    CTGCCTCCAAGGAATCTAGT         
Tmem34_e2 3R    AGAGTGAGCTCCAAAGACAG         
Tmem34_e4F      GTGACAAGATCCCCGATT           
Tmem34_e4R      ACTAGCTGTGGATCACGAAC         
Tmem34_e5F      GTTCCCTCCTGTTTTAGAGG         
Tmem34_e5R      CTGTCAGAGGGTGTGAATCT         
Tmem34_e6F      CACCCATAGGCTCTCTAA           
Tmem34_e6R      CTTCTCTGTCTGAGGGTCT          
Tmem34_e7F      GAGTGCCAGGGAAAATGT           
Tmem34_e7R      CTGGCACAGGACTAGCTTT          
Tmem34_e8F      CCAGCATATCCATGTTGC           
Tmem34_e8R      ACTGTTGGCACGTTGTTC           
Tmem34_e9F      GCTACCTTTCAGTCCTTGG          
Tmem34_e9R      CCAATCTGACAGCTCCTG           
Tradd_e1F       TTCTTGTCAAAGGCAGTGGAG        
Tradd_e1R       GAGCCTAAACCACAAAGCAAAG       
Tradd_e2F       GACTACGGGCTTAGCTTCCTC        
Tradd_e2R       GTTTGCAGAACTCATCCTCCAG       
Tradd_e3F       GGTGCTGGTGTCTGTAGTTAGG       
Tradd_e3R       GAGGTAAGTAAGCATCGGTTCC       
Tradd_e4.1F     GTCACCAGCAGGTAGATCTGAG       
Tradd_e4.1R     AAACACTGGCTGAACTGGTTG        
Tradd_e4.2F     TGGAGGAGAACGAGCTCAC          
Tradd_e4.2R     GGGCTAGACCTCAGTATTTCCAC      
Tradd_e4.3F     ACTGTCACGAGCAGGATGC          
Tradd_e4.3R     TGTCCTGGAATTCACTCGGTAG       
Tsnaxip1_e10F   AGCCATCTAGAGCTCATCATCC       
Tsnaxip1_e10R   CACCCTACTCCCTACCATCTTG       
Tsnaxip1_e11F   ACTTCAGCTCCAGTTTGAGGAG       
Tsnaxip1_e11R   CCAAAGTCTATAAGAGGGAAGCAG     
Tsnaxip1_e12F   GTCCCCGGCACAAAATGG           
Tsnaxip1_e12R   CCCTTTCCCTGAATCTGACC         
Tsnaxip1_e13F   TGTTGAAATAATAATGGGGATGG      
Tsnaxip1_e13R   GCAAGGTGAGGCCATTTG           
Tsnaxip1_e14F   AAGACACAAAACTTGCCAGTCC       
Tsnaxip1_e14R   GTTGCCTGGGGAGACTCAG          
Tsnaxip1_e15F   CCCCAGGCAACAGGTACTATG        
Tsnaxip1_e15R   TAGGGCCTGCCCAGATCAC          
Tsnaxip1_e1F    GAGAGCACACTCTGTGAGGAAG       
Tsnaxip1_e1R    TTATGCTTTGGGGTTGTAGGTG       
Tsnaxip1_e2F    TGGGTTCAATCCTCAACAATAC       
Tsnaxip1_e2R    GCCGCAAACTCCACTAAGTTC        
Tsnaxip1_e3F    ACGAAAGCCCTGTTCAGATG         
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Tsnaxip1_e3R    TCCCCGTGAAGGTCTATTATTC       
Tsnaxip1_e4F    GGCCAGACATAGGCAGTCTC         
Tsnaxip1_e4R    GGCAAGCAAAACAACTAGAAAG       
Tsnaxip1_e5F    AGAGATCTGCCTCCTCTCTGC        
Tsnaxip1_e5R    AATGTGATAGCTCCTCCATTCC       
Tsnaxip1_e6F    GATCGGTTTGCTTTCCTTTTC        
Tsnaxip1_e6R    ATCTCCCACCATGTATGGACAC       
Tsnaxip1_e8F    AGGAGAGACTTCGAAATGCAAG       
Tsnaxip1_e8R    GCTATGACACCTGCAAGTTGG        
Tsnaxip1_e9F    CCAAATGCGAAAGTAATGATTG       
Tsnaxip1_e9R    CCTGTTTGTAAATGGGATGATG       
Zfp90_e1F       GGCCGAAGTGGCTACAGAG          
Zfp90_e1R       CAAAGCGATCCAGACTAAGAATC      
Zfp90_e2F       CTTGGAGCAGCAAACACAAG         
Zfp90_e2R       TAAGGATCTTCCATGCTCAAAG       
Zfp90_e3F       TGCTAGTGTGTCTCCTTAAGTTGC     
Zfp90_e3R       GGAACACCTGACTGGAGAAGAG       
Zfp90_e4.1F     TGACATGACAGACACTCTGGTG       
Zfp90_e4.1R     CTTACATTCGCTGGGCCTTATG       
Zfp90_e4.2F     GAGAGTTGGAGAAGACATCTTGG      
Zfp90_e4.2R     GACCAAGGGATGAGCTGTG          
Zfp90_e4.3F     ACTTTCCTGTGGAGAACACAGC       
Zfp90_e4.3R     TTGTTACTTTGGTAAGGTTTGCTTC    
Zfp90_e4.4F     CCCTTGTTCAACATGAGAGG         
Zfp90_e4.4R     AGTGACGAGAGTCGACTGAAGG       
Zfp90_e4.5F     GTCAGCAGTCCCTGTCTCATC        
Zfp90_e4.5R     ACAGTGTTTCCTACCCATCCTG       
 
 
For qRT-PCR of rat samples: 
Arhgap10_F   tgtcaccattccccctctc       
Arhgap10_R   gccttgcggttgataagg        
C19orf57_2F   caaacctcagcccagacc        
C19orf57_2R   tctgttgcgtcctgcatc        
C19orf57_F   tcccaggatcaccaaaagag      
C19orf57_R   acaaacctccccactgagc       
Cdh1_2F      gatcctggccctcctgat        
Cdh1_2R      tctttgaccaccgttctcct      
Cdh15F       ctatacggaccccaagacca      
Cdh15R       gctcacggctctcataatcc      
Cdh1F        gatcctggccctcctgat        
Cdh1R        tctttgaccaccgttctcct      
Cdh2F        ccatcatcgcgatacttctg      
Cdh2R        ccataccacgaacatgagga      
Cdh3F        gttccggagggggtaag         
Cdh3R        agtattgatggcgtcgtcct      
Cdh4F        tgcatcgtgatcctgctaac      
Cdh4R        cttttccctccgcttcatc       
Ctnna1F      tcagaatacatgggcaatgct     
Ctnna1R      tttatctatggcagagttgagtgc  
Ctnnb1F      gtccatgggtggaacacag       
Ctnnb1R      cccagtgcacccttcaac        
Ctnnd1F      ggagtcagtgctcaccaaca      
Ctnnd1R      tcactcctctccgagcttaca     
Dsg1b_2F     gctcatcatggggttcctagt     
Dsg1b_2R     aatccagctccaccacca        
Dsg1bF       gggggcctcaatatgaattt      
Dsg1bR       ggacgtccttcatcttcatcc     
Dsg2_2F      gaaaatcacgcaccaagaaag     
Dsg2_2R      tcggagatgaggaagggaat      
Dsg2F        cctcatgattctggctctcc      
Dsg2R        cagtggcacatcaacaacaa      
Dsg3F        cggatgaggacactggtaaag     
Dsg3R        accatcattacgacccagga      
Dsg4_2F      ggaatccgattgccagaat       
Dsg4_2R      ccgctccagagattcgataa      
Dsg4F        gcctctaacacccaagatcg      
Dsg4R        tgttcctccaccagcataagt     
House-ActbF  ccaaccgtgaaaagatgacc      
House-ActbR  accagaggcatacagggaca      
House-Mrp2F  atcgcacagctcagctcac       
House-Mrp2R  cgccatggccaactctta        
House-Prdx2F gactctcagttcacccacctg     
House-Prdx2R tattcagtgggcccaagc        
House-R5piaF tgctgagctcaatctcatcaag    
House-R5piaR ggcataaccagccacaatct      
House-Rpl4F  tttggtggttgaagataaagttga  
House-Rpl4R  ttctctgggaggcatagacc      
House-Rps18F cagaaggacgtgaaggatgg      
House-Rps18R tctatgggctcggattttctt     
House-TbpF   cccaccagcagttcagtagc      
House-TbpR   caattctgggtttgatcattctg   
House-YwhazF agatcagggacagagtctcagc    
House-YwhazR gcaccagctcatttttatcca     
JupF         attttcccagagacgcgatt      
JupR         aggttcatcacctccatcgt      
Krt25F       cgcagggttctggatgaa        
Krt25R       gcagagcctgcatttcct        
Krt26F       caatccatcacggctatgaa      
Krt26R       cagcccaatctgctcctg        
Krt27F       cctggttccaagagaagagc      
Krt27R       ggtttggagagtccgtttca      
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Krt28_2F     tgaacaacatgagagccgagt     
Krt28_2R     agtcattggagatctgctgct     
Krt28F       cacggctgctaacgctaata      
Krt28R       tgaagggtgagttcgttttca     
Krt73F       gaggacattgccctgaagag      
Krt73R       tggtgtgcttgaggtcatct      
Mmp12_2F     tggctcgaattccaagagtt      
Mmp12_2R     aggttttggttggtgcaaa       
Mmp12F       gctgtcacaacagtgggaga      
Mmp12R       gaagtaatgttggtggctgga     
Nol3F        gcctgccaggaactactgc       
Nol3R        gcatggagggtcatagctg       
RGD1308358F  caaactgcatagctggctga      
RGD1308358R  cccgtgtgtgtgtttctgat      
Rltpr_2F     ccactcagagcaggtcagtg      
Rltpr_2R     cctggtgcacagcaacct        
Rltpr_F      acacttgccttcccctgag       
Rltpr_R      aaaggtgacccgaggaggt       
TcchF        gcagctgagggacagaaaa       
TcchR        cggaactttctctctcgttctt    
 
 
For microsatellite analysis: 
D19Mit7_F  6'FAM-AGGGCTTTGCTGAATGCTTA    
D19Mit7_R  AGAGTGGTGGTGAAAGTGGG          
D19Rat11_F 6'FAM-GGAAACTCACTTTGCAGGGT    
D19Rat11_R TCAGAGTTTTCAACTGGCTGG         
D19Rat14_F HEX-CACTGGCATACAGATGCAGG      
D19Rat14_R TTCAGGGTCAGTCTGAGCAA          
D19Rat22_F 6'FAM-CCTGCAATGGGATGAATACA    
D19Rat22_R CAAGGACAGAACTGAACTGGC         
D19Rat23_F 6'FAM-TCTGATCAGGCATGGAACTCT   
D19Rat23_R CCTTCTTGGTCCTTGTCTCCT         
D19Rat24_F 6'FAM-GTCCATGTGATGGGATGTGA    
D19Rat24_R TGGGTGTTTCAGAATTCATTTTT       
D19Rat25_F HEX-CCAGCCCTTAGATGCAACTG      
D19Rat25_R GAAAAACCTGGCATTTCAGG          
D19Rat33_F 6'FAM-CCTGAAAACCTAAGTTCAATCCC 
D19Rat33_R CTCACAGCGGCAATAGCATA          
D19Rat7_F  HEX-CTAGTCATCCATTGGTCGGG      
D19Rat7_R  TAGAAAGCCATGCTCACGTG          
D19Rat70_F 6'FAM-GTGTAGGTCAGAGGACAACCT  
D19Rat70_R AAGCTGGACAACCTGCTTTG          
D19Rat72_F 6'FAM-AGGAAGCATTTGTCTGCCTT    
D19Rat72_R TCAATGCAAAATGAATCACCA         
D19Rat88_F 6'FAM-CCCATTACCATGTCCTTGTT    
D19Rat88_R CGAGTCCCAGTGGGAAGTTA          
D19Rat90_F 6'FAM-CAGAGGGGAAGGACACTCAG    
D19Rat90_R TGTCCCAAACATGTATGAGTAACA      
D19Rat91_F 6'FAM-CTTCCTCTCTCACACAAAATACG 
D19Rat91_R GTAGCAGCAGCAGCAGCA            
D19Rat98_F 6'FAM-ATACATGGGTGTGTGTGCCC    
D19Rat98_R CATACACACACAGAAGGTCAACTT      
 
 
For qRT-PCR of human samples: 
hACTB_F        ccaaccgcgagaagatga        
hACTB_R        ccagaggcgtacagggatag      
DMKN_F         tgacagcggcagtgagtc        
DMKN_R         acccgggtttatgtccattt      
KRTDAP_F       agatcccggtccttcctg        
KRTDAP_R       cgcataattctcaatggtgct     
LOC100289218_F cctgtctgcacggtattctg      
LOC100289218_R tcacttcagacgcacagca       
RPL31P61_F     cacaaggtggtgacctgaga      
RPL31P61_R     cccatctccttcatgcaaat      
SBSN_F         tcaacaacgctgctggac        
SBSN_R         cccagtgtggaacccttg        
ZNF383_F       gggaaagagccctggatg        
ZNF383_R       ggtttcacacatcgattcca      
ZNF567_F       aagaggctaacatgactgataccac 
ZNF567_R       ttctgagcatgatccaggtg      
ZNF568_F       aatgtttgggaggcactgtc      
ZNF568_R       atcacttcagacgcacagca      
ZNF829_F       gacccttagatctgggaggaa     
ZNF829_R       tcaggggaaaggttgtgttc     
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For high resolution melting curve analysis of human samples:
ZNF567_e1F TGGAAGCCTGAAATGTGAAAG 
ZNF567_e1R AGGTTCCAAGCAGCAGGTTC 
ZNF567_e2-3F AAGCTATTCTCCTGCCTCAGC 
ZNF567_e2-3R AGGCACTTTGAGAGGAAGTG 
ZNF567_e4F CTTACCCAGTGCAAGGTGCT 
ZNF567_e4R GAGCCACCATACCTAGCCTAAA 
ZNF567_e5.1F GGCCAGTGGTCATTTGTTCT 
ZNF567_e5.1R TGAAAGCTCTGGCACTTTGAT 
ZNF567_e5.2F GGATATGGGAAATCACTCCTGA 
ZNF567_e5.2R TCAGTGAGGGCTGTCTTGAG 
ZNF567_e5.3R TGTCATCAATGTGGAAATGC 
ZNF567_e5.3R TCATGAAGAGCAAGGGTTGTC 
ZNF567_e5.4F CACACCTCATTCGTCATCAG 
ZNF567_e5.4R TGATGTGCTACAAGGGTTGTCT 
ZNF567_e5.5F AAGACAACCCTTGCTCTTCA 
ZNF567_e5.5R TAGGATTTCTGGCCGGTATG 
ZNF567_e5.6F TTTCGCCAGAAAGCAACC 
ZNF567_e5.6R TGTTTCAGCATGCTTTTCTTTT 
ZFN568_e1F ACCCTCACACAGGAAAGCAG 
ZNF568_e1R ACACAACCACACACCCACAC 
ZNF568_e2F GAGGGTGTGAGGAATTGGAC 
ZNF568_e2R AAAGGGATAAGGTGAATTTGC 
ZNF568_e3R TTGGAAGCTGGTTATCACAGG 
ZNF568_e3F CCCAAATGTAGAGCCTTTCTC 
ZFN568_e4F GAGGGTCTTCTAGCCACCTG 
ZNF568_e4R AGAACCCACCGTAACTGCAC 
ZNF568_e5F GCTAAACAAGTTCTTGTATGTTGTG 
ZNF568_e5R AAGAATTCTCTGTTAAATTGCAAGG 
ZNF568_e6F TGGTTGTCTCCAGCATTGAC 
ZNF568_e6R CTCATGTGGCTTTCTCATTCAG 
ZNF568_e7.1F TTGGTTGACTAGGCCAACATC 
ZNF568_e7.1R TGGTTTCCCAAACTCATTACTC 
ZNF568_e7.2F TGACTCACTTGATAAGGGTTTGG 
ZNF568_e7.2R GTCTAATGAGGTCAAATTTATGACTG 
ZNF568_e7.3F TTGTGCATCCTATGTTGTAACC 
ZNF568_e7.3R AGCGTAACAGATGACATTCGAG 
ZNF568_e7.4F ATCCTTCAGCCAGAAGCAAA 
ZNF568_e7.4R TTCGCATATGTACGGTTAGGG 
ZNF568_e7.5F CATCTGTTACGCTACATATGAGAA 
ZNF568_e7.5R TGAGGGATGAGATTCGAGAGA 
ZNF568_e7.6F TGCGAAATCATACAGCTGAG 
ZNF568_e7.6R AGAAAGGGATGCTCTTTGAGA 
ZNF568_e7.7F TCTCTCGAATCTCATCCCTCA 
ZNF568_e7.7R TGGTATTTCTTTCCATTTATTCCA 
ZNF568_e7.8R AAAGCCAGGATCTTTATGGAAA 
ZNF568_e7.8R TTCATGAATCTGCTTCTGGATATT 
ZNF568_e7.9F AGTGTATGAATTGCTGCGACA 
ZNF568_e7.9_4R AAAGCAGAGGCTGCAGTGAG 
ZNF568_e7.9_3F GGGAAATGATGACCTAGTCAATAAA 
ZNF568_e7.9_3R TCAAGACTACCCTGGCCAAC 
ZNF568_e7.10F GGAGTACGGTGGTGCAATCT 
ZNF568_e7.10_2R CAGGTGCAGTGGCTCAAG 
ZNF568_e7.10_2F CATGTTGGCCAGGGTAGTCT 
ZNF568_e7.10R ATCAGCCTCCCAAGTAGCTG 
ZNF568_e7.11_2F GTTGAGGCCAAGGAGCTTT 
ZNF568_e7.11_2R TGGATCTGGTTCACTGCTTT 
ZNF568_e7.12_2F AAACAACCTAAATATTCATCAGTGG 
ZNF568_e7.12_2R TCAATAATTGGGTGTGTATCCTTC 
ZNF568_e7.13F TGGAATGAAATCATTTATAAAGAACAA 
ZNF568_e7.13R TGGCCTGTTGTGAGAAAGAA 
ZNF568_e8.1F GCACCCACCTCTGGACTACA 
ZNF568_e8.1R CTGACACCCTTCTCCCATCC 
ZNF568_e8.2F AGGTGGCTCTCGGAGATGT 
ZNF568_e8.2_2R CCGCGATACCCTAGACCTC 
ZNF568_e8.2_2F GGAGTGGGTGTGGTGTGAG 
ZNF568_e8.2R AATGTACAGCGAGGGTGTCC 
ZNF568_e9F AGGGATTCAGGATGGCTTCT 
ZNF568_e9R CCTTTGTCCAAATCATGAATGTAA 
ZNF568_e10F  AGTCTCATGGTTGCGCTTG 
ZNF568_e10R  GCGGTGGTTCACACCTGTA 
ZNF568_e11F  ACTCCCGACCTCAGGTGAT 
ZNF568_e11_2R  GATACCTCTGACAGCTAAAGAAGG 
ZNF568_e12_2F  GGGACTGAACACCCATGTTA 
ZNF568_e12_2R  GGAGTTCAAGAATGTTCACTGG 
ZNF568_e13_2F  CCTCCAACGAGTGTTCAAGAG 
ZNF568_e13_2R  GGGCTCAACCTCATTTAGTACC 
ZNF568_e14F  ACCTGCTCCTCTTTCTTGGT 
ZNF568_e14R  CTGCCTTCTCACAGATGAGC 
ZNF568_e15.1F  TTTCTTTGTCCTGCAATGTGA 
ZNF568_e15.1R  CATTCTCCACATTCAGGTTCTTT 
ZFN568_e15.2F  TCCTGTGAATGCAGGAAATG 
ZNF568_e15.2R  AGGTGTGAGGGACGGGTAA 
ZNF568_e15.3F  TCCATCCACTGCACAGCTTA 
ZNF568_e15.3R  GAGCTCTCTGATGTCGGGTAA 
ZNF568_e15.4F  TGTGCCTCACAGCTGAGTCT 
ZNF568_e15.4R  GGCCTTTCCACACTGCTG
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2. Detailed Expression Analysis Data from Rat Samples 
 
Table 11: 50 highest fold changes in skin expression data. Highlighted in blue: genes affecting hair 
structure. Highlighted in mauve: genes affecting the immune system. Highlighted in grey: p-values above 0.05. 
Probeset_id Chr. 
Variation 
coefficient 
DEB_skin 
Variation 
coefficient 
Wi_skin 
Significance 
(p.ttest) 
False 
discovery 
rate (q.ttest) 
Fold 
change 
Gene 
10747051 chr10 0.0771 0.3397 0.0004 0.0545 1.6866 Krt25 
10866195 chr4 0.1589 0.2029 0.0004 0.0545 1.6639 (cDNA) 
10747067 chr10 0.0898 0.3187 0.0008 0.0545 1.6133 Krt27 
10907448 chr7 0.1124 0.2969 0.0015 0.0545 1.5567 Krt73 
10755135 chr11 0.1117 0.2331 0.0009 0.0545 1.4988 Kng1l1 
10750958 chr11 0.1254 0.1999 0.0010 0.0545 1.4773 Trat1 
10875985 chr5 0.0816 0.2740 0.0016 0.0545 1.4740 (cDNA) 
10756147 chr12 0.1963 0.2015 0.0064 0.0663 1.4722 Cd209d  
10747058 chr10 0.1328 0.2268 0.0020 0.0559 1.4687 Krt26 
10824711 chr2 0.0759 0.2289 0.0006 0.0545 1.4643 (cDNA) 
10801978 chr18 0.1030 0.1931 0.0005 0.0545 1.4635 RGD1305184 
10784054 chr15 0.0987 0.2739 0.0025 0.0576 1.4618 Gzmb 
10859174 chr4 0.1492 0.2213 0.0033 0.0581 1.4539 Klre1 
10866193 chr4 0.1571 0.2576 0.0063 0.0659 1.4530 (cDNA) 
10907869 chr8 0.1073 0.2530 0.0030 0.0581 1.4309 Mmp12 
10866197 chr4 0.1428 0.2469 0.0055 0.0634 1.4307 (cDNA) 
10817168 chr2 0.0991 0.2401 0.0022 0.0566 1.4240 Tchh 
10771649 chr14 0.1067 0.1574 0.0005 0.0545 1.4213 Cxcl11 
10866061 chr4 0.1198 0.1860 0.0014 0.0545 1.4177 Klrc1 
10747075 chr10 0.0912 0.2219 0.0015 0.0545 1.4117 Krt28 
10866167 chr4 0.1192 0.1561 0.0009 0.0545 1.4091 Ly49i4  
10765497 chr13 0.0940 0.1259 0.0001 0.0545 1.4068 Fcgr3a 
10771655 chr14 0.0768 0.1955 0.0008 0.0545 1.3923 Cxcl10  
10751793 chr11 0.0683 0.2018 0.0008 0.0545 1.3896 Lrrc15 
10866056 chr4 0.1017 0.1636 0.0009 0.0545 1.3765 Klrc2 
10751988 chr11 0.0663 0.1965 0.0009 0.0545 1.3695 Kng1 
10863051 chr4 0.3506 0.1336 0.0985 0.1635 1.3667 (cDNA) 
10866163 chr4 0.2101 0.1559 0.0195 0.0907 1.3579 Ly49s4 
10866146 chr4 0.0943 0.1651 0.0011 0.0545 1.3533 Ly49s6 
10771660 chr14 0.0548 0.1750 0.0006 0.0545 1.3420 Cxcl9  
10907858 chr8 0.1773 0.1261 0.0099 0.0744 1.3369 Mmp13 
10845784 chr3 0.1343 0.0500 0.0010 0.0545 1.3368 Slc38a11  
10718954 chr1 0.0882 0.1119 0.0003 0.0545 1.3340 Lilrb4 
10747228 chr10 0.1174 0.2353 0.0115 0.0774 1.3305 Krt35 
10863038 chr4 0.4440 0.0623 0.2037 0.2279 1.3292 (cDNA) 
10859164 chr4 0.0974 0.1335 0.0009 0.0545 1.3288 Klrd1 
10821370 chr2 0.1213 0.1373 0.0025 0.0576 1.3258 Gzma 
10772522 chr14 0.0771 0.1459 0.0006 0.0545 1.3246 Gabra4 
10800368 chr18 0.1424 0.2128 0.0141 0.0822 1.3240 Dsg4 
10780175 chr15 0.1324 0.1528 0.0049 0.0615 1.3230 (cDNA) 
10866182 chr4 0.1178 0.0991 0.0012 0.0545 1.3194 (cDNA) 
10752990 chr11 0.1602 0.2268 0.0240 0.0960 1.3179 (cDNA) 
10830267 chr20 0.1715 0.2015 0.0227 0.0937 1.3168 Fam26d 
10747292 chr10 0.1295 0.2870 0.0317 0.1054 1.3159 Krt16 
10745631 chr10 0.0699 0.1673 0.0013 0.0545 1.3151 Ccl5 
10869527 chr5 0.0534 0.1705 0.0010 0.0545 1.3113 (cDNA) 
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Continuation of table 11: 50 highest fold changes in skin expression data. 
Probeset_id Chr. 
Variation 
coefficient 
DEB_skin 
Variation 
coefficient 
Wi_skin 
Significance 
(p.ttest) 
False 
discovery 
rate (q.ttest) 
Fold 
change 
Gene 
10866413 chr4 0.1852 0.1983 0.0296 0.1035 1.3110 Gprc5d 
10907375 chr7 0.1179 0.2083 0.0104 0.0755 1.3101 Krt85 
10716704 chr1 0.1026 0.1539 0.0026 0.0576 1.3097 Samd5 
10866052 chr4 0.0745 0.1572 0.0013 0.0545 1.3055 Klrc3 
 
 
Table 12: 50 lowest fold changes in skin expression data. Highlighted in blue: genes involved in milk 
synthesis. Highlighted in grey: p-values above 0.05. 
Probeset_id Chr. 
Variation 
coefficient 
DEB_skin 
Variation 
coefficient 
Wi_skin 
Significance 
(p.ttest) 
False 
discovery 
rate (q.ttest) 
Fold 
change 
Gene 
10888777 chr6 0.2089 0.3756 0.0174 0.0879 0.5822 cDNA 
10776190 chr14 0.7512 0.3829 0.1025 0.1662 0.5878 Csn1s1 
10827201 chr2 0.3786 0.4038 0.0569 0.1293 0.6184 Clca3 
10776133 chr14 0.6283 0.3590 0.1017 0.1655 0.6247 Csn3 
10776160 chr14 0.4980 0.3886 0.1005 0.1649 0.6470 RGD1310384 
10886994 chr6 0.2225 0.3207 0.0254 0.0979 0.6528 snoRNA 
10886880 chr6 0.2144 0.2858 0.0188 0.0898 0.6639 snoRNA 
10886886 chr6 0.1761 0.3059 0.0206 0.0921 0.6639 --- 
10886870 chr6 0.0928 0.2596 0.0070 0.0681 0.6675 ncRNA 
10887010 chr6 0.2818 0.3982 0.0765 0.1464 0.6709 ncRNA 
10771893 chr14 0.5183 0.3367 0.1181 0.1771 0.6755 Csn2 
10886930 chr6 0.1902 0.2773 0.0191 0.0903 0.6797 ncRNA 
10906857 chr7 0.4845 0.3341 0.1146 0.1747 0.6831 Lalba 
10844331 chr3 0.2578 0.2648 0.0259 0.0987 0.6837 Lcn2 
10886874 chr6 0.1229 0.2447 0.0082 0.0709 0.6845 ncRNA 
10776175 chr14 0.6213 0.4108 0.2060 0.2292 0.6864 Csn1s2a 
10796418 chr17 0.4274 0.3482 0.1073 0.1693 0.6880 Olah 
10886896 chr6 0.1916 0.2898 0.0276 0.1011 0.6916 ncRNA 
10886850 chr6 0.2156 0.2477 0.0195 0.0907 0.6955 ncRNA 
10907749 chr7 0.4727 0.4246 0.1739 0.2107 0.6962 Glycam1 
10886898 chr6 0.2140 0.2971 0.0366 0.1097 0.6975 ncRNA 
10886938 chr6 0.2318 0.2541 0.0268 0.0999 0.7025 ncRNA 
10886856 chr6 0.1652 0.2509 0.0178 0.0883 0.7059 ncRNA 
10886876 chr6 0.2285 0.2470 0.0267 0.0997 0.7084 ncRNA 
10795245 chr17 0.3714 0.3268 0.1263 0.1830 0.7266 Btn1a1 
10887014 chr6 0.0938 0.2671 0.0243 0.0962 0.7286 ncRNA 
10886868 chr6 0.1602 0.2193 0.0170 0.0873 0.7322 ncRNA 
10886862 chr6 0.1615 0.2304 0.0207 0.0925 0.7325 ncRNA 
10886848 chr6 0.1943 0.2312 0.0291 0.1028 0.7372 ncRNA 
10886888 chr6 0.1641 0.2206 0.0209 0.0929 0.7398 ncRNA 
10886890 chr6 0.1128 0.2891 0.0432 0.1168 0.7402 ncRNA 
10887008 chr6 0.1521 0.2951 0.0550 0.1279 0.7424 ncRNA 
10886964 chr6 0.1590 0.2190 0.0211 0.0930 0.7434 ncRNA 
10886986 chr6 0.1644 0.2080 0.0209 0.0929 0.7496 ncRNA 
10887004 chr6 0.1644 0.2080 0.0209 0.0929 0.7496 ncRNA 
10886864 chr6 0.1548 0.2140 0.0221 0.0934 0.7514 ncRNA 
10886884 chr6 0.2162 0.2708 0.0655 0.1366 0.7514 ncRNA 
10781962 chr15 0.1006 0.3074 0.0622 0.1341 0.7522 cDNA 
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Continuation of table 12: 50 lowest fold changes in skin expression data. 
Probeset_id Chr. 
Variation 
coefficient 
DEB_skin 
Variation 
coefficient 
Wi_skin 
Significance 
(p.ttest) 
False 
discovery 
rate (q.ttest) 
Fold 
change 
Gene 
10864711 chr4 0.1006 0.3074 0.0622 0.1341 0.7522 cDNA 
10851577 chr3 0.0805 0.1183 0.0005 0.0545 0.7545 Slpil3 
10886882 chr6 0.1525 0.2092 0.0221 0.0934 0.7561 ncRNA 
10886942 chr6 0.1552 0.2063 0.0221 0.0934 0.7571 ncRNA 
10886902 chr6 0.1549 0.2053 0.0224 0.0934 0.7587 ncRNA 
10886978 chr6 0.1549 0.2053 0.0224 0.0934 0.7587 ncRNA 
10886944 chr6 0.1506 0.2085 0.0228 0.0939 0.7588 ncRNA 
10886974 chr6 0.1882 0.2128 0.0338 0.1072 0.7597 snoRNA 
10886976 chr6 0.1556 0.2026 0.0224 0.0934 0.7606 ncRNA 
10886982 chr6 0.1556 0.2026 0.0224 0.0934 0.7606 ncRNA 
10886998 chr6 0.1556 0.2026 0.0224 0.0934 0.7606 ncRNA 
10886982 chr6 0.1556 0.2026 0.0224 0.0934 0.7606 ncRNA 
 
 
Table 13: Skin expression data in candidate region Chr19:32.986.041..36.535.127 
Highlighted in grey: p-values above 0.05. 
Probeset_id Chr. 
Variation 
coefficient 
DEB_skin 
Variation 
coefficient 
Wi_skin 
Significance 
(p.ttest) 
False 
discovery 
rate (q.ttest) 
Fold 
change 
Gene 
10807083 chr19 0.0618 0.1120 0.0130 0.0801 1.1515 RGD1308358 
10807525 chr19 0.0369 0.0641 0.0014 0.0545 1.1254 Cdh3 
10810556 chr19 0.0426 0.0649 0.0116 0.0776 1.0936 Tradd  
10810727 chr19 0.0392 0.0651 0.0107 0.0757 1.0924 Psmb10 
10810703 chr19 0.0393 0.0511 0.0072 0.0685 1.0856 Cenpt 
10807071 chr19 0.0467 0.0515 0.0173 0.0878 1.0793 RGD1308358 
10807464 chr19 0.0508 0.0313 0.0135 0.0807 1.0743 Pla2g15 
10810795 chr19 0.0340 0.0616 0.0394 0.1132 1.0642 Rbm35b 
10810717 chr19 0.0382 0.0433 0.0198 0.0907 1.0634 cDNA 
10807272 chr19 0.0549 0.0390 0.1044 0.1673 1.0493 Hsd11b2 
10807177 chr19 0.0266 0.0190 0.0044 0.0604 1.0482 cDNA 
10807542 chr19 0.0348 0.0642 0.1363 0.1891 1.0455 Cdh1 
10807131 chr19 0.0233 0.0277 0.0314 0.1051 1.0354 Cbfb 
10810689 chr19 0.0333 0.0220 0.0625 0.1343 1.0339 Ranbp10 
10807085 chr19 0.0257 0.0229 0.0342 0.1077 1.0336 LOC498940 
10807188 chr19 0.0401 0.0340 0.1784 0.2136 1.0305 Elmo3 
10807473 chr19 0.0379 0.0281 0.1771 0.2127 1.0276 Slc7a6 
10810811 chr19 0.0246 0.0161 0.0448 0.1186 1.0272 Slc7a6os 
10807211 chr19 0.0343 0.0213 0.1416 0.1917 1.0262 Tmem208 
10807384 chr19 0.0350 0.0222 0.1664 0.2065 1.0251 Thap11 
10807114 chr19 0.0566 0.1831 0.7426 0.4531 1.0245 RGD1307418 
10810614 chr19 0.0113 0.0427 0.2478 0.2517 1.0204 Kctd19 
10810649 chr19 0.0103 0.0119 0.0075 0.0691 1.0203 Atp6vod1 
10810662 chr19 0.0220 0.0192 0.1191 0.1777 1.0198 Acd 
10807391 chr19 0.0251 0.0141 0.1372 0.1896 1.0189 Edc4 
10810791 chr19 0.0295 0.0187 0.2123 0.2329 1.0188 Ddx28 
10807504 chr19 0.0426 0.0247 0.4444 0.3443 1.0159 Zfp90 
10807140 chr19 0.0244 0.0132 0.1923 0.2220 1.0157 RGD621098 
10810553 chr19 0.0313 0.0508 0.5212 0.3749 1.0153 B3gnt9 
10810685 chr19 0.0380 0.0416 0.5218 0.3752 1.0147 Gfod2 
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Continuation of table 13: Skin expression data in candidate region Chr19:32.986.041..36.535.127 
Probeset_id Chr. 
Variation 
coefficient 
DEB_skin 
Variation 
coefficient 
Wi_skin 
Significance 
(p.ttest) 
False 
discovery 
rate (q.ttest) 
Fold 
change 
Gene 
10810778 chr19 0.0609 0.0398 0.6412 0.4194 1.0141 Dpep2 
10807300 chr19 0.0128 0.0187 0.1995 0.2259 1.0120 Ctcf 
10807560 chr19 0.0277 0.0228 0.4938 0.3639 1.0101 RGD1559841 
10807435 chr19 0.0098 0.0049 0.0585 0.1310 1.0094 Dus2l 
10807311 chr19 0.0283 0.0207 0.5695 0.3935 1.0082 RGD1562390 
10807157 chr19 0.0267 0.0167 0.5917 0.4021 1.0070 Fbxl8 
10810585 chr19 0.0456 0.0358 0.7866 0.4671 1.0064 LOC502201 
10810743 chr19 0.0363 0.0181 0.8108 0.4737 1.0040 Slc12a4 
10807514 chr19 0.0195 0.0061 0.6939 0.4374 1.0034 Rps12 
10807452 chr19 0.0233 0.0134 0.8339 0.4804 1.0023 Nfatc3 
10807098 chr19 0.0310 0.0186 0.9738 0.5184 1.0005 LOC689754 
10810549 chr19 0.0195 0.0677 0.9128 0.5027 0.9970 RGD1564421 
10810562 chr19 0.0201 0.0302 0.8002 0.4709 0.9964 MGC116202 
10807353 chr19 0.0198 0.0410 0.7786 0.4649 0.9950 Pard6a 
10810570 chr19 0.0214 0.0037 0.4730 0.3560 0.9934 Exoc3l 
10807386 chr19 0.0133 0.0236 0.4938 0.3639 0.9927 Nutf2 
10807484 chr19 0.0317 0.0157 0.6104 0.4090 0.9925 Prmt7 
10807430 chr19 0.0256 0.0188 0.5490 0.3857 0.9922 Pskh1 
10807235 chr19 0.0295 0.0425 0.6734 0.4313 0.9914 Plekhg4 
10810677 chr19 0.0164 0.0279 0.4602 0.3506 0.9905 RGD1307357 
10810631 chr19 0.0344 0.0517 0.6639 0.4278 0.9893 Tppp3 
10810736 chr19 0.0524 0.0287 0.5981 0.4044 0.9871 Lcat 
10807367 chr19 0.0772 0.0555 0.7154 0.4442 0.9859 Tsnaxip1 
10807517 chr19 0.0359 0.0190 0.3020 0.2798 0.9825 cDNA 
10810768 chr19 0.0399 0.0517 0.4375 0.3414 0.9797 Dpep3 
10810817 chr19 0.0631 0.0586 0.5477 0.3853 0.9792 Smpd3 
10810635 chr19 0.0229 0.0247 0.1025 0.1662 0.9768 Zdhhc1 
10807278 chr19 0.0217 0.0201 0.0483 0.1221 0.9744 Fam65a 
10810828 chr19 0.0189 0.0435 0.1667 0.2065 0.9733 cDNA 
10810551 chr19 0.0335 0.0176 0.0799 0.1490 0.9712 Slc25a36 
10810719 chr19 0.0194 0.0223 0.0161 0.0861 0.9677 Ctrl 
10807360 chr19 0.0305 0.0422 0.1066 0.1688 0.9650 RGD1561415 
10810583 chr19 0.0263 0.0327 0.0401 0.1139 0.9626 rno-mir-328 
10807217 chr19 0.0443 0.0537 0.1818 0.2158 0.9619 Slc9a5 
10807256 chr19 0.0453 0.0358 0.1127 0.1732 0.9614 Lrrc36 
10810658 chr19 0.0417 0.0426 0.0920 0.1586 0.9577 Agrp 
10807160 chr19 0.0395 0.0574 0.0966 0.1621 0.9519 Hsf4 
10807068 chr19 0.0470 0.0599 0.0802 0.1493 0.9442 LOC688462 
10810591 chr19 0.0201 0.0410 0.0076 0.0691 0.9439 Fhod1 
10807520 chr19 0.0281 0.0306 0.0033 0.0581 0.9411 --- 
10810793 chr19 0.0303 0.0958 0.1033 0.1665 0.9329 ncRNA 
10807174 chr19 0.0593 0.0441 0.0250 0.0973 0.9274 Nol3 
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Table 14: 50 highest and lowest heart expression fold changes. Highlighted in mauve: genes affecting the 
immune system. Highlighted in grey: p-values above 0.05. 
50 highest fold changes heart expression 50 lowest fold changes heart expression 
Probeset_id Chr. 
Fold 
change 
Significance 
(p.ttest) 
Gene Probeset_id Chr. 
Fold 
change 
Significance 
(p.ttest) 
Gene 
10817071 chr2 1.4408 0.3317 S100a8 10776519 chr14 0.8528 0.1476 Spata18 
10907913 chr8 1.4389 0.3050 Mmp8 10771893 chr14 0.8520 0.3964 Csn2 
10824695 chr2 1.4380 0.2881 S100a9 10766910 chr13 0.8500 0.0607 --- 
10924245 chr9 1.4226 0.1983 Il8rb 10805092 chr18 0.8485 0.0194 LOC680077 
10751434 chr11 1.3773 0.0062 Stfa2l3 10752266 chr11 0.8478 0.0519 --- 
10863410 chr4 1.3772 0.3713 Reg3g 10748193 chr10 0.8472 0.2079 --- 
10702716 chr1 1.3658 0.0042 --- 10856082 chr4 0.8462 0.0043 --- 
10915103 chr8 1.3658 0.0042 --- 10939791 chrX 0.8459 0.0557 --- 
10902859 chr7 1.3419 0.0623 --- 10854417 chr4 0.8452 0.0049 Akr1b10 
10749818 chr11 1.3245 0.0334 --- 10820494 chr2 0.8448 0.0356 Bhmt 
10791602 chr16 1.3210 0.0548 --- 10817331 chr2 0.8428 0.0031 Tmod4 
10833416 chr20 1.3210 0.0548 --- 10791552 chr16 0.8414 0.0281   
10881659 chr5 1.3171 0.0115 Cort 10862978 chr4 0.8403 0.0305 --- 
10746588 chr10 1.3095 0.0083 Calcoco2 10824742 chr2 0.8392 0.4894 Smcp 
10869527 chr5 1.2930 0.0149 --- 10726346 chr1 0.8392 0.0001 Uros 
10718954 chr1 1.2804 0.2035 Lilrb4 10846740 chr3 0.8384 0.0006 Frzb 
10746914 chr10 1.2756 0.3849 --- 10883595 chr6 0.8377 0.2587 Nt5c1b 
10794866 chr17 1.2722 0.3614 Serpinb1a 10931678 chrUn 0.8371 0.0128 Sctr 
10858599 chr4 1.2699 0.1751 Clec4d 10928337 chr9 0.8368 0.3310 Als2cr11 
10850208 chr3 1.2685 0.0532 Pak7 10778247 chr14 0.8360 0.0004 Myl7 
10886210 chr6 1.2651 0.2391 --- 10859162 chr4 0.8357 0.0187 Lkre1 
10852682 chr4 1.2632 0.2108 --- 10920741 chr8 0.8342 0.1345 --- 
10856474 chr4 1.2588 0.4847 Reg3b 10892493 chr6 0.8339 0.1040 --- 
10842660 chr3 1.2586 0.0297 --- 10909307 chr8 0.8321 0.0379 --- 
10866195 chr4 1.2566 0.1301 --- 10751988 chr11 0.8308 0.0603 Kng1 
10842663 chr3 1.2565 0.0079 --- 10871413 chr5 0.8239 0.1231 --- 
10831099 chr20 1.2534 0.0019 RT1-CE5 10910047 chr8 0.8223 0.0001 Sln 
10806198 chr19 1.2511 0.0215 LOC679726 10779790 chr15 0.8192 0.2102 Olr1627 
10765195 chr13 1.2487 0.2693 Selp 10888777 chr6 0.8181 0.2964 --- 
10750624 chr11 1.2485 0.2391 Olr1541 10903290 chr7 0.8123 0.2964 RGD1565493 
10762254 chr12 1.2470 0.1255 Oas1k 10922027 chr9 0.8116 0.4417 Crisp2 
10718944 chr1 1.2460 0.0366 Kir3dl1 10704115 chr1 0.8113 0.1381 --- 
10733849 chr10 1.2455 0.2749 LOC24906 10857541 chr4 0.8071 0.0251 Lrrn1 
10781630 chr15 1.2433 0.0727 --- 10740496 chr10 0.8070 0.0207 LOC497860 
10839307 chr3 1.2420 0.0857 MGC105649 10903292 chr7 0.8060 0.2436 RGD1565493 
10939699 chrX 1.2411 0.0804 --- 10746040 chr10 0.8051 0.0078 --- 
10740331 chr10 1.2409 0.0196 --- 10771002 chr14 0.7978 0.2849 --- 
10886870 chr6 1.2395 0.2121 --- 10937179 chrX 0.7974 0.2217 Akap4 
10722481 chr1 1.2384 0.0402 --- 10891491 chr6 0.7956 0.0587 --- 
10712090 chr1 1.2369 0.1396 Cyp2e1 10776190 chr14 0.7925 0.1949 Csn1s1 
10722451 chr1 1.2358 0.0681 --- 10889213 chr6 0.7862 0.0037 Vsnl1 
10847174 chr3 1.2343 0.0432 Olr687 10823819 chr2 0.7835 0.0054 Rxfp1 
10710338 chr1 1.2322 0.0343 --- 10866576 chr4 0.7833 0.0419 RGD1561357 
10837604 chr3 1.2310 0.1789 Olr648 10829888 chr20 0.7776 0.0065 Pbld 
10847076 chr3 1.2293 0.0015 Olr587 10830962 chr20 0.7503 0.1569 --- 
10722419 chr1 1.2267 0.0017 --- 10875983 chr5 0.7503 0.1569 --- 
10806012 chr19 1.2263 0.0081 --- 10727806 chr1 0.7390 0.1833 --- 
10847156 chr3 1.2252 0.0185 Olr673 10775968 chr14 0.7167 0.0275 Alb 
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Continuation of table 14: 50 highest and lowest heart expression fold changes 
50 highest fold changes heart expression 50 lowest fold changes heart expression 
Probeset_id Chr. 
Fold 
change 
Significance 
(p.ttest) 
Gene Probeset_id Chr. 
Fold 
change 
Significance 
(p.ttest) 
Gene 
10913664 chr8 1.2246 0.4211 Ngp 10714106 chr1 0.6784 2.88E-05 Fam111a 
10924441 chr9 1.2244 1.50E-06 --- 10765850 chr13 0.6622 0.0058 Spta1 
 
 
Table 15: Heart expression data in candidate region Chr19:32.986.041..36.535.127 
Highlighted in grey: p-values above 0.05. 
Probeset_id Chr. 
Fold 
change 
Significance 
(p.ttest) 
Gene Probeset_id Chr. 
Fold 
change 
Significance 
(p.ttest) 
Gene 
10810717 chr19 1.1527 0.1492 --- 10807360 chr19 0.9915 0.6995 RGD1561415  
10807083 chr19 1.1280 0.1796 RGD1308358 10810743 chr19 0.9914 0.2880 Slc12a4 
10807071 chr19 1.1228 0.0302 RGD1308358 10807140 chr19 0.9903 0.2717 RGD621098 
10807367 chr19 1.0632 0.2684 Tsnaxip1 10807235 chr19 0.9881 0.4494 Plekhg4 
10810727 chr19 1.0481 0.0229 Psmb10 10807174 chr19 0.9881 0.2541 Nol3 
10810556 chr19 1.0389 0.2052 Tradd 10810631 chr19 0.9875 0.1511 Tppp3 
10810793 chr19 1.0313 0.4296 --- 10807256 chr19 0.9872 0.3512 Lrrc36  
10807217 chr19 1.0228 0.5513 Slc9a5 10810562 chr19 0.9866 0.5300 MGC116202 
10807514 chr19 1.0193 0.4253 Rps12 10807160 chr19 0.9864 0.6175 Hsf4  
10810553 chr19 1.0187 0.0955 B3gnt9  10810551 chr19 0.9859 0.1064 Slc25a36 
10810689 chr19 1.0179 0.4510 Ranbp10  10807177 chr19 0.9843 0.4683 --- 
10807157 chr19 1.0167 0.6522 Fbxl8 10807386 chr19 0.9843 0.1052 Nutf2 
10810549 chr19 1.0149 0.4196 RGD1564421 10807384 chr19 0.9836 0.2061 Thap11 
10807473 chr19 1.0134 0.5511 Slc7a6 10810791 chr19 0.9805 0.0311 Ddx28 
10807278 chr19 1.0105 0.3806 Fam65a 10807560 chr19 0.9792 0.4784 RGD1559841 
10807300 chr19 1.0095 0.4916 Ctcf 10807452 chr19 0.9784 0.1016  Nfatc3  
10810658 chr19 1.0083 0.7791 Agrp  10810635 chr19 0.9778 0.1256 Zdhhc1 
10807430 chr19 1.0073 0.5682 Pskh1  10807068 chr19 0.9775 0.1180 LOC688462 
10810817 chr19 1.0072 0.8192 Smpd3 10810591 chr19 0.9774 0.2730 Fhod1  
10810736 chr19 1.0052 0.8365 Lcat 10810570 chr19 0.9763 0.0455 Exoc3l 
10807211 chr19 1.0044 0.8856 Tmem208 10810778 chr19 0.9746 0.6598 Dpep2  
10807391 chr19 1.0038 0.7839 Edc4  10807272 chr19 0.9737 0.1760 Hsd11b2 
10807517 chr19 1.0031 0.9305 --- 10810677 chr19 0.9713 0.0493 RGD1307357 
10807435 chr19 1.0028 0.8198 Dus2l 10810585 chr19 0.9699 0.1527 LOC502201 
10807504 chr19 1.0013 0.9446 Zfp90 10807464 chr19 0.9697 0.1027 Pla2g15  
10807188 chr19 1.0012 0.9601 Elmo3 10807525 chr19 0.9677 0.2132 Cdh3 
10810703 chr19 0.9999 0.9971 Cenpt 10810583 chr19 0.9649 0.0864 --- 
10807520 chr19 0.9997 0.9952 --- 10810768 chr19 0.9642 0.3571 Dpep3 
10807098 chr19 0.9996 0.9899 LOC689754 10807311 chr19 0.9629 0.2362 RGD1562390 
10810811 chr19 0.9991 0.9597 Slc7a6os 10810685 chr19 0.9627 0.2349  Gfod2 
10807484 chr19 0.9988 0.9389 Prmt7 10810614 chr19 0.9590 0.2527 Kctd19 
10810828 chr19 0.9986 0.9712 --- 10810795 chr19 0.9563 0.5894 Rbm35b 
10807085 chr19 0.9973 0.9639 LOC498940 10810719 chr19 0.9489 0.1100 Ctrl  
10807131 chr19 0.9971 0.7111 Cbfb  10807353 chr19 0.9476 0.1217 Pard6a  
10810662 chr19 0.9920 0.5247 Acd 10807542 chr19 0.9175 0.1636 Cdh1 
10810649 chr19 0.9917 0.2527 Atp6v0d1 10807114 chr19 0.9160 0.1045 RGD1307418 
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3. Detailed Association and Linkage Analysis Data from Human Samples 
 
Table 17: P-values for each SNP in a case control analysis using PLINK. 
P value für dominant and recessive model p_DOM/p_REC; data not available NA 
SNP_ID     CHR POSITION p_DOM   p_REC    SNP_ID     CHR POSITION p_DOM   p_REC    
rs541169   19 40410860 0.3356 0.7556 rs1035441  19 42045631 0.6142 0.9720 
rs12975589 19 40531570 0.5540 0.4095 rs10403306 19 42067119 0.0253 0.2697 
rs8107905  19 40613537 0.4379 0.7058 rs543518   19 42078051 NA      NA       
rs409093   19 40633088 NA      NA       rs7250197  19 42081310 0.4812 0.7589 
rs926026   19 40659264 NA      NA       rs547483   19 42133205 0.1061 0.3142 
rs11880530 19 40660984 0.8735 0.9267 rs496730   19 42143279 0.8797 0.0155 
rs8102875  19 40661629 0.1739 0.6505 rs569371   19 42145837 0.9071 0.1510 
rs6510490  19 40669149 NA      NA       rs565721   19 42147671 0.8728 0.0090 
rs7976     19 40670139 0.5842 0.5134 rs7251087  19 42147743 0.8912 0.0081 
rs10407971 19 40671304 0.1213 0.8614 rs7254717  19 42149242 0.4328 0.7871 
rs11880364 19 40680634 NA      NA       rs472226   19 42150553 NA      NA       
rs4254439  19 40690202 0.2143 0.9764 rs17639910 19 42158969 0.7965 0.0145 
rs7254211  19 40695561 0.1599 0.6284 rs1667354  19 42173991 0.3162 0.7904 
rs4806163  19 40695946 0.5348 0.2055 rs8102196  19 42274044 0.9165 0.2701 
rs17705633 19 40707492 0.1021 0.9691 rs1533736  19 42346816 NA      NA       
rs12151182 19 40715572 NA      NA       rs11084878 19 42362309 0.5133 0.2386 
rs17705657 19 40716582 0.2988 0.4396 rs12459637 19 42381838 0.1096 0.4842 
rs2239945  19 40725300 0.2876 0.7732 rs320890   19 42395940 0.0373 0.3394 
rs7599     19 40730230 0.4468 0.9720 rs172786   19 42404824 0.5329 0.8808 
rs2301617  19 40734047 0.3895 0.4269 rs2460950  19 42445079 0.9559 0.4283 
rs17776451 19 40736289 0.5538 0.8358 rs1530500  19 42515651 NA      NA       
rs2733743  19 40742809 NA      NA       rs3745765  19 42546075 0.7150 0.8805 
rs2285421  19 40860754 NA      NA       rs10422527 19 42586308 NA      NA       
rs437168   19 41026259 0.4475 0.6890 rs12461941 19 42676490 0.7754 0.3080 
rs2285424  19 41191013 NA      NA       rs12977460 19 42716111 0.0465 0.8221 
rs1008328  19 41287276 0.5126 0.9692 rs10500277 19 42749242 0.0532 0.7884 
rs3108186  19 41876810 0.3459 0.8828 rs4803277  19 42764767 NA      NA       
rs1830031  19 41895089 0.7945 0.8119 rs2927743  19 42824174 NA      NA       
rs1673082  19 41932981 0.7648 0.8982 rs35153242 19 42843582 0.1866 0.8623 
rs1227820  19 41949357 NA      NA       rs2909109  19 42861195 0.0451 0.1280 
rs2245366  19 41956174 0.2460 0.4044 rs17246792 19 42876102 NA      NA       
rs8107274  19 41977233 0.4435 0.5899 rs1469698  19 43685396 0.2460 0.3390 
rs1148399  19 42021145 0.0119 0.1706 rs8103362  19 44452031 NA      NA       
rs1144540  19 42022453 0.2368 0.4015   
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 Table 18: P-values for each SNP in a TDT analysis using PLINK. 
CHR SNP Position P-Value CHR SNP Position P-Value 
19 rs11672876 34923945 0.2087 19 rs1144540 42022453 0.4579 
19 rs541169 40410860 0.5583 19 rs1035441 42045631 0.9387 
19 rs12975589 40531570 0.5715 19 rs10403306 42067119 0.5472 
19 rs8107905 40613537 0.6473 19 rs543518 42078051 0.1003 
19 rs409093 40633088 0.4658 19 rs7250197 42081310 0.9183 
19 rs926026 40659264 0.6494 19 rs547483 42133205 0.5108 
19 rs11880530 40660984 0.3008 19 rs496730 42143279 0.6144 
19 rs8102875 40661629 0.0660 19 rs569371 42145837 0.9368 
19 rs6510490 40669149 0.9379 19 rs565721 42147671 0.8131 
19 rs7976 40670139 0.7216 19 rs7251087 42147743 0.5637 
19 rs10407971 40671304 0.8575 19 rs7254717 42149242 0.0955 
19 rs11880364 40680634 0.8597 19 rs472226 42150553 0.9376 
19 rs4254439 40690202 0.6737 19 rs17639910 42158969 0.1530 
19 rs7254211 40695561 0.5076 19 rs1667354 42173991 1.0000 
19 rs4806163 40695946 0.7216 19 rs8102196 42274044 0.8864 
19 rs17705633 40707492 0.5445 19 rs1533736 42346816 0.5469 
19 rs12151182 40715572 0.8551 19 rs11084878 42362309 0.7371 
19 rs17705657 40716582 0.9270 19 rs12459637 42381838 1.0000 
19 rs2239945 40725300 0.2752 19 rs320890 42395940 0.5900 
19 rs7599 40730230 0.9334 19 rs172786 42404824 0.9376 
19 rs2301617 40734047 0.4726 19 rs2460950 42445079 0.2273 
19 rs17776451 40736289 1.0000 19 rs1530500 42515651 0.8460 
19 rs2733743 40742809 0.7098 19 rs3745765 42546075 0.6799 
19 rs2285421 40860754 0.3202 19 rs10422527 42586308 0.2170 
19 rs437168 41026259 0.6949 19 rs12461941 42676490 0.3843 
19 rs2285424 41191013 0.0955 19 rs12977460 42716111 0.8981 
19 rs1008328 41287276 0.1508 19 rs10500277 42749242 0.7518 
19 rs3108186 41876810 0.8774 19 rs4803277 42764767 1.0000 
19 rs1830031 41895089 0.6394 19 rs2927743 42824174 0.4083 
19 rs1673082 41932981 0.2643 19 rs35153242 42843582 0.7389 
19 rs1227820 41949357 0.5839 19 rs2909109 42861195 0.2636 
19 rs2245366 41956174 0.8608 19 rs17246792 42876102 0.9404 
19 rs8107274 41977233 0.8501 19 rs1469698 43685396 0.0294 
19 rs1148399 42021145 1.0000 19 rs8103362 44452031 0.7216 
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Table 19: HLOD and npLOD values for each SNP in an ASP linkage analysis using MERLIN. 
Positions in Build36.3. Highest LOD scores exceeding significance threshold of 2.6 highlighted in red. 
SNP_ID CHR POSITION HLOD npLOD SNP_ID CHR POSITION HLOD npLOD 
rs11672876 19 34923945 0.652 0.570 rs1144540 19 42022453 2.584 3.100 
rs541169 19 40410860 1.488 1.480 rs1035441 19 42045631 2.587 3.100 
rs12975589 19 40531570 1.765 1.680 rs10403306 19 42067119 2.649 3.160 
rs8107905 19 40613537 1.762 1.680 rs543518 19 42078051 2.839 3.390 
rs409093 19 40633088 1.762 1.680 rs7250197 19 42081310 2.847 3.400 
rs926026 19 40659264 1.762 1.680 rs547483 19 42133205 2.953 3.500 
rs11880530 19 40660984 1.762 1.680 rs496730 19 42143279 2.971 3.510 
rs8102875 19 40661629 1.762 1.680 rs569371 19 42145837 2.884 3.400 
rs6510490 19 40669149 1.762 1.680 rs565721 19 42147671 2.810 3.430 
rs7976 19 40670139 1.762 1.680 rs7251087 19 42147743 2.807 3.420 
rs10407971 19 40671304 1.790 1.710 rs7254717 19 42149242 2.807 3.420 
rs11880364 19 40680634 1.971 1.950 rs472226 19 42150553 2.807 3.420 
rs4254439 19 40690202 2.006 1.990 rs17639910 19 42158969 2.808 3.430 
rs7254211 19 40695561 2.025 2.010 rs1667354 19 42173991 2.810 3.430 
rs4806163 19 40695946 2.027 2.010 rs8102196 19 42274044 2.670 3.280 
rs17705633 19 40707492 2.067 2.050 rs1533736 19 42346816 2.547 3.120 
rs12151182 19 40715572 1.878 1.790 rs11084878 19 42362309 2.724 3.270 
rs17705657 19 40716582 1.881 1.800 rs12459637 19 42381838 2.714 3.250 
rs2239945 19 40725300 1.924 1.850 rs320890 19 42395940 2.705 3.230 
rs7599 19 40730230 1.935 1.860 rs172786 19 42404824 2.695 3.220 
rs2301617 19 40734047 1.943 1.870 rs2460950 19 42445079 2.650 3.140 
rs17776451 19 40736289 1.948 1.880 rs1530500 19 42515651 2.562 3.000 
rs2733743 19 40742809 1.961 1.890 rs3745765 19 42546075 2.408 2.810 
rs2285421 19 40860754 2.225 2.170 rs10422527 19 42586308 2.180 2.560 
rs437168 19 41026259 2.360 2.340 rs12461941 19 42676490 1.995 2.240 
rs2285424 19 41191013 2.482 2.540 rs12977460 19 42716111 1.947 2.140 
rs1008328 19 41287276 2.542 2.650 rs10500277 19 42749242 1.902 2.050 
rs3108186 19 41876810 2.812 3.120 rs4803277 19 42764767 1.880 2.010 
rs1830031 19 41895089 2.886 3.240 rs2927743 19 42824174 1.786 1.810 
rs1673082 19 41932981 2.373 2.840 rs35153242 19 42843582 1.770 1.790 
rs1227820 19 41949357 2.415 2.860 rs2909109 19 42861195 1.978 2.080 
rs2245366 19 41956174 2.416 2.870 rs17246792 19 42876102 1.972 2.070 
rs8107274 19 41977233 2.418 2.870 rs1469698 19 43685396 1.349 1.450 
rs1148399 19 42021145 2.424 2.890 rs8103362 19 44452031 1.122 1.140 
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Table 20: HLOD and npLOD values for each SNP in a family based linkage analysis using MERLIN. 
Positions in Build36.3. Highest LOD scores exceeding significance threshold of 3.6 highlighted in red. 
SNP_ID CHR POSITION HLOD npLOD SNP_ID CHR POSITION HLOD npLOD 
rs11672876 19 34923945 1.939 1.430 rs1144540 19 42022453 3.798 3.980 
rs541169 19 40410860 2.846 2.570 rs1035441 19 42045631 3.915 4.170 
rs12975589 19 40531570 3.252 2.870 rs10403306 19 42067119 4.019 4.310 
rs8107905 19 40613537 3.333 2.930 rs543518 19 42078051 4.207 4.550 
rs409093 19 40633088 3.352 2.940 rs7250197 19 42081310 4.220 4.570 
rs926026 19 40659264 3.377 2.960 rs547483 19 42133205 4.357 4.730 
rs11880530 19 40660984 3.379 2.960 rs496730 19 42143279 4.374 4.740 
rs8102875 19 40661629 3.379 2.960 rs569371 19 42145837 4.298 4.650 
rs6510490 19 40669149 3.386 2.970 rs565721 19 42147671 4.234 4.670 
rs7976 19 40670139 3.386 2.970 rs7251087 19 42147743 4.231 4.670 
rs10407971 19 40671304 3.410 3.000 rs7254717 19 42149242 4.231 4.670 
rs11880364 19 40680634 3.571 3.210 rs472226 19 42150553 4.231 4.670 
rs4254439 19 40690202 3.570 3.220 rs17639910 19 42158969 4.228 4.660 
rs7254211 19 40695561 3.571 3.230 rs1667354 19 42173991 4.222 4.650 
rs4806163 19 40695946 3.572 3.230 rs8102196 19 42274044 3.967 4.370 
rs17705633 19 40707492 3.592 3.280 rs1533736 19 42346816 3.726 4.090 
rs12151182 19 40715572 3.123 3.010 rs11084878 19 42362309 3.837 4.160 
rs17705657 19 40716582 3.122 3.020 rs12459637 19 42381838 3.831 4.140 
rs2239945 19 40725300 3.044 2.960 rs320890 19 42395940 3.826 4.130 
rs7599 19 40730230 2.993 2.910 rs172786 19 42404824 3.817 4.110 
rs2301617 19 40734047 2.961 2.890 rs2460950 19 42445079 3.889 4.170 
rs17776451 19 40736289 2.936 2.880 rs1530500 19 42515651 3.950 4.190 
rs2733743 19 40742809 2.852 2.830 rs3745765 19 42546075 3.809 4.040 
rs2285421 19 40860754 2.932 2.990 rs10422527 19 42586308 3.614 3.850 
rs437168 19 41026259 3.024 3.040 rs12461941 19 42676490 3.438 3.600 
rs2285424 19 41191013 3.166 3.170 rs12977460 19 42716111 3.386 3.530 
rs1008328 19 41287276 3.244 3.240 rs10500277 19 42749242 3.336 3.460 
rs3108186 19 41876810 3.719 3.640 rs4803277 19 42764767 3.310 3.430 
rs1830031 19 41895089 3.739 3.730 rs2927743 19 42824174 3.190 3.280 
rs1673082 19 41932981 3.274 3.400 rs35153242 19 42843582 3.144 3.250 
rs1227820 19 41949357 3.289 3.410 rs2909109 19 42861195 3.148 3.370 
rs2245366 19 41956174 3.291 3.410 rs17246792 19 42876102 3.140 3.360 
rs8107274 19 41977233 3.397 3.480 rs1469698 19 43685396 2.270 2.300 
rs1148399 19 42021145 3.657 3.800 rs8103362 19 44452031 1.891 1.820 
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Table 22: P-values for clustered SNPs in a case control analysis with a dominant model using PLINK for 
chr 5 only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  P - VALUE 
rs10512779 5 5334408 2.34E-05 
rs6555346  5 5351102 1.19E-05 
rs6555347  5 5351142 1.13E-05 
rs6555348  5 5351767 1.36E-05 
rs7720820  5 5352206 5.55E-06 
rs6555349  5 5352686 0.002773 
rs6555350  5 5352740 1.36E-05 
rs11134108 5 5353735 1.77E-05 
rs4473739  5 5361229 3.71E-05 
 
 
Table 23: P-values for clustered SNPs in a case control analysis with a dominant model using PLINK for 
chr 5 only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  P - VALUE SNP_ID     CHR POSITION  P - VALUE 
rs6596007  5 130616449 5.89E-06 rs3776007  5 130902984 3.38E-06 
rs6890410  5 130622646 2.84E-05 rs250888   5 131043245 2.25E-05 
rs3756295  5 130720739 0.002284 rs251015   5 131057582 9.46E-06 
rs798413   5 130724485 1.00E-05 rs251012   5 131058194 9.69E-06 
rs27421    5 130771670 8.76E-07 rs32115    5 131079227 3.29E-06 
rs6596024  5 130797684 2.95E-06 rs548635   5 131083445 1.24E-05 
rs1422081  5 130803952 1.65E-06 rs4705894  5 131107187 1.44E-06 
rs3776030  5 130804637 2.11E-06 rs11242095 5 131180474 2.23E-05 
rs10463887 5 130804753 1.70E-06 rs2896961  5 131192905 2.25E-06 
rs31239    5 130841276 6.17E-06 rs1875176  5 131230356 1.49E-05 
rs40400    5 130859264 6.78E-05 rs10045303 5 131230700 1.24E-05 
rs10067982 5 130863839 1.38E-06 rs13174462 5 131245887 5.10E-06 
rs13163091 5 130863940 1.88E-06 rs12653237 5 131269677 6.18E-06 
rs4705890  5 130882899 7.91E-06 
     
 
Table 24: P-values for clustered SNPs in a case control analysis with a dominant model using PLINK for 
chr 6 only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  P - VALUE 
rs1233367  6 29730199 0.002285 
rs29228    6 29731718 4.87E-06 
rs3129063  6 29753592 0.0001571 
rs387642   6 29753613 0.006505 
rs3129045  6 29760555 0.036 
rs3129046  6 29778631 7.19E-05 
rs1610742  6 29785931 6.50E-05 
rs2523405  6 29803284 0.06543 
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Table 25: P-values for clustered SNPs in a case control analysis with a dominant model using PLINK for 
chr 6 only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  P - VALUE 
rs3135363  6 32497626 0.0006048 
rs3129847  6 32504484 1.59E-06 
rs3135342  6 32504593 3.60E-07 
rs5000563  6 32512113 6.68E-07 
rs3129872  6 32515131 9.08E-07 
rs3129877  6 32516575 9.72E-08 
rs7194     6 32520458 0.0007573 
rs9268856  6 32537697 4.34E-09 
rs9268877  6 32539125 0.007743 
rs615672   6 32682149 0.004358 
rs41269947 6 32716055 0.01457 
rs9469220  6 32766288 5.54E-08 
rs6457617  6 32771829 5.07E-06 
rs3892710  6 32790840 1.16E-04 
 
 
Table 26: P-values for clustered SNPs in a case control analysis with a dominant model using PLINK for 
chr 6 only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  P - VALUE 
rs6557200  6 150314225 0.04341 
rs5017316  6 150375182 3.14E-07 
rs9479403  6 150379439 2.10E-07 
rs494825   6 150395716 0.001051 
rs3860823  6 150398219 1.39E-06 
rs2181923  6 150403682 2.90E-05 
 
 
Table 27: P-values for clustered SNPs in a case control analysis with a dominant model using PLINK for 
chr 16 only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  P - VALUE 
rs6498146  16 11014208 0.005808 
rs3893660  16 11101431 7.40E-07 
rs9941107  16 11103542 2.65E-07 
rs17806299 16 11107481 0.0004071 
rs7198004  16 11115118 1.93E-06 
rs7203150  16 11115223 9.41E-08 
rs9746695  16 11115395 0.005313 
 
 
  
148 
 
Table 28: P-values for clustered SNPs in a case control analysis with a trend model using PLINK for chr 5 
only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  p_TREND   
rs2913657  5 5316152 0.03871 
rs10512779 5 5334408 1.31E-06 
rs6555342  5 5346260 0.08207 
rs6555346  5 5351102 2.61E-06 
rs6555347  5 5351142 2.63E-06 
rs6555348  5 5351767 3.16E-06 
rs7720820  5 5352206 1.81E-07 
rs6555349  5 5352686 0.000316 
rs6555350  5 5352740 3.42E-06 
rs11134108 5 5353735 3.77E-06 
rs4473739  5 5361229 2.77E-05 
 
 
Table 29: P-values for clustered SNPs in a case control analysis with a trend model using PLINK for chr 5 
only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  p_TREND   SNP_ID     CHR POSITION  p_TREND   
rs17165964 5 130557021 0.003323 rs251012   5 131058194 4.02E-06 
rs6596007  5 130616449 5.66E-06 rs32115    5 131079227 2.31E-06 
rs6890410  5 130622646 1.30E-05 rs548635   5 131083445 4.84E-06 
rs3756295  5 130720739 0.0004998 rs4705894  5 131107187 1.37E-06 
rs798413   5 130724485 4.17E-06 rs11242095 5 131180474 6.59E-06 
rs27421    5 130771670 2.55E-06 rs2896961  5 131192905 4.59E-06 
rs6596024  5 130797684 1.77E-06 rs1875176  5 131230356 6.26E-06 
rs1422081  5 130803952 4.93E-06 rs10045303 5 131230700 5.23E-06 
rs3776030  5 130804637 6.70E-06 rs13174462 5 131245887 2.14E-06 
rs10463887 5 130804753 5.50E-06 rs12653237 5 131269677 2.94E-06 
rs31239    5 130841276 3.31E-06 rs667437   5 131303408 1.21E-05 
rs40400    5 130859264 9.50E-05 rs667419   5 131309963 7.79E-06 
rs10067982 5 130863839 4.14E-06 rs477086   5 131312509 2.97E-06 
rs13163091 5 130863940 5.91E-06 rs676944   5 131316367 3.17E-05 
rs4705890  5 130882899 4.05E-06 rs2240525  5 131343783 0.02957 
rs3776007  5 130902984 9.21E-06 rs559971   5 131344063 2.11E-05 
rs17671387 5 130911895 0.0005832 rs173812   5 131347359 2.64E-05 
rs250888   5 131043245 9.63E-06 rs253943   5 131348629 6.91E-05 
rs251015   5 131057582 3.30E-06         
 
  
149 
 
Table 30: P-values for clustered SNPs in a case control analysis with a trend model using PLINK for chr 6 
only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  p_TREND   SNP_ID     CHR POSITION  p_TREND   
rs1611699  6 29935732 0.01103 rs2517672  6 30045241 0.01215 
rs1611703  6 29936414 4.53E-06 rs4947244  6 30062343 0.08682 
rs1611711  6 29937087 0.01108 rs3115631  6 30094303 0.0008066 
rs1611714  6 29937386 1.99E-06 rs259940   6 30119913 0.008756 
rs2734970  6 29942451 3.18E-05 rs3869070  6 30131847 0.002092 
rs3094159  6 29943813 0.01385 rs9261301  6 30149538 0.02827 
rs3132718  6 29944556 0.0124 rs3132682  6 30152367 0.03356 
rs1611637  6 29944720 0.006318 rs9261317  6 30156284 0.08271 
rs3132712  6 29949000 0.008305 rs6457144  6 30171347 0.05627 
rs2523807  6 29958253 0.07597 rs9261394  6 30172541 0.04527 
rs1632882  6 30024347 0.0007669 rs1264704  6 30173298 0.03399 
rs417162   6 30024484 0.003631 rs1264703  6 30173395 5.29E-06 
rs1655900  6 30024597 1.66E-06 rs1264702  6 30173554 7.69E-06 
rs2508037  6 30026415 0.003011 rs2517595  6 30192528 0.02589 
 
Table 31: P-values for clustered SNPs in a case control analysis with a trend model using PLINK for chr 6 
only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  p_TREND   SNP_ID     CHR POSITION  p_TREND   
rs9268429  6 32453030 0.003674 rs9268877  6 32539125 0.05446 
rs3129953  6 32469799 1.35E-07 rs615672   6 32682149 0.0001881 
rs2076530  6 32471794 0.03144 rs9272346  6 32712350 0.01135 
rs9268480  6 32471822 0.00215 rs41269947 6 32716055 0.03702 
rs10947261 6 32481210 0.01789 rs3129716  6 32765414 4.35E-05 
rs3763307  6 32482600 0.004194 rs9469220  6 32766288 5.35E-12 
rs2001097  6 32491836 1.42E-09 rs6457617  6 32771829 6.40E-08 
rs3135378  6 32493077 2.37E-09 rs2858308  6 32777978 0.02038 
rs2395161  6 32495730 2.81E-09 rs3892710  6 32790840 4.79E-05 
rs2395164  6 32495838 6.68E-09 rs9275618  6 32792365 0.04749 
rs2395167  6 32496286 5.72E-10 rs5024432  6 32792446 0.06377 
rs3135366  6 32496687 4.02E-09 rs3916765  6 32793528 0.07974 
rs9268557  6 32497283 0.05422 rs9461799  6 32797507 1.08E-05 
rs3135363  6 32497626 0.0001255 rs2227127  6 32819760 7.56E-05 
rs3129847  6 32504484 8.49E-08 rs9276429  6 32820082 2.61E-06 
rs3135342  6 32504593 1.84E-08 rs9276431  6 32820225 3.86E-07 
rs5000563  6 32512113 1.83E-08 rs9276432  6 32820362 2.90E-07 
rs3129872  6 32515131 2.38E-08 rs28420297 6 32822738 1.94E-05 
rs3129877  6 32516575 4.13E-09 rs9276440  6 32822761 2.26E-07 
rs3135393  6 32516820 2.76E-09 rs7768538  6 32837799 7.33E-07 
rs7194     6 32520458 8.81E-06 rs2051549  6 32838064 1.86E-06 
rs9268831  6 32535726 0.03867 rs6902723  6 32839938 2.58E-06 
rs9268856  6 32537697 1.05E-10 rs9296044  6 32844122 3.83E-05 
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Table 32: P-values for clustered SNPs in a case control analysis with a trend model using PLINK for chr 6 
only. Positions in Build36.3. Lowest p-value in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  p_TREND   
rs4870174  6 150345094 0.01517 
rs5017316  6 150375182 3.31E-08 
rs9479403  6 150379439 2.67E-08 
rs494825   6 150395716 4.33E-05 
rs3860823  6 150398219 1.07E-07 
rs6935051  6 150398646 0.03236 
rs2181923  6 150403682 3.98E-06 
rs644866   6 150405702 1.39E-06 
rs9479513  6 150409013 3.60E-07 
rs11155699 6 150409590 0.07373 
 
 
Table 33: npLOD values for clustered SNPs in a family based non parametric linkage analysis using 
PLINK for chr 10 only. Positions in Build36.3. Highest npLOD score in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  npLOD SNP_ID     CHR POSITION  npLOD 
rs12246970 10 414200 3.62 rs10466270 10 546129 3.95 
rs10904083 10 419977 3.63 rs4881399  10 557325 3.89 
rs11594718 10 422103 3.63 rs12252141 10 579228 3.63 
rs4488125  10 427940 3.64 rs11253096 10 580418 3.62 
rs3935081  10 459349 3.78 rs7076375  10 582926 3.62 
rs7077209  10 474159 3.85 rs7914425  10 585877 3.61 
rs4881313  10 477973 3.86 rs2605905  10 596908 3.6 
rs2050970  10 505870 3.95 rs816627   10 608409 3.58 
rs1539231  10 520644 3.99 rs17221323 10 608685 3.58 
rs11252693 10 522139 3.99 rs816628   10 609170 3.57 
rs2096134  10 523331 3.99 rs816620   10 635916 3.36 
rs11252756 10 528811 3.98 rs816570   10 670475 3.26 
rs885593   10 530161 3.98 rs17136375 10 698293 3.11 
rs11252842 10 542355 3.97         
 
 
Table 34: npLOD values for clustered SNPs in a family based non parametric linkage analysis using 
PLINK for chr 10 only. Positions in Build36.3. Highest npLOD score in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  npLOD SNP_ID     CHR POSITION  npLOD 
rs17294166 10 1866813 3.31 rs2492866  10 1912296 3.75 
rs10903569 10 1887722 3.74 rs962762   10 1913115 3.75 
rs7084728  10 1888169 3.75 rs962760   10 1913557 3.75 
rs11250832 10 1888716 3.75 rs962759   10 1913602 3.75 
rs7921481  10 1888756 3.75 rs11250876 10 1913685 3.75 
rs7082514  10 1890661 3.77 rs11250877 10 1913821 3.75 
rs11250838 10 1892085 3.77 rs10128507 10 1925529 3.71 
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SNP_ID     CHR POSITION  npLOD SNP_ID     CHR POSITION  npLOD 
rs4077784  10 1892429 3.77 rs10903593 10 1935296 3.68 
rs9919410  10 1892486 3.77 rs2039568  10 1943525 3.65 
rs10794793 10 1892639 3.77 rs12413921 10 1948188 3.63 
rs10794794 10 1892670 3.77 rs7079003  10 1967135 3.65 
rs10903579 10 1899520 3.76 rs11250965 10 1998811 3.37 
rs7098110  10 1906190 3.76         
 
 
Table 35: npLOD values for clustered SNPs in a family based non parametric linkage analysis using 
PLINK for chr 10 only. Positions in Build36.3. Highest npLOD score in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  npLOD SNP_ID     CHR POSITION  npLOD SNP_ID     CHR POSITION  npLOD 
rs10751884 10 2728447 3.38 rs7922626  10 2772413 3.84 rs1577249  10 2826854 3.76 
rs2050343  10 2733897 3.64 rs1537616  10 2772787 3.84 rs11251521 10 2839913 3.59 
rs2050342  10 2734009 3.65 rs7093144  10 2773069 3.84 rs7080882  10 2854447 3.56 
rs10903846 10 2736750 3.67 rs7093433  10 2773225 3.84 rs10794949 10 2855170 3.56 
rs1931865  10 2743676 3.72 rs7094332  10 2774947 3.84 rs10736962 10 2859096 3.53 
rs11251447 10 2747337 3.74 rs2065683  10 2794898 3.88 rs9633756  10 2865792 3.49 
rs11251448 10 2747555 3.74 rs2184413  10 2794997 3.88 rs7098771  10 2866202 3.49 
rs11593477 10 2748071 3.74 rs2065685  10 2795185 3.88 rs11593983 10 2867503 3.5 
rs11251468 10 2756759 3.78 rs11251502 10 2800427 3.88 rs1909692  10 2881279 3.61 
rs11251469 10 2756921 3.78 rs7895748  10 2807535 3.87 rs6601988  10 2891165 3.61 
rs17158961 10 2770813 3.83 rs11251504 10 2808244 3.87 rs7093545  10 2891275 3.61 
rs11599371 10 2771027 3.83 rs11251505 10 2808320 3.87 rs6601989  10 2891320 3.61 
rs11593350 10 2771146 3.83 rs11251508 10 2818596 3.82 rs1909690  10 2900624 3.45 
rs1106272  10 2772045 3.84 rs10736960 10 2821743 3.81         
 
 
Table 36: npLOD values for clustered SNPs in a family based non parametric linkage analysis using 
PLINK for chr 19 only. Positions in Build36.3. Highest npLOD score in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  npLOD SNP_ID     CHR POSITION  npLOD 
rs2432055  19 41413208 3.49 rs10417204 19 42726562 5.9 
rs2271844  19 41592850 3.78 rs11083428 19 42775807 5.89 
rs2945989  19 41595102 3.8 rs16958863 19 42816075 5.87 
rs17206393 19 41630434 4.2 rs2927740  19 42832806 5.86 
rs10421461 19 41707727 4.63 rs2909105  19 42859746 5.85 
rs2967449  19 41708165 4.64 rs11083433 19 42901141 5.81 
rs17707014 19 41709636 4.64 rs2972437  19 42902351 5.81 
rs2912438  19 41718283 4.66 rs856300   19 42942664 5.75 
rs3108548  19 41742622 4.69 rs241960   19 42976129 5.68 
rs3096620  19 41762083 4.7 rs10409487 19 42976951 5.68 
rs2162296  19 41792090 4.7 rs3910952  19 42984209 5.66 
rs10419469 19 41826577 4.69 rs8101752  19 42985327 5.66 
rs3108559  19 41874511 4.88 rs241935   19 42985803 5.66 
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SNP_ID     CHR POSITION  npLOD SNP_ID     CHR POSITION  npLOD 
rs3108181  19 41879580 4.88 rs11878269 19 42997553 5.65 
rs3108214  19 41894154 4.89 rs241937   19 43002500 5.65 
rs826969   19 41939312 4.89 rs8110293  19 43004942 5.65 
rs1673086  19 41955857 4.89 rs10420891 19 43012379 5.65 
rs1673087  19 41956030 4.89 rs10402530 19 43013478 5.65 
rs2245366  19 41956174 4.89 rs17249138 19 43047720 5.64 
rs2431776  19 42018124 5.28 rs7250821  19 43065318 5.62 
rs1144540  19 42022453 5.29 rs3894129  19 43076261 5.62 
rs486221   19 42030704 5.26 rs4802150  19 43107654 5.59 
rs493482   19 42057888 5.45 rs705495   19 43118825 5.57 
rs477725   19 42066106 5.49 rs705496   19 43118937 5.57 
rs9304878  19 42089141 5.6 rs17249336 19 43132976 5.51 
rs484001   19 42114062 5.71 rs705500   19 43138890 5.46 
rs547483   19 42133205 5.75 rs1725494  19 43138950 5.46 
rs528504   19 42139188 5.75 rs941038   19 43156628 5.23 
rs569371   19 42145837 5.76 rs6508755  19 43164562 5.04 
rs523979   19 42148245 5.76 rs1725468  19 43165769 4.99 
rs472226   19 42150553 5.76 rs833915   19 43165900 4.98 
rs1375476  19 42157015 5.76 rs1643459  19 43168013 4.64 
rs1667337  19 42159352 5.76 rs833911   19 43168897 4.63 
rs1644666  19 42167326 5.75 rs833904   19 43177305 4.55 
rs1612652  19 42169480 5.75 rs860627   19 43178032 4.55 
rs1644673  19 42170551 5.75 rs17309382 19 43196877 4.45 
rs1667353  19 42172993 5.75 rs705503   19 43206158 4.38 
rs8106386  19 42195739 5.75 rs6508757  19 43214032 4.24 
rs2562587  19 42202099 5.75 rs8110656  19 43218023 4.24 
rs2562599  19 42208214 5.78 rs1628394  19 43226848 4.25 
rs7248948  19 42239059 5.83 rs1620082  19 43233843 4.24 
rs2385374  19 42274857 5.85 rs1618385  19 43234734 4.24 
rs6510588  19 42289235 5.85 rs1725510  19 43247682 4.22 
rs1402468  19 42312088 5.85 rs1614979  19 43269277 4.16 
rs11084878 19 42362309 5.84 rs855640   19 43272184 4.15 
rs320891   19 42397185 5.83 rs941039   19 43296954 4.03 
rs7246657  19 42438948 5.83 rs3852911  19 43297276 4.03 
rs12709812 19 42486690 5.82 rs855614   19 43311582 4.01 
rs7408736  19 42488151 5.82 rs332860   19 43348970 3.92 
rs1530500  19 42515651 6.09 rs10420506 19 43362295 3.87 
rs713256   19 42557205 6.13 rs3745945  19 43365138 3.86 
rs256733   19 42567471 6.13 rs2278431  19 43398829 3.67 
rs8106839  19 42650315 6.12 rs10993    19 43435431 3.61 
rs1236810  19 42658501 6.12 rs7250689  19 43445465 3.6 
rs12461941 19 42676490 6.08 rs7253245  19 43445626 3.6 
rs8109038  19 42707549 5.98 rs41465446 19 43454980 3.57 
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Table 37: npLOD values for clustered SNPs in a family based non parametric linkage analysis using 
PLINK for chr 19 only. Positions in Build36.3. Highest npLOD score in SNP cluster highlighted in red. 
 
SNP_ID     CHR POSITION  npLOD SNP_ID     CHR POSITION  npLOD 
rs16970276 19 40562188 3.55 rs528504   19 42139188 4.05 
rs10420543 19 40589758 3.62 rs1667337  19 42159352 4.06 
rs756971   19 40635609 3.72 rs8106386  19 42195739 4.07 
rs17705450 19 40667407 3.75 rs7248948  19 42239059 4.10 
rs4806163  19 40695946 3.76 rs2385374  19 42274857 4.11 
rs17705657 19 40716582 3.80 rs1402468  19 42312088 4.11 
rs1033330  19 40761472 3.88 rs11084878 19 42362309 4.11 
rs4805131  19 40789137 3.73 rs320891   19 42397185 4.11 
rs8106576  19 40816016 3.73 rs256733   19 42567471 4.15 
rs107068   19 40896530 3.74 rs10417204 19 42726562 4.13 
rs179570   19 40943166 3.72 rs11083428 19 42775807 4.12 
rs10409299 19 41016164 3.66 rs11083433 19 42901141 4.07 
rs12462868 19 41163676 3.54 rs241960   19 42976129 4.03 
rs17639286 19 41212605 3.50 rs241937   19 43002500 4.01 
rs7257383  19 41255260 3.48 rs17249138 19 43047720 4.00 
rs4555271  19 41302030 3.50 rs3894129  19 43076261 3.99 
rs2438517  19 41412230 3.64 rs4802150  19 43107654 3.98 
rs2271844  19 41592850 3.78 rs17249336 19 43132976 3.97 
rs17206393 19 41630434 3.80 rs941038   19 43156628 3.94 
rs2967449  19 41708165 3.83 rs833904   19 43177305 3.90 
rs3108548  19 41742622 3.84 rs705503   19 43206158 3.87 
rs3108559  19 41874511 3.80 rs1628394  19 43226848 3.85 
rs826969   19 41939312 3.79 rs3852911  19 43297276 3.69 
rs2431776  19 42018124 3.87 rs332860   19 43348970 3.61 
rs484001   19 42114062 4.03 rs2278431  19 43398829 3.50 
 
 
Table 38: npLOD values for clustered SNPs in a family based non parametric linkage analysis using 
PLINK for chr 19 only. Positions in Build36.3. Highest npLOD score in SNP cluster highlighted in red. 
SNP_ID     CHR POSITION  npLOD SNP_ID     CHR POSITION  npLOD 
rs16970293 19 40590481 3.49 rs12973004 19 40750614 3.85 
rs17304632 19 40620406 3.75 rs1033330  19 40761472 3.86 
rs8108454  19 40634973 3.85 rs4805131  19 40789137 3.70 
rs756971   19 40635609 3.86 rs8106576  19 40816016 3.70 
rs17705450 19 40667407 3.85 rs12459634 19 40922014 3.72 
rs7254211  19 40695561 3.84 rs179570   19 40943166 3.71 
rs4806163  19 40695946 3.84 rs41426049 19 41001358 3.65 
rs7254744  19 40702499 3.83 rs10409299 19 41016164 3.64 
rs17705657 19 40716582 3.86 rs12462868 19 41163676 3.48 
rs2239945  19 40725300 3.87         
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endet nicht mit einem Schlusspunkt, sondern mit einem Fragezeichen. 
 
Hermann Hesse (1877-1962), dt. Dichter, 1946 Nobelpr. f. Lit. 
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